<SEC-DOCUMENT>0000906709-23-000008.txt : 20230510
<SEC-HEADER>0000906709-23-000008.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230509175346
ACCESSION NUMBER:		0000906709-23-000008
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		23903617

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:50d7cf34-c614-4bcd-898f-e96601bbe45e,g:0a2e4e36-7a77-4bd6-a518-b664e3e6425f,d:53ffcfe41df94c13bfe514c5b23d1b65--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nktr="http://www.nektar.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM18yLTEtMS0xLTQ4NTk0_6443facf-8a92-43de-855f-267b559632c5">false</ix:nonNumeric><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM180LTEtMS0xLTQ4NTk0_a362b336-1c21-41fe-b764-54e041f80d57">2023</ix:nonNumeric><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM181LTEtMS0xLTQ4NTk0_0d304210-1136-4cb4-b080-97dcedb7efcd">Q1</ix:nonNumeric><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM184LTEtMS0xLTQ4NTk0_b290adaf-1b7e-4e08-8cda-fd74338fb5e4">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM185LTEtMS0xLTQ4NTk0_dcaadd97-4d19-4c33-a6d0-bdf1099f14ee">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353f6dfdad124cf895b486b31ecc03e3_I20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ibce58931b7d241b7a58b00661b49392d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iedc5a121de294018bf52ef250166d0cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7474e215440423fb6a4944a3ef1c112_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bff78a906cc446f9c38659e714a0991_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120490afb52049e28bacdb27bba440d2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia918b3420fe94c7497c1964c27923368_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c90841203bc402ebda13222c297e7b0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13b6287af2fb458e9dabde17f604aeb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3795d80c499a47ffb23780f216279dd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8558d20a9404b2b9666d7e7ac9e04e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9c049960c045d389ad24714ff388b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if35b840456e243088bc83a33ff9929d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb94b83c0574f40994d258fd6f726ac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a2bdc6f20b4830a5391065713122ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6bd69c0c70945bea566d50bd61df2c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4df987b0bc42539160068723e3c35b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc70df4b4d8449992572edf6df98bb6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2a84be71ba453bb40cfd7c3b534a9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ab4c4b6c284ad3a661dc38dc01e5f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8361cd8a1de744a594fc0cdb561e6003_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c43dfae2834078a893893586390205_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ac92307e2549dd9ec0c7643db84d0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f442d205bc45afbe1def2527c44fee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2adc2069cb43649c5971f223b18c65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b935c9a9f6e4254978f843e88b6b14e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5464511d66984607836e04c3376ea0a2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f798d53e2a645d9a4273b63d8030705_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37de0bff6b41411ba350a255586c2c82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556866edd8b5476d870f3d0567b42572_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08bf37b20de42a79a37455e0a5403db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e12e371ab794958bf783671a51d9a9b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9901f8efb7a84fd383997f807d327718_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65e32b44a5744e18b29a445360764ac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7697166d42e141bd9a7bbec30e8e7d48_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ief4395c62e394de284ed9e69496b6151_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e3a6b241b64c388617839ca0e84f74_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91f661d01a94c13b05ca1bffece360b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169cb82e795a48b79820f86db1cd190a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5b1ea2c25240e78087bc3f10b8ba5f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a68493d157c4d499d9c6cfe4dbcd7c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf7c09b99a3408ab39bfdee5594026c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b17d6fbf5d49d1827a4d756e9436ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e6b2bd66034d0595587cea80e41b9c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8adc60ceae453793ca7d4b82bd2863_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73846d6859c748ad9e0bcaec151a95db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9a2d6862b34886bc6eb8bd085e313d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdbb7c8346d54dc6ab904f9d8a1cfa32_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0cde2ed24ec4607bb959fcc112e1fa8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c7d7f6cfef46afa7d17a7648fa22d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ddd871d7e454404902df8e801682458_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7135b84ff3e4425b84bf50f571ac57ce_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i032e78f5ed7c4d648dc75900dc5651df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7ef44e372d4c86842156ea38bc9a05_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6aa244acf4d42e5af8f92393337c196_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac97bb571c524e1ea1a69c1042cdf6ff_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557700c0d761400a82e19e7b49256e39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a52bcfffe64473afd94d1ad70a2304_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i825095a4840447b1884c349d7a55b45d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bed044d7775412580048660b77fa954_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e54efca0a94e31868b7e6b05760280_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b13a843a33e4bc08464584072e4b021_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec325a50f7844edda0d300d4f35dafa2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ac5fe1f84b4a0b91a45b1c7657c57d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f42788641442cdad7182512b26d5e2_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adb82d027d849da802db4b49a43ee2a_I20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0868cb5a09c844a796ffe2c4ecb34a5b_D20170723-20170723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-23</xbrli:startDate><xbrli:endDate>2017-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7959c4e63c52467ca26c517b3783d65d_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf20dc9f8d6f48baa0bd1294dba2654b_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba9f64c9bff4236965a5e18df3794a6_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib249192b630141c98908c973940137df_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48302ef504774ac6a0914253d9ac0a95_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15412e5663004a80831838e6da60e1fe_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2debb833d9b47b6a265922060678a06_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ff1e5d834349cfb697a5e4a5c4bbaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9f83081651457596b4bbe97aaaa513_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248ad8f8306145d79a154379e4c144c7_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c61fe105dd4f8ca0cb30e7ae9ca967_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5256132357e4151bc701fffe762e23c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1d381685d046eb8df1f1376d3da9d4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87894f2d277d4d689189754384742bf3_D20220101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ea4f7910ee46acbba924e43878e0d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1590dec7f141ddb038c9a92effcf1e_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997d98245f4048f997e82ffee6686137_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40ec0a96ce54f1bb18634012ce405b9_D20230401-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20c572ba8d44958a9a79ca58b613c8d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526526b23308431d88efcd30d4d1d51d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85a2540650e49ff827fe78c21240f01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62f8fac2f829451080ed7031388fb268_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6620bfd483ba4ec1bd4a2ee734818286_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7cadf538c2947f1b43fbef0ac736b9f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb06267cb11c41e98b47d0d573f0e09a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa6e43a4bdee434d8a2152922832b63a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id695df1ce72740ec955bff4bb989faa8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ed89f1fe464363a9e387568ead9993_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3598e30999e54f9f9f575e5b881f2da3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55817a7194945f1ae4c0a8163778b09_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86a36c4159774aedad86844713f0d8bc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3677d6c99212474f8786bb289678a42c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2ab344bd4f4b498f29e789a11c1690_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62ae4528157426aba132831bb9e3a69_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cda02f4555947ccabad36bcc6480d92_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34546a7702c6424eb4d1bd5155173002_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793f4a945cbb4640999a6a1a0da30ac5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ebf75335184f2eb6750cf5620342bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f16114b074f437fbd1d96555474845a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebffda948b374043aba705095a8d4ade_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYx_faa48113-6248-4041-9d79-0f885705a6a1">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZDQwMDRiOWI2OWFiNDQ1YTg3N2M5YmMzZGM3OWYwNjUvdGFibGVyYW5nZTpkNDAwNGI5YjY5YWI0NDVhODc3YzliYzNkYzc5ZjA2NV8wLTAtMS0xLTQ4NTk0_679ae417-d830-49ab-8226-de1e8567a2c6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yNjY_49aabee5-66e5-4155-877e-1fe6b2e42410">March&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6YjE5NDkzZWJlM2NiNGQ3ZjkxMjc5YTgwNWViODZmODMvdGFibGVyYW5nZTpiMTk0OTNlYmUzY2I0ZDdmOTEyNzlhODA1ZWI4NmY4M18wLTAtMS0xLTQ4NTk0_b14e6ea0-693e-4b65-8d82-0de10f3ce177">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYy_3d2c0cbd-b4ec-46c9-ba88-04d6b51be8da">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYz_78cdedbb-2f96-4ec6-ac95-79ee25c635da">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6MWQ5YTFkZjNkNjBjNGQ0MDgyZDU3YzFjMzdjNzVmZjgvdGFibGVyYW5nZToxZDlhMWRmM2Q2MGM0ZDQwODJkNTdjMWMzN2M3NWZmOF8wLTAtMS0xLTQ4NTk0_b7a480af-c869-4c7c-b402-ce7c27436968">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6MWQ5YTFkZjNkNjBjNGQ0MDgyZDU3YzFjMzdjNzVmZjgvdGFibGVyYW5nZToxZDlhMWRmM2Q2MGM0ZDQwODJkNTdjMWMzN2M3NWZmOF8wLTItMS0xLTQ4NTk0_583df4a4-56cc-4662-b2b3-92e5aac0d92f">94-3134940</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU2_4b9280ae-616d-4699-8e83-f363fe206b6a">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU3_08cc3e3e-9420-404e-89be-5ec913eb3c1e">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY2_078e4929-3fa3-4d25-80cc-fabf29483e36">California</ix:nonNumeric> <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY3_d1cd52e3-3055-4486-b9e9-4de50b4e62f0">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY4_383645ce-bb33-46d7-af02-38d5e860fbb8">415</ix:nonNumeric>-<ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU4_d994820d-d2ba-4559-81c8-e36c40dfb82f">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6NDQ3NDQ3OGVjZDhkNDY4ZDk1YTJhMmU2MDcwY2ZkOTgvdGFibGVyYW5nZTo0NDc0NDc4ZWNkOGQ0NjhkOTVhMmEyZTYwNzBjZmQ5OF8yLTAtMS0xLTQ4NTk0_569f133c-0e82-4885-8a23-761b382c6fb7">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6NDQ3NDQ3OGVjZDhkNDY4ZDk1YTJhMmU2MDcwY2ZkOTgvdGFibGVyYW5nZTo0NDc0NDc4ZWNkOGQ0NjhkOTVhMmEyZTYwNzBjZmQ5OF8yLTEtMS0xLTQ4NTk0_d9b9b58b-fbbf-4720-98f0-f241b7193e24">NKTR</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6NDQ3NDQ3OGVjZDhkNDY4ZDk1YTJhMmU2MDcwY2ZkOTgvdGFibGVyYW5nZTo0NDc0NDc4ZWNkOGQ0NjhkOTVhMmEyZTYwNzBjZmQ5OF8yLTItMS0xLTQ4NTk0_f4b87212-bef9-4705-ae4e-1272c6bb9e4f">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU5_3fac94af-e9d4-4e1d-bf7a-ba0f49815e4f">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYw_c84ce3e2-4965-41dc-8cb3-098c8d8972ce">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZjkxNzYwMmJlMDIxNDY0Zjk5MTA5NzEwZmY1MGM4N2MvdGFibGVyYW5nZTpmOTE3NjAyYmUwMjE0NjRmOTkxMDk3MTBmZjUwYzg3Y18wLTAtMS0xLTQ4NTk0_16e39734-fbbe-455a-8ef8-f9c5a98b711a">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZjkxNzYwMmJlMDIxNDY0Zjk5MTA5NzEwZmY1MGM4N2MvdGFibGVyYW5nZTpmOTE3NjAyYmUwMjE0NjRmOTkxMDk3MTBmZjUwYzg3Y18yLTYtMS0xLTQ4NTk0_0156c284-f66a-420e-86ff-539fb8c00e9c">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZjkxNzYwMmJlMDIxNDY0Zjk5MTA5NzEwZmY1MGM4N2MvdGFibGVyYW5nZTpmOTE3NjAyYmUwMjE0NjRmOTkxMDk3MTBmZjUwYzg3Y180LTItMS0xLTQ4NTk0_304635c0-e768-4a30-ae5d-05c8c01965ff">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY1_0cc672d8-9208-407b-b86a-5f49bd16a067">&#9746;</ix:nonNumeric></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was <ix:nonFraction unitRef="shares" contextRef="i353f6dfdad124cf895b486b31ecc03e3_I20230502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjQ4_a9846f54-0690-4024-af01-ba3c78cc378b">189,235,157</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n May&#160;2, 2023.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_13">Summary of Risks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_16">PART I: FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_19">Condensed Consolidated Financial Statements &#8212; Unaudited:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_22">Condensed Consolidated Balance Sheets &#8212; March 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_25">Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_28">Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_34">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_85">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_88">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_88">29</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_91">PART II: OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_94">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_94">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_94">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_97">Item 1A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_97">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_97">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_100">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_100">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_103">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_106">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_109">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_112">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_112">50</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_115">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i53ffcfe41df94c13bfe514c5b23d1b65_115">52</a></span></div></td></tr></table></div><div style="text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_13"></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item 1A in this Form 10-Q, which risks include, among others:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical drug development is a lengthy and uncertain process and we may not be able to generate and develop successful drug candidates for commercial use;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255 and our business will be significantly harmed if either rezpegaldesleukin or NKTR-255 do not continue to advance in clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive immunotherapy clinical trials, and the discovery and development of new therapies could have a material and adverse impact on the value of our pipeline;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are implementing a new strategic reprioritization and cost restructuring plan (which follows a 2022 strategic reorganization plan and cost restructuring plan) to focus on prioritizing key research and development efforts and our business will be significantly harmed if these plans are unsuccessful;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a significant source of our revenue is derived from our collaboration agreements, and if we are unable to establish and maintain collaboration partnerships with attractive commercial terms, including significant development milestones and research and development cost-sharing, our business, results of operations and financial condition could suffer; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we expect to continue to incur substantial net losses from operations and may not achieve or sustain profitability in the future. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on advancing rezpegaldesleukin in clinical trials, and our ability to perform important development activities will be significantly harmed if Eli Lilly and Company fails to deliver to us quickly the regulatory rights, safety and efficacy data, testing assays, and other materials that are necessary for us to continue clinical development; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may rely on academic and private non-academic institutions to conduct investigator-sponsored clinical studies or trials of our product candidates and any failure by the investigator-sponsor to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval or commercialize for our product candidates. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be harmed; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available to us on commercially reasonable terms; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">from time to time, we are involved in legal proceedings and may incur substantial litigation costs and liabilities that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_19"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_22"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMy0xLTEtMS00ODU5NA_8097fb0e-0d88-45da-ace7-db640ff789ea">76,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMy0zLTEtMS00ODU5NA_7cac3072-6ed6-42f0-b7d5-55dd08238721">88,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNC0xLTEtMS00ODU5NA_75f944e1-16cd-473c-8334-96dbb6333755">379,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNC0zLTEtMS00ODU5NA_2485aa69-9504-4591-8536-b7ec707783c9">416,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNS0xLTEtMS00ODU5NA_abbbf736-10da-46af-bc3f-a449454741a9">2,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNS0zLTEtMS00ODU5NA_6817c814-e5e0-4f8e-9581-799e2e9ef577">5,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNi0xLTEtMS00ODU5NA_43267d34-88dd-4e9e-a23c-0a5fe50c9cd4">20,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNi0zLTEtMS00ODU5NA_1e5016d0-16e3-4997-ba48-fa1730c8baba">19,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNy0xLTEtMS00ODU5NA_82845712-3f75-488a-afc7-4c709588809b">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNy0zLTEtMS00ODU5NA_060ff487-5ab0-42ad-a6cc-8d6aafb04cb2">15,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfOC0xLTEtMS00ODU5NA_00c7fd6f-1cd0-4aeb-8ad9-f0dc96696f7a">491,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfOC0zLTEtMS00ODU5NA_c2d1ed60-492a-4308-a0da-ccf5b3a88fe5">545,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTAtMS0xLTEtNDg1OTQ_2a06a522-3637-4854-a016-ae9b3b1b85c4">27,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTAtMy0xLTEtNDg1OTQ_1d2f6122-23e6-408f-9448-c682b33e6504">32,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTEtMS0xLTEtNDg1OTQ_959050ef-5ac5-4705-982b-b16945198351">42,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTEtMy0xLTEtNDg1OTQ_b3cdf7f1-becb-457a-8dd6-0b89f2a35817">53,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTItMS0xLTEtNDg1OTQ_0a4ac31b-580c-4dc5-8bcd-260d31d05609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTItMy0xLTEtNDg1OTQ_76df6c39-b3b4-49e4-bb1b-104e56073169">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTMtMS0xLTEtNDg1OTQ_402479a1-0fcc-43b5-a894-ac0417058857">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTMtMy0xLTEtNDg1OTQ_c8ed3fdc-82da-4373-a230-be7d145c284d">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTQtMS0xLTEtNDg1OTQ_654e4f6c-29f4-493d-abc5-4e80f6e809ae">561,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTQtMy0xLTEtNDg1OTQ_606845a9-56a9-4a3e-b1af-3b84bfb5aee9">710,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTctMS0xLTEtNDg1OTQ_69846c38-bc66-4c7b-9ef1-cbdbd5fec0bb">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTctMy0xLTEtNDg1OTQ_38f1d761-46e3-4f6a-92e8-248c1c3e42e3">12,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMS0xLTEtNTE2MTg_bc0418c2-723d-44ac-90f0-f5a4f43deb85">37,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMy0xLTEtNTE2MjY_23308b4c-2878-4476-99d8-543de46bdb7c">36,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMS0xLTEtNDg1OTQ_fab5b821-0c4a-480f-bca6-eee8b6dbf3a5">18,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMy0xLTEtNDg1OTQ_571f6765-4ee2-4650-8cc2-d7860fec59b8">18,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjItMS0xLTEtNDg1OTQ_7717a767-962e-44fd-88e0-1dd3902e133c">59,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjItMy0xLTEtNDg1OTQ_df3af52a-440e-4c78-ad48-43e2c6a3c902">68,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjMtMS0xLTEtNDg1OTQ_a1e2b820-d02a-4b96-aede-214b155835eb">109,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjMtMy0xLTEtNDg1OTQ_9c49092d-5919-42ea-9631-0d8afb687c23">112,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjUtMS0xLTEtNDg1OTQ_958e7d4a-aba9-4b84-bc6e-2e3f392d9e33">145,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjUtMy0xLTEtNDg1OTQ_ca6f3265-296c-4256-ad8c-5d7b9b0af574">155,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjYtMS0xLTEtNDg1OTQ_01165e62-86a1-4d9a-8624-e279d8942d73">6,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjYtMy0xLTEtNDg1OTQ_62ce66de-ae18-4c88-977f-a03f8162f41e">7,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjctMS0xLTEtNDg1OTQ_53efd73e-94b0-4121-a7e2-7b802084e25a">320,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjctMy0xLTEtNDg1OTQ_d8f4dffb-0a33-4db6-af05-e7fc66191e3e">343,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjgtMS0xLTEtNDg1OTQ_9c6d0716-2ebe-4f22-b5fd-7c2dc7d39396"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjgtMy0xLTEtNDg1OTQ_6cba65a5-4576-4eee-8c71-f1439d600279"></ix:nonFraction>Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8yMQ_1dc055d8-9ee9-4953-9dd4-07195a410ef4"><ix:nonFraction unitRef="usdPerShare" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8yMQ_e5176c35-b896-4f60-8528-c7c56a322567">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8zNQ_093f385b-c24c-4d14-9220-6fadab580514"><ix:nonFraction unitRef="shares" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8zNQ_67a732d9-220c-461b-9ff2-8d1f30bcbd1e">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_386c4dbf-c264-48f0-afde-580ca3af2705"><ix:nonFraction unitRef="shares" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_83ec13c3-b59d-4434-b26b-7312c2993046"><ix:nonFraction unitRef="shares" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_ba0f0766-ff56-4a15-aa0b-2167c1358b1a"><ix:nonFraction unitRef="shares" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_c5b643a6-e5a8-40e4-9a02-253694717261">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated or outstanding at March 31, 2023 or December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMS0xLTEtNDg1OTQ_53f22ef4-bd51-46d9-a906-5511e1ca4ed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMy0xLTEtNDg1OTQ_4fa17126-ec3e-4682-baac-176785f5225a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8xOA_3e9f0251-d396-449e-9e7e-eb96bef10b94"><ix:nonFraction unitRef="usdPerShare" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8xOA_98dad5ea-ca02-491b-8b15-9554b4aa6d52">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8zMg_a4359de6-6910-4d2c-8dd9-6970321df1bf"><ix:nonFraction unitRef="shares" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8zMg_ab27a348-4654-4419-83b0-4e48f2a9352a">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF81NA_8ecd02c0-b2ec-4137-ac18-b9841b0cbb89">189,235</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF82OA_411da63a-61db-4fea-9f72-4c6372e9023b">188,560</ix:nonFraction> shares outstanding at March 31, 2023 and December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMS0xLTEtNDg1OTQ_909fe6ff-5ab9-483a-8a4e-6a97e778700c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMy0xLTEtNDg1OTQ_bc833978-3e09-4bf6-aa79-b046218967d7">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital in excess of par value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzItMS0xLTEtNDg1OTQ_1b5fa1e9-24e1-4a44-8c2f-0add7849f927">3,584,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzItMy0xLTEtNDg1OTQ_567aeb90-d4d2-4b03-a40b-c37209b948ba">3,574,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzMtMS0xLTEtNDg1OTQ_193a4be4-57e0-4a01-87b5-a80c3627d250">5,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzMtMy0xLTEtNDg1OTQ_e815d0a5-8a5f-47d7-a16d-bba73b854854">6,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzQtMS0xLTEtNDg1OTQ_cfaa0442-4ff9-41f7-94fa-2e497befd353">3,338,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzQtMy0xLTEtNDg1OTQ_475939d4-bcd5-4142-840a-2b6f506d49e2">3,201,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzUtMS0xLTEtNDg1OTQ_fa1848df-be45-4c4d-b4e4-f6dd7e1064c0">240,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzUtMy0xLTEtNDg1OTQ_a426fe53-73be-4cf0-848d-c427b97792d8">366,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzYtMS0xLTEtNDg1OTQ_9a501a48-cf05-40ef-b566-5c6746d8a090">561,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzYtMy0xLTEtNDg1OTQ_8079c4f3-a6ae-403a-8e29-df5100aff397">710,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.710%"><tr><td style="width:1.0%"></td><td style="width:72.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc5a121de294018bf52ef250166d0cd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMy0xLTEtMS00ODU5NA_a86aeead-5a92-4608-be29-5e8e292c1823">4,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7474e215440423fb6a4944a3ef1c112_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMy0zLTEtMS00ODU5NA_c1e1f109-d7bc-433b-8c24-d29a219f20ea">5,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bff78a906cc446f9c38659e714a0991_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNC0xLTEtMS00ODU5NA_bc191708-1f63-4764-9944-97b3ab25d80f">16,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120490afb52049e28bacdb27bba440d2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNC0zLTEtMS00ODU5NA_069ab7cb-a889-41e2-a7f0-f9fca6acb393">17,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia918b3420fe94c7497c1964c27923368_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNS0xLTEtMS00ODU5NA_a3ac4c4d-6d29-425e-a9cb-0bae9d230228">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c90841203bc402ebda13222c297e7b0_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNS0zLTEtMS00ODU5NA_0b767355-eae7-4adb-9ca4-c36b53c0e8ba">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNi0xLTEtMS00ODU5NA_82300825-4cf4-4050-b3d4-cb8331c972a2">21,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNi0zLTEtMS00ODU5NA_f90a71f3-7ca9-4ebb-a9ff-ff127897f88c">24,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOC0xLTEtMS00ODU5NA_f72dec94-cd0d-4b79-bafa-72e7f815e6ed">7,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOC0zLTEtMS00ODU5NA_4bd80475-f66e-434c-a476-7c0d0104de7f">5,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOS0xLTEtMS00ODU5NA_ca6f9b5b-70b3-4668-b7a3-fe2adff1848b">30,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOS0zLTEtMS00ODU5NA_f71b5b86-034a-4e0b-8994-37f178546f82">107,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTAtMS0xLTEtNDg1OTQ_f0b0ff55-1943-44bb-bc1b-930d577e2d29">21,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTAtMy0xLTEtNDg1OTQ_fba673a5-c523-4546-946a-a5ff3208662f">27,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTEtMS0xLTEtNDg1OTQ_58402f9a-2b65-4730-9b89-9e429c1b4a4e">21,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTEtMy0xLTEtNDg1OTQ_43b153d3-ecd2-4cac-929f-ace7ab27f522">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMS0xLTEtNTE4NDk_0d56b4ac-5925-4957-8bf1-1679539e2427">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMy0xLTEtNTE2NDY_c3242916-9da4-4e86-ae7a-4a83a9f55ca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMS0xLTEtNDg1OTQ_e3e7b2e1-4d0a-4915-8fb5-088fbcc0ba9f">156,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMy0xLTEtNDg1OTQ_7d960e7f-7a37-4940-ac59-1b44f3309872">141,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTMtMS0xLTEtNDg1OTQ_6d660580-0cde-463a-885d-ea6a3495f387">134,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTMtMy0xLTEtNDg1OTQ_ec87e38a-2e18-4b92-b010-aa0182d1dd79">116,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTUtMS0xLTEtNDg1OTQ_f2280b34-7e1d-4942-aa19-5d3ad61b6f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTUtMy0xLTEtNDg1OTQ_70c86cef-7ab2-4c39-9292-bf7aa963966f">33,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTYtMS0xLTEtNDg1OTQ_639c4c69-997d-4acc-a658-1c8bc1917405">6,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTYtMy0xLTEtNDg1OTQ_08e8b16e-2ca2-44c4-bcfc-576cfd7b0815">7,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTctMS0xLTEtNDg1OTQ_4e9c7651-9744-40d3-b88d-a68635b94a7f">4,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTctMy0xLTEtNDg1OTQ_d5fbafa6-f702-4642-8cbf-b21e8c811f39">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTgtMS0xLTEtNDg1OTQ_ebfd9989-b1d8-4f74-9c3b-8f37a4f85e41">2,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTgtMy0xLTEtNDg1OTQ_47d67fbe-d87d-468b-8ab6-630b133b2ee6">26,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTktMS0xLTEtNDg1OTQ_656143af-ca5a-495f-b166-f8ee7378104c">137,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTktMy0xLTEtNDg1OTQ_b9e5a499-acf5-4183-8d3e-49ee94d3f5af">90,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjAtMS0xLTEtNDg1OTQ_3fa77b11-f244-49c0-bf37-54c2b87622cf">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjAtMy0xLTEtNDg1OTQ_09bc1ee6-00ae-4ac3-aa72-f9e906c22d7d">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjEtMS0xLTEtNDg1OTQ_09f11698-4b3e-4795-9ace-fcefca53cc7d">137,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjEtMy0xLTEtNDg1OTQ_a887334d-9769-4446-8630-7fe04743101e">90,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMS0xLTEtNDg1OTQ_7d0550ac-2e19-4f6b-a63c-9d29b1e0bcf2"><ix:nonFraction unitRef="usdPerShare" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMS0xLTEtNDg1OTQ_d11ca5eb-7cef-4cd0-b36a-d1c8ce04c5be">0.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMy0xLTEtNDg1OTQ_4e0eb83d-ab4e-4d1c-8057-7b6777200ea1"><ix:nonFraction unitRef="usdPerShare" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMy0xLTEtNDg1OTQ_c899267d-3132-460b-9c59-bb76806ede79">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMS0xLTEtNDg1OTQ_2923bba2-d871-4778-9814-1e345f89f62e"><ix:nonFraction unitRef="shares" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMS0xLTEtNDg1OTQ_d5687a88-1037-4f10-b19f-6166cb6e3e85">188,875</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMy0xLTEtNDg1OTQ_4828d82d-1c63-4b2f-b8b1-6c4b21f8ea60"><ix:nonFraction unitRef="shares" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMy0xLTEtNDg1OTQ_f6b1df19-4f52-4dcf-9d44-4028a25eddd8">185,848</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.379%"><tr><td style="width:1.0%"></td><td style="width:70.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfMi0xLTEtMS00ODU5NA_0420dd7d-2abd-4442-b772-054d3125c647">137,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfMi0zLTEtMS00ODU5NA_eabb4d63-bbfd-48dc-9d57-cce85e22d1cb">90,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNC0xLTEtMS00ODU5NA_a1ba5fe9-ee74-41a2-ab4b-421742040d71">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNC0zLTEtMS00ODU5NA_06994001-2eab-4b4f-8f3f-deae8b6a5b9f">2,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNS0xLTEtMS00ODU5NA_e17f905b-b8cf-40c2-adfc-5625e27fa927">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNS0zLTEtMS00ODU5NA_a5bce057-a97e-4ad0-9560-6f18360b216b">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNi0xLTEtMS00ODU5NA_4403548e-1154-40e5-bbb1-6ed325650d22">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNi0zLTEtMS00ODU5NA_a4b6de49-c0f0-4939-86c2-abbece5c7981">2,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNy0xLTEtMS00ODU5NA_46af24b0-7501-4cde-b644-b5448f071c01">135,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNy0zLTEtMS00ODU5NA_04f4e934-5d56-4be0-8e3a-b51fc9ae04bb">92,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13b6287af2fb458e9dabde17f604aeb5_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS0xLTEtMS00ODU5NA_5383354a-de77-4452-a930-ce11e5a8c12a">185,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b6287af2fb458e9dabde17f604aeb5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS0zLTEtMS00ODU5NA_7273d405-ec92-4f81-bd46-7a452026af0c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3795d80c499a47ffb23780f216279dd5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS01LTEtMS00ODU5NA_c3b7a8dc-95e2-4fab-87f3-3d8c9f4487a3">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8558d20a9404b2b9666d7e7ac9e04e3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS03LTEtMS00ODU5NA_14edd90c-19a3-41df-aa7e-3881c4bb3f28">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea9c049960c045d389ad24714ff388b2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS05LTEtMS00ODU5NA_f464b062-18e7-4763-8dee-3ab89d2e419a">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35b840456e243088bc83a33ff9929d1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS0xMS0xLTEtNDg1OTQ_12c6a719-bd2d-4868-959e-0864d9560b60">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fb94b83c0574f40994d258fd6f726ac_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMi0xLTEtMS00ODU5NA_d2dc22b2-cb2a-4701-a2e0-9fe2cfa7c839">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a2bdc6f20b4830a5391065713122ea_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMi01LTEtMS00ODU5NA_cb3babe0-067e-41c5-ad53-a5e647ad2f12">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMi0xMS0xLTEtNDg1OTQ_c13d72e2-994c-44a9-afd5-3b2c1b68bcb1">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a2bdc6f20b4830a5391065713122ea_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMy01LTEtMS00ODU5NA_a0f4f0f6-7b2e-49ca-ab35-043a46156a4b">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMy0xMS0xLTEtNDg1OTQ_a77b4872-6eac-4cae-b449-a671ed9c18b2">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6bd69c0c70945bea566d50bd61df2c8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNC03LTEtMS00ODU5NA_2c59e4c7-52bc-41b1-8e86-53d1f4581df1">2,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf4df987b0bc42539160068723e3c35b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNC05LTEtMS00ODU5NA_12cb17ac-46c1-4f3f-8ba7-5bbffda62cef">90,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNC0xMS0xLTEtNDg1OTQ_837a78b7-823f-452b-a284-7b2f7af05f76">92,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dc70df4b4d8449992572edf6df98bb6_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS0xLTEtMS00ODU5NA_1261988a-512d-40bf-83a5-e21ae990f4e8">186,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc70df4b4d8449992572edf6df98bb6_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS0zLTEtMS00ODU5NA_3fd175cf-f14b-4a80-b22e-9c4e3c414441">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2a84be71ba453bb40cfd7c3b534a9e_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS01LTEtMS00ODU5NA_65305bfb-10d9-465e-93f9-38650233f440">3,537,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04ab4c4b6c284ad3a661dc38dc01e5f9_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS03LTEtMS00ODU5NA_28ce042c-e3fb-406d-9967-c1d65785bafa">6,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8361cd8a1de744a594fc0cdb561e6003_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS05LTEtMS00ODU5NA_a67d0ec0-9d11-4363-a8d9-47466271eda8">2,923,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c43dfae2834078a893893586390205_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS0xMS0xLTEtNDg1OTQ_3ecd4b8c-ba8c-41ab-bd50-1d90048f1a42">607,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95ac92307e2549dd9ec0c7643db84d0a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS0xLTEtMS00ODU5NA_9c436482-1b7e-4ce6-9161-c8505e332868">188,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ac92307e2549dd9ec0c7643db84d0a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS0zLTEtMS00ODU5NA_0cc8b874-0870-4db0-a6e8-4c26f4eb27bd">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f442d205bc45afbe1def2527c44fee_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS01LTEtMS00ODU5NA_09a0c13e-7993-41e9-b7c8-4d6704976a1a">3,574,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2adc2069cb43649c5971f223b18c65_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS03LTEtMS00ODU5NA_23004611-2724-4012-a25d-252efe76b1c3">6,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b935c9a9f6e4254978f843e88b6b14e_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS05LTEtMS00ODU5NA_e41e06ec-11e2-4988-a4dd-707d2ff1a50e">3,201,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS0xMS0xLTEtNDg1OTQ_9bcdc6b3-8af2-4860-8214-eccf68d30785">366,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5464511d66984607836e04c3376ea0a2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMi0xLTEtMS00ODU5NA_14442ead-83f4-4ca5-a25a-43800bb21bcc">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f798d53e2a645d9a4273b63d8030705_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMi01LTEtMS00ODU5NA_591743c0-4273-47fd-90f1-d0d6ad318a37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMi0xMS0xLTEtNDg1OTQ_6479df77-619f-4904-b555-4cc2fe9c6138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f798d53e2a645d9a4273b63d8030705_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMy01LTEtMS00ODU5NA_26bc1e5f-ca94-4230-bee2-bc7830fa13b2">10,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMy0xMS0xLTEtNDg1OTQ_262e9bc8-9b47-4c85-bdc4-e4d33f357101">10,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37de0bff6b41411ba350a255586c2c82_D20230101-20230331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNC03LTEtMS00ODU5NA_ef87913d-60ac-4771-969b-c6a800240dea">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i556866edd8b5476d870f3d0567b42572_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNC05LTEtMS00ODU5NA_e2be5130-cef1-4c4b-812d-0ff5f704915e">137,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNC0xMS0xLTEtNDg1OTQ_6a0a8f0a-63af-4045-b7f4-ebfb7103d9f6">135,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id08bf37b20de42a79a37455e0a5403db_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS0xLTEtMS00ODU5NA_744997cd-afa2-4ed0-bb44-874ff75463c7">189,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf37b20de42a79a37455e0a5403db_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS0zLTEtMS00ODU5NA_48231cc4-c72a-411d-aac0-502fd15df43d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e12e371ab794958bf783671a51d9a9b_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS01LTEtMS00ODU5NA_9061a569-0cfe-4ece-9253-fc41fc7f0854">3,584,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9901f8efb7a84fd383997f807d327718_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS03LTEtMS00ODU5NA_f9e5d9df-1e73-4bbf-a8d0-a2a49a37ee95">5,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id65e32b44a5744e18b29a445360764ac_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS05LTEtMS00ODU5NA_1902a867-8c4e-419a-b1fe-f6f4b7fbc993">3,338,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS0xMS0xLTEtNDg1OTQ_64812398-416b-45aa-99a1-f304a97fe072">240,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMy0xLTEtMS00ODU5NA_80669d1d-6cc0-4482-b060-51258d4db49c">137,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMy0zLTEtMS00ODU5NA_943d0a7c-71b2-4dd3-b79b-8da682b43134">90,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNS0xLTEtMS00ODU5NA_fb5a290f-b83f-4ae7-a847-c6aacf891469">16,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNS0zLTEtMS00ODU5NA_a5a2d0c0-2ea3-4f7f-b43f-f0ee6233b614">17,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNi0xLTEtMS00ODU5NA_6629ba6a-917b-44ee-80f8-3d8ff81ee7c4">6,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNi0zLTEtMS00ODU5NA_f499d520-b359-4fdc-9c5d-1293d571516b">7,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNy0xLTEtMS00ODU5NA_f301c851-40ec-45de-a102-86206114d6f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNy0zLTEtMS00ODU5NA_2141c3de-580b-493e-9fc0-e15bcd1dbff2">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOC0xLTEtMS00ODU5NA_9e99db16-9958-4a59-82a9-75c4a357db2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOC0zLTEtMS00ODU5NA_59930016-3619-40e5-8404-381a5dc0644e">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOS0xLTEtMS00ODU5NA_bfd40287-6e45-49de-a7a0-17259689f676">10,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOS0zLTEtMS00ODU5NA_dde8efcc-feca-4fc2-b169-959f4cd65294">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTAtMS0xLTEtNDg1OTQ_4302b71e-4cbb-4241-8581-76913a924530">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTAtMy0xLTEtNDg1OTQ_92cec53d-4f32-47b9-b824-8909ce967870">3,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMS0xLTEtNTQ5MzI_b4e82d17-618f-4bd5-8d34-b4850939a4e5">1,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMy0xLTEtNTQ5MjI_642c8719-e5b7-46d1-a649-cb15f6a01f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMS0xLTEtNDg1OTQ_93deb2b5-4ba6-4804-bf7d-7557c71de635">13,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMy0xLTEtNDg1OTQ_3805df17-7ec6-4a3e-8b12-23f5e11942d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMS0xLTEtNTI4MjI_ed771787-d9e7-4340-9a48-aa81e047da9a">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMy0xLTEtNTI4MTQ_4655fa77-9b40-48dd-8b12-ded4f403624a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMS0xLTEtNDg1OTQ_2c26db4c-64da-4530-95f8-e97409805522">3,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMy0xLTEtNDg1OTQ_304eb500-b8e7-43ff-b380-664c36aa3114">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTQtMS0xLTEtNDg1OTQ_da2346a2-5337-41c2-84b6-e571167c94bd">2,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTQtMy0xLTEtNDg1OTQ_75f55c9c-0c92-4f33-985a-98bc820ad245">7,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTUtMS0xLTEtNDg1OTQ_505a178b-a7dd-44d5-807f-2e40c32dc70d">1,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTUtMy0xLTEtNDg1OTQ_02c001be-e925-4696-84aa-f06c0405b0a2">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTYtMS0xLTEtNDg1OTQ_c4eae026-c72b-4457-b72d-43146ca17418">1,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTYtMy0xLTEtNDg1OTQ_997941eb-18d4-4c41-aa3e-f7d3706e37b6">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTctMS0xLTEtNDg1OTQ_d88a0b0e-b3f7-4c6a-a8f8-77569fff2f93">5,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTctMy0xLTEtNDg1OTQ_09b2313e-9a39-4e56-9b69-739a39b32122">2,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTgtMS0xLTEtNDg1OTQ_091e4a55-bf63-4902-9362-7886c76328e8">8,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTgtMy0xLTEtNDg1OTQ_0838caa5-7acb-4b30-81e6-04b3524fec87">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjAtMS0xLTEtNDg1OTQ_cd6684ab-3ee6-49b6-945e-fc7de1ca1bf1">1,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjAtMy0xLTEtNDg1OTQ_46381562-4b8a-4504-80bb-210c5d9e5f27">14,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjEtMS0xLTEtNDg1OTQ_3988cd3e-111b-46a6-a32d-efcf7f4b6f40">51,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjEtMy0xLTEtNDg1OTQ_cd3d659e-2720-48df-86b2-f910ed03482a">88,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjMtMS0xLTEtNDg1OTQ_d7852be5-5062-4943-8a1a-711eaa44ccaf">107,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjMtMy0xLTEtNDg1OTQ_387df5f5-b977-4ce2-b8d0-18ae39ebb461">93,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjQtMS0xLTEtNDg1OTQ_c486c6a1-3b61-41f9-a545-fc903dd72e42">148,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjQtMy0xLTEtNDg1OTQ_472944b9-df65-45e6-a968-b98b92785e5d">227,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjYtMS0xLTEtNDg1OTQ_4a5f0324-1243-4736-8e27-0a90699c1f2f">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjYtMy0xLTEtNDg1OTQ_68743085-35da-4463-8628-9da7cd099581">4,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjctMS0xLTEtNDg1OTQ_f5f799a6-cc79-4b7b-be99-3d7d2cc1f015">40,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjctMy0xLTEtNDg1OTQ_0e1c1a35-44da-4496-b6f9-3933653a88ce">130,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjktMS0xLTEtNDg1OTQ_6f109dac-4a8e-4fb0-be7e-203ed668dc77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjktMy0xLTEtNDg1OTQ_2fda837e-9445-491b-96c9-9c1c5ff1e2c5">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzAtMS0xLTEtNDg1OTQ_2aedd267-bc23-493b-9c7c-3b0a187d1c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzAtMy0xLTEtNDg1OTQ_d427e19f-6825-42c2-a147-0085f10676d6">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzEtMS0xLTEtNDg1OTQ_e573d2df-4cca-4eb1-9065-c14b56cb7325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzEtMy0xLTEtNDg1OTQ_20a57099-09de-4155-b09f-a30c756869d9">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzItMS0xLTEtNDg1OTQ_01ba43bb-1c05-45c5-85e1-dba1d621499d">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzItMy0xLTEtNDg1OTQ_a579a3ce-fc69-4974-a673-804cd30a9eb4">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzMtMS0xLTEtNDg1OTQ_28a35e7e-3005-4f58-9a09-8852909348b8">11,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzMtMy0xLTEtNDg1OTQ_cfd2cc7a-a34c-444e-918c-9836a876daa2">42,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzQtMS0xLTEtNDg1OTQ_e19e6465-f405-4c94-ba6c-3edad0923819">88,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35b840456e243088bc83a33ff9929d1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzQtMy0xLTEtNDg1OTQ_e5c3e9a6-1b19-45a9-8e72-eaff92877b4a">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzUtMS0xLTEtNDg1OTQ_3c23651f-e94a-42ad-a95d-bb46994587f2">76,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c43dfae2834078a893893586390205_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzUtMy0xLTEtNDg1OTQ_32eb45b5-7bc3-4302-8210-ecc59eee122a">67,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2023</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzA_122049d5-7081-4266-ac6a-f2be8a145960" continuedAt="i40091c51120440eaa700b59c4561ab77" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i40091c51120440eaa700b59c4561ab77" continuedAt="i291d05653b14461b9b3ef62b58b64610"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzI_17e3ee8c-81bd-488f-b500-c6afefbb4562" continuedAt="i2857baf78c5d4c08b2f6687671e7eeee" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in the field of immunotherapy.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2857baf78c5d4c08b2f6687671e7eeee">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> As of March&#160;31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-5" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTA1Nw_8a14b548-7cd9-419c-8452-356b687cf27e">456.8</ix:nonFraction> million in cash and investments in marketable securities.</span></div><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Nzg_ea7fbd21-be4a-4a6e-b567-41a44c8298c8" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Clinical Trial Programs and the Restructuring Plans</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced that our registrational trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma, renal cell carcinoma and locally advanced or metastatic urothelial cancer under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS) did not meet their primary endpoints. Based on these results, in April 2022, we announced our decisions to discontinue all development of bempegaldesleukin in combination with checkpoint inhibitors, including these trials, our registrational trial in adjuvant melanoma under our BMS Collaboration Agreement, and our Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 5 for additional information regarding our BMS Collaboration Agreement and Co-Development Agreement with SFJ Pharmaceuticals. Pursuant to the Strategic Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan), pursuant to which we we completed an approximately <ix:nonFraction unitRef="number" contextRef="i7697166d42e141bd9a7bbec30e8e7d48_D20220401-20220430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODc5NjA5MzA1MTg5MA_6df7beff-c24d-4ebb-8523-209d4e0cfd48">70</ix:nonFraction>% reduction of our workforce during 2022 and sold our research facility in India in December 2022.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study) under our collaboration agreement with Eli Lilly and Company (Lilly). Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to plans approved by our Board of Directors (the Board) on March 29, 2023, we announced on April 17, 2023, a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we are reducing our San Francisco-based workforce by approximately <ix:nonFraction unitRef="number" contextRef="ief4395c62e394de284ed9e69496b6151_D20230301-20230331" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMzg0ODI5MDcyNTYzOA_e4874e19-d13f-4899-83aa-c08ae1eed4a5">60</ix:nonFraction>%, which is expected to be substantially completed by June 2023.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to incur significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 6 for additional information on the effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Nzk_89d66852-e590-412e-b47c-5431fa36eb1e" continuedAt="i89cb6d96c57f473e83d6f4ef35f32af4" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="i291d05653b14461b9b3ef62b58b64610" continuedAt="ia6909ea4e90c4a8394e7532fbeac5cbd"><ix:continuation id="i89cb6d96c57f473e83d6f4ef35f32af4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2022 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 filed with the SEC on February 28, 2023. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:continuation><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Njk_56e2df1f-a481-4d23-92c0-f40747a8bce9" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzU_2b7cef1e-71ad-4a96-b790-74f5e9dbd5a6" continuedAt="ida54d68abab140679b1f983916b11bab" escape="true">Significant Concentrations</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida54d68abab140679b1f983916b11bab" continuedAt="if9e15778d771442ca56995eca6c10b29">Our customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. </ix:continuation>We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have <ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODQwNw_e42d459a-597b-48a6-aa18-69cf332ae4de"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODQwNw_f6719913-a98c-47de-9791-9c6b306582d9">no</ix:nonFraction></ix:nonFraction>t experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the three months ended March&#160;31, 2023 and 2022, nor have recorded such an allowance as of March&#160;31, 2023 or December&#160;31, 2022.</span></div><ix:continuation id="if9e15778d771442ca56995eca6c10b29"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div></ix:continuation><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Nzc_f3e4e36e-63a7-438b-a0cd-fdfb8d32b71b" continuedAt="i97aa347010034bc99424625ff1315679" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="ia6909ea4e90c4a8394e7532fbeac5cbd"><ix:continuation id="i97aa347010034bc99424625ff1315679"><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated,</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms, and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.</span></div></ix:continuation><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfNTQ5NzU1ODM4NjIx_37a7245a-ee8f-4f39-88de-69d01d198c9c" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit&#8217;s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information regarding the impairment charges we recorded in connection with our goodwill.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzM_f644b704-4fee-4bc5-b9eb-2a7fa1774a2b" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfNDM5ODA0NjUyNjU3MQ_53f1b5e7-a3cb-40e2-aee1-cb4b9ae41f07" continuedAt="i5b48a7bced8e4046b9cff41d96975fdf" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b48a7bced8e4046b9cff41d96975fdf">  For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share.</ix:continuation> We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), which totaled <ix:nonFraction unitRef="shares" contextRef="i69e3a6b241b64c388617839ca0e84f74_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfNDM5ODA0NjUyNjU3MA_4682982c-4493-49d5-a325-a86035c671bd">22.8</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="ic91f661d01a94c13b05ca1bffece360b_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODc5NjA5MzAzNzY2MA_4e6b619c-d39f-4f87-a4eb-cdb27bdd397d">22.3</ix:nonFraction>&#160;million for the three months ended March 31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfODE1_ac0bed6f-c6be-4f2d-b7b0-a35b6b986e96" continuedAt="ie974a49caeee410ebb0590820c2f9df8" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ie974a49caeee410ebb0590820c2f9df8"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfODE3_eca6adc1-a689-429d-8d57-1d3003b17da4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMi0xLTEtMS00ODU5NA_5217d5ff-903e-403e-a8c8-2d1a96b1a7df">76,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMi0zLTEtMS00ODU5NA_e22680a3-b577-475f-8283-ce28a4a21262">88,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMy0xLTEtMS00ODU5NA_23254b28-a850-4d85-b31e-0ff400061ba8">379,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMy0zLTEtMS00ODU5NA_4bebc599-e074-4e68-af35-5124c1e886f8">416,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfNS0xLTEtMS00ODU5NA_5da5fd40-d878-435c-90b1-ab91c26487a5">456,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfNS0zLTEtMS00ODU5NA_d047ab9a-2e3b-41ec-9508-55a79f4a6baa">504,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfODE5_cb7f4bb2-2bd0-482c-93f6-f1d1b248d0ce" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi00LTEtMS00ODU5NA_d1d64dd9-c138-4f34-8d6b-cd48adfbeeee">60,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi02LTEtMS00ODU5NA_f3982855-ed98-4731-adf8-82d0361e38f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi04LTEtMS00ODU5NA_8199f73b-d6ef-4d18-9f64-d9fb4ecb3b14">271</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi0xMC0xLTEtNDg1OTQ_d93bc911-1abc-4b06-b274-31085a390775">59,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b1ea2c25240e78087bc3f10b8ba5f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi0xMi0xLTEtNDg1OTQ_d0703ed1-6ad1-47ed-9134-02191fa22bb7">83,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy00LTEtMS00ODU5NA_43b20137-82fe-4e57-8dc1-215d9b0c4330">298,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy02LTEtMS00ODU5NA_39c0ab79-03d7-46c7-96b3-9814eba3cc56">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy04LTEtMS00ODU5NA_3aaec605-9604-4881-88bc-00657e873c11">421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy0xMC0xLTEtNDg1OTQ_3650f26e-fb98-4b41-a8f7-99b0740acf1e">297,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a68493d157c4d499d9c6cfe4dbcd7c1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy0xMi0xLTEtNDg1OTQ_13533ccf-e7aa-4e08-a880-db012e81681b">344,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC00LTEtMS00ODU5NA_bcc200ef-faa6-4a36-8a23-f010662406b3">16,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC02LTEtMS00ODU5NA_4bd1f22a-5eec-454e-881d-d3fef43b4dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC04LTEtMS00ODU5NA_c08f5016-ec3e-4a82-8c13-23cfaf7531ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC0xMC0xLTEtNDg1OTQ_fb3e72e8-c975-417a-9a71-12636cdfd2a3">16,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b17d6fbf5d49d1827a4d756e9436ee_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC0xMi0xLTEtNDg1OTQ_d66378a6-cdb0-4c97-a201-8ac68fbcc894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS00LTEtMS00ODU5NA_df7cfcc2-79f3-487f-9bdb-56c2ed32579d">375,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS02LTEtMS00ODU5NA_bc795709-c6ff-4dab-8219-5df60e846d67">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS04LTEtMS00ODU5NA_0e799508-ecbc-4c48-a137-206577a810f3">692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS0xMC0xLTEtNDg1OTQ_78684afa-82f7-4421-b14f-671523165186">374,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8adc60ceae453793ca7d4b82bd2863_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS0xMi0xLTEtNDg1OTQ_c1b5ea38-6b2d-416d-8ad7-09dcadeb07e5">427,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73846d6859c748ad9e0bcaec151a95db_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNi0xMC0xLTEtNDg1OTQ_31c10e1e-ff28-4b8e-9a87-4e16221b7203">48,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9a2d6862b34886bc6eb8bd085e313d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNi0xMi0xLTEtNDg1OTQ_f67db87e-625b-4aee-83aa-30efb41d9273">47,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdbb7c8346d54dc6ab904f9d8a1cfa32_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNy0xMC0xLTEtNDg1OTQ_42678f49-6aa7-45ca-ab86-762f462f284c">7,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0cde2ed24ec4607bb959fcc112e1fa8_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNy0xMi0xLTEtNDg1OTQ_ca3e4bee-5fdc-4b36-85bb-72105d28a1b9">21,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOC0xMC0xLTEtNDg1OTQ_2bcf394d-2db3-4316-800e-f67abfa813f7">26,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOC0xMi0xLTEtNDg1OTQ_c9f83f5a-4d6d-4111-b5c7-c730ae3ebe72">8,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOS0xMC0xLTEtNDg1OTQ_a54b152f-2518-44f9-8d64-d84c9622453c">456,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOS0xMi0xLTEtNDg1OTQ_9be43e67-e208-4f99-9312-396e630d0468">504,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2022, our gross unrealized losses totaled $<ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfNzYx_6742f9d9-25b9-4b0c-8f4d-d880612d9588">1.8</ix:nonFraction>&#160;million, and our gross unrealized gains were insignificant.</span></div></ix:continuation><div id="i53ffcfe41df94c13bfe514c5b23d1b65_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODQ1_e53d4ee7-4c8b-4bfb-8a6b-33b2b3bfccb7" continuedAt="if9a8275d66f341c58e8e6228f441d310" escape="true">Condensed Consolidated Financial Statement Details</ix:nonNumeric></span></div><ix:continuation id="if9a8275d66f341c58e8e6228f441d310" continuedAt="i5270c96b3d8e4976a7438abd12cdb254"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODQz_4fffa539-0d27-4860-96a4-3c2eb0c19335" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMS0xLTEtMS00ODU5NA_9632621c-0591-400c-aebb-678e4da1c1cb">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMS0zLTEtMS00ODU5NA_ca0e90bb-bbb5-4f96-8bfb-1b219773ddc7">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMi0xLTEtMS00ODU5NA_27da6400-9ba9-4f30-a980-ee26c1851d5e">13,167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMi0zLTEtMS00ODU5NA_0c284ea0-d754-4087-bd0f-74bea2aaba30">10,749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMy0xLTEtMS00ODU5NA_b130e0b7-ba9f-4266-91fb-cac19b8fab8a">4,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMy0zLTEtMS00ODU5NA_a9178790-23af-4dbe-b513-7e4f0050c71d">5,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfNC0xLTEtMS00ODU5NA_e6eeb25b-fe88-49a8-9ec5-f33234336482">20,235</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfNC0zLTEtMS00ODU5NA_29bbe36e-b6b4-4bad-8d83-4b35bd6b3a45">19,202</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODQ0_4e6a6fef-aa41-4f4f-ac27-5ad5b8de9125" escape="true">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="i5270c96b3d8e4976a7438abd12cdb254" continuedAt="ic8f6537fc7cb4050a979b4aa82320449"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTYyOA_a74a4fc1-b54c-43f1-9170-5bba59d7517b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c7d7f6cfef46afa7d17a7648fa22d6_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0xLTEtMS01MTIwNA_555b8657-f533-464a-bb2a-55a9c1849367">69,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddd871d7e454404902df8e801682458_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0zLTEtMS01MTI0Nw_5701ead3-dc04-4678-bec0-de909f2cf248">74,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7135b84ff3e4425b84bf50f571ac57ce_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0xLTEtMS01MDIzOA_5f4e2a39-aad3-4745-97ba-3134f8b570c7">24,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i032e78f5ed7c4d648dc75900dc5651df_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0zLTEtMS01MDIzOA_291ea3d2-a8b8-435c-a90c-7947ea486857">26,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7ef44e372d4c86842156ea38bc9a05_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMi0xLTEtMS01MTAxMw_27c297b2-c184-4b75-91e4-373702c0e377">25,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6aa244acf4d42e5af8f92393337c196_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMy0zLTEtMS01MTI4MA_4c8b8a1c-10e8-43e3-b0c8-bec44911ed8b">25,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac97bb571c524e1ea1a69c1042cdf6ff_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMy0xLTEtMS01MTAyMg_fc070b0c-5a1b-4fbc-82f4-06ec55b1e71b">13,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557700c0d761400a82e19e7b49256e39_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0zLTEtMS01MTI2Nw_0c1392a1-faf4-4704-a0c8-b7851345c339">24,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a52bcfffe64473afd94d1ad70a2304_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0xLTEtMS01MTA1Ng_e4238f29-4ac0-40cf-b354-ae2c13742091">3,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i825095a4840447b1884c349d7a55b45d_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNS0zLTEtMS01MTI4OQ_ab1ef332-8fb3-4e40-83b3-51feb12d404a">4,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNi0xLTEtMS01MTIyMQ_29a6faaa-a692-4a3d-8b13-ff0e000c113d">136,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNi0zLTEtMS01MTMwNQ_b6d5ae4e-adaf-457e-b77d-3206ebd36fc6">154,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNi0xLTEtMS01MTA4Mw_638bc908-f170-4c2a-8812-0093b9425a1c">110,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNy0zLTEtMS01MTMxMw_4e33bb8f-9414-4b56-91cb-06100a740b55">124,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfOC0xLTEtMS01MTIyOQ_a39a83cd-cc50-4b06-9dca-ef8df27f080c">26,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfOC0zLTEtMS01MTMyMQ_13e5a2a3-264c-47a3-9862-ffd02c152e3e">29,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMi0xLTEtMS01MDIzOA_feec51b0-d8b0-4d6e-9a58-e5e898784007">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMi0zLTEtMS01MDIzOA_d218e596-d19e-4e32-9f56-38286ec3941b">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0xLTEtMS01MDIzOA_effdb983-00e4-4229-8b1e-35132d1b8009">27,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0zLTEtMS01MDIzOA_927687f0-6551-45d5-a3df-03acc2f0f3a5">32,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the decrease in the fair value of our single reporting unit during the three months ended March 31, 2023, we recorded a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODc5NjA5MzAyNjcyNQ_ffdd8507-b3e9-49d6-bcee-feede323bd54">3.5</ix:nonFraction>&#160;million for property, plant and equipment, which we report in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. See Note 6 for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTYyOQ_a1888878-68d4-4351-9ad1-3ecb9e768f99" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the changes in our goodwill for the three months ended March 31, 2023 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:84.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill &#8211; beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjg1NGE4OTBjNzUzZTRkN2Q5ZWU5NDA3NDdiMzE2YTc1L3RhYmxlcmFuZ2U6ODU0YTg5MGM3NTNlNGQ3ZDllZTk0MDc0N2IzMTZhNzVfMS0yLTEtMS01MjczMg_92f3261f-1560-4995-9f40-5a0afbb1c48f">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjg1NGE4OTBjNzUzZTRkN2Q5ZWU5NDA3NDdiMzE2YTc1L3RhYmxlcmFuZ2U6ODU0YTg5MGM3NTNlNGQ3ZDllZTk0MDc0N2IzMTZhNzVfMi0yLTEtMS01MjczMg_a4d27058-1147-491d-a9b6-6ec2b75f866b">76,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill &#8211; ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjg1NGE4OTBjNzUzZTRkN2Q5ZWU5NDA3NDdiMzE2YTc1L3RhYmxlcmFuZ2U6ODU0YTg5MGM3NTNlNGQ3ZDllZTk0MDc0N2IzMTZhNzVfMy0yLTEtMS01MjczMg_f69837d3-43eb-478c-a203-d21d79ef3992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the decrease in the fair value of our single reporting unit during the three months ended March 31, 2023, we recorded a non-cash goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfMTA5OTUxMTYzMjE4Mg_b8c1863d-30b9-4205-8e90-ecc2044496fc">76.5</ix:nonFraction>&#160;million, which we report as impairment of goodwill in our Condensed Consolidated Statement of Operations. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. See Note 6 for additional information.</span></div><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTcxNQ_9b5804cf-bc08-44f7-bb0b-67a0e8bfef60" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0xLTEtMS01NDU1NQ_f3c70ed4-4fe5-49ad-8364-bcc112be9cba">14,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0zLTEtMS01NDU1Nw_9118d5cc-d5aa-4fd3-931f-d42f71f31a27">9,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0xLTEtMS01Mzg1NQ_7d85384e-c2c1-4404-9ccb-001c7d3efda5">7,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0zLTEtMS01Mzg1NQ_a6290324-b82b-4320-8670-edfcc568f089">12,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability to collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:LiabilityToCollaborationPartnersCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMy0xLTEtMS01NDU1OQ_231aefd4-3051-4607-9d00-5eb8115a49fd">3,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:LiabilityToCollaborationPartnersCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMy0zLTEtMS01NDU2MQ_a2c87c03-4188-41f1-a707-76cf49870aba">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract termination costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:AccruedContractTerminationCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNC0xLTEtMS01Mzg1NQ_f527f909-9589-475f-977e-dabd5cb26dbd">3,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:AccruedContractTerminationCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNC0zLTEtMS01Mzg1NQ_43ec4c3c-5c6e-4551-9273-3f4cdf1a1d44">3,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNS0xLTEtMS01Mzg1NQ_fb0c7504-ba98-462e-8a83-a037a0c0be06">7,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNS0zLTEtMS01Mzg1NQ_f4bf8f72-e24c-4812-9e12-625087ef155b">7,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNi0xLTEtMS01Mzg1NQ_4c538f63-8973-459b-a3d2-60b4186ecd10">37,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNi0zLTEtMS01Mzg1NQ_324557e9-f7e7-4e98-9ca3-05443b0e1c6a">36,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="ic8f6537fc7cb4050a979b4aa82320449"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liabilities Related to the Sales of Future Royalties</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively. We account for these transactions as debt and recognize non-cash royalty revenue and non-cash interest expense to amortize the proceeds over the lives of the respective arrangements. We periodically update our prospective non-cash interest rate based on our estimates of future royalties. As of March 31, 2023, our imputed interest rates for the arrangements with RPI and HCR were <ix:nonFraction unitRef="number" contextRef="i66e54efca0a94e31868b7e6b05760280_I20230331" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODc5NjA5MzAyNDk1Ng_fca04cb4-8d2e-4d41-92df-ca648dbcd003">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4b13a843a33e4bc08464584072e4b021_I20230331" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODc5NjA5MzAyNDk2NA_7c523e30-240f-40e0-b7ab-cebc899a586b">20</ix:nonFraction>%, respectively.</span></div><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTYzMg_c2507a5a-a355-4fe5-95f6-09c8afdc31fa" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net &#8211; beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec325a50f7844edda0d300d4f35dafa2_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMi0xLTEtMS01MDI4NQ_67ea50cc-9ce4-483e-961a-5770e3ed04af">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ac5fe1f84b4a0b91a45b1c7657c57d_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMi0zLTEtMS01MDI4NQ_64cc1739-a19e-4074-b652-ef6bfe63bf0d">100,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMi01LTEtMS01MDI4NQ_479c5e52-e8ed-41c6-bfc8-97e70f271899">155,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMy0xLTEtMS01MDI4NQ_30024f2a-1b70-4a82-9414-5366c360a128">9,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMy0zLTEtMS01MDI4NQ_e1215c5c-0435-4037-b5a6-41e3e5f3e55d">7,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMy01LTEtMS01MDI4NQ_62eb37af-ce18-4367-829b-8fa958436cac">16,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNC0xLTEtMS01MDI4NQ_9a521847-f677-41dd-8ad2-1186a872e7a5">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNC0zLTEtMS01MDI4NQ_f0fa6db0-2cc5-4a05-bbaa-f4bf09cce5b0">5,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNC01LTEtMS01MDI4NQ_5089519e-5b7d-487d-a847-cd082b8bdbd1">6,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNi0xLTEtMS01MDI4NQ_981dfb6e-c9f0-44cd-b2bb-84378b2e2560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNi0zLTEtMS01MDI4NQ_8aea7771-fe17-4293-9861-f5bda46b2abe">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNi01LTEtMS01MDI4NQ_1e7eeba2-5eb4-4253-b341-a0b7cbbde073">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net &#8211; ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e54efca0a94e31868b7e6b05760280_I20230331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNy0xLTEtMS01MDI4NQ_884db306-01fb-4335-a059-ce32703d8a5c">47,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b13a843a33e4bc08464584072e4b021_I20230331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNy0zLTEtMS01MDI4NQ_ca48214d-357d-428e-837d-2886d5f391b5">97,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNy01LTEtMS01MDI4NQ_66c081ef-f658-45fd-9a45-a62af642763b">145,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i53ffcfe41df94c13bfe514c5b23d1b65_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81NS9mcmFnOjA5MTg1YmEyNTFhZTQ4Zjg4ZmZjNWM1ZDhlM2YyNGQzL3RleHRyZWdpb246MDkxODViYTI1MWFlNDhmODhmZmM1YzVkOGUzZjI0ZDNfNDU5MA_bbeae718-46c5-44e0-8fe5-881d4ce850bc" continuedAt="i6fd50c991470477c9323157798afb88e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i6fd50c991470477c9323157798afb88e" continuedAt="ifbe5cd273cfb4e39ab634cb129da76e6"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2023, we and our directors were named in a putative class action complaint filed in the Court of Chancery of the State of Delaware. The plaintiff in this complaint alleges section 13 of our bylaws relating to stockholder action without meeting violates Delaware law and is therefore void. Upon service of this complaint, we will have twenty days to reply.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded <ix:nonFraction unitRef="usd" contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331" decimals="INF" name="us-gaap:LitigationReserve" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81NS9mcmFnOjA5MTg1YmEyNTFhZTQ4Zjg4ZmZjNWM1ZDhlM2YyNGQzL3RleHRyZWdpb246MDkxODViYTI1MWFlNDhmODhmZmM1YzVkOGUzZjI0ZDNfOTg5NTYwNDY1NjYwMg_a2e7fa75-a5ef-402b-84db-cd08a66a217b"><ix:nonFraction unitRef="usd" contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231" decimals="INF" name="us-gaap:LitigationReserve" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81NS9mcmFnOjA5MTg1YmEyNTFhZTQ4Zjg4ZmZjNWM1ZDhlM2YyNGQzL3RleHRyZWdpb246MDkxODViYTI1MWFlNDhmODhmZmM1YzVkOGUzZjI0ZDNfOTg5NTYwNDY1NjYwMg_f8dec868-e1cf-44bc-8115-4950334fd978">no</ix:nonFraction></ix:nonFraction> liability for any litigation matters in our Consolidated Balance Sheets at either March&#160;31, 2023 or December&#160;31, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifbe5cd273cfb4e39ab634cb129da76e6">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.</ix:continuation> </span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNDM5ODA0NjUxOTYxMQ_bf1935bc-b2bb-42a9-8b06-cece7b393633" continuedAt="icbc1e7d71d314e8c9161b21cc016d722" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="icbc1e7d71d314e8c9161b21cc016d722" continuedAt="i8e7aa4494dfd4f5ab4e76b85fad4d08f"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): Rezpegaldesleukin (previously referred to as NKTR-358) </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i49f42788641442cdad7182512b26d5e2_D20170723-20170723" decimals="INF" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzY2NA_73096ac4-7438-4be9-afb8-a60f6b2fa946">150.0</ix:nonFraction>&#160;million and were eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i7adb82d027d849da802db4b49a43ee2a_I20170723" decimals="INF" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzY5NQ_22a929f3-08ad-444a-9ba7-a455104ccb16">250.0</ix:nonFraction>&#160;million in additional development and regulatory milestones. The Lilly Agreement provided that, during Phase 1B and Phase 2 development, we would share development costs wherein <ix:nonFraction unitRef="number" contextRef="i0868cb5a09c844a796ffe2c4ecb34a5b_D20170723-20170723" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzcxNQ_4268448b-d00c-4ba2-8287-bcec79ca68e5">75</ix:nonFraction>% of the costs are borne by Lilly and <ix:nonFraction unitRef="number" contextRef="i49f42788641442cdad7182512b26d5e2_D20170723-20170723" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzcyNA_183b7a22-9a35-4c33-b2bb-dd0b2a213249">25</ix:nonFraction>% of the costs are borne by us. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). Although the Phase 2 Lupus Study did not meet its primary endpoint, patients who received the middle dose within the modified intent-to-treat population, defined as all patients who were randomized and received at least one dose of rezpegaldesleukin, demonstrated improvement in SLEDAI-2K score as compared to placebo. Nonetheless, Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2023, Nektar received from Lilly a notice of-at will termination of the Lilly Agreement. On April 27, 2023, we announced that we would regain full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 3, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="i7959c4e63c52467ca26c517b3783d65d_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTkyMw_430903be-3c7d-485d-853b-d82e96278f8d">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="iaf20dc9f8d6f48baa0bd1294dba2654b_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTk0Ng_5734b85b-31cc-45d4-807f-e699745e1905">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing and pre-commercial costs of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="icba9f64c9bff4236965a5e18df3794a6_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjA1MA_747d4210-03b1-4dae-84aa-3e8e39d01eb4">35</ix:nonFraction>% of the costs to BMS and <ix:nonFraction unitRef="number" contextRef="ib249192b630141c98908c973940137df_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjA3Nw_d0d79068-3ca9-4c5f-8eff-dbc96c3a6080">65</ix:nonFraction>% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i48302ef504774ac6a0914253d9ac0a95_D20180401-20180430" decimals="INF" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjIxOQ_92df7a1b-91ef-44ad-8e7e-b6de89132a1a">1.0</ix:nonFraction>&#160;billion and purchased <ix:nonFraction unitRef="shares" contextRef="i15412e5663004a80831838e6da60e1fe_I20180430" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjIzNg_1916b68b-03c4-401a-a2c3-184cee86fc54">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ib2debb833d9b47b6a265922060678a06_D20180401-20180430" decimals="-5" name="nktr:SaleOfStockConsiderationReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjM1MA_8d246f12-28af-4ca7-8ac1-bf11f3e695a2">850.0</ix:nonFraction>&#160;million. In 2020, we received additional non-refundable milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i17ff1e5d834349cfb697a5e4a5c4bbaf_I20201231" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjQxMg_fff5db9d-320d-4436-bbc3-26af5dc31ef1">50.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, in April 2022, we announced that BMS and we decided to discontinue all development of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. Pursuant to the BMS Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. Based on the cost sharing percentages described above, we recognized BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. As discussed in Note 6, beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring and costs of terminated program. The net reimbursement payable to BMS for the three months ended March 31, 2023 was not significant. For the three months ended March 31, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i2a9f83081651457596b4bbe97aaaa513_D20220101-20220930" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNDUwMg_e711e92f-3fba-4b0b-bffa-36cb695107a1">24.9</ix:nonFraction>&#160;million for the net reimbursement from BMS as a reduction of research and development expense.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="i8e7aa4494dfd4f5ab4e76b85fad4d08f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SFJ Pharmaceuticals</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $<ix:nonFraction unitRef="usd" contextRef="i248ad8f8306145d79a154379e4c144c7_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTA5OTUxMTYyOTA5NDk_4c91193d-c3c7-4ec2-9e59-4f1d1da30a7a">150.0</ix:nonFraction>&#160;million to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial). SFJ had primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we were the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $<ix:nonFraction unitRef="usd" contextRef="i248ad8f8306145d79a154379e4c144c7_D20210212-20210212" decimals="-5" name="nktr:CollaborativeArrangementSuccessBasedPaymentsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTA5OTUxMTYyOTE0NjU_d2da0378-cb8d-4ef2-afae-3fa46b653216">637.5</ix:nonFraction>&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin in up to three indications.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the SFJ Agreement as a derivative liability, which we remeasured to fair value at each reporting date. We recorded increases to the liability for non-cash research and development expense as SFJ conducted the SCCHN Clinical Trial and for cash receipts from SFJ to us to support our internal costs of conducting the trial. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to <ix:nonFraction unitRef="usd" contextRef="ia9c43dfae2834078a893893586390205_I20220331" decimals="INF" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTA5OTUxMTYyOTYyOTE_60f300d4-5eb9-4cb5-8b8e-1cdf33a9793e">zero</ix:nonFraction> as of March 31, 2022, and we recognized a corresponding gain in change in fair value of development derivative liability. In April 2022, we announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNDM5ODA0NjUzNjM1MQ_34f9f307-4deb-48b8-b160-fa3d9f7fdafb" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in the derivative liability for the three months ended March 31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c61fe105dd4f8ca0cb30e7ae9ca967_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfMi02LTEtMS01MDQ4NQ_230946b7-989c-40a1-bd64-6f1ac4ac41d6">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfMy02LTEtMS01MDQ4NQ_4327a393-4480-4eb9-8ac2-d400fbc9d7e4">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfNC02LTEtMS01MDQ4NQ_e6a33ac9-dc55-49bf-abd1-138b7baaff0f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfNS02LTEtMS01MDQ4NQ_bd27791c-e71b-40a5-91bc-8bb61690845d">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5256132357e4151bc701fffe762e23c_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfNi02LTEtMS01MDQ4NQ_c4717aa5-5300-4eb1-9191-f7a6f58aab96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 3, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue, which totaled $<ix:nonFraction unitRef="usd" contextRef="i6bff78a906cc446f9c38659e714a0991_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNzY3NQ_e85ad1a0-ed65-4492-8ef7-c7c66d1641cb">16.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i120490afb52049e28bacdb27bba440d2_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfODc5NjA5MzA0NzM2OA_722f4ce6-2df6-4578-85d5-4d1cfcedafac">17.6</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, represents revenue for granting licenses which we had satisfied in prior periods.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="ibe1d381685d046eb8df1f1376d3da9d4_I20230331" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfODAxNg_174025e9-0be8-430c-b41d-f7518c34b188">40.0</ix:nonFraction>&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfNjI2NQ_15e67658-0d2e-4b43-ab7c-f5fe3ce95779" continuedAt="i01e9a5a425654f2485c4c5f05be14143" escape="true">Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill</ix:nonNumeric></span></div><ix:continuation id="i01e9a5a425654f2485c4c5f05be14143" continuedAt="i0688bcada3894bcabe584948cecb56d3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Costs of Terminated Program</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 and 2023 Restructuring Plans, we report the following costs in restructuring, impairment and  costs of terminated program:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, initiated in 2022;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the 2022 and 2023 Restructuring Plans;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-cash impairment of right-of-use assets and property, plant and equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with these plans.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior periods through March&#160;31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. Beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Restructuring Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all development of bempegaldesleukin and wind down the clinical trials studying bempegaldesleukin. In April 2022, we announced the 2022 Restructuring Plan pursuant to which we completed an approximately <ix:nonFraction unitRef="number" contextRef="i7697166d42e141bd9a7bbec30e8e7d48_D20220401-20220430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA0MzM4Mw_6df7beff-c24d-4ebb-8523-209d4e0cfd48">70</ix:nonFraction>% reduction of our workforce during 2022. We also sold our research facility in India in December 2022 and decided to sublease certain of our leased premises in San Francisco, CA, including our office leased space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTM0NTg0ODg3MTMzOA_0f25516c-135f-4672-a25f-5d25ce42ad22" continuedAt="i0daba96f749f431eb4270ec1ce5588b9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program pertaining to the 2022 Restructuring Plan includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi0yLTEtMS01NDc2NQ_86530f71-6432-4374-90e5-4da6cc9baed5">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi00LTEtMS01NDc2Nw_e8d129e3-4a16-4d37-a7e1-90f1718c0489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331" decimals="-3" name="us-gaap:LossOnContractTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi0yLTEtMS01NDU4MA_6393b1e4-d4eb-4d12-9ccf-a925aa51853e">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331" decimals="-3" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi00LTEtMS01NDU4Mg_8cfad4cb-72c6-4c9e-910b-047bc2dd1d01">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMy0yLTEtMS01NDU4NA_6634853d-fb87-49fa-8f5a-c7e8a9280d02">2,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMy00LTEtMS01NDU4Ng_e6681cf9-cacf-4928-87f9-1587c3308848">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, restructuring, impairment and other costs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin. Through March&#160;31, 2023, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i87894f2d277d4d689189754384742bf3_D20220101-20230331" decimals="-5" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA2MDMyNA_1d42a444-c1bd-44fd-b3aa-23200b19bb27">11.8</ix:nonFraction>&#160;million cumulatively for contract termination and other costs for the 2022 Restructuring Plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, pursuant to plans approved by our Board in March 2023, we announced the 2023 Restructuring Plan to further reduce our San Francisco-based workforce by approximately <ix:nonFraction unitRef="number" contextRef="ief4395c62e394de284ed9e69496b6151_D20230301-20230331" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfMzg0ODI5MDczNDM2MQ_e4874e19-d13f-4899-83aa-c08ae1eed4a5">60</ix:nonFraction>%, which is expected to be substantially completed by June 2023.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:continuation id="i0daba96f749f431eb4270ec1ce5588b9" continuedAt="i004bda0407fd423284c92f349b6d4ae9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program pertaining to the 2023 Restructuring Plan includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfMy0yLTEtMS00ODU5NA_1dc22245-85b5-4aad-a025-cbde3562d62b">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfNC0yLTEtMS00ODU5NA_bd26e490-fd27-41cb-bfc4-b06f28cc4f68">13,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331" decimals="-3" name="us-gaap:LossOnContractTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfNS0yLTEtMS00ODU5NA_b8fd9544-c14d-47be-9f81-2852b0f28d2f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfNi0yLTEtMS00ODU5NA_3d4cc6ab-4c89-4f8b-a3f5-de0e3dd060f4">18,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="i0688bcada3894bcabe584948cecb56d3" continuedAt="i68adb63c65134f529c32c427f3ff97d1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Benefit Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under the 2022 and 2023 Restructuring Plans are entitled to receive severance payments and certain Company funded benefits. The restructuring charges are recorded at fair value. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2022 Restructuring Plan, we recognized severance and benefit expense in full for employees who had no requirements for future service when the 2022 Restructuring Plan was approved by the Board in April 2022. We recognized severance and benefit expense for employees who were required to render services to receive their severance and benefits ratably over the service period. This service period began on the communication date in April 2022 and was completed for all employees during 2022. We recognized $<ix:nonFraction unitRef="usd" contextRef="i54ea4f7910ee46acbba924e43878e0d8_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA1MTE4NA_587adc7b-f199-4255-b544-fa4d2bcf5194">30.9</ix:nonFraction>&#160;million in total severance and benefit expense during 2022 and paid the remaining liability of $<ix:nonFraction unitRef="usd" contextRef="iac1590dec7f141ddb038c9a92effcf1e_D20230101-20230131" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfNDM5ODA0NjU0MDgxMA_5972a09a-be3c-4b67-8a6a-98874ad5fdcb">3.3</ix:nonFraction>&#160;million in January 2023.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2023 Restructuring Plan, we recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="i997d98245f4048f997e82ffee6686137_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzQ3NA_3ed23136-3b74-4bf3-ae2a-1752064c8348">5.5</ix:nonFraction>&#160;million of severance and benefit expense as of March 31, 2023, reflecting severance and benefits which the employees had vested into and for which payment was probable and reasonably estimable as of March&#160;31, 2023. We expect to recognize an additional $<ix:nonFraction unitRef="usd" contextRef="if40ec0a96ce54f1bb18634012ce405b9_D20230401-20230630" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfNDM5ODA0NjU0MDgyNA_cd2feb38-2f95-46f8-8234-bf627ff4cf2d">1.9</ix:nonFraction>&#160;million for severance and benefit expense for the 2023 Restructuring Plan, primarily in the second quarter of 2023. </span></div><ix:continuation id="i004bda0407fd423284c92f349b6d4ae9" continuedAt="i558ca660e0074ca5b3377fc8dd41f939"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details regarding the severance and benefit expense for the three months ended March&#160;31, 2023 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three months ended March&#160;31, 2023, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Restructuring Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Restructuring Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20c572ba8d44958a9a79ca58b613c8d_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMi0yLTEtMS01Mzg5Nw_481dbdeb-0742-425e-a264-8e92762f284e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526526b23308431d88efcd30d4d1d51d_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMi00LTEtMS01Mzg5Nw_15a4441e-8b36-4ce6-b9e5-40796153d5ef">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85a2540650e49ff827fe78c21240f01_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMi02LTEtMS01Mzg5Nw_5a4aad6c-3450-417b-b216-ff269043f12c">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f8fac2f829451080ed7031388fb268_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMy0yLTEtMS01Mzg5Nw_17b1ff5f-9899-4248-88d8-c49d7b0966ee">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6620bfd483ba4ec1bd4a2ee734818286_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMy00LTEtMS01Mzg5Nw_90f6da24-0882-48ad-86f9-f61058a88517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997d98245f4048f997e82ffee6686137_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMy02LTEtMS01Mzg5Nw_90124466-0f3a-48a9-8f79-8bf5cd0631e2">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f8fac2f829451080ed7031388fb268_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNC0yLTEtMS01Mzg5Nw_bb74ec50-547f-45b2-a636-429ac54e5fb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6620bfd483ba4ec1bd4a2ee734818286_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNC00LTEtMS01Mzg5Nw_a81c6d6f-4b10-46e4-9059-94ae0ece99ef">3,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i997d98245f4048f997e82ffee6686137_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNC02LTEtMS01Mzg5Nw_4fbfc393-60db-4389-a568-097b14303d16">3,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7cadf538c2947f1b43fbef0ac736b9f_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNS0yLTEtMS01Mzg5Nw_51b82e85-c0c8-4bb1-876b-12b4ffd8208c">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb06267cb11c41e98b47d0d573f0e09a_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNS00LTEtMS01Mzg5Nw_84db282b-4791-421b-9eef-a4c3f830e4a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa6e43a4bdee434d8a2152922832b63a_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNS02LTEtMS01Mzg5Nw_c5eb03b9-dddb-4bdf-9062-422846a06aaf">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets and Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. Accordingly, we assessed our long-lived assets, including our property, plant and equipment, right-of-use assets and goodwill, for impairment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our impairment analysis, we first assessed which long-lived assets have identifiable cash flows that are largely independent of the cash flows of other groups of assets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that the long-lived assets associated with our leased spaces that we had previously decided to sublease under our 2022 Restructuring Plan continue to have cash flows that are independent of our entity-wide group. We concluded that these assets, for which we had recognized impairment charges during 2022, were recoverable based on estimated sublease income and therefore did not record any impairment charges for these long-lived assets for the three months ended March&#160;31, 2023. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated our remaining long-lived assets for impairment and performed a recoverability test using the undiscounted cash flows approach. We concluded that our net assets were not recoverable within the remaining useful lives. Accordingly, we estimated the fair value of the asset or asset group based on discounted future cash flows of the asset or asset group using a discount rate commensurate with the related risk. For the operating lease asset related to our Mission Bay facility, we estimated the fair value based on market participant assumptions, including the length of time to enter into a sublease, sublease payments, tenant improvement allowances and broker commissions, which we evaluated using current real estate trends and market conditions. We discounted the sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be <ix:nonFraction unitRef="number" contextRef="id695df1ce72740ec955bff4bb989faa8_D20230101-20230331" decimals="3" name="nktr:OperatingLeaseMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA0ODE3OA_8754093f-006f-4092-b89f-6a038b9a7f77">7.9</ix:nonFraction>%. As a result of this analysis, we recorded a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzUxMw_63179864-6c3b-4619-8d29-170ee7147440">11.5</ix:nonFraction>&#160;million. We also recorded an additional non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-5" name="nktr:ImpairmentLongLivedAssetHeldForUseOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzU0NQ_1fc27a6f-51b9-4e36-aa54-933acc8ae6ba">1.7</ix:nonFraction>&#160;million for certain laboratory equipment. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We report the aggregate non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzU3OQ_9e2bdbe3-0e8a-4b6b-a408-f8bdba79d13a">13.2</ix:nonFraction>&#160;million in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. <ix:continuation id="i558ca660e0074ca5b3377fc8dd41f939" continuedAt="i06ec2fd0da1b4b5a9e43f21521beea5a">The following table presents a reconciliation of the non-cash impairment charge we recorded for these long-lived assets for the three months ended March&#160;31, 2023 (in thousands):</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><ix:continuation id="i68adb63c65134f529c32c427f3ff97d1"><div style="margin-top:9pt"><ix:continuation id="i06ec2fd0da1b4b5a9e43f21521beea5a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired facilities before write-off</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ed89f1fe464363a9e387568ead9993_I20230331" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMi0xLTEtMS01MzkxMQ_5d4cb3f5-af0d-4597-8bb0-ce9c4a99c2c1">5,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3598e30999e54f9f9f575e5b881f2da3_I20230331" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMi0zLTEtMS01MzkxMQ_64f7e0a0-40ae-4a27-8105-96c2eda7da89">28,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55817a7194945f1ae4c0a8163778b09_I20230331" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMi01LTEtMS01MzkxMQ_1f5083c7-6c18-4124-956f-031028989cf2">33,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired facilities &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86a36c4159774aedad86844713f0d8bc_I20230331" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMy0xLTEtMS01MzkxMQ_a23575ce-4308-42cf-8dea-978ce0c88ede">3,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3677d6c99212474f8786bb289678a42c_I20230331" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMy0zLTEtMS01MzkxMQ_e2cc6eae-6182-4c1b-af65-37aaec3e53d7">18,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc2ab344bd4f4b498f29e789a11c1690_I20230331" decimals="-3" name="nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMy01LTEtMS01MzkxMQ_d3e56961-7382-455f-9060-ed8928c26ab6">22,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment expense for facilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNC0xLTEtMS01MzkxMw_1890228a-ccb2-4a81-a4c5-6e22e8ab94d2">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62ae4528157426aba132831bb9e3a69_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNC0zLTEtMS01MzkxMQ_b72d4958-cab9-4bf7-803c-fdd4219380f8">9,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNC01LTEtMS01MjA0Mg_31ae4e40-746b-4c37-a68a-953bff006692">11,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331" decimals="-3" name="nktr:ImpairmentLongLivedAssetHeldForUseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNS0xLTEtMS01MzkxMQ_96444ec6-1919-49f1-929f-00c2f53ae573">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="nktr:ImpairmentLongLivedAssetHeldForUseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNS01LTEtMS01MjA1Mg_9fd42b18-e05e-4fb9-b772-e7bb7fa7a7b8">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of right-of-use assets and property, plant and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNi0xLTEtMS01MjI3OQ_ffdd8507-b3e9-49d6-bcee-feede323bd54">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62ae4528157426aba132831bb9e3a69_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNi0zLTEtMS01MzkxMQ_7c815810-8630-4067-b1d8-8dae148749b8">9,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNi01LTEtMS01MjA2NA_ee2db79f-39c6-4534-a961-b9adec52b85a">13,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After we recorded the non-cash impairment charges for our long-lived assets, we next assessed goodwill for impairment. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. Accordingly, in accordance with ASC 350-20 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC 820-10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we measured the fair value of our reporting unit utilizing both income and market approaches for our entity-wide asset impairment analysis. Based on this analysis, we wrote off all of our goodwill, resulting in a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA0ODkzOQ_6bbacb00-b763-4302-b537-69971992422d">76.5</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2023, which we reported as impairment of goodwill in our Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div id="i53ffcfe41df94c13bfe514c5b23d1b65_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RleHRyZWdpb246YjI0NTY0MWM3NmI3NDhlZTgyMDUyOGVlMWQwZTU5OWZfNzEy_18bfd0ea-6422-48e0-bc1d-bcc3e3207cd2" continuedAt="i616f10f48dbc4fc5bd17b1288b9e4c8f" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:continuation id="i616f10f48dbc4fc5bd17b1288b9e4c8f"><ix:nonNumeric contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RleHRyZWdpb246YjI0NTY0MWM3NmI3NDhlZTgyMDUyOGVlMWQwZTU5OWZfNzEz_98891d58-b6e8-4aa4-98a5-f70c19fc12ce" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cda02f4555947ccabad36bcc6480d92_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMi0xLTEtMS00ODU5NA_b3e5afe3-e20c-4b0c-b422-2f4eb5a8f71c">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34546a7702c6424eb4d1bd5155173002_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMi0zLTEtMS00ODU5NA_6585e262-41d3-4121-a91d-64270e5e6722">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793f4a945cbb4640999a6a1a0da30ac5_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMy0xLTEtMS00ODU5NA_802529ca-0071-4d47-ab7f-0bc21c7cc04b">4,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ebf75335184f2eb6750cf5620342bd_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMy0zLTEtMS00ODU5NA_12e2a9b9-dac4-413f-acfa-a2d737900628">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f16114b074f437fbd1d96555474845a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNC0xLTEtMS00ODU5NA_fca70dc8-7e2c-44e0-bd8f-db4c004ef3c4">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebffda948b374043aba705095a8d4ade_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNC0zLTEtMS00ODU5NA_4c788b48-d8e6-4847-ae86-1ad1f1e8ea86">8,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNi0xLTEtMS00ODU5NA_3e23e881-4cd4-4803-9cef-e69ee02c6ba7">10,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNi0zLTEtMS00ODU5NA_01d53df3-231d-422f-8d7a-3e399d213a7c">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> apply our deep understanding of immunology and unparalleled expertise in polymer chemistry to create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development. Our pipeline of clinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin) and cancer (e.g. NKTR-255). We continue to make significant investments in building and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term shareholder value. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April of 2022 and 2023, we announced the 2022 Restructuring Plan and 2023 Restructuring Plan, respectively, which both focused on prioritizing key research and development efforts that will be most impactful to the Company&#8217;s future. Central to both plans is the continuation of clinical development of both rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255 programs as well as our core research programs in immunology that include a polymer conjugate of colony stimulating factor (CSF-1) and a separate tumor necrosis factor receptor 2 agonist antibody.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body&#8217;s self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Our drug candidate rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases. It is designed to target the interleukin-2 (IL-2) receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells (Treg cells). By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance. Rezpegaldesleukin is being developed as a once or twice monthly self-administered injection for a number of autoimmune disorders and inflammatory diseases. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to develop and commercialize rezpegaldesleukin, pursuant to which we received an initial payment of $150.0 million and were eligible for up to an additional $250.0 million for development and regulatory milestones. Under the collaboration, we completed our responsibilities for Phase 1 clinical development and certain drug product development and supply activities. In a Phase 2 Lupus Study carried out by Lilly, although the study did not meet its primary endpoint, patients who received the middle dose within the modified intent-to-treat population, defined as all patients who were randomized and received at least one dose of rezpegaldesleukin, demonstrated improvement in SLEDAI-2K score as compared to placebo. Additionally, clinically meaningful improvements at the mid-dose level were observed in the British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) response and Lupus Low Disease Activity State (LLDAS) as compared to placebo, and exploratory biomarker data also showed that rezpegaldesleukin led to dose-dependent proliferation of Treg cells, which was consistent with prior studies. Despite these results, Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. On April 27, 2023, we announced we would be regaining full rights to rezpegaldesleukin from Lilly. Following the return of our rights to develop rezpegaldesleukin, we will bear all costs of development. The Phase 1b data for rezpegaldesleukin in atopic dermatitis presented at a meeting of the European Academy of Dermatology and Venereology (EADV) showed a dose-dependent improvement in atopic dermatitis symptoms with 12 weeks of treatment. Based on this and other positive data, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines that target biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. Our drug candidate NKTR-255 is an investigational biologic that is designed to target the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Our development strategy for NKTR-255 is focused on three therapeutic areas: to enhance response to antibody-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dependent cellular cytotoxicity (ADCC) mediated therapies by restoring NK cells, to improve CAR-T cell persistency in cellular therapies and to augment response to checkpoint inhibitors. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying NKTR-255 in ADCC combinations in both liquid and solid tumors. We have initiated a Phase 1 dose escalation and expansion study of NKTR-255 in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma where patients are treated with NKTR-255 as a monotherapy or NKTR-255 in combination with daratumumab. We have also initiated a Phase 1/2 study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer where patients are treated with NKTR-255 in combination with cetuximab. In addition, we initiated a Nektar-sponsored Phase 2/3 study to evaluate NKTR-255 following Yescarta&#174; or Breyanzi&#174;  CD19 CAR-T cell therapy in patients with large B-cell lymphoma. Two ongoing investigator sponsored trials are evaluating NKTR-255 following treatment with a CAR-T cell therapy. These studies include a Phase 1 study evaluating NKTR-255 in combination with CD19 CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphoma and a Phase 1 study evaluating NKTR-255 in combination with CD19/22 CAR-T cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. A third investigator sponsored study is evaluating NKTR-255 in combination with darvulamab in patients with unresectable Stage 3 non-small lung cancer who have received chemoradiation. We are continuing our oncology clinical collaboration with Merck KGaA and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early-stage research programs to human clinical studies over the next several years. Our lead research program is focused on developing a tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist antibody. TNFR2 signaling drives immunoregulatory function and can provide a direct protective effect for tissue cells. Our focus is on TNFR2 antibody candidates that show selective Treg cell binding and signaling profiles that may be developed for treatment of autoimmune diseases. In connection with this program, we are targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">readiness for a lead TNFR2 agonist antibody candidate by the end of 2023 in order to submit an Investigational New Drug (IND) filing for the first clinical study in 2024. Our preclinical pipeline also includes NKTR-288, an investigational PEG conjugate of the protein interferon gamma that is designed utilizing a site-specific conjugation approach to modify binding of interferon gamma with one of its substrates and to optimize the pharmacodynamic duration of interferon gamma signaling. We believe this program has applications in a number of therapeutic indications including oncology as well as in other infectious diseases. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived substantially all of our revenue and significant amounts of research and development operating capital from our collaboration agreements. In addition to payments received under the Lilly Agreement, we have received upfront and milestone payments and cost-sharing reimbursements under a number of other previous collaboration agreements, and certain of our collaboration partners, including Lilly, have borne substantial costs of developing our drug candidates. Following the return of our rights to develop rezpegaldesleukin from Lilly, however, unless we enter into a new collaboration agreement, we will bear all the costs of developing our pipeline drug candidates, other than the Phase II JAVELIN Bladder Medley study under which we pay our share of the study&#8217;s costs as a doublet therapy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our historical collaboration agreements have resulted in approved drugs, for which we may continue to manufacture the polymer reagents used in the production of the drug products and may be entitled to royalties for net sales of these approved drugs. However, we have sold the majority of our rights to receive royalties under these arrangements, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2012 Purchase and Sale Agreement: In 2012, we sold all of our rights to receive royalties from CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of Crohn&#8217;s disease and other autoimmune indications) and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2020 Purchase and Sale Agreement: In December 2020, we sold our rights, subject to a cap, to receive royalties from MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of opioid-induced constipation), ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a half-life extension product of Factor VIII) and other hemophilia products, under our arrangements with AstraZeneca AB, Baxalta, Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.), and Novo Nordisk A/S, respectively, for $150.0 million to entities managed by HealthCare Royalty Management (HCR) under a capped sale arrangement, such that all future royalties return to Nektar if HCR receives $210.0 million in royalties by December 31, 2025 (the 2025 Threshold) or $240.0 million if the 2025 Threshold is not met.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market opportunities. We continue to actively monitor the COVID-19 pandemic and applicable government </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommendations in light of new developments. If the COVID-19 pandemic becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our prospects for growth. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in "Key Developments and Trends in Liquidity and Capital Resources," we estimate we have working capital to fund our current business plans for at least the next twelve months. At March&#160;31, 2023, we had approximately $456.8 million in cash and investments in marketable securities.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth our Condensed Consolidated Statements of Operations data for each of the periods indicated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except percentages).</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change 2023 vs. 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change 2023 vs. 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,371)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,081)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,267)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,018)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m - not meaningful</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. For the three months ended March&#160;31, 2023 and March&#160;31, 2022, our revenues and related expenses did not have a material effect on our cash flows and financial position.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Product sales and Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. Accordingly, the revenue recognized in a given period is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this partner in future years. As a result of this arrangement, gross margin was negative for the three months ended March 31, 2022. Although we recognized negative gross margin for the full year 2022 and expect to recognize negative gross margin for the full year 2023, such negative gross margin is not significant to our cash flows and financial position.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Non-cash royalty revenue and Non-cash interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We recognize non-cash royalty revenue and non-cash interest expense resulting from royalties on several products for which we had previously sold our rights to receive royalties under the 2012 and 2020 Purchase and Sale Agreements. See Note 3 for additional information regarding these agreements. These non-cash revenues and expenses have no affect on our cash flows, and we do not consider them material to our operations.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">License, collaboration and other revenue: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements. The amount of revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any. License, collaboration and other revenue was not material for the periods presented or for the full year 2022, and we do not expect to recognize significant revenue for the full year 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 to our Condensed Consolidated Financial Statements, in April 2022, BMS and we decided to discontinue development of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we have also decided to discontinue all other development of bempegaldesleukin. BMS and we have each substantially wound down our respective clinical trials under the BMS Collaboration Agreement as of March 31, 2022. Beginning with the second quarter of 2022, we report clinical trial expense, other third-party costs and employee costs for the bempegaldesleukin program, net of the reimbursement from BMS, within restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. Accordingly, research and development expensed decreased by $29.6 million for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, for third-party costs, net of the BMS reimbursement, for the termination of the bempegaldesleukin program.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6 to our Condensed Consolidated Financial Statements, pursuant to our 2022 Restructuring Plan,  we completed the termination of approximately 70% of our workforce during 2022. Accordingly, research and development expense decreased by $26.6 million for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, for employee costs, including non-cash stock-based compensation expense, net of the BMS reimbursement, primarily as a result of the 2022 Restructuring Plan. Research and development expense also decreased for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, due to lower allocations of support and facilities-related costs, primarily as a result of the 2022 Restructuring Plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred research and development expense in the three months ended March&#160;31, 2023 and March&#160;31, 2022 for development costs and manufacturing activities for NKTR-255 and development costs for rezpegaldesleukin as Lilly conducted its Phase 1B and Phase 2 studies, for which we were responsible for 25% of costs and Lilly was responsible for 75% of costs. We will continue to incur research and development costs as the development of NKTR-255 continues, and we intend to develop rezpegaldesleukin independently or with another partner, following the return from Lilly to us of the full rights to rezpegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6 to our Condensed Consolidated Financial Statements, in April 2023, we announced our 2023 Restructuring Plan to reduce our San Francisco-based workforce by approximately 60%, which we expect to substantially complete by June 2023. As a result of the 2022 and 2023 Restructuring Plans, we expect research and development expense to significantly decrease for the full year 2023 as compared to 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and amount of our future clinical trial expenses will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug candidates that we plan to evaluate in clinical development during 2023 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates across a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as the collaboration that we have already completed for rezpegaldesleukin, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense includes the cost of administrative staffing, commercial, finance and legal activities. As discussed in Note 6 to our Condensed Consolidated Financial Statements, pursuant to our 2022 Restructuring Plan, which we announced in April 2022, we completed the termination of approximately 70% of our workforce during 2022. As a result of our 2022 Restructuring Plan, the commercial organization was eliminated and all other bempegaldesleukin-related commercialization activities ceased. Accordingly, general and administrative expense decreased for the three months ended March&#160;31, 2023 compared with the three months ended March&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as discussed in Note 6 to our Condensed Consolidated Financial Statements, in April 2023, we announced our 2023 Restructuring Plan to further reduce our San Francisco-based workforce by approximately 60%, which we expect to substantially complete by June 2023.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2022 and 2023 Restructuring Plans, we expect general and administrative expense for the full year 2023 to significantly decrease as compared to 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Costs of Terminated Program</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6 to our Condensed Consolidated Financial Statements, in April 2022, we announced the termination of the bempegaldesleukin program and the 2022 Restructuring Plan, pursuant to which we completed an approximately 70% reduction of our workforce in 2022, and in April 2023, we announced our 2023 Restructuring Plan to reduce our San Francisco-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based workforce by approximately 60%, which was approved by our Board in March 2023. In connection with these events, we reported the following costs in Restructuring, impairment and costs of terminated program as further described and disclosed in Note 6 to our Condensed Consolidated Financial Statements (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we did not recognize significant expenses for restructuring, impairment and costs of terminated program, because the 2022 Restructuring Plan was not approved until April 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program: We recognized $31.7 million for the full year of 2022 for the wind down of the bempegaldesleukin program. We expect these costs for the full year 2023 to be significantly lower.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and benefits expense: We recognized $30.9 million for severance and benefit expense in 2022 for the 2022 Restructuring Plan. We expect to recognize $7.4 million in total in 2023 for the 2023 Restructuring Plan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of right-of-use assets and property, plant and equipment: We recognized $65.8 million in non-cash impairment charges for the full year 2022, primarily for our leased space on Third St. which we intend to sublease, primarily due to lower rental recovery rates and extended time to enter into a sublease. The non-cash impairment charge for the three months ended March 31, 2023 primarily reflects an impairment for our office and laboratory space on Mission Bay Blvd. South. We will continue to update our estimates based on changes in market conditions, whether or not we are able to enter into subleases and, if we do enter into subleases, the economic terms of those subleases, and we may record non-cash impairment charges in future periods as these estimates change.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss (gain) on sale or disposal of property, plant and equipment: We recognized a net gain of $3.3 million for the sale of property, plant and equipment for the full year 2022, primarily resulting from the sale of our research and development facility in India. We do not expect to recognize significant gains or losses in 2023.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other restructuring charges: We recognized $10.9 million in contract termination and other restructuring costs for the full year 2022. We may recognize additional contract termination and other restructuring charges for the full year 2023 as a result of the 2023 Restructuring Plan, but we currently cannot estimate such costs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6 to our Condensed Consolidated Financial Statements, during the three months ended March&#160;31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. As a result and in accordance with ASC 350-20 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 820-10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we measured the fair value of the company based on income and market approaches. Based on this analysis, we wrote off all of our goodwill in the three months ended March 31, 2023. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Development Derivative Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a gain for the change in fair value of development derivative liability in the three months ended March 31, 2022 because we decided to discontinue the development of bempegaldesleukin, and therefore reduced the liability to zero as of March 31, 2022. See Note 5 to our Condensed Consolidated Financial Statements for additional information. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense) increased for the three months ended March&#160;31, 2023 as compared to the three months ended March&#160;31, 2022 due to increases in interest rates. We expect that our interest income and other income (expense), net will increase for 2023 compared to 2022 for the same reason.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public and private placements of debt and equity securities. As of March&#160;31, 2023, we had approximately $456.8 million in cash and investments in marketable securities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the clinical development of our drug candidates, including rezpegaldesleukin and NKTR-255, will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Lilly for our collaboration agreement for rezpegaldesleukin. Additionally, certain of our collaboration partners, including Lilly, have borne substantial costs of developing our drug candidates. Following the return of our rights to develop rezpegaldesleukin from Lilly, however, unless we enter into a new collaboration agreement, we will bear all the costs of developing our pipeline drug candidates, other than the Phase II JAVELIN Bladder Medley study under which we pay our share of the study&#8217;s costs as a doublet therapy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for rezpegaldesleukin and NKTR-255; the sales levels for those products, if and when they are approved; whether, when and on what terms we are able to enter into new collaboration transactions; expenses being higher than anticipated, unplanned expenses and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations; and cash receipts, including sublease income, being lower than anticipated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no credit facility or any other sources of committed capital. The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our 2022 Restructuring Plan, we have executed subleases for a portion of our excess laboratory spaces and are seeking to sublease additional laboratory and office space. For our vacant office space on Third St., however, there is significant uncertainty as to whether or when we will be able to enter into a sublease as well as the economic terms of such subleases, if any. The San Francisco Bay Area office lease market has been negatively impacted by economic uncertainties, particularly impacting the technology industry, and the change in work habits due to the COVID-19 pandemic, as employees continue to work remotely. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of various conditions on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the three months ended March&#160;31, 2023 and 2022 totaled $51.9&#160;million and $88.4&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will decrease for 2023 as compared to 2022 as a result of the various cost restructuring activities described above and because we do not expect any further costs for the wind down of the bempegaldesleukin program to be significant.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the maturities and sales of our investments, net of purchases, totaled $41.0&#160;million and $134.5&#160;million, respectively, which we used to fund our operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $4.2&#160;million for the purchase of property, plant and equipment in the three months ended March 31, 2022, and our purchases of property, plant and equipment for the three months ended March&#160;31, 2023 were not significant.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows from financing activities for the three months ended March&#160;31, 2023 and 2022 were not significant.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. Other than the impairment of goodwill as discussed in Note 6 to our Condensed Consolidated Financial Statements, there have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.                Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of inflation, which has increased significantly during 2022 and may result in increases to our operating expenses. Our market risks at March&#160;31, 2023 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2022 on file with the SEC.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_88"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended March&#160;31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_94"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 6 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_97"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of drug candidates, including rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255.&#160;If these drug candidates fail in clinical development our business will be significantly harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on the clinical success of our drug candidates, including rezpegaldesleukin and NKTR-255. In general, most investigational drugs, including drug candidates designed to treat patients suffering from autoimmune disorders and cancers, such as rezpegaldesleukin and NKTR-255, respectively, do not become approved drugs. Accordingly, there is a very meaningful risk that our drug candidates will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals. Further, if Lilly fails to return to us quickly the regulatory rights, safety and efficacy data, testing assays, and other materials that are necessary for us to continue clinical development of rezpegaldesleukin, or if continued development of rezpegaldesleukin is not ultimately successful, our market valuation, prospects, financial condition and results of operations would be materially harmed. In February 2023, we announced that, although the Phase 2 Lupus Study of rezpegaldesleukin in SLE conducted by Lilly did not meet the study&#8217;s primary endpoint and that Lilly does not intend to advance rezpegaldesleukin to Phase 3 development in SLE, patients in the study who received the middle dose within the modified intent-to-treat population, defined as patients who were randomized and received at least one dose of rezpegaldesleukin, demonstrated improvement in SLEDAI-2K score compared to placebo. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly. We plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin. One or more clinical failures of our drug candidates would jeopardize and could result in reduced, delayed or eliminated revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in conducting clinical trials of our drug candidates. Clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as rezpegaldesleukin) partnered with other companies, delays caused by our partner; </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial due to the detriment of enrollment rates;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options; and</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays associated with third parties, such as a past collaboration partner, failing to provide us with all the necessary documents, data and materials necessary to conduct clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay the ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on academic and private non-academic institutions to conduct investigator-sponsored clinical studies or trials of our product candidates. Any failure by the investigator-sponsor to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval or commercialize for other product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on academic and private non-academic institutions to conduct and sponsor clinical studies or trials relating to our product candidates. We do not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored studies or trials as providing adequate support for future clinical trials, whether controlled by us or independent investigators, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such arrangements will likely provide us certain information concerning our drug candidates with respect to the investigator-sponsored studies or trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored studies or trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored studies or trials. If we are unable to confirm or replicate the results from the investigator-sponsored studies or trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored studies or trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA or non-U.S. regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored studies or trials or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored studies or trials. If so, the FDA or other non-U.S. regulatory authorities may require us to obtain and submit additional preclinical, manufacturing or clinical data before we may initiate our planned clinical trials and/or may not accept such additional data as adequate to initiate our planned clinical trials.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from the clinical trials of drug candidates from others, and the discovery and development of new potential therapies in immunology and oncology, could have a material and adverse impact on the value of the drug candidates in our research and development pipeline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of immune-modulatory agents is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year. Our clinical trial plans for rezpegaldesleukin, NKTR-255 and other immunomodulatory agents drug candidates face substantial competition from other regimens already approved, and many more that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As immunotherapy represent a relatively new approach to treatment of autoimmune disorders and cancer and few have successfully completed late stage development, drug development in this area entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of components when therapeutic combinations are employed, patient enrollment competition, evolving regulatory frameworks to evaluate regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of our drug candidates.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval and there can be no assurance that our product candidates will obtain regulatory approval for any particular indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or noncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.),  NOF Corporation and Aurigene Pharmaceutical Services. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our drug candidates currently in development. For rezpegaldesleukin, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based, microbiome-based, or toleragenic-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Sangamo Therapeutics, Inc., Quell Therapeutics, Ltd, TxCell, Inc., Sonoma Biotherapeutics, Inc., GentiBio, Inc. Kyvema Therapeutics, Inc. and and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., BMS, Novartis, Inc., ILTOO Pharma, Xencor, Inc. Merck &amp; Co, through its acquisition of Pandion Therapeutics, and Sanofi SA, through its acquisition of Synthorx, Inc.). For NKTR-255, we believe companies that are currently researching </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., Nkarta Therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies noncompetitive or obsolete.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partner to initiate, properly conduct and prioritize clinical trials for rezpegaldesleukin and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously relied on Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for rezpegaldesleukin. Currently, we will rely on Lilly to promptly and completely transfer the documents, regulatory rights, safety and efficacy data, testing assays, and materials necessary for us to continue the clinical development for rezpegaldesleukin. In the event Lilly fails to promptly and completely transfer to us these materials, we will not be able to continue quickly the clinical development of rezpegaldesleukin and our business will be significantly harmed. Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that these efforts would succeed or be sufficient to fully address the harm.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategic reorganization plan and cost restructuring plans may not be successful.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 and 2023 Restructuring Plans prioritize key research and development efforts that will impact the Company&#8217;s future business activities, including activities involving rezpegaldesleukin, NKTR-255 and several core research programs. In connection with the 2022 and 2023 Restructuring Plans, we also announced cost restructuring measures aimed at ensuring we will have significant capital to fund key programs over a multi-year time horizon. There is no guarantee that the 2022 and 2023 Restructuring Plans will achieve their intended benefits or that our post-restructuring focus will be sufficient for us to achieve success. We may undertake additional restructuring and cost-saving activities to further prioritize our key research and development efforts. There is no guarantee these new efforts will be successful and may further harm our business. For example, our cost restructuring efforts may not result in the anticipated savings or other economic benefits, may prioritize the wrong drug candidates or wrong indications to study for those drug candidates, or could result in total costs and expenses that are greater than expected, which would require us to seek potentially dilutive financing alternatives, disrupt or restrain the scope of our business activities, and would make it more difficult to attract and retain qualified personnel, each of which could have a material adverse effect on our business, financial condition and prospects</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies, our collaboration partner is generally solely responsible for:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the development or marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters or health epidemics, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash and investments in marketable securities valued at approximately $456.8 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates, particularly rezpegaldesleukin;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that could negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including changing standards of care, third party payer reimbursement standards, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic and biosimilar versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We may also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that receive regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid in the U.S., managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a biologic candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. For more information, see &#8220;Business &#8211; Government Regulation &#8211; Coverage, Reimbursement, and Pricing.&#8221; </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payers tend to follow CMS to a substantial degree. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any of our drug product candidates that are commercialized and, if reimbursement is available, the level of reimbursement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future biologic candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements (whether based on our drug candidates or polymeric reagents), from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any biologic candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, we reported a net loss of $137.0 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestones and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary biologic candidates and the regulatory approval and market success of our biologic candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for rezpegaldesleukin and NKTR-255;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive revenue or royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or biologic candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop biologic candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our biologic candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or biologic candidates. In addition, in the case of the CMOs that supply our biologic candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Business Operations</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our biologic candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our biologic candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development of our proprietary and partnered biologic candidates. Our strategy also calls for us to manage the capital necessary to fund key programs through value-enhancing data and other milestones. If we are unable to manage effectively our current operations, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. Furthermore, as a result of our Restructuring Plan, our employees may experience distractions or decreases in employee morale and we may experience increased levels of employee attrition and turnover, which would adversely affect our business. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rising inflation rates have increased our operating costs and could negatively impact our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inflation rates, particularly in the United States, have increased recently to levels not seen in decades. Increased inflation has resulted in increased operating costs. In addition, the United States Federal Reserve has raised, and is expected to continue to raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; pandemic.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. To date, the COVID-19 pandemic has not had a significant, long-term impact on our business. However, any prolonged or worsening effects in the progression of the COVID-19 pandemic could cause a negative impact on our clinical trial timelines, operations, financial condition and prospects. Our clinical trials and those run by our collaborators or other third parties may be affected by delays in investigator recruitment, clinical site initiation, patient screening, or patient enrollment due to challenges associated with the COVID-19 pandemic. Supply chain disruptions or shortages in raw materials and equipment caused by the COVID-19 pandemic may affect our ability to manufacture our products and to supply drug candidates for clinical trials. Throughout the pandemic we modified our policies to allow our employees to safely work, including remotely when possible, and we may experience unpredictability in our expenses, employee productivity and availability and employee work culture. The COVID-19 pandemic has had a broad impact on global financial markets and could reduce our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from a health epidemic, including the COVID-19 pandemic, could materially affect our business and the value of our common stock.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to actively monitor the COVID-19 pandemic and applicable government recommendations in light of new developments, including the recently announced intention to end the national emergency and public health emergency declarations in May 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for biologic candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Biologic candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a biologic candidate. In addition, undesirable side effects caused by our biologic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered biologic candidate development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, we could be subject to substantial liabilities, which would harm our financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our biologic candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or biologic candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the biologic, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 300 U.S. and 1,500 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the biologic. Moreover, even if a patent encompassing a biologic has not expired prior to the biologic&#8217;s commercialization, the patent may only provide a short period of protection following the commercialization of the covered </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product.&#160;In addition, our patents may be subject to post grant proceedings, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our biologic candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our biologic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any biologic candidates for which we obtain marketing approval. Our current and future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. For more information, see &#8220;Business &#8211; Government Regulation - Other Healthcare Laws and Regulations.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government- paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Governmental policy can also change the commercial potential of our product candidates, including efforts to increase patient access to lower-cost generic and biosimilar drugs. For example, on July 9, 2021, President Biden issued an executive order directing the FDA to, among other things, continue to clarify and improve the approval framework for generic drugs and biosimilars, including the standards for interchangeability of biological products, facilitate the development and approval of biosimilar and interchangeable products, clarify existing requirements and procedures related to the review and submission of BLAs, and identify and address any efforts to impede generic drug and biosimilar competition. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the Affordable Care Act and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business &#8211; Government Regulation &#8211; Legislative and Regulatory Landscape</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In the past, average review times at the agency have fluctuated, and this may continue in the future. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government shutdowns, if prolonged,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could significantly impact the ability of government agencies upon which rely (such as the FDA and SEC) to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Disruptions at the FDA and other agencies may slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since March 2020, when foreign and domestic inspections were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. Third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or biologic candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. For example, we were involved in litigation with Aether Therapeutics Inc., who in March 2020 filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging that MOVANTIK&#174; infringes U.S. Patent Nos. 6,713,488,8,748,448, 8,883,817 and 9,061,024, which litigation was settled on March 17, 2023, without us paying consideration to Aether Therapeutics Inc. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our biologic candidates and platform technologies. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain biologics or biologic candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also be involved in legal proceedings other than those related to intellectual property, including securities actions or derivative actions or other complaints. For example, on May 2, 2023, we and our directors were named in a putative class action complaint filed in the Court of Chancery of the State of Delaware. The plaintiff in this complaint alleges section 13 of our bylaws relating to stockholder action without meeting violates Delaware law and is therefore void. The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from any litigation or the settlement would be sufficient and could result in substantial financial risk to the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of lawsuits and complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses for any of the legal proceedings we may be involved in. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages.We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at March&#160;31, 2023.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and/or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our biologic candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste) is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk related to Investment and Securities</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial                                losses for investors and securities class action and shareholder derivative litigation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the three months ended March&#160;31, 2023, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $0.64 to $3.15 per share. In response to volatility in the price of our common stock in the past, plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into alleged securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by plaintiffs&#8217; securities litigation firms following share price fluctuations. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of our 2022 Restructuring Plan; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, the results from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by collaboration partners as to their plans or expectations related to biologic candidates and approved biologics in which we have a substantial economic interest;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our results of operations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved partnered products or products under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financing needs and activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions, including the impacts of rising inflation and interest rates and global geopolitical tensions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years. In addition, as a result of our lower stock price, we are no longer a well-known seasoned issuer, which otherwise would allow us to, among other things, file automatically effective shelf registration statements. As a result, any attempt to access the public capital markets will be more expensive and subject to delays.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Additionally, the risk of cyber-attacks or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other privacy or data security incidents may be heightened as a result of an increase in the number of employees who adopted a remote working environment during the COVID-19 pandemic, which may be less secure and more susceptible to hacking attacks. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our biologic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the EU, a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we, our collaboration partners and others could face new regulatory costs and challenges.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; In addition, our operations and performance may be affected by political or civil unrest or military action, terrorist activity, and unstable governments and legal systems. For example, in late February 2022, Russia commenced a military invasion of Ukraine, and the sustained conflict in Ukraine, including the potential effects of sanctions and retaliatory cyber-attacks on the world economy and markets, has contributed to increased market volatility and uncertainty. In particular, sanctions imposed by the U.S., EU and other countries in response to the conflict between Russia and Ukraine and the potential response to such sanctions may have an adverse impact on our business, including our clinical trials, the financial markets and the global economy. As the conflict in Ukraine continues, there can be no certainty regarding whether the U.S., EU or other governments will impose additional sanctions, or other economic or military measured relating to Russia.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global economic and political conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. Our ability to conduct clinical trials in regions experiencing political or civil unrest could negatively affect clinical trial enrollment or the timely completion of a clinical trial. We believe the aforementioned economic conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs that result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, civil unrest, or terrorist event in any of these locations, our ability to manufacture and supply materials for biologic candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_100"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended March&#160;31, 2023.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_103"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_106"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_109"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:9pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Exhibit Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Description of Documents</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.1(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.2(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.3(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.4(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.5(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">10.1(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2023-03x31xexx1011.htm">Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC dated April 7, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.1(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2023-03x31xexx311.htm#i7438946f47e444ed92668c2c903c58d2_1">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.2(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2023-03x31xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2023-03x31xexx321.htm#i54b1d197c4654a05a8a61332e2a467ff_1">Section 1350 Certifications.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.SCH(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Schema Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.CAL(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.LAB(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.PRE(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.DEF(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">_____________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       1. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 1998.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       2. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 2000.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       3.     Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               January 23, 2003.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       4. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">                December 31, 2009.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       5. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               December 21, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       6.     Filed herewith.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i53ffcfe41df94c13bfe514c5b23d1b65_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i53ffcfe41df94c13bfe514c5b23d1b65_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SANDRA GARDINER</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sandra Gardiner<br/>Interim Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2023</span></td></tr></table></div><div style="margin-top:6pt;text-align:right"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>nktr2023-03x31xexx1011.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i07c6d2e506d4489fb6f2db71daf31c76_33"></div><div style="min-height:85.68pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:199px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIAL CONSULTING AGREEMENT</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This Confidential Consulting Agreement (the &#8220;Agreement&#8221;) is executed as of the date shown on the signature page (the &#8220;Effective Date&#8221;), by and between FLG Partners, LLC, a California limited liability company (&#8220;FLG&#8221;), and Nektar Therapeutics, a Delaware company, with its principal place of business at 455 Mission Bay Boulevard South, Suite 100, San Francisco, California 94158 (&#8220;Client&#8221;).</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, FLG is in the business of providing certain financial services&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows&#58;</font></div><div id="i07c6d2e506d4489fb6f2db71daf31c76_58"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:50.000%"><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Services.</font></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:50.000%"></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">Commencing on the Effective Date, FLG will perform those services (the &#8220;Services&#8221;) described in one or more exhibits attached hereto.  Such services shall be performed by the member or members of FLG identified in Exhibit A (collectively, the &#8220;FLG Member&#8221;).</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Client acknowledges and agrees that FLG&#8217;s success in performing the Services hereunder will depend upon the participation, cooperation and support of Client&#8217;s most senior management.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Notwithstanding anything in Exhibit A or elsewhere in this Agreement to the contrary, neither FLG nor any of its members shall serve as an employee, an appointed officer, or an elected director of Client.  Consistent with the preceding&#58; (i) Client shall not appoint FLG Member as a corporate officer in Client&#8217;s corporate minutes&#59; (ii) Client shall not elect FLG Member to its board of directors or equivalent governing body&#59; and (iii) the FLG Member shall have no authority to sign any documents on behalf of Client, including, but not limited to, federal or state securities filings, tax filings, or representations and warranties on behalf of Client except in each case as pursuant to a specific resolution(s) of Client&#8217;s board of directors or equivalent governing body granting such authority to FLG Member as a non-employee consultant to Client. so by Client in writing.  FLG agrees that all taxes payable as a result of compensation payable to FLG hereunder shall be FLG&#8217;s sole liability.  FLG shall defend, indemnify and hold harmless Client, Client&#8217;s officers, directors, employees and agents, and the administrators of Client&#8217;s benefit plans from and against any claims, liabilities or expenses relating to such taxes or compensation.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">The Services provided by FLG and FLG Member hereunder shall not constitute an audit, attestation, review, compilation, or any other type of financial statement reporting engagement (historical or prospective) that is subject to the rules of the California Board of Accountancy, the AICPA, or other similar state or national licensing or professional bodies.  Client agrees that any such services, if required, will be performed separately by its independent public accountants or other qualified consultants.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.62pt">During the term of this Agreement, Client shall not hire or retain the FLG Member as an employee, consultant or independent contractor except pursuant to this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Compensation&#59; Payment&#59; Deposit&#59; Expenses.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">As compensation for Services rendered by FLG hereunder, Client shall pay FLG the amounts set forth in Exhibit A for Services performed by FLG hereunder (the &#8220;Fees&#8221;).  The Fees shall be net of any and all taxes, withholdings, duties, customs, bank fees, social contributions or other reductions imposed by any and all authorities which are required to be withheld or collected by Client or FLG, including ad valorem, sales, gross receipts or similar taxes, but excluding US income taxes based upon FLG&#8217;s or FLG Member&#8217;s net taxable income.</font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Consistent with common practice in professional services, FLG reserves the right to increase the Fee set forth in Exhibit A no more frequently than annual anniversary of the Effective Date, and no sooner than twelve (12) months from the Effective Date. </font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">As additional compensation to FLG, Client will pay FLG the incentive bonus or warrants or options, if any, set forth in Exhibit A.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">FLG shall submit an invoice for Services rendered to NEKTAR no less frequently than monthly&#59; the terms of this Agreement shall prevail over any inconsistent statements or provisions contained in any bill or other writing passing between the parties unless agreed to in writing by both parties.  FLG&#8217;s invoices shall be submitted electronically to Nektar Therapeutics to </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AP&#64;nektar.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and shall reference the applicable Client&#8217;s purchase order number.  NEKTAR shall remit payment within fifteen (15) days of receipt of FLG's invoice, except that NEKTAR may withhold any invoiced amounts that it disputes, in which case Client will so notify FLG and the parties agree to work in good faith to resolve any such disputes.  Any invoices more than forty-five (45) days overdue will accrue a late payment fee at the rate of one and 50&#47;100 percent (1.5%) per month.  FLG shall be entitled to recover all costs and expenses (including, without limitation, attorneys&#8217; fees) incurred by it in collecting any amounts overdue under this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.62pt">Client hereby agrees to pay FLG a deposit as set forth on Exhibit A (the &#8220;Deposit&#8221;) to be held in its entirety as security for Client&#8217;s future payment obligations to FLG under this Agreement.  Upon termination of this Agreement, all amounts then owing to FLG under this Agreement shall be charged against the Deposit and the balance thereof, if any, shall be refunded to Client.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.06pt">Within fifteen (15) days of Client&#8217;s receipt of an expense report from FLG&#8217;s personnel performing Services hereunder, Client shall immediately reimburse FLG personnel directly for reasonable travel and out-of-pocket business expenses detailed in such expense report.  Any required air travel, overnight accommodation and resulting per diem expenses shall be approved in writing and shall be consistent with Client&#8217;s travel &#38; expense policies for Client&#8217;s employed executive staff.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Relationship of the Parties</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">FLG&#8217;s relationship with Client will be that of an independent contractor and nothing in this Agreement shall be construed to create a partnership, joint venture, or employer-employee relationship.  FLG is not the agent of Client and is not authorized to make any presentation, contract, or commitment on behalf of Client unless specifically requested or authorized to do so by Client in writing.  FLG agrees that all taxes payable as a result of compensation payable to FLG hereunder shall be FLG&#8217;s sole liability.  FLG shall defend, indemnify and hold harmless Client, Client&#8217;s officers, directors, employees and agents, and the administrators of Client&#8217;s benefit plans from and against any </font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:199px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">claims, liabilities or expenses relating to such taxes or compensation.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Term and Termination.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">The term of this Agreement shall be for the period set forth in Exhibit A.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Either party may terminate this Agreement upon sixty (60) calendar days advance written notice to the other party.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Either party may terminate this Agreement immediately upon a material breach of this Agreement by the other party and a failure by the other party to cure such breach within ten (10) days of written notice thereof by the non-breaching party to the breaching party.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">FLG shall have the right to terminate this Agreement immediately without advance written notice (i) if Client is engaged in, or requests that FLG or the FLG Member undertake or ignore any illegal or unethical activity, or (ii) upon the death or disability of the FLG Member.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.62pt">This Agreement shall be deemed terminated if during any six month period no billable hours occur and following notification in writing, with the termination date effective on the date of the last billable hour therein.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.06pt">If at any time during this engagement there is a conversion of the FLG Member from 1099 to W2 with Client, then a placement fee shall be immediately payable to FLG.  In addition, to the extent within one year of the end of this engagement Client directly hires, employs or retains the FLG Member or any FLG Member either via 1099 or W2, then Client will also immediately pay to FLG a placement fee. The Placement fee paid by Client to FLG will be equal to thirty percent (30%) of FLG Member&#8217;s annual base salary including bonus, that is agreed to by Client and the FLG Member.  Client will not withhold any taxes from any placement fee paid to FLG.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Disclosures.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">IRS Circular 230.  To ensure compliance with requirements imposed by the IRS effective June 20, 2005, FLG hereby informs Client that any tax advice offered during the course of providing, or arising out of, the Services rendered pursuant to this Agreement, unless expressly stated otherwise, is not intended or written to be used, and cannot be used, for the purpose of&#58; (i) avoiding tax-related penalties under the Internal Revenue Code, or (ii) promoting, marketing or recommending to another party any tax-related matter(s) said tax advice address(es).</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Attorney-Client Privilege.  Privileged communication disclosed to FLG or FLG Member may waive the privilege through no fault of FLG.  FLG strongly recommends that Client consult with legal counsel before disclosing privileged information to FLG or FLG Member.  Pursuant to Paragraph 6, neither FLG nor FLG Member will be responsible for damages caused through Client&#8217;s waiver of privilege, whether deliberate or inadvertent, by disclosing such information to FLG or FLG Member.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">DISCLAIMERS AND LIMITATION OF LIABILITY.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EXCEPT AS EXPRESSLY SET FORTH HEREIN, ALL SERVICES TO BE PROVIDED BY FLG AND FLG MEMBER (FOR PURPOSES OF THIS PARAGRAPH 6, COLLECTIVELY &#8220;FLG&#8221;) HEREUNDER ARE PROVIDED &#8220;AS IS&#8221; WITHOUT ANY WARRANTY WHATSOEVER.  CLIENT RECOGNIZES THAT THE &#8220;AS IS&#8221; CLAUSE OF THIS AGREEMENT IS AN IMPORTANT PART OF THE BASIS OF THIS AGREEMENT, </font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WITHOUT WHICH FLG WOULD NOT HAVE AGREED TO ENTER INTO THIS AGREEMENT.  FLG EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, TERMS OR CONDITIONS, WHETHER EXPRESS, IMPLIED, OR STATUTORY, REGARDING THE PROFESSIONAL SERVICES, INCLUDING ANY, WARRANTIES OF MERCHANTABILITY, TITLE, FITNESS FOR A PARTICULAR PURPOSE AND INFRINGEMENT.  NO REPRESENTATION OR OTHER AFFIRMATION OF FACT REGARDING THE SERVICES PROVIDED HEREUNDER SHALL BE DEEMED A WARRANTY FOR ANY PURPOSE OR GIVE RISE TO ANY LIABILITY OF FLG WHATSOEVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">IN NO EVENT SHALL FLG BE LIABLE FOR ANY INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, UNDER ANY CIRCUMSTANCES, INCLUDING, BUT NOT LIMITED TO&#58; LOST PROFITS&#59; REVENUE OR SAVINGS&#59; WAIVER BY CLIENT, WHETHER INADVERTENT OR INTENTIONAL, OF CLIENT&#8217;S ATTORNEY-CLIENT PRIVILEGE THROUGH CLIENT&#8217;S DISCLOSURE OF LEGALLY PRIVILEGED INFORMATION TO FLG&#59; OR THE LOSS, THEFT, TRANSMISSION OR USE, AUTHORIZED OR OTHERWISE, OF ANY DATA, EVEN IF CLIENT OR FLG HAVE BEEN ADVISED OF, KNEW, OR SHOULD HAVE KNOWN, OF THE POSSIBILITY THEREOF.  NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, FLG&#8217;S AGGREGATE CUMULATIVE LIABILITY HEREUNDER, WHETHER IN CONTRACT, TORT, NEGLIGENCE, MISREPRESENTATION, STRICT LIABILITY OR OTHERWISE, SHALL NOT EXCEED AN AMOUNT EQUAL TO THE LAST FOUR (4) MONTHS OF FEES PAYABLE BY CLIENT UNDER PARAGRAPH 2(A) OF THIS AGREEMENT.  CLIENT ACKNOWLEDGES THAT THE COMPENSATION PAID BY IT UNDER THIS AGREEMENT REFLECTS THE ALLOCATION OF RISK SET FORTH IN THIS AGREEMENT AND THAT FLG WOULD NOT ENTER INTO THIS AGREEMENT WITHOUT THESE LIMITATIONS ON ITS LIABILITY. THIS PARAGRAPH SHALL NOT APPLY TO EITHER PARTY WITH RESPECT TO A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">As a condition for recovery of any amount by Client against FLG, Client shall give FLG written notice of the alleged basis for liability within ninety (90) days of discovering the circumstances giving rise thereto, in order that FLG will have the opportunity to investigate in a timely manner and, where possible, correct or rectify the alleged basis for liability&#59; provided that the failure of Client to give such notice will only affect the rights of Client to the extent that FLG is actually prejudiced by such failure.  Notwithstanding anything herein to the contrary, Client must assert any claim against FLG by the sooner of&#58; (i) ninety (90) days after discovery&#59; (ii) ninety (90) days after the termination of this Agreement&#59; (iii) ninety (90) days after the last date on which the Services were performed&#59; or, (iv) sixty (60) days after completion of a financial or accounting audit for the period(s) to which a claim pertains.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Indemnification.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">FLG and FLG Member acting in relation to any of the affairs of Client shall, to the fullest extent permitted by law, as now or hereafter in effect, be indemnified and held harmless, and such right to indemnification shall continue to apply to FLG and FLG Member following the term of this Agreement out of the assets and profits of the Client from and against all actions, costs, charges, losses, damages, liabilities and expenses which FLG or FLG </font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:199px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Member, or FLG&#8217;s or FLG Member&#8217;s heirs, executors or administrators, shall or may incur or sustain by or by reason for any act done, concurred in or omitted in or about the execution of FLG&#8217;s or FLG Member&#8217;s duty or services performed on behalf of Client&#59; and Client shall advance the reasonable attorney&#8217;s fees, costs and expenses incurred by FLG or FLG&#8217;s Member in connection with litigation related to the foregoing on the same basis as such advancement would be available to the Client&#8217;s officers and directors, PROVIDED THAT Client shall not be obligated to make payments to or on behalf of any person (i) in connection with services provided  by such person outside the scope of Services contemplated by this Agreement, and not authorized or consented to by Client&#8217;s CEO or Board of Directors, or (ii) in respect of any (a) gross negligence or willful misconduct of such person, or (b) negligence of such person, but only to the extent that FLG&#8217;s errors and omissions liability insurance would cover such person for such negligence without regard to Client&#8217;s obligation to indemnify FLG hereunder.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">FLG and FLG Member shall have no liability to Client relating to the performance of its duties under this Agreement except in the event of FLG&#8217;s or FLG Member&#8217;s gross negligence or willful misconduct.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">FLG and FLG Member agree to waive any claim or right of action FLG or FLG Member might have whether individually or by or in the right of Client, against any director, secretary and other officers of Client and the liquidator or trustees (if any) acting in relation to any of the affairs of Client and every one of them on account of any action taken by such director, officer, liquidator or trustee or the failure of such director, officer, liquidator or trustee to take any action in the performance of his duties with or for Client&#59; PROVIDED THAT such waiver shall not extend to any matter in respect of any gross negligence or willful misconduct which may attach to any such persons.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Representations and Warranties.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">Each of FLG, FLG Member, and Client represents and warrants to the others that it is authorized to enter into this Agreement and can fulfill all of its obligations hereunder.  FLG and FLG Member represents and warrants to Client that the FLG Member  (a) has not been debarred by the FDA pursuant to its authority under Sections 306(a) and (b) of the U.S. Food, Drug, and Cosmetic Act (21 U.S.C.. &#167; 335(a) and (b))&#59; (b) is not the subject of any investigation or proceeding which may result in debarment or similar disqualification in any professional licensure or certification organization&#59; and (c) will promptly notify Client in writing if FLG Member becomes aware of any such debarment, investigation or proceeding.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">FLG and FLG Member warrant that they shall perform the Services diligently, with due care, and in accordance with prevailing industry standards for comparable engagements and the requirements of this Agreement.  FLG and FLG Member warrant that FLG Member has sufficient professional experience to perform the Services in a timely and competent manner.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Each party represents and warrants that it has and will maintain a policy or policies of insurance with reputable insurance companies providing the members, officers and directors, as the case may be, of itself with coverage for losses from wrongful acts. FLG covenants that it has an error and omissions insurance policy in place in the form provided to Client prior to or contemporaneously with the date of execution of this Agreement and will continue to maintain such policy or equivalent policy provided that such policy or equivalent policy shall be available at commercially reasonable rates.</font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Work Product License.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The parties do not anticipate that FLG or FLG Member will create any intellectual property for Client in performing the Services pursuant to this Agreement.  However, FLG and FLG Member grant to Client a world-wide, perpetual, exclusive, royalty-free, irrevocable license to use and create derivative works from all tangible and electronic documents, spreadsheets, and financial models (collectively, &#8220;Work Product&#8221;) produced or authored by FLG Member in the course of performing the Services pursuant to this Agreement. Any patent rights arising out of the Services will be assigned to and owned by Client and not FLG or FLG Member. All other rights, including, but not limited to, the residual memory of any methods, discoveries, developments, improvements, know-how, ideas, insights, analytical concepts and skills directly inherent to, or reasonably required for, the competent execution of FLG Member&#8217;s profession as a chief financial officer are reserved in their entirety by FLG and FLG Member.</font></div><div style="margin-bottom:6pt;padding-left:4.5pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:30.5pt;text-decoration:underline">Miscellaneous.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">Any notice required or permitted to be given by either party hereto under this Agreement shall be in writing and shall be personally delivered or sent by a reputable courier mail service (e.g., Federal Express) or by facsimile or email transmission confirmed by reputable courier mail service, to the other party as set forth in this Paragraph 10(A).  Notices will be deemed effective two (2) days after deposit with a reputable courier service or upon confirmation of receipt by the recipient from such courier service or the same day if sent by facsimile or email transmission and confirmed as set forth above.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If to FLG&#58;</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U. Heather Ogan</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">FLG Partners, LLC</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">228 Hamilton Ave., 3rd Floor, </font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Palo Alto, CA 94301</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PO BOX 192304</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">San Francisco, CA  94119</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; 415-508-4048, ext 201</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fax&#58; 415-508-6896</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E-mail&#58; accounting&#64;flgpartners.com</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If to Client&#58;</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Mr. Mark. A. Wilson, Chief Legal Officer </font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nektar Therapeutics</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">455 Mission Bay Boulevard South</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">San Francisco, CA 94158</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58;  415-482-5629</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E-mail&#58;  mwilson&#64;nektar.com</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">This Agreement will be governed by and construed in accordance with the laws of California without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement (including any other agreement(s) contemplated hereunder), including, without limitation, any action or claim based on tort, contract, or statute (including any claims of breach or violation of statutory or common law protections from discrimination, harassment and hostile working environment), or concerning the interpretation, effect, termination, validity, performance and&#47;or breach of this Agreement (&#8220;Claim&#8221;), shall be resolved by final and binding arbitration before a single arbitrator (&#8220;Arbitrator&#8221;) selected from and administered by the San Francisco office of JAMS (the &#8220;Administrator&#8221;) in accordance with its then existing commercial arbitration rules and procedures.  The arbitration shall be held in San Francisco, California.  The </font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:199px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Arbitrator shall, within fifteen (15) calendar days after the conclusion of the Arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded.  The Arbitrator also shall be authorized to grant any temporary, preliminary or permanent equitable remedy or relief he or she deems just and equitable and within the scope of this Agreement, including, without limitation, an injunction or order for specific performance.  Each party shall bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the Administrator and the Arbitrator&#59; provided, however, the Arbitrator shall be authorized to determine whether a party is the prevailing party, and if so, to award to that prevailing party reimbursement for its reasonable attorneys&#8217; fees, costs and disbursements, and&#47;or the fees and costs of the Administrator and the Arbitrator. The Arbitrator's award may be enforced in any court of competent jurisdiction.  Notwithstanding the foregoing, nothing in this Paragraph 10(C) will restrict either party from applying to any court of competent jurisdiction for injunctive relief.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">Neither party may assign its rights or delegate its obligations hereunder, either in whole or in part, whether by operation of law or otherwise, without the prior written consent of the other party&#59; provided, however, that FLG may assign its rights and delegate its obligations hereunder to any affiliate of FLG, and each party may assign this Agreement without such consent to its successor in interest by way of merger, acquisition or sale of all or substantially all of its assets.  The rights and liabilities of the parties under this Agreement will bind and inure to the benefit of the parties&#8217; respective successors and permitted assigns.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.62pt">If any provision of this Agreement, or the application thereof, shall for any reason and to any extent be invalid or unenforceable, the remainder of this Agreement and application of such provision to other persons or circumstances shall be interpreted so as best to reasonably effect the intent of the parties.  The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provision.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:7.06pt">This Agreement, the Exhibits, and any executed Non-Disclosure Agreements specified herein and thus incorporated by reference constitute the entire understanding and agreement of the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous agreements or understandings, express or implied, written or oral, between the parties with respect hereto.  The express terms hereof control and supersede any course of performance or usage of the trade inconsistent with any of the terms hereof.</font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">Any term or provision of this Agreement may be amended, and the observance of any term of this Agreement may be waived, only by a writing signed by the parties.  The waiver by a party of any breach hereof for default in payment of any amount due hereunder or default in the performance hereof shall not be deemed to constitute a waiver of any other default or succeeding breach or default.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">RESERVED</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.84pt">If Client discloses FLG Member&#8217;s name on Client&#8217;s website (such as in an executive biography, for example), press releases, SEC filings and other public documents and media, then Client shall include in the description of FLG Member a sentence substantially the same as &#8220;&#91;FLG Member&#93; is also a partner at FLG Partners, a leading CFO services firm in Silicon Valley.&#8221;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.39pt">If and to the extent that a party&#8217;s performance of any of its obligations pursuant to this Agreement is prevented, hindered or delayed by fire, flood, earthquake, elements of nature or acts of God, acts of war, terrorism, riots, civil disorders, rebellions or revolutions, or any other similar cause beyond the reasonable control of such party (each, a &#8220;Force Majeure Event&#8221;), and such non-performance, hindrance or delay could not have been prevented by reasonable precautions of the non-performing party, then the non-performing, hindered or delayed party shall be excused for such non-performance, hindrance or delay, as applicable, of those obligations affected by the Force Majeure Event for as long as such Force Majeure Event continues and such party continues to use its best efforts to recommence performance whenever and to whatever extent possible without delay, including through the use of alternate sources, workaround plans or other means.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5.73pt">This Agreement may be executed in any number of counterparts and by the parties on separate counterparts, each of which when executed and delivered shall constitute an original, but all the counterparts together constitute one and the same instrument.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.62pt">This Agreement may be executed by facsimile signatures (including electronic versions of this document in Adobe Acrobat Portable Document Format form which contain scanned or secure, digitally signed signatures) by any party hereto and such signatures shall be deemed binding for all purposes hereof, without delivery of an original signature being thereafter required.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.39pt">Survivability. The following Paragraphs shall survive the termination of this Agreement&#58; 6 (&#8220;Disclaimers and Limitation of Liability&#8221;)&#59; 7 (&#8220;Indemnification&#8221;)&#59; 8 (&#8220;Representations and Warranties&#8221;)&#59; 9 (&#8220;Work Product License&#8221;)&#59; and 10 (&#8220;Miscellaneous&#8221;).</font></div><div id="i07c6d2e506d4489fb6f2db71daf31c76_120"></div></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the parties hereto have executed this Agreement as of the Effective Date.</font></div><div style="text-align:justify;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CLIENT&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FLG&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nektar Therapeutics, Inc.,</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FLG Partners, LLC, </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a Delaware corporation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a California limited liability company.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;  Mark. A. Wilson</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;  U. Heather Ogan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160; &#47;s&#47; Mark A. Wilson</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Signed&#58;  &#47;s&#47; U. Heather Ogan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  Chief Legal Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  Administrative Partner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Address&#58;  455 Mission Bay Blvd South, Suite 100,</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Date&#58;  April 7, 2023.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Francisco, California 94158</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160; mwilson&#64;nektar.com</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div id="i07c6d2e506d4489fb6f2db71daf31c76_131"></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:199px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="padding-right:-9pt;text-align:center;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">EXHIBIT A</font></div><div style="padding-right:-9pt;text-align:center"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">Description of Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58;  CFO level services typical for a publicly held corporation.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">FLG Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58;  Sandra Gardiner.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58;  $650 per hour, up to 30 hours a week, subject to any changes as agreed to by Client and FLG Member.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58; None.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58; $50,000.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58;  Indefinite, and terminable pursuant to Paragraph 4 of the Agreement.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:10.5pt;text-decoration:underline">Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">&#58; FLG-Client Mutual Non-Disclosure Agreement dated March 30, 2023 (the &#8220;NDA&#8221;). FLG hereby expressly consents to the public disclosure of the existence of FLG&#8217;s relationship with Client, by Client, provided that the terms and conditions herein shall remain confidential pursuant to the terms of the NDA.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">REMAINDER OF THIS PAGE LEFT BLANK</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>nktr2023-03x31xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7438946f47e444ed92668c2c903c58d2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:48.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; HOWARD W. ROBIN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin<br>Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>nktr2023-03x31xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i76ec24a0b89245c8a009838557ab61c1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sandra Gardiner, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:49.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SANDRA GARDINER</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sandra Gardiner<br>Interim Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>nktr2023-03x31xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i54b1d197c4654a05a8a61332e2a467ff_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Sandra Gardiner, Interim Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HOWARD W. ROBIN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; SANDRA GARDINER</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer, President and Director</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sandra Gardiner<br>Interim Chief Financial Officer &#160;&#160;&#160;&#160;<br>(Principal Financial Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nktr-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:50d7cf34-c614-4bcd-898f-e96601bbe45e,g:0a2e4e36-7a77-4bd6-a518-b664e3e6425f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>0000009 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails">
        <link:definition>0000010 - Disclosure - Condensed Consolidated Financial Statement Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>0000011 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>0000012 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill" roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill">
        <link:definition>0000013 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>0000014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>0000016 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsTables" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables">
        <link:definition>0000017 - Disclosure - Condensed Consolidated Financial Statement Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>0000018 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables" roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables">
        <link:definition>0000019 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>0000020 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000021 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>0000022 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>0000023 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>0000024 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails">
        <link:definition>0000025 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000026 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails">
        <link:definition>0000027 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails">
        <link:definition>0000028 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails">
        <link:definition>0000029 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails" roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails">
        <link:definition>0000030 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail">
        <link:definition>0000031 - Disclosure - Commitments and Contingencies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>0000032 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails">
        <link:definition>0000033 - Disclosure - License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails">
        <link:definition>0000034 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails">
        <link:definition>0000035 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Summary of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails">
        <link:definition>0000036 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Restructuring Reserve Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails">
        <link:definition>0000037 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Sublease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>0000038 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OperatingLeaseMeasurementInput" abstract="false" name="OperatingLeaseMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LiabilityToCollaborationPartnersCurrent" abstract="false" name="LiabilityToCollaborationPartnersCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentNet" abstract="false" name="DepreciablePropertyPlantAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" abstract="true" name="SubleaseOperatingLeaseRightOfUseAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_RoyaltiesLiabilityMeasurementInput" abstract="false" name="RoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_StockOptionsRSUsAndPSUsMember" abstract="true" name="StockOptionsRSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" abstract="true" name="MeasurementInputMarketParticipantSubtenantBorrowingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_AccruedContractTerminationCostsCurrent" abstract="false" name="AccruedContractTerminationCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_ImpairmentLongLivedAssetHeldForUseOther" abstract="false" name="ImpairmentLongLivedAssetHeldForUseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_TwoThousandTwentyTwoRestructuringPlanMember" abstract="true" name="TwoThousandTwentyTwoRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SubleasePropertyPlantAndEquipmentMember" abstract="true" name="SubleasePropertyPlantAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_TwoThousandTwentyThreeRestructuringPlanMember" abstract="true" name="TwoThousandTwentyThreeRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentGross" abstract="false" name="DepreciablePropertyPlantAndEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_ManufacturingLaboratoryAndOtherEquipmentMember" abstract="true" name="ManufacturingLaboratoryAndOtherEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ComputerFurnitureAndOtherMember" abstract="true" name="ComputerFurnitureAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" abstract="false" name="LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nktr-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:50d7cf34-c614-4bcd-898f-e96601bbe45e,g:0a2e4e36-7a77-4bd6-a518-b664e3e6425f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a904333c-849b-421a-99f9-b4fe0742b55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bb60024f-c8e0-49cd-bedb-e0db636307b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a904333c-849b-421a-99f9-b4fe0742b55a" xlink:to="loc_us-gaap_AccountsPayableCurrent_bb60024f-c8e0-49cd-bedb-e0db636307b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_63a0688b-b94f-48f8-be5c-dfac09514f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a904333c-849b-421a-99f9-b4fe0742b55a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_63a0688b-b94f-48f8-be5c-dfac09514f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2bc55c6b-c808-4966-93be-6b5579eb3a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a904333c-849b-421a-99f9-b4fe0742b55a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2bc55c6b-c808-4966-93be-6b5579eb3a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a541d70a-43fc-41bc-88d9-ac9a5ba02c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b15485b0-0593-4d88-a91d-572ad35dd8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a541d70a-43fc-41bc-88d9-ac9a5ba02c21" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b15485b0-0593-4d88-a91d-572ad35dd8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ea38fc9f-55f2-49cb-b088-84186b213640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a541d70a-43fc-41bc-88d9-ac9a5ba02c21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ea38fc9f-55f2-49cb-b088-84186b213640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ccf32243-91ec-41b4-9f1c-1b2e97dd7130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a541d70a-43fc-41bc-88d9-ac9a5ba02c21" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ccf32243-91ec-41b4-9f1c-1b2e97dd7130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_88ee35d7-fe70-4eaf-8ef5-5e521e42363d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a541d70a-43fc-41bc-88d9-ac9a5ba02c21" xlink:to="loc_us-gaap_InventoryNet_88ee35d7-fe70-4eaf-8ef5-5e521e42363d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6eeb0ff7-8b92-4a58-aa7b-0424523cf54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a541d70a-43fc-41bc-88d9-ac9a5ba02c21" xlink:to="loc_us-gaap_OtherAssetsCurrent_6eeb0ff7-8b92-4a58-aa7b-0424523cf54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_01cd3ee0-0962-4be2-a581-515a4e5acf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_58827cd0-ad18-4262-a734-22e46058d72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01cd3ee0-0962-4be2-a581-515a4e5acf34" xlink:to="loc_us-gaap_AssetsCurrent_58827cd0-ad18-4262-a734-22e46058d72c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69203170-d9b6-4cda-9dd4-6b9404d47ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01cd3ee0-0962-4be2-a581-515a4e5acf34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69203170-d9b6-4cda-9dd4-6b9404d47ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e2353c1b-4679-4320-ade6-62e88f4738b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01cd3ee0-0962-4be2-a581-515a4e5acf34" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e2353c1b-4679-4320-ade6-62e88f4738b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_42bf8384-fd17-4f66-94e1-46d8887a8a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01cd3ee0-0962-4be2-a581-515a4e5acf34" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_42bf8384-fd17-4f66-94e1-46d8887a8a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bb14318b-c6e2-4ef2-b10c-51914ce74af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01cd3ee0-0962-4be2-a581-515a4e5acf34" xlink:to="loc_us-gaap_Goodwill_bb14318b-c6e2-4ef2-b10c-51914ce74af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b370803-c47c-43e9-ab8a-970870b49a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6447317a-36c7-423d-b4b4-c89c5f8c654b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b370803-c47c-43e9-ab8a-970870b49a65" xlink:to="loc_us-gaap_Liabilities_6447317a-36c7-423d-b4b4-c89c5f8c654b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e186e029-d35b-4731-9765-4cc082ede80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b370803-c47c-43e9-ab8a-970870b49a65" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e186e029-d35b-4731-9765-4cc082ede80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c2dbe97-43d7-4f6c-aa64-08a0b7dd3238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b370803-c47c-43e9-ab8a-970870b49a65" xlink:to="loc_us-gaap_StockholdersEquity_2c2dbe97-43d7-4f6c-aa64-08a0b7dd3238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7dcaaa52-67e6-42a4-be86-60a0a7d097ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_19973b1a-11cd-44ab-94fc-f8c88c00c9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7dcaaa52-67e6-42a4-be86-60a0a7d097ee" xlink:to="loc_us-gaap_PreferredStockValue_19973b1a-11cd-44ab-94fc-f8c88c00c9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ea005fa5-82b7-44f5-8ab3-f62e2612508a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7dcaaa52-67e6-42a4-be86-60a0a7d097ee" xlink:to="loc_us-gaap_CommonStockValue_ea005fa5-82b7-44f5-8ab3-f62e2612508a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cb60027d-a051-4f05-aa61-dbdc45da3ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7dcaaa52-67e6-42a4-be86-60a0a7d097ee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cb60027d-a051-4f05-aa61-dbdc45da3ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41fa5ccc-7a5a-447a-b1cc-25ad2d243683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7dcaaa52-67e6-42a4-be86-60a0a7d097ee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41fa5ccc-7a5a-447a-b1cc-25ad2d243683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_02703f34-25ed-4b80-b157-675314a605d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7dcaaa52-67e6-42a4-be86-60a0a7d097ee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_02703f34-25ed-4b80-b157-675314a605d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f5a5bee-91a8-4bc8-863a-167c7e79546c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6a19589d-665f-401a-9cc8-d078a46396f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5f5a5bee-91a8-4bc8-863a-167c7e79546c" xlink:to="loc_us-gaap_LiabilitiesCurrent_6a19589d-665f-401a-9cc8-d078a46396f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_933e779d-0a95-4ce1-8579-34a81578d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5f5a5bee-91a8-4bc8-863a-167c7e79546c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_933e779d-0a95-4ce1-8579-34a81578d36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_b0ce797f-c35b-4b39-a606-ee5f2de90fea" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5f5a5bee-91a8-4bc8-863a-167c7e79546c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_b0ce797f-c35b-4b39-a606-ee5f2de90fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_84698b40-0aa2-49ce-a42d-cbe014c963a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5f5a5bee-91a8-4bc8-863a-167c7e79546c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_84698b40-0aa2-49ce-a42d-cbe014c963a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10b4982d-3326-46b0-8759-c975cf8a0083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9771b86f-9688-48c3-9672-d6b4da45eee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10b4982d-3326-46b0-8759-c975cf8a0083" xlink:to="loc_us-gaap_OperatingIncomeLoss_9771b86f-9688-48c3-9672-d6b4da45eee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_321d2a52-05c1-4377-a769-d09d3f9ee29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10b4982d-3326-46b0-8759-c975cf8a0083" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_321d2a52-05c1-4377-a769-d09d3f9ee29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0fe086be-52ef-4602-ae95-f39a59608ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b9966aad-ea36-4abc-9902-56331f40283e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0fe086be-52ef-4602-ae95-f39a59608ca1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b9966aad-ea36-4abc-9902-56331f40283e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25dfda0e-c573-4c35-bad7-89b2c87b5687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0fe086be-52ef-4602-ae95-f39a59608ca1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25dfda0e-c573-4c35-bad7-89b2c87b5687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_722f49d9-ba4a-486c-8679-599c1dfc3ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0fe086be-52ef-4602-ae95-f39a59608ca1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_722f49d9-ba4a-486c-8679-599c1dfc3ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_80085e5e-5b4c-40e4-9f52-5a2806d5e692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0fe086be-52ef-4602-ae95-f39a59608ca1" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_80085e5e-5b4c-40e4-9f52-5a2806d5e692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3cc8160b-3a11-413b-929b-f1fd61f65f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0fe086be-52ef-4602-ae95-f39a59608ca1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3cc8160b-3a11-413b-929b-f1fd61f65f3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8d7f78e7-00bb-4958-93ef-0f478d01e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db6f999d-f47d-4470-8734-5dca99889b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8d7f78e7-00bb-4958-93ef-0f478d01e5bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db6f999d-f47d-4470-8734-5dca99889b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_574bf0c8-9c20-425b-b46d-a9a90163c160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8d7f78e7-00bb-4958-93ef-0f478d01e5bb" xlink:to="loc_us-gaap_CostsAndExpenses_574bf0c8-9c20-425b-b46d-a9a90163c160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_36dd35aa-b29d-492c-a702-6b4287a7c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a75eccb6-6932-4d2e-8984-eb93c8ec0553" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_36dd35aa-b29d-492c-a702-6b4287a7c45a" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a75eccb6-6932-4d2e-8984-eb93c8ec0553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a5a2612b-d7e3-4cf0-90ba-ce3ed5a4adae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_36dd35aa-b29d-492c-a702-6b4287a7c45a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a5a2612b-d7e3-4cf0-90ba-ce3ed5a4adae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_9f4897cd-86fa-4529-9b80-36b07241fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_36dd35aa-b29d-492c-a702-6b4287a7c45a" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_9f4897cd-86fa-4529-9b80-36b07241fd3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98887566-de2b-41fe-901e-8dbb4308bb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19f9c462-dbcb-4cca-94f8-0b047c7f88dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98887566-de2b-41fe-901e-8dbb4308bb1e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19f9c462-dbcb-4cca-94f8-0b047c7f88dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_13bd3c50-da0f-42af-9ac7-3143586ff8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98887566-de2b-41fe-901e-8dbb4308bb1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_13bd3c50-da0f-42af-9ac7-3143586ff8e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_92ebf847-2dd5-4c2c-aeb2-637b0cb4c709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8aa2c807-6809-4707-ada8-0a6eed035eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_92ebf847-2dd5-4c2c-aeb2-637b0cb4c709" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8aa2c807-6809-4707-ada8-0a6eed035eed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7eb57da2-1646-4ddd-8db6-e53b19969038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_92ebf847-2dd5-4c2c-aeb2-637b0cb4c709" xlink:to="loc_us-gaap_NetIncomeLoss_7eb57da2-1646-4ddd-8db6-e53b19969038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0206b752-0fc5-4b07-8dab-7e49687fc8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_607c5fbd-2439-4f2b-826c-3b8d7dae7332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0206b752-0fc5-4b07-8dab-7e49687fc8bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_607c5fbd-2439-4f2b-826c-3b8d7dae7332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_81b49c91-47fe-439c-a7ac-db0123c4d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0206b752-0fc5-4b07-8dab-7e49687fc8bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_81b49c91-47fe-439c-a7ac-db0123c4d10c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1e4d972-2fb4-4e3d-b61c-0b57ba749b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c83f6c0f-ec9b-429c-89b5-63681a5d204e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1e4d972-2fb4-4e3d-b61c-0b57ba749b81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c83f6c0f-ec9b-429c-89b5-63681a5d204e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c108083c-840d-4b81-8547-0f961cee8953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1e4d972-2fb4-4e3d-b61c-0b57ba749b81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c108083c-840d-4b81-8547-0f961cee8953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74a37213-243c-4d20-b75e-7bc41a9013e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1e4d972-2fb4-4e3d-b61c-0b57ba749b81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74a37213-243c-4d20-b75e-7bc41a9013e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10bc2938-31ad-4ab5-8e24-74b6883578fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1e4d972-2fb4-4e3d-b61c-0b57ba749b81" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10bc2938-31ad-4ab5-8e24-74b6883578fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bce8c6b2-1ad3-4c71-a2b9-8d7e10d6fdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_fc99f875-8bd0-4059-8e9c-1aca8faf2f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bce8c6b2-1ad3-4c71-a2b9-8d7e10d6fdb1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_fc99f875-8bd0-4059-8e9c-1aca8faf2f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_7cb5594b-482b-4d7b-bd75-c133526bce58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bce8c6b2-1ad3-4c71-a2b9-8d7e10d6fdb1" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_7cb5594b-482b-4d7b-bd75-c133526bce58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_f6eee916-548d-441c-a35b-9e3af83ab03d" xlink:href="nktr-20230331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_f6eee916-548d-441c-a35b-9e3af83ab03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_fdd91054-25d3-49f8-be2d-c3cd4b57942b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_fdd91054-25d3-49f8-be2d-c3cd4b57942b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_60988377-8eb8-45a7-80d0-ca7c88457669" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_60988377-8eb8-45a7-80d0-ca7c88457669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9873e65e-69b8-41fa-9d3f-1ce8ca044748" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9873e65e-69b8-41fa-9d3f-1ce8ca044748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a7607a40-2208-45d6-afdc-c7c492a25d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a7607a40-2208-45d6-afdc-c7c492a25d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2fc3d3fb-dd59-4568-8583-d255ed422455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_DepreciationAndAmortization_2fc3d3fb-dd59-4568-8583-d255ed422455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5d9e975-d6e7-4226-b18c-4b9f5ab3c4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5d9e975-d6e7-4226-b18c-4b9f5ab3c4e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fabf4ca2-5646-4319-9466-c41884d43c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_ProfitLoss_fabf4ca2-5646-4319-9466-c41884d43c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9192c623-b48e-4c4e-b8e3-4252faf86bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9192c623-b48e-4c4e-b8e3-4252faf86bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_886951bb-3bf2-46f8-955b-97bbd0210320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_886951bb-3bf2-46f8-955b-97bbd0210320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_48bd6624-d6da-4de3-828c-de1349e0ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_48bd6624-d6da-4de3-828c-de1349e0ae88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c6122011-5c01-4a8f-911c-ff9867b8a419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c6122011-5c01-4a8f-911c-ff9867b8a419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_5018e9bc-0ce3-416e-9ae3-ce1748353c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_5018e9bc-0ce3-416e-9ae3-ce1748353c61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_70132ada-2559-417f-98a8-29f8d125bfa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_70132ada-2559-417f-98a8-29f8d125bfa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9ffb3557-1868-46eb-add7-8e06654a396c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9ffb3557-1868-46eb-add7-8e06654a396c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_48b00cb1-9d62-4b32-9be3-124d1261b7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_48b00cb1-9d62-4b32-9be3-124d1261b7fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5f7fb98d-215a-4b38-aa84-c4a4295bfac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55bcfbbd-c7db-4e3c-a836-70aebfe03bc3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5f7fb98d-215a-4b38-aa84-c4a4295bfac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_da865091-324e-4d55-95dc-068d91a18681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4349d5a1-0a93-43fc-9d56-3d2d5268d944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_da865091-324e-4d55-95dc-068d91a18681" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4349d5a1-0a93-43fc-9d56-3d2d5268d944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c4d5fe0b-f45b-4424-8fc2-d7332df744be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_da865091-324e-4d55-95dc-068d91a18681" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c4d5fe0b-f45b-4424-8fc2-d7332df744be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_82063803-b581-493b-a5ad-7aebf1840b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_da865091-324e-4d55-95dc-068d91a18681" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_82063803-b581-493b-a5ad-7aebf1840b3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a78bd050-eb1d-4fa4-bb6d-754cdabd2b83" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46234276-8bbe-4e00-a45e-7b370c73e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a78bd050-eb1d-4fa4-bb6d-754cdabd2b83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46234276-8bbe-4e00-a45e-7b370c73e2b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_70000ad1-8e77-42cc-a255-796f81586c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a78bd050-eb1d-4fa4-bb6d-754cdabd2b83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_70000ad1-8e77-42cc-a255-796f81586c6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bc01307-fd0d-4be5-90c1-1f883e73d309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8b3f4b3-911d-48f5-a13f-2c0ff230f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bc01307-fd0d-4be5-90c1-1f883e73d309" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8b3f4b3-911d-48f5-a13f-2c0ff230f8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03759985-6d97-4a39-a0ef-4f08765989e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bc01307-fd0d-4be5-90c1-1f883e73d309" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_03759985-6d97-4a39-a0ef-4f08765989e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e7ae16cc-059e-4c9e-ba10-acd54e344b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bc01307-fd0d-4be5-90c1-1f883e73d309" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e7ae16cc-059e-4c9e-ba10-acd54e344b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_04534d7b-923c-4961-b1d8-19dc37a54770" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55609804-03a6-4059-aca1-75de38b366a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_04534d7b-923c-4961-b1d8-19dc37a54770" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55609804-03a6-4059-aca1-75de38b366a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f5dd7176-b6cb-4bb6-bc8f-98bab37fcc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_04534d7b-923c-4961-b1d8-19dc37a54770" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f5dd7176-b6cb-4bb6-bc8f-98bab37fcc4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_fd25a2e6-e0f2-49f3-870a-0e7f00b65b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_04534d7b-923c-4961-b1d8-19dc37a54770" xlink:to="loc_us-gaap_Cash_fd25a2e6-e0f2-49f3-870a-0e7f00b65b95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_50bec323-af05-497a-aee6-606435e55fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3925b702-abc5-4448-abfd-56555ccb77b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_50bec323-af05-497a-aee6-606435e55fe6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3925b702-abc5-4448-abfd-56555ccb77b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2ef69ebc-40de-4350-87ae-5d011d0e92ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_50bec323-af05-497a-aee6-606435e55fe6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2ef69ebc-40de-4350-87ae-5d011d0e92ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_734bae8f-316f-4446-a538-9ccc6748f47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_50bec323-af05-497a-aee6-606435e55fe6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_734bae8f-316f-4446-a538-9ccc6748f47f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_c89e474f-1f30-4993-b362-6933ec723474" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dd482d02-072e-4f23-99b4-62d5a4210229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_c89e474f-1f30-4993-b362-6933ec723474" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dd482d02-072e-4f23-99b4-62d5a4210229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_e624daaa-8b2f-4f9b-a640-e71d661d68f5" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_c89e474f-1f30-4993-b362-6933ec723474" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_e624daaa-8b2f-4f9b-a640-e71d661d68f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a9c92290-bf58-46de-b68d-7c6b5fa1d0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_1c09c76b-653d-4274-b48b-595fb2e27f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a9c92290-bf58-46de-b68d-7c6b5fa1d0ad" xlink:to="loc_us-gaap_ConstructionInProgressGross_1c09c76b-653d-4274-b48b-595fb2e27f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_b45b7454-1c6e-4f14-b5d4-f92c200c341a" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a9c92290-bf58-46de-b68d-7c6b5fa1d0ad" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_b45b7454-1c6e-4f14-b5d4-f92c200c341a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1eb46ebb-cea7-444f-a347-9df2368bada6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityToCollaborationPartnersCurrent_ce282158-112a-46d3-aa69-a4848ad490b2" xlink:href="nktr-20230331.xsd#nktr_LiabilityToCollaborationPartnersCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1eb46ebb-cea7-444f-a347-9df2368bada6" xlink:to="loc_nktr_LiabilityToCollaborationPartnersCurrent_ce282158-112a-46d3-aa69-a4848ad490b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_ca9a213d-8c92-4a99-b4cf-855320199eb2" xlink:href="nktr-20230331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1eb46ebb-cea7-444f-a347-9df2368bada6" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_ca9a213d-8c92-4a99-b4cf-855320199eb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cff98791-a694-42cc-872d-f66e53e6b1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1eb46ebb-cea7-444f-a347-9df2368bada6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cff98791-a694-42cc-872d-f66e53e6b1e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractTerminationCostsCurrent_5221ab04-6cf1-4a31-85e2-b3ab02f93c6e" xlink:href="nktr-20230331.xsd#nktr_AccruedContractTerminationCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1eb46ebb-cea7-444f-a347-9df2368bada6" xlink:to="loc_nktr_AccruedContractTerminationCostsCurrent_5221ab04-6cf1-4a31-85e2-b3ab02f93c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51f44074-95a4-47f9-b47e-896e227f266a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1eb46ebb-cea7-444f-a347-9df2368bada6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51f44074-95a4-47f9-b47e-896e227f266a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_05f45e90-529c-4311-a8a1-5a00679a5283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_714bddb9-f231-4454-a5b6-58423fd458ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_05f45e90-529c-4311-a8a1-5a00679a5283" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_714bddb9-f231-4454-a5b6-58423fd458ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_8177fc4e-34bf-471a-b78b-a3dc39758586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_05f45e90-529c-4311-a8a1-5a00679a5283" xlink:to="loc_us-gaap_SeveranceCosts1_8177fc4e-34bf-471a-b78b-a3dc39758586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_cc7cbdd1-89cc-4312-8d43-2bcb0794e1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_05f45e90-529c-4311-a8a1-5a00679a5283" xlink:to="loc_us-gaap_BusinessExitCosts1_cc7cbdd1-89cc-4312-8d43-2bcb0794e1a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_7ab75531-a7a2-4a58-a107-2a179b14cab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_05f45e90-529c-4311-a8a1-5a00679a5283" xlink:to="loc_us-gaap_LossOnContractTermination_7ab75531-a7a2-4a58-a107-2a179b14cab9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9a09cb81-ca59-4ef2-9590-972e82164a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther_f1ff6b7c-e41d-4c95-87a5-33e226e29130" xlink:href="nktr-20230331.xsd#nktr_ImpairmentLongLivedAssetHeldForUseOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9a09cb81-ca59-4ef2-9590-972e82164a44" xlink:to="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther_f1ff6b7c-e41d-4c95-87a5-33e226e29130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_b7bc7083-960c-4991-bde8-0e4eae6168fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9a09cb81-ca59-4ef2-9590-972e82164a44" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_b7bc7083-960c-4991-bde8-0e4eae6168fd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nktr-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:50d7cf34-c614-4bcd-898f-e96601bbe45e,g:0a2e4e36-7a77-4bd6-a518-b664e3e6425f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i9e4bde8917374c328320b44c556caf9d_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2e43b82a-c985-49da-8dc9-649eafdb9283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_RevenuesAbstract_2e43b82a-c985-49da-8dc9-649eafdb9283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dcf9cd-738b-49c0-accb-347ee4ead441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2e43b82a-c985-49da-8dc9-649eafdb9283" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dcf9cd-738b-49c0-accb-347ee4ead441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1759ef1f-f6ec-47df-8fc9-33ca6f5f0bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1759ef1f-f6ec-47df-8fc9-33ca6f5f0bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a80a9c1-ab11-485a-912a-771a3c2ada0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a80a9c1-ab11-485a-912a-771a3c2ada0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_338b539e-31c2-4fac-b968-7a8c2c54313f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_338b539e-31c2-4fac-b968-7a8c2c54313f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_21a4260b-a89c-45fc-9714-ac20d053c735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_21a4260b-a89c-45fc-9714-ac20d053c735" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ca2f1258-0bc0-44c5-8519-40cbe6979ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ca2f1258-0bc0-44c5-8519-40cbe6979ef9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9adcbef5-4a16-44dd-8bff-354ef396ae23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_CostsAndExpenses_9adcbef5-4a16-44dd-8bff-354ef396ae23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dcc6e8d8-ad1f-402b-bebf-6f90683a8e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_OperatingIncomeLoss_dcc6e8d8-ad1f-402b-bebf-6f90683a8e43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_c9d263d2-f40f-4cb4-bb49-9df80f20f9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_c9d263d2-f40f-4cb4-bb49-9df80f20f9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f6ee9770-5e44-464b-b98c-259cc4bed841" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f6ee9770-5e44-464b-b98c-259cc4bed841" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_350c4dd3-815d-441c-9578-e15caf567f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_350c4dd3-815d-441c-9578-e15caf567f71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bf23fc08-8cbb-48d3-89ea-21707636c538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bf23fc08-8cbb-48d3-89ea-21707636c538" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ba1f4bf-d204-477a-b316-621cc84eba36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ba1f4bf-d204-477a-b316-621cc84eba36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c6163b8-71a4-4816-9f19-7d21048ac1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c6163b8-71a4-4816-9f19-7d21048ac1f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2c11aea-f94d-4976-acf1-eebe789b1ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_NetIncomeLoss_c2c11aea-f94d-4976-acf1-eebe789b1ed9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a4f6580f-9d34-4b71-baaf-65d9334afd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_EarningsPerShareBasic_a4f6580f-9d34-4b71-baaf-65d9334afd10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9e9305f9-cac6-412c-98f4-6792a6bb9952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9e9305f9-cac6-412c-98f4-6792a6bb9952" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9143c363-ab65-4ea6-958d-ace95c1a878e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9143c363-ab65-4ea6-958d-ace95c1a878e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6bf3a42-09be-4fb1-b9bd-c25f5a99fad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6bf3a42-09be-4fb1-b9bd-c25f5a99fad2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:to="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:to="loc_srt_ProductsAndServicesDomain_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:to="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b64078ef-ddf7-41ef-b75a-6892aae8e858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:to="loc_us-gaap_ProductMember_b64078ef-ddf7-41ef-b75a-6892aae8e858" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_58b9eb29-0f7f-42e5-bec0-fe339b9ecf65" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_58b9eb29-0f7f-42e5-bec0-fe339b9ecf65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_8c9a74ea-270a-4dee-b5f5-db7f8b59f175" xlink:href="nktr-20230331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_8c9a74ea-270a-4dee-b5f5-db7f8b59f175" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i07f52cc8dfef4be68ee85f075cbd8363_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0118570c-0258-4c1a-bd23-08f14fda07cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0118570c-0258-4c1a-bd23-08f14fda07cc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14869fa7-ad0f-4fe2-b6b6-f1fc4e0daeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14869fa7-ad0f-4fe2-b6b6-f1fc4e0daeb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51a6f9f0-0e74-4415-8671-6d02f301572a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockholdersEquity_51a6f9f0-0e74-4415-8671-6d02f301572a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_deb2c15b-4bbe-483c-b26f-78f9a434c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_deb2c15b-4bbe-483c-b26f-78f9a434c85b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ec81a92a-b050-4587-9249-676b48f5be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ec81a92a-b050-4587-9249-676b48f5be8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_532a857b-4fee-48c9-a771-805296c6efa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_532a857b-4fee-48c9-a771-805296c6efa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc56d5b4-44a8-4676-b466-4768f9d40b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc56d5b4-44a8-4676-b466-4768f9d40b89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_adec49a8-5c10-41cb-b24b-db1e28acf730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a72d02f8-b51f-49b9-a33c-5f0104e5cbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0118570c-0258-4c1a-bd23-08f14fda07cc" xlink:to="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:to="loc_us-gaap_EquityComponentDomain_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:to="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_98ed1c79-a1b8-40d6-9c83-093037e386d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_CommonStockMember_98ed1c79-a1b8-40d6-9c83-093037e386d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_36ad0c4e-689f-4d4b-bcf8-800c83446222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_36ad0c4e-689f-4d4b-bcf8-800c83446222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4353cb88-3596-4d0d-8380-b381c973155c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4353cb88-3596-4d0d-8380-b381c973155c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_213d549a-61c5-4180-bb8e-05a51366299f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_RetainedEarningsMember_213d549a-61c5-4180-bb8e-05a51366299f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="ia49b6cf5f33c4e55bcdfeefaa982dff7_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:href="nktr-20230331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_182b0c41-df72-4b16-87e7-f69bafc69f7e" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_182b0c41-df72-4b16-87e7-f69bafc69f7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_a67a6ed2-584b-40e5-b7f6-43a80aa32702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_a67a6ed2-584b-40e5-b7f6-43a80aa32702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_93183e33-af37-4bcd-bfdd-2ddedab1b791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_93183e33-af37-4bcd-bfdd-2ddedab1b791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0a849baa-a48d-4f32-a06a-a9d24a746fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0a849baa-a48d-4f32-a06a-a9d24a746fd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:href="nktr-20230331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a6cb38c4-9234-4c6f-a832-0f3bb5b26990_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a6cb38c4-9234-4c6f-a832-0f3bb5b26990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f586cde8-7e74-4c58-99b1-4bae9a56e4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f586cde8-7e74-4c58-99b1-4bae9a56e4c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_3991074e-d316-4c7b-9020-e69b1ece874e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f586cde8-7e74-4c58-99b1-4bae9a56e4c4" xlink:to="loc_us-gaap_EmployeeSeveranceMember_3991074e-d316-4c7b-9020-e69b1ece874e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6bcabff4-2768-47c7-a225-b58b0c0273f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6bcabff4-2768-47c7-a225-b58b0c0273f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed8ab308-19d7-4a70-bd61-886f9d177e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed8ab308-19d7-4a70-bd61-886f9d177e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember_bf369a4b-8313-4971-bb25-bd80fd1d4a3c" xlink:href="nktr-20230331.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed8ab308-19d7-4a70-bd61-886f9d177e24" xlink:to="loc_nktr_StockOptionsRSUsAndPSUsMember_bf369a4b-8313-4971-bb25-bd80fd1d4a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_fc00e423-e9f3-49f5-bba9-c4822dda307a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:to="loc_us-gaap_RestructuringPlanDomain_fc00e423-e9f3-49f5-bba9-c4822dda307a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c8949115-8e3c-46f1-9e97-333b508caf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:to="loc_us-gaap_RestructuringPlanDomain_c8949115-8e3c-46f1-9e97-333b508caf73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_0ab763cf-c139-4922-8022-636ea003e1bf" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_c8949115-8e3c-46f1-9e97-333b508caf73" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_0ab763cf-c139-4922-8022-636ea003e1bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="i95c53775ec2d4f6195a64a2e410818c6_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a257640c-5e1e-4b56-aece-0eec605a5e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a257640c-5e1e-4b56-aece-0eec605a5e61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9eaac09f-fa5c-4b91-85c5-06bf0664081c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9eaac09f-fa5c-4b91-85c5-06bf0664081c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c36bd741-2908-4a13-8aed-625c0b2f382c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c36bd741-2908-4a13-8aed-625c0b2f382c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71c5a2f7-9f9e-4b2e-ad1c-6e3c7d23142b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71c5a2f7-9f9e-4b2e-ad1c-6e3c7d23142b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8cb35f59-c91b-487d-8673-4746c32f9c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8cb35f59-c91b-487d-8673-4746c32f9c6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_b6b3854b-2a12-4064-abac-6a01dde8d768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_Cash_b6b3854b-2a12-4064-abac-6a01dde8d768" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7149f168-a961-4a6a-beab-c4e83912f4d7" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7149f168-a961-4a6a-beab-c4e83912f4d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39dfcdf8-f2d8-4cbe-9881-533be671a4cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39dfcdf8-f2d8-4cbe-9881-533be671a4cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cad0e27c-0d5e-42aa-b202-10e0ddc7d494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cad0e27c-0d5e-42aa-b202-10e0ddc7d494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f0c0b194-45a6-44bd-8a7d-056bfdcd6573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f0c0b194-45a6-44bd-8a7d-056bfdcd6573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf9f15ef-fba0-4ded-b52f-378b31da4f9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf9f15ef-fba0-4ded-b52f-378b31da4f9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_720034cb-4916-42ea-892c-95920077f735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_720034cb-4916-42ea-892c-95920077f735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0b384672-991a-4bae-a8b3-6ddcc5d5b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_CommercialPaperMember_0b384672-991a-4bae-a8b3-6ddcc5d5b95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29c61b30-044f-472b-ad98-12bb936c8405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29c61b30-044f-472b-ad98-12bb936c8405" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c217b1df-f88e-43e4-974a-e98bdf2b11ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c217b1df-f88e-43e4-974a-e98bdf2b11ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_be18f2e9-5c2a-4277-a4d4-34d347aafe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_be18f2e9-5c2a-4277-a4d4-34d347aafe12" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i17fcd9a65683495180e0383b055f01b4_CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_99af9c52-1c8d-4329-a75a-3a5e9a66e9ed" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_99af9c52-1c8d-4329-a75a-3a5e9a66e9ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a38ea96-2856-4fca-bf56-93be320eecfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a38ea96-2856-4fca-bf56-93be320eecfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_d100c882-b378-41ca-b108-c975b7496c46" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_d100c882-b378-41ca-b108-c975b7496c46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_8af3f7cd-a319-4d4b-b73a-45c4d860096a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_ConstructionInProgressGross_8af3f7cd-a319-4d4b-b73a-45c4d860096a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dddd4ae6-3730-456f-a68c-1e8f6c32ecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dddd4ae6-3730-456f-a68c-1e8f6c32ecbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_c5bfc7c7-1451-4f8f-875a-905a612e2043" xlink:href="nktr-20230331.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_c5bfc7c7-1451-4f8f-875a-905a612e2043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_3005d098-c3eb-4640-a89b-05c65c9b190f" xlink:href="nktr-20230331.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_3005d098-c3eb-4640-a89b-05c65c9b190f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_328dd5ec-7644-4fbd-804b-9c9cfac51b04" xlink:href="nktr-20230331.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_328dd5ec-7644-4fbd-804b-9c9cfac51b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_57f09784-9eb4-49b7-b7b5-b82205a71695" xlink:href="nktr-20230331.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_LaboratoryEquipmentMember_57f09784-9eb4-49b7-b7b5-b82205a71695" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c24b4c0b-631c-4c34-bbe0-2c6c18bfb2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c24b4c0b-631c-4c34-bbe0-2c6c18bfb2bb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" xlink:type="extended" id="i71334a3f2db8419cb1e08b50bb1fe30d_CondensedConsolidatedFinancialStatementDetailsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_918894f2-1625-44cc-a4b9-52c893a4afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_918894f2-1625-44cc-a4b9-52c893a4afb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_f37daea4-24f0-4f5f-8c58-029755ed1ec6" xlink:href="nktr-20230331.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_f37daea4-24f0-4f5f-8c58-029755ed1ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da965651-0864-49b3-983f-a31f4e93021a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da965651-0864-49b3-983f-a31f4e93021a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_174e7009-f611-4375-b4ae-d310c7901e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_174e7009-f611-4375-b4ae-d310c7901e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_cbf87c71-5766-4230-b11e-9ca4ac200595" xlink:href="nktr-20230331.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_174e7009-f611-4375-b4ae-d310c7901e9a" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_cbf87c71-5766-4230-b11e-9ca4ac200595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bdb369b8-6754-4e5f-b925-97de153d9e90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bdb369b8-6754-4e5f-b925-97de153d9e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_4e26916d-900f-4987-b540-fc63b240c882" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_4e26916d-900f-4987-b540-fc63b240c882" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_e57414a6-675a-4bb4-9410-cab3074362fa" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_e57414a6-675a-4bb4-9410-cab3074362fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails" xlink:type="extended" id="i507dffb6f8684ec4b1c044433162b15c_CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1e66fae3-3046-4b42-a75c-dc10080e77a4" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1e66fae3-3046-4b42-a75c-dc10080e77a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_280bf54f-8dcb-492a-9209-ed44960b36b8" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_280bf54f-8dcb-492a-9209-ed44960b36b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_dcc8c288-4734-43f9-9cbe-ff0b42f71192" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_dcc8c288-4734-43f9-9cbe-ff0b42f71192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_d02cf7b7-cc83-46bd-b314-37ae103a6314" xlink:href="nktr-20230331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_d02cf7b7-cc83-46bd-b314-37ae103a6314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_8fbeb6d5-5939-4a8c-b46c-4804b5524fc4" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db82a62e-fcee-400f-91f2-837da711dc78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db82a62e-fcee-400f-91f2-837da711dc78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_aaa418fc-5872-4cce-b120-7b9f6e16ccc0" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_aaa418fc-5872-4cce-b120-7b9f6e16ccc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_495c18a3-6a1b-49d5-b079-3642e385a48f" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_495c18a3-6a1b-49d5-b079-3642e385a48f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="i6947707fca9440cf91821011c4e62620_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be97bf96-f7e9-4ef8-9103-65e91dabcbca" xlink:href="nktr-20230331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be97bf96-f7e9-4ef8-9103-65e91dabcbca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_f01df0c8-672a-49b0-afa2-edd1641463dc" xlink:href="nktr-20230331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_f01df0c8-672a-49b0-afa2-edd1641463dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_a416e977-fbd0-4db0-b0fb-e9dcfbbb5e1b" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_a416e977-fbd0-4db0-b0fb-e9dcfbbb5e1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_31cdafb0-a745-4d31-9bdd-3c43e3a10059" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_31cdafb0-a745-4d31-9bdd-3c43e3a10059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_d789b452-e596-4720-af99-ac2b3201fd27" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_d789b452-e596-4720-af99-ac2b3201fd27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_d18856e4-afd8-4f9d-97e1-936f1fdff918" xlink:href="nktr-20230331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_d18856e4-afd8-4f9d-97e1-936f1fdff918" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ef84c1e4-09aa-4cb0-b3d4-c9c864b4946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_SharesIssued_ef84c1e4-09aa-4cb0-b3d4-c9c864b4946a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_a615d1a3-896f-41c8-9dfb-b02a03899c9e" xlink:href="nktr-20230331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_a615d1a3-896f-41c8-9dfb-b02a03899c9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_691a46e2-3fab-4723-9b54-94e16fff3aba" xlink:href="nktr-20230331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PotentialDevelopmentMilestones_691a46e2-3fab-4723-9b54-94e16fff3aba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_9e4e6ad5-06a3-4b4a-8b36-a53a821abcb7" xlink:href="nktr-20230331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_ReimbursementOfExpenses_9e4e6ad5-06a3-4b4a-8b36-a53a821abcb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_c84394c0-c23a-4415-9a7d-573fe8edc827" xlink:href="nktr-20230331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_c84394c0-c23a-4415-9a7d-573fe8edc827" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_38fb22a7-5e1b-4379-badb-3f8b216997bc" xlink:href="nktr-20230331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_38fb22a7-5e1b-4379-badb-3f8b216997bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2ec4bd48-bbc8-4637-8c71-4903f1501bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_DerivativeLiabilities_2ec4bd48-bbc8-4637-8c71-4903f1501bee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2430d079-2e42-4132-85cc-5d02280a681b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2430d079-2e42-4132-85cc-5d02280a681b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:to="loc_srt_ProductsAndServicesDomain_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:to="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_ef2ed338-375a-4a28-acfe-56d626aa374c" xlink:href="nktr-20230331.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:to="loc_nktr_Nektar214Member_ef2ed338-375a-4a28-acfe-56d626aa374c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_ea6fe23c-f3ae-4d81-a316-510790ef01fd" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_ea6fe23c-f3ae-4d81-a316-510790ef01fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0f90e10b-eac8-4374-82fd-d6a77c764d34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0f90e10b-eac8-4374-82fd-d6a77c764d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_392d6422-69ea-4869-83d1-a15a8b31b2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_392d6422-69ea-4869-83d1-a15a8b31b2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_750d9a49-860d-4a05-882e-53bcdad3f048" xlink:href="nktr-20230331.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_392d6422-69ea-4869-83d1-a15a8b31b2b2" xlink:to="loc_nktr_OpdivoMember_750d9a49-860d-4a05-882e-53bcdad3f048" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c26ae4b2-5668-458c-8429-8ccbca9446a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c26ae4b2-5668-458c-8429-8ccbca9446a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_0f620729-3971-432e-8ca1-e1689aedee16" xlink:href="nktr-20230331.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:to="loc_nktr_Nektar358Member_0f620729-3971-432e-8ca1-e1689aedee16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0b9e931e-0485-4a67-bcf9-5689a6c78bfd" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0b9e931e-0485-4a67-bcf9-5689a6c78bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_69428275-7931-4896-9227-7d1fb359cc2a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:to="loc_dei_EntityDomain_69428275-7931-4896-9227-7d1fb359cc2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:to="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_a852520b-0214-4a88-8b98-2c3c28188adf" xlink:href="nktr-20230331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_EliLillyAndCompanyMember_a852520b-0214-4a88-8b98-2c3c28188adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_0f114784-aa66-43c6-8d41-2117a9f612c2" xlink:href="nktr-20230331.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_EliLillyMember_0f114784-aa66-43c6-8d41-2117a9f612c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_539210ec-793a-423e-99eb-02adf9b4763d" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_539210ec-793a-423e-99eb-02adf9b4763d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_4f5bc846-6e65-4519-94a4-8f3646da95dd" xlink:href="nktr-20230331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_OtherPartnerMember_4f5bc846-6e65-4519-94a4-8f3646da95dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6da6c4ff-4441-4e6c-afe3-f3d5020a5492_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6da6c4ff-4441-4e6c-afe3-f3d5020a5492_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2374e05c-3d44-4187-ad05-10e3b6fbdc6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2374e05c-3d44-4187-ad05-10e3b6fbdc6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_78a2ed72-03b6-4b2d-a5d8-ab31af34fb0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2374e05c-3d44-4187-ad05-10e3b6fbdc6b" xlink:to="loc_srt_ParentCompanyMember_78a2ed72-03b6-4b2d-a5d8-ab31af34fb0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba396591-58a1-4272-ba5d-31b97776eb92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba396591-58a1-4272-ba5d-31b97776eb92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb681fa2-b50d-4e92-9048-7d5109a00f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb681fa2-b50d-4e92-9048-7d5109a00f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_da886821-34df-40d0-9dd7-e8bdf9b693db" xlink:href="nktr-20230331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb681fa2-b50d-4e92-9048-7d5109a00f7a" xlink:to="loc_nktr_SharePurchaseAgreementMember_da886821-34df-40d0-9dd7-e8bdf9b693db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:href="nktr-20230331.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_1bc7b478-922d-4b8d-aadc-fad6874f4ed8_default" xlink:href="nktr-20230331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:to="loc_nktr_MilestoneDomain_1bc7b478-922d-4b8d-aadc-fad6874f4ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_2ca5aec1-9224-4e2e-a2d9-42f27a70a1cf" xlink:href="nktr-20230331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:to="loc_nktr_MilestoneDomain_2ca5aec1-9224-4e2e-a2d9-42f27a70a1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_27a89dd6-513d-4fde-b9a0-a3d2bcab0546" xlink:href="nktr-20230331.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_2ca5aec1-9224-4e2e-a2d9-42f27a70a1cf" xlink:to="loc_nktr_MilestoneOneMember_27a89dd6-513d-4fde-b9a0-a3d2bcab0546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35d20ff7-3f8c-4802-aa45-5380204f1c51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35d20ff7-3f8c-4802-aa45-5380204f1c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_336c1a33-c461-498d-8da7-4b2f2a0650ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_336c1a33-c461-498d-8da7-4b2f2a0650ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37b6213d-19cc-4f85-9d47-f9d84486fa06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_336c1a33-c461-498d-8da7-4b2f2a0650ba" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37b6213d-19cc-4f85-9d47-f9d84486fa06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_466bec00-4924-47c5-8b71-b654187f8839_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_466bec00-4924-47c5-8b71-b654187f8839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_3368f4d8-2b52-4c4a-8eeb-47a368265604" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_3368f4d8-2b52-4c4a-8eeb-47a368265604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_263f1a8e-cc46-4778-b1a1-69faf6791426" xlink:href="nktr-20230331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:to="loc_nktr_SFJPharmaceuticalsMember_263f1a8e-cc46-4778-b1a1-69faf6791426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f27a1c3e-00a2-4263-9e64-53807211efa1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:to="loc_srt_RangeMember_f27a1c3e-00a2-4263-9e64-53807211efa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27681fdf-907f-4a3d-b1a8-a7101d76f481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:to="loc_srt_RangeMember_27681fdf-907f-4a3d-b1a8-a7101d76f481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bf3d0fc1-7548-4ad1-a703-f2821b62027d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27681fdf-907f-4a3d-b1a8-a7101d76f481" xlink:to="loc_srt_MaximumMember_bf3d0fc1-7548-4ad1-a703-f2821b62027d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails" xlink:type="extended" id="i98fc131c77db497387ff2986677c64f8_LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1814378d-1dc1-42e6-b6ad-96abde61ed87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1814378d-1dc1-42e6-b6ad-96abde61ed87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a2a57429-2abe-497a-973e-7a2408d5af6a" xlink:href="nktr-20230331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a2a57429-2abe-497a-973e-7a2408d5af6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_283220bd-3466-436a-85e3-0dc7746fe5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_283220bd-3466-436a-85e3-0dc7746fe5e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8fa6777f-cb0e-4dea-bc32-ff489a18b66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8fa6777f-cb0e-4dea-bc32-ff489a18b66d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66e333a0-6f48-4cbc-88d6-b099bbbe7109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f67d718d-ee7d-4029-8bbc-32b969e8760b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f67d718d-ee7d-4029-8bbc-32b969e8760b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_971e615d-73a6-417a-bdf1-dde33f0ccb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_971e615d-73a6-417a-bdf1-dde33f0ccb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8e15745d-20b6-4154-bed1-373cec41874c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_971e615d-73a6-417a-bdf1-dde33f0ccb14" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8e15745d-20b6-4154-bed1-373cec41874c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5fac24d6-5035-4ec0-90c4-5094a0b2fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5fac24d6-5035-4ec0-90c4-5094a0b2fc33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b018d6d2-ebee-4541-8fd9-b29163a355d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5fac24d6-5035-4ec0-90c4-5094a0b2fc33" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b018d6d2-ebee-4541-8fd9-b29163a355d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails" xlink:type="extended" id="i636757f4531c40a6887507626002608d_RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d940dde0-77ac-4284-b98e-bedaff3130a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d940dde0-77ac-4284-b98e-bedaff3130a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_367ca7fd-035b-46a0-9ffd-081cd54b20a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_LossOnContractTermination_367ca7fd-035b-46a0-9ffd-081cd54b20a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_058b3af6-d918-4065-a601-4bfe0f2483b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_RestructuringCharges_058b3af6-d918-4065-a601-4bfe0f2483b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_16125f95-ca64-45d3-8bb4-2781e9463e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_PaymentsForRestructuring_16125f95-ca64-45d3-8bb4-2781e9463e39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_e9d999b3-3d61-4b20-a293-cec9834c3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_SeveranceCosts1_e9d999b3-3d61-4b20-a293-cec9834c3b55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLeaseMeasurementInput_cbafb82d-9b29-4df2-9ff8-71aa77183fb0" xlink:href="nktr-20230331.xsd#nktr_OperatingLeaseMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_nktr_OperatingLeaseMeasurementInput_cbafb82d-9b29-4df2-9ff8-71aa77183fb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_af2131e7-0953-4944-9169-764e6071cc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_af2131e7-0953-4944-9169-764e6071cc02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c851b8d9-f316-4c24-831f-76fced79ff82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c851b8d9-f316-4c24-831f-76fced79ff82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d3ac5fe-0538-491c-9d2f-35b834e31501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d3ac5fe-0538-491c-9d2f-35b834e31501" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6f384660-5ce2-4f13-a917-3fd1de5c8ba8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6f384660-5ce2-4f13-a917-3fd1de5c8ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_91535384-c437-4e63-8cce-ba9f5a519762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_91535384-c437-4e63-8cce-ba9f5a519762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_24f8ac77-9934-4d08-8d87-a40dcb2ed2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_91535384-c437-4e63-8cce-ba9f5a519762" xlink:to="loc_us-gaap_EmployeeSeveranceMember_24f8ac77-9934-4d08-8d87-a40dcb2ed2ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8948de0c-ab16-402a-b635-335c18ac971d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8948de0c-ab16-402a-b635-335c18ac971d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fc3c6cf1-290b-425d-a9c9-17daee107f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fc3c6cf1-290b-425d-a9c9-17daee107f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_0a9eb01e-f6c0-48a9-9733-4401fbd3fdf4" xlink:href="nktr-20230331.xsd#nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fc3c6cf1-290b-425d-a9c9-17daee107f3b" xlink:to="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_0a9eb01e-f6c0-48a9-9733-4401fbd3fdf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6927140a-709a-4373-b0f3-7fb07a2576a2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6927140a-709a-4373-b0f3-7fb07a2576a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8783b97d-5f65-46a8-bcef-ca99ebade5e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8783b97d-5f65-46a8-bcef-ca99ebade5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a34645f1-31ff-4b20-9957-3f4c74cc095d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8783b97d-5f65-46a8-bcef-ca99ebade5e2" xlink:to="loc_srt_ScenarioForecastMember_a34645f1-31ff-4b20-9957-3f4c74cc095d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:to="loc_us-gaap_RestructuringPlanDomain_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:to="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_18933c8a-4e4d-46cd-9337-fd83f08fb93a" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:to="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_18933c8a-4e4d-46cd-9337-fd83f08fb93a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_4a280d71-89a5-40bd-935e-e527a11ddb54" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_4a280d71-89a5-40bd-935e-e527a11ddb54" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" xlink:type="extended" id="i8389c549687845448d482cfd00e40810_RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_2cc1cfe6-082f-4c3e-a8a2-f1f47b7a86fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_BusinessExitCosts1_2cc1cfe6-082f-4c3e-a8a2-f1f47b7a86fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c9467ca6-b30f-42e7-b058-cc5895fe0a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_SeveranceCosts1_c9467ca6-b30f-42e7-b058-cc5895fe0a22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_97189bfe-88b0-4736-a576-42cdfb2f3eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_97189bfe-88b0-4736-a576-42cdfb2f3eec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_a79ca96c-0033-4eb1-8272-84f21746dd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_LossOnContractTermination_a79ca96c-0033-4eb1-8272-84f21746dd33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_939aa8dd-d176-4be8-9062-ae38b182cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_939aa8dd-d176-4be8-9062-ae38b182cd0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:to="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a2c63cae-1d90-4bb2-9068-c164900ddee4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:to="loc_us-gaap_RestructuringPlanDomain_a2c63cae-1d90-4bb2-9068-c164900ddee4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:to="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_72ab1ea3-ceed-4eb0-8272-678716d98974" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_72ab1ea3-ceed-4eb0-8272-678716d98974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_c02ba0b2-9bb7-4674-9465-bc2ae53929af" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:to="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_c02ba0b2-9bb7-4674-9465-bc2ae53929af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails" xlink:type="extended" id="i7dfff5c0ebf3464baa5e7175a8c7cdb4_RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_991eb105-13d4-4f23-93be-2bcc423611e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_991eb105-13d4-4f23-93be-2bcc423611e7" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ccfd7214-8e48-49b1-995b-4d79ff411f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_RestructuringReserve_ccfd7214-8e48-49b1-995b-4d79ff411f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c51a9e75-dff8-4841-82ef-302a6e66cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_RestructuringCharges_c51a9e75-dff8-4841-82ef-302a6e66cd9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_bee2346c-d6da-4c8e-9ac2-1e3c652ebb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_PaymentsForRestructuring_bee2346c-d6da-4c8e-9ac2-1e3c652ebb76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_46a383d8-4a1e-479c-9e65-48410ebc544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_991eb105-13d4-4f23-93be-2bcc423611e7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7c2de994-2234-4ec0-aeb6-ed6d814866e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7c2de994-2234-4ec0-aeb6-ed6d814866e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0d9e3a8c-35cf-4f08-be13-192a62c250a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0d9e3a8c-35cf-4f08-be13-192a62c250a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_865f032b-20d3-4513-b9d8-83fa5be1a251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0d9e3a8c-35cf-4f08-be13-192a62c250a3" xlink:to="loc_us-gaap_EmployeeSeveranceMember_865f032b-20d3-4513-b9d8-83fa5be1a251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:to="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:to="loc_us-gaap_RestructuringPlanDomain_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:to="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_33f627aa-e3a5-4a21-91ef-1ff6cda11b4d" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_33f627aa-e3a5-4a21-91ef-1ff6cda11b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_55a69190-a2af-46eb-a0c2-e04dda72b454" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:to="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_55a69190-a2af-46eb-a0c2-e04dda72b454" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" xlink:type="extended" id="i5c556d99ed9c47a79ab45099171a3248_RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5b6be3cf-d68c-4ca2-bff6-30d0e84f0f30" xlink:href="nktr-20230331.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5b6be3cf-d68c-4ca2-bff6-30d0e84f0f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_f7a38e5a-310a-418a-92d6-b41d1ab1668c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_f7a38e5a-310a-418a-92d6-b41d1ab1668c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther_9cc38dfc-2bb0-4dcb-9db7-efe585a0cada" xlink:href="nktr-20230331.xsd#nktr_ImpairmentLongLivedAssetHeldForUseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther_9cc38dfc-2bb0-4dcb-9db7-efe585a0cada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a4ed167e-70b5-4c80-8d74-1b6343bd218e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a4ed167e-70b5-4c80-8d74-1b6343bd218e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5818e2e7-52c1-44e8-9ac9-fb4372fca352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5818e2e7-52c1-44e8-9ac9-fb4372fca352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb017bab-6887-40ac-9e1b-f1254ae06f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb017bab-6887-40ac-9e1b-f1254ae06f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d3378e0c-b962-45a1-b70e-929a9cd688cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb017bab-6887-40ac-9e1b-f1254ae06f35" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d3378e0c-b962-45a1-b70e-929a9cd688cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d072c30f-8ea2-4932-ad0f-3b05635133e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d072c30f-8ea2-4932-ad0f-3b05635133e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5529727a-1fdf-479d-8cfe-0aaf839a7a58" xlink:href="nktr-20230331.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5529727a-1fdf-479d-8cfe-0aaf839a7a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_30ec38bc-0397-4750-8a48-9019674f6ad4" xlink:href="nktr-20230331.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:to="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_30ec38bc-0397-4750-8a48-9019674f6ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fb3e383b-ac1b-4a5a-8066-40f448618456_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fb3e383b-ac1b-4a5a-8066-40f448618456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13a2a953-2ec9-4c74-b9ba-d68dcb91c954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13a2a953-2ec9-4c74-b9ba-d68dcb91c954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13a2a953-2ec9-4c74-b9ba-d68dcb91c954" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_76c540c8-7679-4f60-b734-02f3896b5e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_76c540c8-7679-4f60-b734-02f3896b5e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5cb8b1b6-7820-4c90-b2df-14be225fb30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5cb8b1b6-7820-4c90-b2df-14be225fb30b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i97d09f4a8cb14cd5ad8e07ff8b15b1d1_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6c1d9e5-51ec-4896-b9d9-42fc5c085b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7adf2467-668b-417f-b567-60c84d5046bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6c1d9e5-51ec-4896-b9d9-42fc5c085b74" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7adf2467-668b-417f-b567-60c84d5046bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6c1d9e5-51ec-4896-b9d9-42fc5c085b74" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_753ad337-d138-4e46-94bc-31faa36c097a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_753ad337-d138-4e46-94bc-31faa36c097a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_5f563ddf-c8b4-4e7c-9ef5-8fd63bd16019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:to="loc_us-gaap_CostOfSalesMember_5f563ddf-c8b4-4e7c-9ef5-8fd63bd16019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_427e838c-61b9-4b42-a0d6-a4350875b3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_427e838c-61b9-4b42-a0d6-a4350875b3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_479cfe38-db17-4da6-8b7c-66668f636f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_479cfe38-db17-4da6-8b7c-66668f636f4a" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nktr-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:50d7cf34-c614-4bcd-898f-e96601bbe45e,g:0a2e4e36-7a77-4bd6-a518-b664e3e6425f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edfdd85f-30f6-4104-bf74-0931c89a9d43_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8897be3d-d14a-409f-9249-1478ebec8f13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9979ce3f-52c2-4280-8cdd-2e9c0f0e4ff1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb642f18-d632-49e7-9c97-595240a1cfc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityToCollaborationPartnersCurrent_7d1a79c2-29ec-4444-9811-980b5df30bf4_terseLabel_en-US" xlink:label="lab_nktr_LiabilityToCollaborationPartnersCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability to collaboration partners</link:label>
    <link:label id="lab_nktr_LiabilityToCollaborationPartnersCurrent_label_en-US" xlink:label="lab_nktr_LiabilityToCollaborationPartnersCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability to Collaboration Partners, Current</link:label>
    <link:label id="lab_nktr_LiabilityToCollaborationPartnersCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityToCollaborationPartnersCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability to Collaboration Partners, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityToCollaborationPartnersCurrent" xlink:href="nktr-20230331.xsd#nktr_LiabilityToCollaborationPartnersCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityToCollaborationPartnersCurrent" xlink:to="lab_nktr_LiabilityToCollaborationPartnersCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_8de25fd8-7cf0-45a3-991c-1b341a3f4a92_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_515e630d-b3a3-4b10-84f3-ac95d1fa7744_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, credit loss expense (reversal)</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4e84a3da-7207-4143-965b-d8d89651b18f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fed68900-df59-4e88-8bba-af902fb9b9cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ae3f2b54-d723-4f41-ad55-c7ea8e31380f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5d5ddeb7-f8e7-417a-8ed8-0c106a4cfacc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fb3ba468-3157-4d2f-9a17-220bb7df3e7c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9b48ef91-f92c-41c9-af84-c2bcfd3ae347_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f32fefe9-bb56-496c-b892-5d4f072bc7b5_totalLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of right-of-use assets and property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b41af3d7-1f83-4344-b91e-1b1de787a21e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d4eb2d87-1cd7-4af5-97be-348f379f60ed_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_faeb33a5-5a6b-4cac-a9aa-b5b047fe5c89_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_b209caf5-3302-4bcf-a2e4-18e1e22d2cc4_terseLabel_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_label_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets [Member]</link:label>
    <link:label id="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_documentation_en-US" xlink:label="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Operating Lease Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:href="nktr-20230331.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:to="lab_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_b3b6921d-2dfc-4fe7-85b0-1f56def1889e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d89e5aee-f1be-4b16-a0d3-c3cae084c921_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6f37554d-2128-40ab-b391-efa406785a97_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_eb5ab3a0-6484-40f8-b232-b9704fc422f6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0210d25c-9903-46a6-afce-9955a0b32d88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ad32a687-23ce-47c7-a5dd-86e6a379f3d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_cadc876a-0fa3-4847-b163-cd3c836e57c3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_fb341a65-ac3b-4425-860a-69c4e0f0d6de_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones (up to)</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20230331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_698d9071-5831-4892-9fb7-35131ed0c57d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_3afc4e78-ed26-4f95-8b64-444f6ef4a8c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from development derivative liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0e1c38e9-a722-46e2-a566-348067086460_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_162b434f-5e76-4162-9b62-43e5c026cb66_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_21c0294c-9d54-4545-963b-0d95afa56d5e_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_a6955199-1bd2-4814-bd26-e99d0a9b4d17_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20230331.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f7085344-294e-40b0-9601-91b18484e322_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 189,235 shares and 188,560 shares outstanding at March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_42ab2060-847f-4caf-a21c-5da2a91f09a8_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_2e8a0023-183a-4165-ab0c-2ca6e940e0af_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20230331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_9a998351-6575-45d8-8deb-14427b4750ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13d227c9-31ec-4656-b8b9-e2961d088913_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8144a66c-dcfd-4ed6-bc3a-b56acd917517_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4de53a37-578f-4c8a-b379-d2d266d4f8c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcc40d17-171f-4221-a3ae-c64e1f35893a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_57e864ad-c615-426b-ae4a-ad230325d210_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20230331.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4925a7cc-c37f-4b96-95c1-012525e3af38_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_f51c7028-fa61-48be-a7a1-d1be4462a93b_terseLabel_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment [Member]</link:label>
    <link:label id="lab_nktr_SubleasePropertyPlantAndEquipmentMember_documentation_en-US" xlink:label="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:href="nktr-20230331.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:to="lab_nktr_SubleasePropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_237ae4fc-9385-45a2-87e6-cd730c2063d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ce7e3d5-9525-4089-bacf-f84179a18fc6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2c809748-15d0-4184-80ed-89b0bfbb044c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_984f4db0-2071-45b1-bf96-f54209ea4c33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_49d32a6f-1aaa-4dfc-90d2-8b5d56a0f825_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_90ccd05b-c073-48ff-9653-7dbcb3cbbb1d_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c46798df-f9fa-4167-85b4-aaaa5d4e78a4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_af60f9a7-b88e-418f-8491-15d3647b1cd4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c155cf82-69e4-4148-837e-6456c757282c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_fe891a83-d335-4464-94d6-cbcdd7fb9ca3_totalLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment, net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_81b75570-a366-408c-902c-650b67f82a17_terseLabel_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:href="nktr-20230331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:to="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_302b4522-d1a0-4acb-95a9-a9748f83c341_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_63ee9228-e8cf-460f-8cbc-98d60eabebcc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_10db6584-d736-4d2e-b9e1-bec7bc073e62_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember_c4703bb8-96fd-40d4-b86d-62d656a9b6d3_terseLabel_en-US" xlink:label="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Restructuring Plan</link:label>
    <link:label id="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember_label_en-US" xlink:label="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Two Restructuring Plan [Member]</link:label>
    <link:label id="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember_documentation_en-US" xlink:label="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Two Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember" xlink:to="lab_nktr_TwoThousandTwentyTwoRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_fab9f6f5-2d84-40c5-b2a5-85376e0e8f40_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20230331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_85e1dc92-d338-4953-9ee7-db2081a94b93_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_37cec201-11f5-4ebb-a9c1-2ad7caa5e4ca_terseLabel_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of transaction costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_label_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Amortized Transaction Costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_documentation_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Amortized Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" xlink:href="nktr-20230331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" xlink:to="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember_0f50e333-9b8b-4e99-a196-483f415298a7_terseLabel_en-US" xlink:label="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Restructuring Plan</link:label>
    <link:label id="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember_label_en-US" xlink:label="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Three Restructuring Plan [Member]</link:label>
    <link:label id="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember_documentation_en-US" xlink:label="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Three Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember" xlink:to="lab_nktr_TwoThousandTwentyThreeRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther_81d4a02c-e191-45f0-9229-cfa2f0c543c2_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other property, plant and equipment</link:label>
    <link:label id="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther_label_en-US" xlink:label="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Other</link:label>
    <link:label id="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther_documentation_en-US" xlink:label="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther" xlink:href="nktr-20230331.xsd#nktr_ImpairmentLongLivedAssetHeldForUseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther" xlink:to="lab_nktr_ImpairmentLongLivedAssetHeldForUseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3e516d0c-c3a6-4e5a-b29a-66a0a2284eb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1f080d12-ffd5-4fb5-bf02-a4b4216bb593_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8f7a091b-9cd6-4282-a63a-78c6dcc8d2b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e192f580-f665-4ef7-abc9-10e29c6eb7bc_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b5cfbc79-3d9d-4b73-a817-76175bef96d9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_ccf743c8-1653-4681-9443-f927a338ff8d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_251ce4f9-e019-4031-b276-ae760255782c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_ebf97837-9649-4fee-81eb-65b6f4b9a86d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e37d8efb-ad8d-4372-af56-817f2b37f807_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5fcefdeb-f7fa-4599-9d36-d26b09e3a2a3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_0e42dc37-3c62-45ec-b601-e22b074adc1a_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_268fbbea-6910-4512-bd5a-935c766b2880_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_59fd392b-c000-45f2-977d-3c8471519d46_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_38cf37c6-eac3-4031-85dd-fe7bff8591ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7da3e47-234f-4607-8218-b15eedde7900_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_8589168a-d02c-4f67-9aba-289b27ed17d7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_b8f0f229-b367-422e-bc0d-c59a85c6a5ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_6596e175-5bd6-4fb4-b764-30198f588b19_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_08e5a884-f37e-4aed-afe4-0f8356038883_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_21267600-9e2b-4e36-a775-dadf72af80ee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_179add6e-1fd5-497e-9c28-5f7a8cb8fb8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_7f161f7d-edae-4a5d-a891-d8444393bb43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment expense for facilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_cc72f505-4d26-4dee-a7ae-35e98cdb016f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4a1b96a8-3726-4114-b41a-d6a2cd8e26a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1a317101-c642-4fea-a220-229ff572aff2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_909f3253-e3f7-4126-854e-ce46c66f55cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_7408a7b6-1b8d-42f0-abf5-e8ace95c4c6a_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20230331.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1091fa99-5cc7-4166-a030-7fcfa9040734_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_65eec13c-6e9b-4cc4-98f4-832ebedec301_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_5ad14765-fd22-4e6e-9a31-137c70ea6a8e_terseLabel_en-US" xlink:label="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Market Participant Subtenant Borrowing Rate</link:label>
    <link:label id="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_label_en-US" xlink:label="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Market Participant Subtenant Borrowing Rate [Member]</link:label>
    <link:label id="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_documentation_en-US" xlink:label="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Market Participant Subtenant Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:href="nktr-20230331.xsd#nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:to="lab_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_a2b22455-8bbc-47ff-8bae-8b46c25a74fb_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1776a9ed-f1fc-42ff-8e4b-d05248e76e6a_negatedTerseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_37dfc835-c620-43d1-9682-f9e8e993dc41_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8daf17fe-4d76-42ac-8fdd-c91905f45485_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8c1e340c-28aa-41d3-81a3-46470a12890c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d50cd251-e050-4bd7-a2f6-bfe9ecd88248_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9013f3d-fc75-4bca-ab8f-9953c7e15a06_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0102ac74-c243-4f55-82ea-dbe780f27ce4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_473efa98-3165-4321-aa80-730542c1d732_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a268ffe-f3a1-4042-b14c-850505db516f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_2b2955c9-79f0-43b1-a109-75dbf46b4de7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2b51e2f0-7562-40f6-be81-6050ad94cdc2_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_09890e04-0cb2-4745-81b4-183748d7e577_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding (up to)</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20230331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ccdbcb2a-a7a3-4558-a74e-5925aa7fdf51_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20230331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_ac7e31dc-7324-4c8b-8e7c-09eaf82d446a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_728ea3a4-9557-479c-acfa-d40fe3397364_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0d23be33-bf58-4536-a724-9176b02b3932_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5eecf52b-8c19-43f5-8448-68571f22d44c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8df45454-658d-4ea6-a713-f010d5feb94c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_4852e6d6-ca76-4be7-8c24-d9d58d1bb4bb_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e59cf2be-1ced-4bb1-b4f5-b4c3799714ec_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_4ed523b1-c35f-4af3-957b-2596c5af709d_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9c820f6d-e657-421b-8da1-36369bbf1e73_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5ffe3f3b-911f-4c03-af02-e2f1819e9e33_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_56380b8f-1a82-4314-8e62-0031b572f7cb_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones (up to)</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20230331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a2e0d6aa-3829-46b1-9876-dee347036036_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f1242662-14ec-4c14-9d95-aebb64b543b5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1c903f8-6214-4d3f-9634-9bc0b52f82a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66f8906e-2f88-4fd2-bc4c-fb3964ebe09d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_ef04380d-82a8-4a6e-9808-5a8afc4e96eb_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3ab7daf9-2436-4571-8fdc-936b5d4457a0_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936e5d87-fb18-4133-a77d-f5768f5a830b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f4d0dab-09c5-493c-9d1e-4d4eef6d9e9c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_408d28d3-0dd8-44ab-a275-923077175aa2_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20230331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_1112a61c-67b0-4321-8afb-2eac9f3a1b66_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_bb115af3-8918-4f23-9e1b-b98bc6b289a3_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6fc6570f-97a6-4acc-b645-a5a06c807a6c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_63a2b582-4aac-4448-92e6-c96d6f2580d7_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e392b14f-348b-4b1d-b3cd-44fbd5b22a88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b1955ea2-149b-4157-965e-7f95e9354d92_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_74590d24-5f53-4da7-a8dc-928ef23cfc19_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_13d39a3a-4eff-4f2b-be39-277e90e3ffb0_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88c067f3-4563-40d9-842f-967f1c6474e2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_471fc372-286b-439c-b796-4cde615d33a4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_a1770572-fed6-4683-93f9-8c53468f52a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_1072e08b-9f2c-487c-adda-cf29f9330ae0_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20230331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6ca39d7d-af2c-47fb-a7d7-5d10d18b3910_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_4def06ce-357e-4955-8b6c-b2cd552a5e63_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_f3bbe586-a4f4-429b-8235-33c6d48d44cb_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and benefit expense</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2829eb0d-f7af-4267-92c4-dff22120fc79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7b9bcce4-8935-4c1b-b782-2b15b9cfab9a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_358add42-0348-4eeb-b8a2-0e952c06c8a3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fb4be365-909a-404b-b87c-23e1b59c5eee_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_14149a38-5604-42b6-9065-189535879bc0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_45e3ace5-d9ea-4e5a-9958-7eb28f91c4e2_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20230331.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_69044b94-55cf-4aa2-b3e1-e0ef3728a7f4_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Policy [Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20230331.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_9c117090-1eae-4a26-b7d7-033fcdae5cb5_terseLabel_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember" xlink:href="nktr-20230331.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LaboratoryEquipmentMember" xlink:to="lab_nktr_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6889fee7-5ef7-4141-813b-4be5b027e3f7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_14b4e606-c89f-4907-8c7b-41ed6aa3e37c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1bc89b20-03be-4039-af55-faa92bb6e2ca_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bde360c9-f6d0-4c39-9d9b-d62a12a3b229_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_b39a23e7-f7d4-46f7-b114-abf14d10fd28_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_646bb53c-a411-4a94-a7e5-c4114936e51b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e8b6cd6e-0d30-4e7e-8fdb-6c8437d592e8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_c9ec19e9-b22f-4c05-bfe1-316635e4702f_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20230331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_22bd75e5-83dd-4f07-9ca7-aa58bedbd890_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_024a39dd-a402-4bcd-8b6d-ee59cbfc5f90_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OperatingLeaseMeasurementInput_0cc95ce4-b903-41b5-bdc6-4ec528150458_terseLabel_en-US" xlink:label="lab_nktr_OperatingLeaseMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, measurement input</link:label>
    <link:label id="lab_nktr_OperatingLeaseMeasurementInput_label_en-US" xlink:label="lab_nktr_OperatingLeaseMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Measurement Input</link:label>
    <link:label id="lab_nktr_OperatingLeaseMeasurementInput_documentation_en-US" xlink:label="lab_nktr_OperatingLeaseMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLeaseMeasurementInput" xlink:href="nktr-20230331.xsd#nktr_OperatingLeaseMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OperatingLeaseMeasurementInput" xlink:to="lab_nktr_OperatingLeaseMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a7a95032-3218-4e69-8d17-8525e2b534b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_3b56ec61-7976-400f-8778-45a771c92648_terseLabel_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment and Operating lease right-of-use assets</link:label>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_label_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</link:label>
    <link:label id="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_documentation_en-US" xlink:label="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:href="nktr-20230331.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:to="lab_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_7495e999-1098-4fff-b4c2-dcb3c8b6dee7_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2afa7282-50e3-4f9e-95f2-6a568e2ddf7f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_5e187e8d-f62b-4e5f-868e-3a171f5a67a7_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20230331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_1398540d-662e-4b79-b9a9-e81fb725474f_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20230331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e67674c0-a24d-4c45-97f7-19e391baf807_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d5ceec62-1813-4e5f-9bb5-635fb56a4fd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_9bb7f615-93f0-4301-ac02-9f5c6992d841_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20230331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8f979950-0925-41e1-b03f-59d37830c28d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92d9218f-75b4-4ae5-a54b-951b7ad53aaa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3c8ae14f-67c9-4670-b175-666d31a96b1d_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_6a196b31-f61e-42ec-b33c-fe7dbfb639f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a3122500-9f1f-41d3-8694-b752e5580f6b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6f1aa83f-7ed4-44de-a469-4fed51abc905_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1152dfd8-39a6-4704-923d-641cc8f1bdf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97d9b07d-f870-49d3-91ac-13236e677467_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05281517-7e23-46a4-b223-fb678a47e2cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_b780b86b-8191-4489-92fe-b5c97fe2dbca_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e2e404d-ea67-4c8b-83d7-88fad6815d2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f11e9038-78ff-4936-9674-3c697b103cca_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_89170878-0586-4a7c-a7d7-83fc19d50112_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a30e6585-26b1-4f3a-aca3-f6602cd98ebd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a1f8b15c-da67-4f58-807e-6f3ce7e31c65_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_dabef22a-cf13-4ba3-81d7-dff95603cc0b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment, and costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_0787d9d4-2da5-414c-b410-0c46c3f5ec54_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized during the period</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73753fe0-7d88-4fbf-ae8d-6b99250da3ae_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a9bb1384-bc00-4e16-8701-886f143d92cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_be506e4c-cacb-4f20-ab0d-bd98c191d4d0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_231ff6f0-1a11-4ec6-92ab-634066b793fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_ed8f5716-ed7a-4a1b-b22b-722487e4a78b_terseLabel_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and computer software</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_label_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Furniture And Other [Member]</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture computer and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember" xlink:href="nktr-20230331.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ComputerFurnitureAndOtherMember" xlink:to="lab_nktr_ComputerFurnitureAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_930c26e0-c189-4b5c-aec9-3da5318577df_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e48544c-e407-4498-ade4-fbeef19dc701_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_46dccd48-98a8-4e64-ab7f-a9659b462fae_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20230331.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_52c06746-7fd7-4723-882e-8f13792f58bb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9248856b-8631-419d-9694-058bfbc0c03d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c19b35b3-49b9-4a8c-a5db-8b70e2e00b66_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0ec043db-3eee-41de-8575-f53179ae2e61_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_08eae486-02f1-4bd3-afc2-d4800b0a6e7d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8392d0e0-3b07-495c-b1d9-70d00ec331cf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8063fac5-6d08-4d2c-9440-41eb0e7e587e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_71badbec-64d0-4d8b-9c31-18d472e3db60_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2023 or December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_8de57d80-9f28-48ff-84df-37c520f9a390_negatedLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20230331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_d3912eb0-49fb-4b94-959c-14fc4e984c7b_periodStartLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net &#8211; beginning balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1045d2d5-c712-4f05-8357-96902bceb18d_periodEndLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net &#8211; ending balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_da2ddc2e-4838-448c-9972-e723e44304d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_8395b9ce-0961-443c-919f-aae503542f49_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination and other restructuring costs</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_b1736cdc-f102-4705-bcbd-75fb75831a97_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6e9c226d-973b-40e8-8335-370adba43795_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_bff00160-c1c0-4232-a888-89585ee6480c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0bc48fee-61af-4515-9b34-5d0d41942a4b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d634c0a-a1d0-4bda-aba2-a7d0dc0e95e3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_80478b3f-7155-4651-bed0-c8e00902bec4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c4d90b5d-edf6-4839-b7b8-5965c5021437_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_47dcd1de-ca6e-45a4-892b-e5eddef21cf0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b530baac-b802-4cfb-9da1-7ef50ddce2f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_43f04a41-be87-42b7-8af5-3990df198a7c_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Results of Clinical Trial Programs and the Restructuring Plans</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f02d7571-59af-4bfa-a5ab-652639004d4e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_494f4a16-a432-4aae-95ec-52110cc333ac_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_01b48f45-dc36-478c-ab18-dd8a44299773_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_f187b6da-6043-4396-84c2-874df6072a84_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bef97274-0417-46f5-ac12-0614d965ef5d_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c40702a2-d73a-4011-8b6a-39bf1fc1ea5b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5e878d21-1e9b-4991-a513-34079d9fe17d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_4591e19b-e2e5-4995-acf6-97a6e6c6d208_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6187ff00-4cdf-427c-b4ee-f73f4209096b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9d5bc385-33d8-47df-879f-425248c58c4f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cddd4f45-5d3c-48a9-a14b-e2eafa099553_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_1ed04712-fe97-432c-95c8-d9c3c44f2394_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_eb7911de-b5e5-43cf-8ab6-ade06789afe1_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_483c6995-3deb-41ff-a799-a7f5bc2c61a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0cfd7927-c619-46e1-a194-0eab736635bb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_06e2989d-a945-45b5-afbe-92127aa85212_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_435d377b-3030-457f-949d-62db788be3e6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e4b3bd90-555d-41ae-9e7f-69f869ac0ddc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_e2b37928-f43a-4598-9591-9cb12d5d5559_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_60efdd14-b875-49e6-80f0-5dce8d833ddc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_ecfd8a24-b145-4eb1-a1b3-fa93208c5a77_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b0750db1-d29b-4d14-99a7-3a687ce9489b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_a83e5fc1-107a-4b20-b1a7-ffbd82055b49_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Related to Sale of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20230331.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b260ce7-1360-4716-b3bc-0884abad62cd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_117e9f60-a14c-4f55-8ac7-f1cb153323c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b5eb5181-27f2-4757-b5f5-06d9785fa0c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from SFJ</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4f2964ab-3851-4f2e-a7a9-bd2c0e56ecaf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_eb9ff549-ba92-42a6-85ea-fad4ef9076dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d2955d76-dcee-4c4e-88bb-612f635982a9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a2f227ce-e14c-4b43-a132-ffaf412851b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b60e5028-e773-4df7-b46c-f1302ca4d09a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_60057e20-1e13-40e0-b9d1-c975fdd78b6a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_0ebe4c6b-1335-46c4-b388-9eb6f6f9aca7_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20230331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_af386a68-3588-4a10-94be-1e9a6c0abe08_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1ca48724-f6f6-4e41-bcc7-ba270bbf73d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6b3a48d5-cf5c-46ee-aee0-46017ab5431e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7c170fc9-c359-4564-8900-dfe380a11311_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_01a3aed7-969e-4bc8-95c1-4e4bd09afc6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7735c4cc-a765-441f-b697-10a05bacfad1_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_a00775ee-c28f-4c81-b007-950580c5915b_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payments (up to)</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:href="nktr-20230331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_1bcd23e2-1edc-4929-a393-f288a18f3906_terseLabel_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:href="nktr-20230331.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ea58f0d1-6a0d-44a1-af3b-5ce8e0e04198_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_cabcfb73-3794-42c6-b828-64e1135f83dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f32b16aa-051f-46c8-9a84-15960f8b33d2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_317b664d-c46e-4146-bd4a-903b5e8ae6b8_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_c27f3a87-f116-4ba8-a5d4-8a5c955f2096_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2117a5e0-2efa-487e-ae2a-b5c9f04177e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f6a24606-9e47-42c3-b64e-4d55ac7fc768_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_3fffe4c9-863a-4926-9569-587f4e808427_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20230331.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_377efe0a-c7ff-47be-b8ac-6bf70e55872c_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20230331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e14800b2-57cf-45c6-b58c-4e555ce7576e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_97287cd6-f897-4384-b0df-3fa88afda626_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_01a541dd-f5e2-4eab-a93e-fd0fd0ae82ea_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_abaff917-0452-4240-a58b-91c148ea83e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_3f8b6453-7dab-4b32-b972-aac942d6804d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_622c21b4-3970-4831-9c61-9b8c29069cc5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4db90176-61d3-4ddc-ae8a-bfba02e97bfc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1e26083e-1b0b-4de0-b728-20063ec529b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_422804d6-fc4f-486e-ad67-8cd2114fe8f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2e87b9ce-8b07-4c14-b6c2-30fb2c5d44ed_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_f38b4b4b-792f-46d2-ba01-b3632e0a5599_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value at</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1b12ba14-ca85-4057-b885-58ec4576a346_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fb3a933c-9aba-42b4-9431-536a738e1acd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_6867ae50-7854-46b1-8cca-23e318632ae7_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20230331.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1e450daa-0338-41cd-b7c2-c414e613b94d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2bb10bd-ffcd-4760-972d-393c06726b3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c281d88c-0afb-45cc-aa52-f595b4cdd994_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_e57b3219-ab7a-4222-89cf-495bea26d401_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Financial Statement Details</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_3918a3d6-fb7b-470b-839b-7b2922d07190_terseLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment at cost</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Gross</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_82f288fd-c053-4c61-8a93-03ac3d56ad21_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_31ac6682-860b-4268-ab72-6b31199594f2_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_02392df2-51bc-414d-a83e-87e81b4d3c93_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_0efa1c9d-1d0e-4dd9-9f85-518c25f091dc_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:href="nktr-20230331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_bc91174b-d981-4687-9857-7d813dd7bf96_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2763b2c0-2e5d-4188-b7c9-34ec242f2597_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_ac98f332-1a10-4b13-b8a7-2f220d92af35_terseLabel_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties liability discount rate</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:href="nktr-20230331.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:to="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_045d34b1-3926-4b0d-a16a-0338ad559f7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8e69d5b4-6016-496f-b7d8-2e1de63a57f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b2babf1a-3cea-44fc-abd6-5d3d6406aa7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_6fbda221-50ed-47ec-80fc-64bc6155cd15_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_de1f0ae9-70dd-47d6-a762-173e5e355c8b_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20230331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5ad17bac-92a8-4d0b-bb13-d4956cf9da6f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_013e295d-55f1-4023-aa03-0d5ec12c5d2d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_842a578b-8591-4c28-9a1a-00f2ee93ca88_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_94d95bcf-d4d3-429c-913c-8570c4973da7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_67537877-b09e-40ca-a6c2-39f14243649e_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e3fde5d6-9f30-48e4-a2a1-905c708bba9f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7fdf966c-0308-40ed-a1c8-e5f8d482c994_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2b819cc8-570e-4752-b5fe-ea1c3537ae37_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2b92d837-c851-46b5-a025-2d4ad2c6030d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f981df11-bbeb-439c-9c92-7a6a73c2f694_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5da37d16-1c9c-4706-a94e-f3c69870a3af_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_f3644a35-128d-4140-8af7-dfe2a529e76d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c06ecb67-7576-42f0-a56e-c569160f8bcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8d2b8a6b-c37b-4777-bbea-e82b15847b6a_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5555c886-b786-4edb-8df8-28b2e0659b24_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_16b3cdb0-06b9-4d4a-99f4-76d67024a7aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_85bcccb5-fcdd-4c8d-befe-03fb7db81f24_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_eecfb5cf-a8ab-4545-83e2-90a5db6c57bb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedContractTerminationCostsCurrent_e84bec1a-ff31-4385-b304-7d1e29bf29ff_terseLabel_en-US" xlink:label="lab_nktr_AccruedContractTerminationCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract termination costs</link:label>
    <link:label id="lab_nktr_AccruedContractTerminationCostsCurrent_label_en-US" xlink:label="lab_nktr_AccruedContractTerminationCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Termination Costs, Current</link:label>
    <link:label id="lab_nktr_AccruedContractTerminationCostsCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedContractTerminationCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Termination Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractTerminationCostsCurrent" xlink:href="nktr-20230331.xsd#nktr_AccruedContractTerminationCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedContractTerminationCostsCurrent" xlink:to="lab_nktr_AccruedContractTerminationCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_29e370fb-4abb-4db2-9718-ca84536f08c8_terseLabel_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs</link:label>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs [Member]</link:label>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember" xlink:href="nktr-20230331.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockOptionsRSUsAndPSUsMember" xlink:to="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_96d63be7-5cf5-4233-83e9-3977c0d7061d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0dbaac38-91e5-4564-83c3-a62b6dc0d676_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ec56f376-f8d2-47cf-8f36-1d6673e8192b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_68f8453b-ea37-4b64-8fe7-5c6f6a112656_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_87c897bc-9e2a-4df6-a8e5-b21a1fab6088_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_c92a411c-f256-4673-bdd7-df2226d5cbba_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for litigation</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2a281292-00a4-4f20-b33b-93589d2926ac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_11429671-de27-4351-aec6-aaa128156189_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_230a1de1-c601-42d7-8f0b-85e99bbdfa2f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ffd06f8d-3e85-417f-9dee-c4622739f637_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_720728e0-ecae-4440-936c-fa792c48c9af_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_9cb3f729-0db7-4637-aa2e-a4d33af1260b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e40a1c35-1d64-4d04-ad60-5b3eecaa12d5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5218ab82-5375-4928-9932-f6dd186f8079_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_056a463f-6e2f-4e73-88c0-47aef23d4fb6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e66a23-cf52-48a2-9041-950d29e3d8ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1f7c57a7-55de-44af-aa8b-61945e8cbb5e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19a78c8b-5e15-4765-95dc-bb8c2152a4c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3cdb43b0-006e-42df-8b20-1bb8bf1161a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91a31e94-e705-4f99-b614-9546bf8450d6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_fec2eb11-d909-4831-86f8-7110c79a2809_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_095a6a5d-4bd1-480f-b614-196af07bc85e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_10c5d541-94b3-43d9-b687-768206ec95cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_557c245d-bbd6-457a-a2e8-9489559bd00e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9e29f27e-5788-49df-8791-4449769848e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d555a615-6eca-40f4-88ce-e89be4c2f173_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7c763cf2-c5f9-4b86-85cd-4bb0e4101dd5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Asset Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_c5faa968-4767-4dea-854b-8dbce5360266_terseLabel_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_label_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Laboratory And Other Equipment [Member]</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_documentation_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing laboratory and other equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:href="nktr-20230331.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:to="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_08a3f73a-1c8f-4cd6-a134-c8ed643ca803_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_c5fa5d28-badf-437a-ab09-5be1b1b76a17_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_34ac03dd-2888-4700-bf71-50fcd8b2a81b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a92a5a1e-82b3-40ff-918b-36b6ef067e1e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_323f85e8-3760-40a0-a501-ef545bbd9974_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20230331.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f52897e-d007-4a48-991b-b234c5dea15b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_03fa998f-a7d5-4556-a5be-f98bb9bb04ef_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b0ee3b4a-5520-44e1-9037-20dc5b450e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8ac9469c-85de-4344-b33a-06496704af85_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_a30704ee-b100-45f1-9ecb-a5b452ee41cd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_8c902b80-3e4d-4c01-811d-7ce9217047eb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_309db414-a885-4991-a0e6-14877c10451f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e5e3dbca-2c94-4829-bc62-093ccb6489f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_103451f7-b672-4411-976d-bac00e36ec62_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_18c980d9-40e9-4704-ae0d-8b85acd9ad2f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce termination, percentage</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_eddb9d7d-714c-4a31-9139-56392e4cde75_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_e6d5d25b-328f-491f-b52b-1b594ada2a76_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill &#8211; beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_94878655-e083-48c5-8ac8-1bed4619968b_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill &#8211; ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nktr-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:50d7cf34-c614-4bcd-898f-e96601bbe45e,g:0a2e4e36-7a77-4bd6-a518-b664e3e6425f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_978696f7-549b-42f8-95dd-b53e07d259cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_DocumentType_978696f7-549b-42f8-95dd-b53e07d259cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_63635732-e1ff-42ab-ae26-7cd6f145f4ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_DocumentQuarterlyReport_63635732-e1ff-42ab-ae26-7cd6f145f4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_062683ce-eb1d-408f-bb8f-825458bb13ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_DocumentPeriodEndDate_062683ce-eb1d-408f-bb8f-825458bb13ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_de7e0426-7051-41c7-8a1d-48eca424581d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_DocumentTransitionReport_de7e0426-7051-41c7-8a1d-48eca424581d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b1434cb5-050d-4faf-acd1-b5a2adbcef77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityFileNumber_b1434cb5-050d-4faf-acd1-b5a2adbcef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c52b9202-4729-4e69-9191-6dec47e4a7d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityRegistrantName_c52b9202-4729-4e69-9191-6dec47e4a7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4d4ab229-9f6a-4d54-a084-5a6afdf594ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4d4ab229-9f6a-4d54-a084-5a6afdf594ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_744bf817-70fc-4561-96e2-6b5b97341cd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityTaxIdentificationNumber_744bf817-70fc-4561-96e2-6b5b97341cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0f1d535c-5c4c-46f8-8677-70c766826f7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityAddressAddressLine1_0f1d535c-5c4c-46f8-8677-70c766826f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b8fd9221-ec34-49b5-9d9c-0aa8677aa1c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityAddressCityOrTown_b8fd9221-ec34-49b5-9d9c-0aa8677aa1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1afcfcb5-36c4-45b1-aa5b-680e47ea484d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityAddressStateOrProvince_1afcfcb5-36c4-45b1-aa5b-680e47ea484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f88a115f-299a-4e50-b137-0a94c617be6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityAddressPostalZipCode_f88a115f-299a-4e50-b137-0a94c617be6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ed6be0c8-4a72-4cd0-8b7c-17776eca3f67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_CityAreaCode_ed6be0c8-4a72-4cd0-8b7c-17776eca3f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a35475e2-c5ca-4b43-b687-df3e4fde2fa1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_LocalPhoneNumber_a35475e2-c5ca-4b43-b687-df3e4fde2fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0b69fc49-c5cc-4767-be5d-af5374b733a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_Security12bTitle_0b69fc49-c5cc-4767-be5d-af5374b733a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e070565a-c263-4802-944a-51c457b9e6c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_TradingSymbol_e070565a-c263-4802-944a-51c457b9e6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1b4fa14f-a9f2-4baa-90f6-a05cd1a1f4e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_SecurityExchangeName_1b4fa14f-a9f2-4baa-90f6-a05cd1a1f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_75d085e2-2c34-4f38-b52a-741522592f45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityCurrentReportingStatus_75d085e2-2c34-4f38-b52a-741522592f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_05a49cd4-6674-4a8d-8bc4-d45936cca51f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityInteractiveDataCurrent_05a49cd4-6674-4a8d-8bc4-d45936cca51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_82d8b838-3767-4b6e-843e-08c88c3e62e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityFilerCategory_82d8b838-3767-4b6e-843e-08c88c3e62e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c681e8d6-4c0d-4b88-8420-b91befde79f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntitySmallBusiness_c681e8d6-4c0d-4b88-8420-b91befde79f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7fb95ca5-964b-4d9c-8927-064b5c8ee5b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityEmergingGrowthCompany_7fb95ca5-964b-4d9c-8927-064b5c8ee5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0b3efd4b-919c-42ba-93fb-4aa245dd05c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityShellCompany_0b3efd4b-919c-42ba-93fb-4aa245dd05c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fabd32f6-eee8-4505-a51d-d71b25fac163" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fabd32f6-eee8-4505-a51d-d71b25fac163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f28f40eb-aed0-488f-9eab-eb2a79b88139" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_AmendmentFlag_f28f40eb-aed0-488f-9eab-eb2a79b88139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_74e10660-dc0a-44a3-b5fa-90bd2e65c2f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_DocumentFiscalYearFocus_74e10660-dc0a-44a3-b5fa-90bd2e65c2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ae08f670-c52a-43a3-b030-967e2d87e77f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ae08f670-c52a-43a3-b030-967e2d87e77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dcf79910-f446-49ae-861c-7f5d2ad01758" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_EntityCentralIndexKey_dcf79910-f446-49ae-861c-7f5d2ad01758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0b42b702-27a1-4a4f-9ea4-236e8f635f83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa2c56f0-a932-47d9-9aca-4d55081d2877" xlink:to="loc_dei_CurrentFiscalYearEndDate_0b42b702-27a1-4a4f-9ea4-236e8f635f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_87f4048a-d1df-4e07-8143-f1080a3c8e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87f4048a-d1df-4e07-8143-f1080a3c8e46" xlink:to="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc9743be-ce67-490e-97f1-fb79a2fcdcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc9743be-ce67-490e-97f1-fb79a2fcdcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3542d443-761b-4e65-af7d-d961e76b9e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3542d443-761b-4e65-af7d-d961e76b9e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0deeacf8-1556-4e5e-86be-3d0a276c559b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0deeacf8-1556-4e5e-86be-3d0a276c559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f9fa1a61-081e-42d4-b485-b30a30bc41da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:to="loc_us-gaap_InventoryNet_f9fa1a61-081e-42d4-b485-b30a30bc41da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_88475ca7-01ce-454c-a15a-d32be02103d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:to="loc_us-gaap_OtherAssetsCurrent_88475ca7-01ce-454c-a15a-d32be02103d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_affe43f7-fde4-4371-a4df-81d036246b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e38a61-1758-46b5-8cd4-5ef03e3f9d3b" xlink:to="loc_us-gaap_AssetsCurrent_affe43f7-fde4-4371-a4df-81d036246b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_412c750a-6a2e-40f5-ab43-5a904a82e309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_412c750a-6a2e-40f5-ab43-5a904a82e309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_996795f4-a698-407c-8a19-4455fb39d5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_996795f4-a698-407c-8a19-4455fb39d5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_62b0bc19-1a82-40a7-a58b-4f550d5eb99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:to="loc_us-gaap_Goodwill_62b0bc19-1a82-40a7-a58b-4f550d5eb99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d5f6a953-01a9-44b7-bfbe-ecc48de86e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d5f6a953-01a9-44b7-bfbe-ecc48de86e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_827ae141-6aaf-43c4-b2ab-11d8c834a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5b4a10-ec9b-4baf-a78f-b9c07beda011" xlink:to="loc_us-gaap_Assets_827ae141-6aaf-43c4-b2ab-11d8c834a08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87f4048a-d1df-4e07-8143-f1080a3c8e46" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6b6f3c67-518c-495f-af7d-95668b83347a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6b6f3c67-518c-495f-af7d-95668b83347a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8ea396b-e331-4b98-8bd1-ce3cabe2bb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b6f3c67-518c-495f-af7d-95668b83347a" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8ea396b-e331-4b98-8bd1-ce3cabe2bb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_81c4a934-b82f-4a21-9b54-7ca8f6bdcb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b6f3c67-518c-495f-af7d-95668b83347a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_81c4a934-b82f-4a21-9b54-7ca8f6bdcb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_507e03a1-1d01-4c38-aaa7-f5d216f64281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b6f3c67-518c-495f-af7d-95668b83347a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_507e03a1-1d01-4c38-aaa7-f5d216f64281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3acc64a7-4c97-4d0f-be42-f36db609d265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6b6f3c67-518c-495f-af7d-95668b83347a" xlink:to="loc_us-gaap_LiabilitiesCurrent_3acc64a7-4c97-4d0f-be42-f36db609d265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc2283b3-1f5b-45ab-8615-a80713b5a468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc2283b3-1f5b-45ab-8615-a80713b5a468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_543c695d-dcab-4967-be42-0e5186012b1d" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_543c695d-dcab-4967-be42-0e5186012b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_224ae47b-4102-4e13-b135-65821e65dd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_224ae47b-4102-4e13-b135-65821e65dd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_292a988f-7091-48db-8df8-7afccd874d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_Liabilities_292a988f-7091-48db-8df8-7afccd874d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5c086959-7848-4a6d-ac27-d4380d03d603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5c086959-7848-4a6d-ac27-d4380d03d603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_02618d3a-bbea-46ce-a641-e4dcb17dc384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:to="loc_us-gaap_PreferredStockValue_02618d3a-bbea-46ce-a641-e4dcb17dc384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b4cb6ba9-ca65-4ef1-b91c-8a21947442e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:to="loc_us-gaap_CommonStockValue_b4cb6ba9-ca65-4ef1-b91c-8a21947442e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7dfa132c-9685-4115-a7b7-5102f70dece1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7dfa132c-9685-4115-a7b7-5102f70dece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6d1b67b7-2054-4675-abc6-df0c9cc2ff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6d1b67b7-2054-4675-abc6-df0c9cc2ff2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65518fb4-5b56-4b47-9070-56082a22d75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65518fb4-5b56-4b47-9070-56082a22d75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_261ebf43-b794-437e-b69e-8bcb4adece9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20abf2c3-52a8-4373-b53e-9f2e96a9754a" xlink:to="loc_us-gaap_StockholdersEquity_261ebf43-b794-437e-b69e-8bcb4adece9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c62fc350-3b78-487a-a727-c69be9eb5917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6dfdf61d-b696-4c23-a166-acaa58845a4d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c62fc350-3b78-487a-a727-c69be9eb5917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28bd9d21-a81d-403d-93b1-8fe63b72beeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28bd9d21-a81d-403d-93b1-8fe63b72beeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_092a3955-0042-4260-b770-5f621bf7e86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_092a3955-0042-4260-b770-5f621bf7e86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_47d69e8a-8deb-42c7-96af-40b749ec818b" xlink:href="nktr-20230331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_nktr_PreferredStockShareDesignated_47d69e8a-8deb-42c7-96af-40b749ec818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8596ae87-cf5e-4e43-a867-5bad0a41a2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8596ae87-cf5e-4e43-a867-5bad0a41a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e11bb01-5e59-4de9-9b3e-1fd9c9f923e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e11bb01-5e59-4de9-9b3e-1fd9c9f923e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9340043d-23ae-4f68-829c-91a66efe65cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9340043d-23ae-4f68-829c-91a66efe65cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93e1fd35-af28-4427-ab2d-99c7c9752298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e0a03f0-f275-4bfb-a06b-03934cf464c0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_93e1fd35-af28-4427-ab2d-99c7c9752298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7415dce9-64e3-49fb-a6be-f79e83b820cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7415dce9-64e3-49fb-a6be-f79e83b820cb" xlink:to="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:to="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e4203b4f-d4ae-4f37-ae8d-027c90f7de6f" xlink:to="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b64078ef-ddf7-41ef-b75a-6892aae8e858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:to="loc_us-gaap_ProductMember_b64078ef-ddf7-41ef-b75a-6892aae8e858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_58b9eb29-0f7f-42e5-bec0-fe339b9ecf65" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_58b9eb29-0f7f-42e5-bec0-fe339b9ecf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_8c9a74ea-270a-4dee-b5f5-db7f8b59f175" xlink:href="nktr-20230331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3e0517a-8e98-4ae4-9c02-30253870fc6f" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_8c9a74ea-270a-4dee-b5f5-db7f8b59f175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1aa981a8-369c-4689-86c2-79a87973ce07" xlink:to="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2e43b82a-c985-49da-8dc9-649eafdb9283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_RevenuesAbstract_2e43b82a-c985-49da-8dc9-649eafdb9283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dcf9cd-738b-49c0-accb-347ee4ead441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2e43b82a-c985-49da-8dc9-649eafdb9283" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31dcf9cd-738b-49c0-accb-347ee4ead441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1759ef1f-f6ec-47df-8fc9-33ca6f5f0bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1759ef1f-f6ec-47df-8fc9-33ca6f5f0bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a80a9c1-ab11-485a-912a-771a3c2ada0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a80a9c1-ab11-485a-912a-771a3c2ada0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_338b539e-31c2-4fac-b968-7a8c2c54313f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_338b539e-31c2-4fac-b968-7a8c2c54313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_21a4260b-a89c-45fc-9714-ac20d053c735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_21a4260b-a89c-45fc-9714-ac20d053c735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ca2f1258-0bc0-44c5-8519-40cbe6979ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ca2f1258-0bc0-44c5-8519-40cbe6979ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9adcbef5-4a16-44dd-8bff-354ef396ae23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d820ca49-0de3-4f66-af12-b60f2eff4411" xlink:to="loc_us-gaap_CostsAndExpenses_9adcbef5-4a16-44dd-8bff-354ef396ae23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dcc6e8d8-ad1f-402b-bebf-6f90683a8e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_OperatingIncomeLoss_dcc6e8d8-ad1f-402b-bebf-6f90683a8e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_c9d263d2-f40f-4cb4-bb49-9df80f20f9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_c9d263d2-f40f-4cb4-bb49-9df80f20f9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f6ee9770-5e44-464b-b98c-259cc4bed841" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f6ee9770-5e44-464b-b98c-259cc4bed841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_350c4dd3-815d-441c-9578-e15caf567f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_350c4dd3-815d-441c-9578-e15caf567f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bf23fc08-8cbb-48d3-89ea-21707636c538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0433479f-fb24-40de-961d-f6cc183a099e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bf23fc08-8cbb-48d3-89ea-21707636c538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ba1f4bf-d204-477a-b316-621cc84eba36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ba1f4bf-d204-477a-b316-621cc84eba36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c6163b8-71a4-4816-9f19-7d21048ac1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c6163b8-71a4-4816-9f19-7d21048ac1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2c11aea-f94d-4976-acf1-eebe789b1ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_NetIncomeLoss_c2c11aea-f94d-4976-acf1-eebe789b1ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a4f6580f-9d34-4b71-baaf-65d9334afd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_EarningsPerShareBasic_a4f6580f-9d34-4b71-baaf-65d9334afd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9e9305f9-cac6-412c-98f4-6792a6bb9952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9e9305f9-cac6-412c-98f4-6792a6bb9952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9143c363-ab65-4ea6-958d-ace95c1a878e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9143c363-ab65-4ea6-958d-ace95c1a878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6bf3a42-09be-4fb1-b9bd-c25f5a99fad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd511899-7bef-45e4-9e90-a12cc8e07dfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6bf3a42-09be-4fb1-b9bd-c25f5a99fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5c3401e6-2ed7-4174-a89b-877e7a14e43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f65ae978-ba3e-4535-93c3-b4635ccee212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5c3401e6-2ed7-4174-a89b-877e7a14e43b" xlink:to="loc_us-gaap_NetIncomeLoss_f65ae978-ba3e-4535-93c3-b4635ccee212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83e71fe1-9707-41f4-b7d1-ab7a9ca23354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5c3401e6-2ed7-4174-a89b-877e7a14e43b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83e71fe1-9707-41f4-b7d1-ab7a9ca23354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1a3a4d92-ecfb-4d30-a3e7-80bed15ea461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83e71fe1-9707-41f4-b7d1-ab7a9ca23354" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1a3a4d92-ecfb-4d30-a3e7-80bed15ea461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c962caf6-fd79-44f5-97e3-8cb4b2b4d7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83e71fe1-9707-41f4-b7d1-ab7a9ca23354" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c962caf6-fd79-44f5-97e3-8cb4b2b4d7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b32a3d2d-8904-43ce-9cbd-1f8b4a965103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_83e71fe1-9707-41f4-b7d1-ab7a9ca23354" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b32a3d2d-8904-43ce-9cbd-1f8b4a965103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6928461d-39d5-48ae-87a9-c12869049923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5c3401e6-2ed7-4174-a89b-877e7a14e43b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6928461d-39d5-48ae-87a9-c12869049923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8941faa5-967b-4886-80d5-89cbe65daf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8941faa5-967b-4886-80d5-89cbe65daf14" xlink:to="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3775bfe8-f738-4e8d-b5c3-cc03b07b2d1e" xlink:to="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_98ed1c79-a1b8-40d6-9c83-093037e386d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_CommonStockMember_98ed1c79-a1b8-40d6-9c83-093037e386d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_36ad0c4e-689f-4d4b-bcf8-800c83446222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_36ad0c4e-689f-4d4b-bcf8-800c83446222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4353cb88-3596-4d0d-8380-b381c973155c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4353cb88-3596-4d0d-8380-b381c973155c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_213d549a-61c5-4180-bb8e-05a51366299f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35e637da-e9f4-4a25-8b42-92593a735c82" xlink:to="loc_us-gaap_RetainedEarningsMember_213d549a-61c5-4180-bb8e-05a51366299f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0118570c-0258-4c1a-bd23-08f14fda07cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a37db93b-ff9a-458c-a20c-608b9a9c7c02" xlink:to="loc_us-gaap_StatementLineItems_0118570c-0258-4c1a-bd23-08f14fda07cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0118570c-0258-4c1a-bd23-08f14fda07cc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14869fa7-ad0f-4fe2-b6b6-f1fc4e0daeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14869fa7-ad0f-4fe2-b6b6-f1fc4e0daeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51a6f9f0-0e74-4415-8671-6d02f301572a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockholdersEquity_51a6f9f0-0e74-4415-8671-6d02f301572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_deb2c15b-4bbe-483c-b26f-78f9a434c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_deb2c15b-4bbe-483c-b26f-78f9a434c85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ec81a92a-b050-4587-9249-676b48f5be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ec81a92a-b050-4587-9249-676b48f5be8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_532a857b-4fee-48c9-a771-805296c6efa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_532a857b-4fee-48c9-a771-805296c6efa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc56d5b4-44a8-4676-b466-4768f9d40b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc56d5b4-44a8-4676-b466-4768f9d40b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_adec49a8-5c10-41cb-b24b-db1e28acf730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_adec49a8-5c10-41cb-b24b-db1e28acf730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a72d02f8-b51f-49b9-a33c-5f0104e5cbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c5383d-7f08-444f-b428-24ccd8b8f9f1" xlink:to="loc_us-gaap_StockholdersEquity_a72d02f8-b51f-49b9-a33c-5f0104e5cbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nktr-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_59568039-ba22-4a1f-9a58-6a4d48572605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_59568039-ba22-4a1f-9a58-6a4d48572605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6b68c144-55b4-41e5-9726-79d52529ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_59568039-ba22-4a1f-9a58-6a4d48572605" xlink:to="loc_us-gaap_ProfitLoss_6b68c144-55b4-41e5-9726-79d52529ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_59568039-ba22-4a1f-9a58-6a4d48572605" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_4da5a25c-ee1e-4af8-8283-9765a76e4d9c" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_4da5a25c-ee1e-4af8-8283-9765a76e4d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_52015203-9a06-4093-9b6d-8cf44adb96cc" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_52015203-9a06-4093-9b6d-8cf44adb96cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_100883cc-a690-44b8-a980-7bba3d6d3b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_100883cc-a690-44b8-a980-7bba3d6d3b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e56f1cc7-fd47-4184-a088-0cbbaeb766c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e56f1cc7-fd47-4184-a088-0cbbaeb766c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_204d56bf-4cf5-418a-baa5-3e32b2c3f958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_204d56bf-4cf5-418a-baa5-3e32b2c3f958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9a86c77c-4dc0-4bde-acc6-809e048c2a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_DepreciationAndAmortization_9a86c77c-4dc0-4bde-acc6-809e048c2a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a3246486-1efd-4a47-bf56-aad95894e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a3246486-1efd-4a47-bf56-aad95894e129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_63224716-705f-4509-97a8-b7174d432e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_63224716-705f-4509-97a8-b7174d432e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3b9acd65-c614-475f-9604-cec1db030549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3b9acd65-c614-475f-9604-cec1db030549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_345db46b-496d-4d64-80d4-30c33d82a835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_345db46b-496d-4d64-80d4-30c33d82a835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bd0131ab-779b-48e0-b4ef-524d14eedef0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a07f52bd-c563-4dbc-98f7-bbd1e8e3a210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a07f52bd-c563-4dbc-98f7-bbd1e8e3a210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_44c6a961-c0b6-471f-844e-12b545ecbdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_44c6a961-c0b6-471f-844e-12b545ecbdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d4271e10-8357-4499-9422-cedfcf59a5f6" xlink:href="nktr-20230331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d4271e10-8357-4499-9422-cedfcf59a5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3e9e5d2-c766-4527-8248-7bb78fade3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3e9e5d2-c766-4527-8248-7bb78fade3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e9a23b22-2c83-44c4-9d75-81b64954249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e9a23b22-2c83-44c4-9d75-81b64954249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_b77425d5-f904-4edd-868c-ee4f20c807b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b8ef8a9-0300-4c10-885a-49bc983c5a45" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_b77425d5-f904-4edd-868c-ee4f20c807b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5f7bb02-153b-43b6-b17a-21430acc472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_59568039-ba22-4a1f-9a58-6a4d48572605" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5f7bb02-153b-43b6-b17a-21430acc472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3579eb8c-ec20-4dcc-b903-dbf6498900a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3579eb8c-ec20-4dcc-b903-dbf6498900a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7178e8c0-635a-4827-9431-a10b5c69ca36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3579eb8c-ec20-4dcc-b903-dbf6498900a7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7178e8c0-635a-4827-9431-a10b5c69ca36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b2c5a13f-0fd6-44df-88a9-dd0b1c2bdcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3579eb8c-ec20-4dcc-b903-dbf6498900a7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b2c5a13f-0fd6-44df-88a9-dd0b1c2bdcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6c30b68c-88a7-412a-a4f0-1d910e2d3b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3579eb8c-ec20-4dcc-b903-dbf6498900a7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6c30b68c-88a7-412a-a4f0-1d910e2d3b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_849b9db3-5e78-4eea-9eb3-2cf9b2c63262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3579eb8c-ec20-4dcc-b903-dbf6498900a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_849b9db3-5e78-4eea-9eb3-2cf9b2c63262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fca2d1a-b53a-4a8e-a60e-021adbae7684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fca2d1a-b53a-4a8e-a60e-021adbae7684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_80f11e70-5af0-4add-9df5-11273d825b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fca2d1a-b53a-4a8e-a60e-021adbae7684" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_80f11e70-5af0-4add-9df5-11273d825b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_14c12645-506b-4f22-a210-b281beda27be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fca2d1a-b53a-4a8e-a60e-021adbae7684" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_14c12645-506b-4f22-a210-b281beda27be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a298167-925f-4621-8eea-a073d67ce01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fca2d1a-b53a-4a8e-a60e-021adbae7684" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a298167-925f-4621-8eea-a073d67ce01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24bccc25-ea5c-4f75-bb58-4fb8dc72826f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24bccc25-ea5c-4f75-bb58-4fb8dc72826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_422e9c8d-c756-49b5-8728-6777d189d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_422e9c8d-c756-49b5-8728-6777d189d59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf3b00e5-e54f-4485-a016-cc97cfa75f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf3b00e5-e54f-4485-a016-cc97cfa75f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00982d76-86da-4a72-9bcc-99ce2abc00c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b9f0709-e639-4f91-9a6d-0f77b9fe3cbf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00982d76-86da-4a72-9bcc-99ce2abc00c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20230331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_adb1c43e-02de-4f72-bdfe-868faa59b123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_8284bc55-7203-428d-9e32-5c0c073d9509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_adb1c43e-02de-4f72-bdfe-868faa59b123" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_8284bc55-7203-428d-9e32-5c0c073d9509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2affee68-691f-4aac-a042-751633eae65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_06286fd1-ac15-4d99-b6c8-ac6899a76e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2affee68-691f-4aac-a042-751633eae65e" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_06286fd1-ac15-4d99-b6c8-ac6899a76e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f263dcc6-250b-4d61-a2ca-30f9fc65f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_540775be-1fc9-48da-894d-efbbd693bc37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f263dcc6-250b-4d61-a2ca-30f9fc65f8c3" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_540775be-1fc9-48da-894d-efbbd693bc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ccb5d7a-879c-42b7-bb77-dd1a1ebbe6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aeb0f810-0049-48fd-bf08-a2793ad04293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9ccb5d7a-879c-42b7-bb77-dd1a1ebbe6d9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aeb0f810-0049-48fd-bf08-a2793ad04293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20230331.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_528d925b-42c3-4795-b9e1-1eef973b3864" xlink:href="nktr-20230331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ab4c13cd-5c59-4d28-ba46-17282bdc55bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_528d925b-42c3-4795-b9e1-1eef973b3864" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ab4c13cd-5c59-4d28-ba46-17282bdc55bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5697c7b4-23f9-49b1-beb5-265e71022e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_3dccceb7-1ee3-41e2-b16d-77e9054de58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5697c7b4-23f9-49b1-beb5-265e71022e20" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_3dccceb7-1ee3-41e2-b16d-77e9054de58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0cb0ec38-c2ee-4f20-949e-fb00614e6b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_55206d85-45d7-4eb6-99eb-772bb083c908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0cb0ec38-c2ee-4f20-949e-fb00614e6b76" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_55206d85-45d7-4eb6-99eb-772bb083c908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20230331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_ee26e57f-505c-451a-b840-c66b9473d484" xlink:href="nktr-20230331.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_nktr_OrganizationPolicyTextBlock_ee26e57f-505c-451a-b840-c66b9473d484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_1d3497dc-7d92-486a-b501-cea4697fbb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_1d3497dc-7d92-486a-b501-cea4697fbb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_800ddc04-9c52-4358-8513-e7614aaf8b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_800ddc04-9c52-4358-8513-e7614aaf8b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_220a1e2e-7bab-4585-b8ba-3b2d98cb5482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_UseOfEstimates_220a1e2e-7bab-4585-b8ba-3b2d98cb5482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a98cfc2b-0b8b-46fe-88cb-e7149cc80266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a98cfc2b-0b8b-46fe-88cb-e7149cc80266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_4d546055-0323-443c-9561-506e2c4bbefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_4d546055-0323-443c-9561-506e2c4bbefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fcef5303-9c21-4fd4-8ef1-39e4f9c11c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fcef5303-9c21-4fd4-8ef1-39e4f9c11c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b69bc7b9-b457-40ce-aba0-73d778c0dcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b69bc7b9-b457-40ce-aba0-73d778c0dcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_48f17888-144e-4eb3-a665-cc2227b5fbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_48f17888-144e-4eb3-a665-cc2227b5fbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_ac276488-ce06-4a31-aa71-c71c0c35bc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4f6a9d8-0aab-4812-8370-788787c2c587" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_ac276488-ce06-4a31-aa71-c71c0c35bc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1649ef74-8d9f-41cb-8f71-2dc1562b3b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8e90a34d-dbe5-4398-aa38-e07dffdc2459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1649ef74-8d9f-41cb-8f71-2dc1562b3b63" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8e90a34d-dbe5-4398-aa38-e07dffdc2459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b59b7535-ed6c-4dbd-b291-47da54f95b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1649ef74-8d9f-41cb-8f71-2dc1562b3b63" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b59b7535-ed6c-4dbd-b291-47da54f95b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b91d9366-7823-4232-9687-ae6a9644208c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c318b1bb-ef26-4e0b-855e-195506838cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b91d9366-7823-4232-9687-ae6a9644208c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c318b1bb-ef26-4e0b-855e-195506838cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fb05e92e-3235-4a27-b535-92b5fa8a0d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b91d9366-7823-4232-9687-ae6a9644208c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fb05e92e-3235-4a27-b535-92b5fa8a0d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_028fb9f6-b9aa-4338-8e1f-5bfad5f64fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b91d9366-7823-4232-9687-ae6a9644208c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_028fb9f6-b9aa-4338-8e1f-5bfad5f64fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_b63b445d-5db6-4314-8b06-be071bfcc7c2" xlink:href="nktr-20230331.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b91d9366-7823-4232-9687-ae6a9644208c" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_b63b445d-5db6-4314-8b06-be071bfcc7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_772fb0ab-bf7d-43e8-a130-64aa76725578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b91d9366-7823-4232-9687-ae6a9644208c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_772fb0ab-bf7d-43e8-a130-64aa76725578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20230331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_5b4224fd-8336-4da5-bae4-270bcf630702" xlink:href="nktr-20230331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_8217fccd-f46a-4059-abd0-ba12a94e77ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_5b4224fd-8336-4da5-bae4-270bcf630702" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_8217fccd-f46a-4059-abd0-ba12a94e77ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e314c28f-0d97-46fc-97db-b8402ae1a461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3d82f3e8-f7eb-431f-b871-b811fe53f124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e314c28f-0d97-46fc-97db-b8402ae1a461" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3d82f3e8-f7eb-431f-b871-b811fe53f124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab31adb2-459c-47f9-b597-424b141aa0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f544da83-8fce-4d69-87d8-b7ac306f61f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab31adb2-459c-47f9-b597-424b141aa0ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f544da83-8fce-4d69-87d8-b7ac306f61f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_257d85bc-dd9a-4a4f-9883-a4fbe8ecbfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:href="nktr-20230331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_257d85bc-dd9a-4a4f-9883-a4fbe8ecbfe6" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f586cde8-7e74-4c58-99b1-4bae9a56e4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a6cb38c4-9234-4c6f-a832-0f3bb5b26990" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f586cde8-7e74-4c58-99b1-4bae9a56e4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_3991074e-d316-4c7b-9020-e69b1ece874e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f586cde8-7e74-4c58-99b1-4bae9a56e4c4" xlink:to="loc_us-gaap_EmployeeSeveranceMember_3991074e-d316-4c7b-9020-e69b1ece874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed8ab308-19d7-4a70-bd61-886f9d177e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6bcabff4-2768-47c7-a225-b58b0c0273f6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed8ab308-19d7-4a70-bd61-886f9d177e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember_bf369a4b-8313-4971-bb25-bd80fd1d4a3c" xlink:href="nktr-20230331.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed8ab308-19d7-4a70-bd61-886f9d177e24" xlink:to="loc_nktr_StockOptionsRSUsAndPSUsMember_bf369a4b-8313-4971-bb25-bd80fd1d4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c8949115-8e3c-46f1-9e97-333b508caf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_fc00e423-e9f3-49f5-bba9-c4822dda307a" xlink:to="loc_us-gaap_RestructuringPlanDomain_c8949115-8e3c-46f1-9e97-333b508caf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_0ab763cf-c139-4922-8022-636ea003e1bf" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_c8949115-8e3c-46f1-9e97-333b508caf73" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_0ab763cf-c139-4922-8022-636ea003e1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:href="nktr-20230331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5ab6706f-16d6-4640-9075-06c8b6714b59" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_182b0c41-df72-4b16-87e7-f69bafc69f7e" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_182b0c41-df72-4b16-87e7-f69bafc69f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_a67a6ed2-584b-40e5-b7f6-43a80aa32702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_a67a6ed2-584b-40e5-b7f6-43a80aa32702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_93183e33-af37-4bcd-bfdd-2ddedab1b791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_93183e33-af37-4bcd-bfdd-2ddedab1b791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0a849baa-a48d-4f32-a06a-a9d24a746fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_9dd1d9a2-9fe4-4aef-977c-c9a6eecf9863" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0a849baa-a48d-4f32-a06a-a9d24a746fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_af0c4f7d-1c9b-47d0-a771-370e4bab1342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_298ed9cc-e359-4232-acec-7452742e0523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_af0c4f7d-1c9b-47d0-a771-370e4bab1342" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_298ed9cc-e359-4232-acec-7452742e0523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7512a474-13ae-4801-9384-cb8de2550281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_298ed9cc-e359-4232-acec-7452742e0523" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7512a474-13ae-4801-9384-cb8de2550281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f62b3245-4cba-4bad-bd1b-1487649ab0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_298ed9cc-e359-4232-acec-7452742e0523" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f62b3245-4cba-4bad-bd1b-1487649ab0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_4f782aed-167b-47c3-b368-35c09a8e80a2" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_298ed9cc-e359-4232-acec-7452742e0523" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_4f782aed-167b-47c3-b368-35c09a8e80a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b0ccb5b0-1d81-4010-beab-ea6646e6bef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b0ccb5b0-1d81-4010-beab-ea6646e6bef6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39dfcdf8-f2d8-4cbe-9881-533be671a4cc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cad0e27c-0d5e-42aa-b202-10e0ddc7d494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cad0e27c-0d5e-42aa-b202-10e0ddc7d494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f0c0b194-45a6-44bd-8a7d-056bfdcd6573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c16d8b0b-be1d-472a-8313-088e99a754e6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f0c0b194-45a6-44bd-8a7d-056bfdcd6573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bf9f15ef-fba0-4ded-b52f-378b31da4f9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_720034cb-4916-42ea-892c-95920077f735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_720034cb-4916-42ea-892c-95920077f735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0b384672-991a-4bae-a8b3-6ddcc5d5b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_CommercialPaperMember_0b384672-991a-4bae-a8b3-6ddcc5d5b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29c61b30-044f-472b-ad98-12bb936c8405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29c61b30-044f-472b-ad98-12bb936c8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c217b1df-f88e-43e4-974a-e98bdf2b11ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c217b1df-f88e-43e4-974a-e98bdf2b11ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_be18f2e9-5c2a-4277-a4d4-34d347aafe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a44bc62-fdbb-4d06-b122-3600456dd75c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_be18f2e9-5c2a-4277-a4d4-34d347aafe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_220db449-e27a-4f78-8f5a-9982a84d64ee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a257640c-5e1e-4b56-aece-0eec605a5e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a257640c-5e1e-4b56-aece-0eec605a5e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9eaac09f-fa5c-4b91-85c5-06bf0664081c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9eaac09f-fa5c-4b91-85c5-06bf0664081c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c36bd741-2908-4a13-8aed-625c0b2f382c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c36bd741-2908-4a13-8aed-625c0b2f382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71c5a2f7-9f9e-4b2e-ad1c-6e3c7d23142b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71c5a2f7-9f9e-4b2e-ad1c-6e3c7d23142b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8cb35f59-c91b-487d-8673-4746c32f9c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8cb35f59-c91b-487d-8673-4746c32f9c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_b6b3854b-2a12-4064-abac-6a01dde8d768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_us-gaap_Cash_b6b3854b-2a12-4064-abac-6a01dde8d768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7149f168-a961-4a6a-beab-c4e83912f4d7" xlink:href="nktr-20230331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dce9dfb7-cbe7-44e6-8440-7addaa5bc0ad" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7149f168-a961-4a6a-beab-c4e83912f4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0e8089c-7750-4b3f-a4e4-8461eb35049c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee8b056c-3be8-4da7-b8e4-763d81301733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0e8089c-7750-4b3f-a4e4-8461eb35049c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee8b056c-3be8-4da7-b8e4-763d81301733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8e2acded-7389-4004-8acd-372727c9e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_bcd515ad-6355-48ae-9918-be0cc0af9bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8e2acded-7389-4004-8acd-372727c9e8b2" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_bcd515ad-6355-48ae-9918-be0cc0af9bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c7e71101-d96b-4a90-b783-c8c274077f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8e2acded-7389-4004-8acd-372727c9e8b2" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c7e71101-d96b-4a90-b783-c8c274077f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bdbbd5a3-0273-4e87-9ed7-178bdf9b49ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8e2acded-7389-4004-8acd-372727c9e8b2" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bdbbd5a3-0273-4e87-9ed7-178bdf9b49ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c4f81ba6-7d29-4368-aea1-3d7d8e2c12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8e2acded-7389-4004-8acd-372727c9e8b2" xlink:to="loc_us-gaap_InventoryNet_c4f81ba6-7d29-4368-aea1-3d7d8e2c12d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0236e113-c70d-4930-931b-6eacb594268b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0236e113-c70d-4930-931b-6eacb594268b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f33a6a-29ec-4bdb-8cef-2fb3d1950c6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_c5bfc7c7-1451-4f8f-875a-905a612e2043" xlink:href="nktr-20230331.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_c5bfc7c7-1451-4f8f-875a-905a612e2043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_3005d098-c3eb-4640-a89b-05c65c9b190f" xlink:href="nktr-20230331.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_3005d098-c3eb-4640-a89b-05c65c9b190f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_328dd5ec-7644-4fbd-804b-9c9cfac51b04" xlink:href="nktr-20230331.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_328dd5ec-7644-4fbd-804b-9c9cfac51b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_57f09784-9eb4-49b7-b7b5-b82205a71695" xlink:href="nktr-20230331.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_nktr_LaboratoryEquipmentMember_57f09784-9eb4-49b7-b7b5-b82205a71695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c24b4c0b-631c-4c34-bbe0-2c6c18bfb2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_af1632df-a124-4c6f-9101-1806cc9f7ca4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c24b4c0b-631c-4c34-bbe0-2c6c18bfb2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ffe52b86-da0b-4f98-a1fb-3fee0a047dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_99af9c52-1c8d-4329-a75a-3a5e9a66e9ed" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_99af9c52-1c8d-4329-a75a-3a5e9a66e9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a38ea96-2856-4fca-bf56-93be320eecfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a38ea96-2856-4fca-bf56-93be320eecfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_d100c882-b378-41ca-b108-c975b7496c46" xlink:href="nktr-20230331.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_d100c882-b378-41ca-b108-c975b7496c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_8af3f7cd-a319-4d4b-b73a-45c4d860096a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_ConstructionInProgressGross_8af3f7cd-a319-4d4b-b73a-45c4d860096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dddd4ae6-3730-456f-a68c-1e8f6c32ecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79f9e89d-c45c-41ef-bd1e-3f56723ae517" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dddd4ae6-3730-456f-a68c-1e8f6c32ecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ddd2431a-3641-4ad9-b6fb-a0deb2714a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ddd2431a-3641-4ad9-b6fb-a0deb2714a1c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_174e7009-f611-4375-b4ae-d310c7901e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_da965651-0864-49b3-983f-a31f4e93021a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_174e7009-f611-4375-b4ae-d310c7901e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_cbf87c71-5766-4230-b11e-9ca4ac200595" xlink:href="nktr-20230331.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_174e7009-f611-4375-b4ae-d310c7901e9a" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_cbf87c71-5766-4230-b11e-9ca4ac200595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bdb369b8-6754-4e5f-b925-97de153d9e90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_4e26916d-900f-4987-b540-fc63b240c882" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_4e26916d-900f-4987-b540-fc63b240c882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_e57414a6-675a-4bb4-9410-cab3074362fa" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec46ba31-8018-4e17-9b94-d20a6d86b612" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_e57414a6-675a-4bb4-9410-cab3074362fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c436e74-b2e6-476b-82dc-34a0dbbe051b" xlink:to="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_918894f2-1625-44cc-a4b9-52c893a4afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_918894f2-1625-44cc-a4b9-52c893a4afb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_f37daea4-24f0-4f5f-8c58-029755ed1ec6" xlink:href="nktr-20230331.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_25d08e09-b31a-4932-b766-ba7670775db2" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_f37daea4-24f0-4f5f-8c58-029755ed1ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a28f70a2-7866-4f3e-9020-f82c6e9add25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_abebc47c-b55f-4126-a91b-53ef54cada26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a28f70a2-7866-4f3e-9020-f82c6e9add25" xlink:to="loc_us-gaap_GoodwillRollForward_abebc47c-b55f-4126-a91b-53ef54cada26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_546f875e-6156-461d-9bcd-30d1c94956d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_abebc47c-b55f-4126-a91b-53ef54cada26" xlink:to="loc_us-gaap_Goodwill_546f875e-6156-461d-9bcd-30d1c94956d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_439cdcd1-de9b-4ade-b4b3-8b3e9952ade1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_abebc47c-b55f-4126-a91b-53ef54cada26" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_439cdcd1-de9b-4ade-b4b3-8b3e9952ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0b43304b-6729-4f76-a9c8-0334503becc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_abebc47c-b55f-4126-a91b-53ef54cada26" xlink:to="loc_us-gaap_Goodwill_0b43304b-6729-4f76-a9c8-0334503becc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_70e7ea1a-ec99-47a5-92b9-a943e164325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a28f70a2-7866-4f3e-9020-f82c6e9add25" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_70e7ea1a-ec99-47a5-92b9-a943e164325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bbb1edd5-2592-4bae-ad5f-aa70d3cf3862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bbb1edd5-2592-4bae-ad5f-aa70d3cf3862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_0a4b20a3-6261-4332-9f54-ff929a5c8b4e" xlink:href="nktr-20230331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_0a4b20a3-6261-4332-9f54-ff929a5c8b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityToCollaborationPartnersCurrent_90e635d6-6232-478c-a743-ae8e02e22a3a" xlink:href="nktr-20230331.xsd#nktr_LiabilityToCollaborationPartnersCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:to="loc_nktr_LiabilityToCollaborationPartnersCurrent_90e635d6-6232-478c-a743-ae8e02e22a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractTerminationCostsCurrent_3ca2b52e-09a8-44c7-8636-6c6436d8b731" xlink:href="nktr-20230331.xsd#nktr_AccruedContractTerminationCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:to="loc_nktr_AccruedContractTerminationCostsCurrent_3ca2b52e-09a8-44c7-8636-6c6436d8b731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f748e98c-96b9-48c0-a5d5-a6c485b71fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f748e98c-96b9-48c0-a5d5-a6c485b71fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_92892bd5-ae9f-4782-8c06-bdc8e4bef47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_974bd2be-2395-4dce-b9ed-2a37a104c257" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_92892bd5-ae9f-4782-8c06-bdc8e4bef47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a7857d05-2ca2-402b-a3ff-59e1740ea0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a7857d05-2ca2-402b-a3ff-59e1740ea0a6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_db82a62e-fcee-400f-91f2-837da711dc78" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_aaa418fc-5872-4cce-b120-7b9f6e16ccc0" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_aaa418fc-5872-4cce-b120-7b9f6e16ccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_495c18a3-6a1b-49d5-b079-3642e385a48f" xlink:href="nktr-20230331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca6448b-b52a-4ae8-8111-6a59cdd18d19" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_495c18a3-6a1b-49d5-b079-3642e385a48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_59969928-489d-490e-a5b7-a89528159adf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1e66fae3-3046-4b42-a75c-dc10080e77a4" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1e66fae3-3046-4b42-a75c-dc10080e77a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_280bf54f-8dcb-492a-9209-ed44960b36b8" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_280bf54f-8dcb-492a-9209-ed44960b36b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_dcc8c288-4734-43f9-9cbe-ff0b42f71192" xlink:href="nktr-20230331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_dcc8c288-4734-43f9-9cbe-ff0b42f71192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_d02cf7b7-cc83-46bd-b314-37ae103a6314" xlink:href="nktr-20230331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts_d02cf7b7-cc83-46bd-b314-37ae103a6314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_8fbeb6d5-5939-4a8c-b46c-4804b5524fc4" xlink:href="nktr-20230331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7296cf8e-5f2a-4a4d-a456-390727c5e777" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_8fbeb6d5-5939-4a8c-b46c-4804b5524fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#CommitmentsandContingenciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea885265-4531-4f6b-acf8-ba8b622294c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_0e2be963-e758-4b46-a7ea-72a37c5b39f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea885265-4531-4f6b-acf8-ba8b622294c8" xlink:to="loc_us-gaap_LitigationReserve_0e2be963-e758-4b46-a7ea-72a37c5b39f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_487d9a28-a365-42cd-97ec-04a9e3b84fd2" xlink:href="nktr-20230331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_487d9a28-a365-42cd-97ec-04a9e3b84fd2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c8c4bb17-d27f-4a46-b4ec-4d8a251f10d6" xlink:to="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_ef2ed338-375a-4a28-acfe-56d626aa374c" xlink:href="nktr-20230331.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:to="loc_nktr_Nektar214Member_ef2ed338-375a-4a28-acfe-56d626aa374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_ea6fe23c-f3ae-4d81-a316-510790ef01fd" xlink:href="nktr-20230331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb4d28f1-2641-451b-a1d8-bcb3c0e3ca4b" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_ea6fe23c-f3ae-4d81-a316-510790ef01fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_392d6422-69ea-4869-83d1-a15a8b31b2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0f90e10b-eac8-4374-82fd-d6a77c764d34" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_392d6422-69ea-4869-83d1-a15a8b31b2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_750d9a49-860d-4a05-882e-53bcdad3f048" xlink:href="nktr-20230331.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_392d6422-69ea-4869-83d1-a15a8b31b2b2" xlink:to="loc_nktr_OpdivoMember_750d9a49-860d-4a05-882e-53bcdad3f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c26ae4b2-5668-458c-8429-8ccbca9446a1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_0f620729-3971-432e-8ca1-e1689aedee16" xlink:href="nktr-20230331.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:to="loc_nktr_Nektar358Member_0f620729-3971-432e-8ca1-e1689aedee16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0b9e931e-0485-4a67-bcf9-5689a6c78bfd" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5904016e-faa3-4b07-be2e-e2000fdc636c" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_0b9e931e-0485-4a67-bcf9-5689a6c78bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_69428275-7931-4896-9227-7d1fb359cc2a" xlink:to="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_a852520b-0214-4a88-8b98-2c3c28188adf" xlink:href="nktr-20230331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_EliLillyAndCompanyMember_a852520b-0214-4a88-8b98-2c3c28188adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_0f114784-aa66-43c6-8d41-2117a9f612c2" xlink:href="nktr-20230331.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_EliLillyMember_0f114784-aa66-43c6-8d41-2117a9f612c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_539210ec-793a-423e-99eb-02adf9b4763d" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_539210ec-793a-423e-99eb-02adf9b4763d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_4f5bc846-6e65-4519-94a4-8f3646da95dd" xlink:href="nktr-20230331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47e4638d-3b87-49f3-a79d-7faa9700ea1a" xlink:to="loc_nktr_OtherPartnerMember_4f5bc846-6e65-4519-94a4-8f3646da95dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2374e05c-3d44-4187-ad05-10e3b6fbdc6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6da6c4ff-4441-4e6c-afe3-f3d5020a5492" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2374e05c-3d44-4187-ad05-10e3b6fbdc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_78a2ed72-03b6-4b2d-a5d8-ab31af34fb0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2374e05c-3d44-4187-ad05-10e3b6fbdc6b" xlink:to="loc_srt_ParentCompanyMember_78a2ed72-03b6-4b2d-a5d8-ab31af34fb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb681fa2-b50d-4e92-9048-7d5109a00f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba396591-58a1-4272-ba5d-31b97776eb92" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb681fa2-b50d-4e92-9048-7d5109a00f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_da886821-34df-40d0-9dd7-e8bdf9b693db" xlink:href="nktr-20230331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb681fa2-b50d-4e92-9048-7d5109a00f7a" xlink:to="loc_nktr_SharePurchaseAgreementMember_da886821-34df-40d0-9dd7-e8bdf9b693db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:href="nktr-20230331.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_2ca5aec1-9224-4e2e-a2d9-42f27a70a1cf" xlink:href="nktr-20230331.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_1bc7b478-922d-4b8d-aadc-fad6874f4ed8" xlink:to="loc_nktr_MilestoneDomain_2ca5aec1-9224-4e2e-a2d9-42f27a70a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_27a89dd6-513d-4fde-b9a0-a3d2bcab0546" xlink:href="nktr-20230331.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_2ca5aec1-9224-4e2e-a2d9-42f27a70a1cf" xlink:to="loc_nktr_MilestoneOneMember_27a89dd6-513d-4fde-b9a0-a3d2bcab0546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_336c1a33-c461-498d-8da7-4b2f2a0650ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35d20ff7-3f8c-4802-aa45-5380204f1c51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_336c1a33-c461-498d-8da7-4b2f2a0650ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37b6213d-19cc-4f85-9d47-f9d84486fa06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_336c1a33-c461-498d-8da7-4b2f2a0650ba" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37b6213d-19cc-4f85-9d47-f9d84486fa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_466bec00-4924-47c5-8b71-b654187f8839" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_3368f4d8-2b52-4c4a-8eeb-47a368265604" xlink:href="nktr-20230331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_3368f4d8-2b52-4c4a-8eeb-47a368265604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_263f1a8e-cc46-4778-b1a1-69faf6791426" xlink:href="nktr-20230331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_007bf542-1a01-42a7-adbf-e2496dbc1c1d" xlink:to="loc_nktr_SFJPharmaceuticalsMember_263f1a8e-cc46-4778-b1a1-69faf6791426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27681fdf-907f-4a3d-b1a8-a7101d76f481" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f27a1c3e-00a2-4263-9e64-53807211efa1" xlink:to="loc_srt_RangeMember_27681fdf-907f-4a3d-b1a8-a7101d76f481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bf3d0fc1-7548-4ad1-a703-f2821b62027d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27681fdf-907f-4a3d-b1a8-a7101d76f481" xlink:to="loc_srt_MaximumMember_bf3d0fc1-7548-4ad1-a703-f2821b62027d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39a7d268-b349-4eab-9bf1-dc2cc3eced23" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be97bf96-f7e9-4ef8-9103-65e91dabcbca" xlink:href="nktr-20230331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be97bf96-f7e9-4ef8-9103-65e91dabcbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_f01df0c8-672a-49b0-afa2-edd1641463dc" xlink:href="nktr-20230331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_f01df0c8-672a-49b0-afa2-edd1641463dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_a416e977-fbd0-4db0-b0fb-e9dcfbbb5e1b" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_a416e977-fbd0-4db0-b0fb-e9dcfbbb5e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_31cdafb0-a745-4d31-9bdd-3c43e3a10059" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_31cdafb0-a745-4d31-9bdd-3c43e3a10059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_d789b452-e596-4720-af99-ac2b3201fd27" xlink:href="nktr-20230331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_d789b452-e596-4720-af99-ac2b3201fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_d18856e4-afd8-4f9d-97e1-936f1fdff918" xlink:href="nktr-20230331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_d18856e4-afd8-4f9d-97e1-936f1fdff918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ef84c1e4-09aa-4cb0-b3d4-c9c864b4946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_SharesIssued_ef84c1e4-09aa-4cb0-b3d4-c9c864b4946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_a615d1a3-896f-41c8-9dfb-b02a03899c9e" xlink:href="nktr-20230331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_a615d1a3-896f-41c8-9dfb-b02a03899c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_691a46e2-3fab-4723-9b54-94e16fff3aba" xlink:href="nktr-20230331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_PotentialDevelopmentMilestones_691a46e2-3fab-4723-9b54-94e16fff3aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_9e4e6ad5-06a3-4b4a-8b36-a53a821abcb7" xlink:href="nktr-20230331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_ReimbursementOfExpenses_9e4e6ad5-06a3-4b4a-8b36-a53a821abcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_c84394c0-c23a-4415-9a7d-573fe8edc827" xlink:href="nktr-20230331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_c84394c0-c23a-4415-9a7d-573fe8edc827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_38fb22a7-5e1b-4379-badb-3f8b216997bc" xlink:href="nktr-20230331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_38fb22a7-5e1b-4379-badb-3f8b216997bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2ec4bd48-bbc8-4637-8c71-4903f1501bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_DerivativeLiabilities_2ec4bd48-bbc8-4637-8c71-4903f1501bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2430d079-2e42-4132-85cc-5d02280a681b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87933e63-f56d-4231-977d-fc8faa25b606" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2430d079-2e42-4132-85cc-5d02280a681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b41771e4-de68-4134-a140-29fbd258a623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b41771e4-de68-4134-a140-29fbd258a623" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_971e615d-73a6-417a-bdf1-dde33f0ccb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f67d718d-ee7d-4029-8bbc-32b969e8760b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_971e615d-73a6-417a-bdf1-dde33f0ccb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8e15745d-20b6-4154-bed1-373cec41874c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_971e615d-73a6-417a-bdf1-dde33f0ccb14" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8e15745d-20b6-4154-bed1-373cec41874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5fac24d6-5035-4ec0-90c4-5094a0b2fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d0dc2331-0f9b-4bed-950b-60d44ba0fcfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5fac24d6-5035-4ec0-90c4-5094a0b2fc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b018d6d2-ebee-4541-8fd9-b29163a355d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5fac24d6-5035-4ec0-90c4-5094a0b2fc33" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b018d6d2-ebee-4541-8fd9-b29163a355d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_06ed2c9a-1f6a-443b-9f73-3a8d8421cf03" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1814378d-1dc1-42e6-b6ad-96abde61ed87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1814378d-1dc1-42e6-b6ad-96abde61ed87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a2a57429-2abe-497a-973e-7a2408d5af6a" xlink:href="nktr-20230331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a2a57429-2abe-497a-973e-7a2408d5af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_283220bd-3466-436a-85e3-0dc7746fe5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_283220bd-3466-436a-85e3-0dc7746fe5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8fa6777f-cb0e-4dea-bc32-ff489a18b66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8fa6777f-cb0e-4dea-bc32-ff489a18b66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66e333a0-6f48-4cbc-88d6-b099bbbe7109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3cb5022e-f3b9-4fe0-bd67-838fca3c65d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66e333a0-6f48-4cbc-88d6-b099bbbe7109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fd5a65c1-5212-4267-bd90-7f4cf25a7d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fd5a65c1-5212-4267-bd90-7f4cf25a7d73" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_91535384-c437-4e63-8cce-ba9f5a519762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6f384660-5ce2-4f13-a917-3fd1de5c8ba8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_91535384-c437-4e63-8cce-ba9f5a519762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_24f8ac77-9934-4d08-8d87-a40dcb2ed2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_91535384-c437-4e63-8cce-ba9f5a519762" xlink:to="loc_us-gaap_EmployeeSeveranceMember_24f8ac77-9934-4d08-8d87-a40dcb2ed2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fc3c6cf1-290b-425d-a9c9-17daee107f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8948de0c-ab16-402a-b635-335c18ac971d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fc3c6cf1-290b-425d-a9c9-17daee107f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_0a9eb01e-f6c0-48a9-9733-4401fbd3fdf4" xlink:href="nktr-20230331.xsd#nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fc3c6cf1-290b-425d-a9c9-17daee107f3b" xlink:to="loc_nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember_0a9eb01e-f6c0-48a9-9733-4401fbd3fdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8783b97d-5f65-46a8-bcef-ca99ebade5e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6927140a-709a-4373-b0f3-7fb07a2576a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8783b97d-5f65-46a8-bcef-ca99ebade5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a34645f1-31ff-4b20-9957-3f4c74cc095d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8783b97d-5f65-46a8-bcef-ca99ebade5e2" xlink:to="loc_srt_ScenarioForecastMember_a34645f1-31ff-4b20-9957-3f4c74cc095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_c177f8a8-27d9-4ec4-a0c3-05cffc77e0f7" xlink:to="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_18933c8a-4e4d-46cd-9337-fd83f08fb93a" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:to="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_18933c8a-4e4d-46cd-9337-fd83f08fb93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_4a280d71-89a5-40bd-935e-e527a11ddb54" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_921ab861-56ea-4632-b620-393974e4b928" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_4a280d71-89a5-40bd-935e-e527a11ddb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6798bb48-a073-48b3-a375-1ad946980728" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d940dde0-77ac-4284-b98e-bedaff3130a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d940dde0-77ac-4284-b98e-bedaff3130a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_367ca7fd-035b-46a0-9ffd-081cd54b20a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_LossOnContractTermination_367ca7fd-035b-46a0-9ffd-081cd54b20a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_058b3af6-d918-4065-a601-4bfe0f2483b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_RestructuringCharges_058b3af6-d918-4065-a601-4bfe0f2483b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_16125f95-ca64-45d3-8bb4-2781e9463e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_PaymentsForRestructuring_16125f95-ca64-45d3-8bb4-2781e9463e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_e9d999b3-3d61-4b20-a293-cec9834c3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_SeveranceCosts1_e9d999b3-3d61-4b20-a293-cec9834c3b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OperatingLeaseMeasurementInput_cbafb82d-9b29-4df2-9ff8-71aa77183fb0" xlink:href="nktr-20230331.xsd#nktr_OperatingLeaseMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_nktr_OperatingLeaseMeasurementInput_cbafb82d-9b29-4df2-9ff8-71aa77183fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_af2131e7-0953-4944-9169-764e6071cc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_af2131e7-0953-4944-9169-764e6071cc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c851b8d9-f316-4c24-831f-76fced79ff82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_c851b8d9-f316-4c24-831f-76fced79ff82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d3ac5fe-0538-491c-9d2f-35b834e31501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3b7d52eb-1261-4e8e-91e5-af84da22a0de" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d3ac5fe-0538-491c-9d2f-35b834e31501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b8fe48e2-bcd0-41d4-b844-585fb65bb76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b8fe48e2-bcd0-41d4-b844-585fb65bb76e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:to="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a2c63cae-1d90-4bb2-9068-c164900ddee4" xlink:to="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_72ab1ea3-ceed-4eb0-8272-678716d98974" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_72ab1ea3-ceed-4eb0-8272-678716d98974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_c02ba0b2-9bb7-4674-9465-bc2ae53929af" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_39a0e92c-061b-4bbf-9cd3-2eace01da818" xlink:to="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_c02ba0b2-9bb7-4674-9465-bc2ae53929af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5f2e08a8-a3c8-48bb-aa06-d1c305eefc06" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_2cc1cfe6-082f-4c3e-a8a2-f1f47b7a86fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_BusinessExitCosts1_2cc1cfe6-082f-4c3e-a8a2-f1f47b7a86fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c9467ca6-b30f-42e7-b058-cc5895fe0a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_SeveranceCosts1_c9467ca6-b30f-42e7-b058-cc5895fe0a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_97189bfe-88b0-4736-a576-42cdfb2f3eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_97189bfe-88b0-4736-a576-42cdfb2f3eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_a79ca96c-0033-4eb1-8272-84f21746dd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_LossOnContractTermination_a79ca96c-0033-4eb1-8272-84f21746dd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_939aa8dd-d176-4be8-9062-ae38b182cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c28ad49b-000d-4540-bcb5-3da8f4e88bf9" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_939aa8dd-d176-4be8-9062-ae38b182cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_18d6b145-308c-499a-b363-42a42f9ab907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_18d6b145-308c-499a-b363-42a42f9ab907" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0d9e3a8c-35cf-4f08-be13-192a62c250a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7c2de994-2234-4ec0-aeb6-ed6d814866e4" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0d9e3a8c-35cf-4f08-be13-192a62c250a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_865f032b-20d3-4513-b9d8-83fa5be1a251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0d9e3a8c-35cf-4f08-be13-192a62c250a3" xlink:to="loc_us-gaap_EmployeeSeveranceMember_865f032b-20d3-4513-b9d8-83fa5be1a251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:to="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6c4f4602-7698-4e8d-9bf5-fa108c0b2bb5" xlink:to="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_33f627aa-e3a5-4a21-91ef-1ff6cda11b4d" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyThreeRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:to="loc_nktr_TwoThousandTwentyThreeRestructuringPlanMember_33f627aa-e3a5-4a21-91ef-1ff6cda11b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_55a69190-a2af-46eb-a0c2-e04dda72b454" xlink:href="nktr-20230331.xsd#nktr_TwoThousandTwentyTwoRestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e0b77770-2f9f-4920-b42d-0463bafaef31" xlink:to="loc_nktr_TwoThousandTwentyTwoRestructuringPlanMember_55a69190-a2af-46eb-a0c2-e04dda72b454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_991eb105-13d4-4f23-93be-2bcc423611e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_dbb3732b-6bb4-4f7b-aa57-1eeb2b0d0bf9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_991eb105-13d4-4f23-93be-2bcc423611e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_991eb105-13d4-4f23-93be-2bcc423611e7" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ccfd7214-8e48-49b1-995b-4d79ff411f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_RestructuringReserve_ccfd7214-8e48-49b1-995b-4d79ff411f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c51a9e75-dff8-4841-82ef-302a6e66cd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_RestructuringCharges_c51a9e75-dff8-4841-82ef-302a6e66cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_bee2346c-d6da-4c8e-9ac2-1e3c652ebb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_PaymentsForRestructuring_bee2346c-d6da-4c8e-9ac2-1e3c652ebb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_46a383d8-4a1e-479c-9e65-48410ebc544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b163a52e-d948-4710-8311-b8677a3e09fa" xlink:to="loc_us-gaap_RestructuringReserve_46a383d8-4a1e-479c-9e65-48410ebc544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" xlink:type="simple" xlink:href="nktr-20230331.xsd#RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2bf2f7ee-52d8-4c6b-8d9d-0bf76e07ec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2bf2f7ee-52d8-4c6b-8d9d-0bf76e07ec2a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb017bab-6887-40ac-9e1b-f1254ae06f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5818e2e7-52c1-44e8-9ac9-fb4372fca352" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb017bab-6887-40ac-9e1b-f1254ae06f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d3378e0c-b962-45a1-b70e-929a9cd688cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eb017bab-6887-40ac-9e1b-f1254ae06f35" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d3378e0c-b962-45a1-b70e-929a9cd688cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d072c30f-8ea2-4932-ad0f-3b05635133e9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5529727a-1fdf-479d-8cfe-0aaf839a7a58" xlink:href="nktr-20230331.xsd#nktr_SubleasePropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:to="loc_nktr_SubleasePropertyPlantAndEquipmentMember_5529727a-1fdf-479d-8cfe-0aaf839a7a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_30ec38bc-0397-4750-8a48-9019674f6ad4" xlink:href="nktr-20230331.xsd#nktr_SubleaseOperatingLeaseRightOfUseAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af4e6f75-e672-4c95-a28b-fdcfc4141f37" xlink:to="loc_nktr_SubleaseOperatingLeaseRightOfUseAssetsMember_30ec38bc-0397-4750-8a48-9019674f6ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13a2a953-2ec9-4c74-b9ba-d68dcb91c954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fb3e383b-ac1b-4a5a-8066-40f448618456" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13a2a953-2ec9-4c74-b9ba-d68dcb91c954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13a2a953-2ec9-4c74-b9ba-d68dcb91c954" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_76c540c8-7679-4f60-b734-02f3896b5e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_76c540c8-7679-4f60-b734-02f3896b5e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5cb8b1b6-7820-4c90-b2df-14be225fb30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2b0b950d-b2a3-4a4f-a69d-b06cba2138a3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5cb8b1b6-7820-4c90-b2df-14be225fb30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0e9cecd3-67f4-4150-b62a-a279fd3d366b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5b6be3cf-d68c-4ca2-bff6-30d0e84f0f30" xlink:href="nktr-20230331.xsd#nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure_5b6be3cf-d68c-4ca2-bff6-30d0e84f0f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_f7a38e5a-310a-418a-92d6-b41d1ab1668c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_f7a38e5a-310a-418a-92d6-b41d1ab1668c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther_9cc38dfc-2bb0-4dcb-9db7-efe585a0cada" xlink:href="nktr-20230331.xsd#nktr_ImpairmentLongLivedAssetHeldForUseOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_nktr_ImpairmentLongLivedAssetHeldForUseOther_9cc38dfc-2bb0-4dcb-9db7-efe585a0cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a4ed167e-70b5-4c80-8d74-1b6343bd218e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5ca67c75-e487-41ae-8719-2b8c67bed493" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a4ed167e-70b5-4c80-8d74-1b6343bd218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cf4cd0c-1625-48a5-90ad-a4c77711ce3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cf4cd0c-1625-48a5-90ad-a4c77711ce3b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_753ad337-d138-4e46-94bc-31faa36c097a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_5f563ddf-c8b4-4e7c-9ef5-8fd63bd16019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:to="loc_us-gaap_CostOfSalesMember_5f563ddf-c8b4-4e7c-9ef5-8fd63bd16019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_427e838c-61b9-4b42-a0d6-a4350875b3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_427e838c-61b9-4b42-a0d6-a4350875b3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_479cfe38-db17-4da6-8b7c-66668f636f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43530ae5-4152-4f40-8e26-253d70634fd7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_479cfe38-db17-4da6-8b7c-66668f636f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6c1d9e5-51ec-4896-b9d9-42fc5c085b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0178e91f-c8e4-4098-8eb7-88329dcf1a5a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6c1d9e5-51ec-4896-b9d9-42fc5c085b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7adf2467-668b-417f-b567-60c84d5046bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6c1d9e5-51ec-4896-b9d9-42fc5c085b74" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7adf2467-668b-417f-b567-60c84d5046bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MN<-G&F16\)[=YR$;!6YKWM!5%'P*X/*1H?.&KB&1M]-5PM+^0#K<*%J-P(D
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M J.Q*>&+X?Z^_X^"PGF[WLBED9358+++<;Q,'*@I\1,HE\7SKQ"X-BT9>>N
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418183938560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,235,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418184135408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 76,955<span></span>
</td>
<td class="nump">$ 88,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">379,872<span></span>
</td>
<td class="nump">416,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="nump">5,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">20,235<span></span>
</td>
<td class="nump">19,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">11,009<span></span>
</td>
<td class="nump">15,808<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">491,066<span></span>
</td>
<td class="nump">545,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">27,084<span></span>
</td>
<td class="nump">32,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">42,187<span></span>
</td>
<td class="nump">53,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">561,743<span></span>
</td>
<td class="nump">710,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">12,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">37,410<span></span>
</td>
<td class="nump">36,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">18,773<span></span>
</td>
<td class="nump">18,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">59,879<span></span>
</td>
<td class="nump">68,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">109,389<span></span>
</td>
<td class="nump">112,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">145,131<span></span>
</td>
<td class="nump">155,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">6,479<span></span>
</td>
<td class="nump">7,551<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">320,878<span></span>
</td>
<td class="nump">343,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2023 or December 31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 189,235 shares and 188,560 shares outstanding at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,584,738<span></span>
</td>
<td class="nump">3,574,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,681)<span></span>
</td>
<td class="num">(6,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,338,211)<span></span>
</td>
<td class="num">(3,201,193)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">240,865<span></span>
</td>
<td class="nump">366,638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 561,743<span></span>
</td>
<td class="nump">$ 710,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418183872928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">189,235,000<span></span>
</td>
<td class="nump">188,560,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185135104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 21,594<span></span>
</td>
<td class="nump">$ 24,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">7,060<span></span>
</td>
<td class="nump">5,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,469<span></span>
</td>
<td class="nump">107,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,081<span></span>
</td>
<td class="nump">27,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring, impairment and costs of terminated program</a></td>
<td class="nump">21,193<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">156,304<span></span>
</td>
<td class="nump">141,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(134,710)<span></span>
</td>
<td class="num">(116,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="num">(6,405)<span></span>
</td>
<td class="num">(7,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">4,034<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="num">(2,371)<span></span>
</td>
<td class="nump">26,293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(137,081)<span></span>
</td>
<td class="num">(90,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (137,018)<span></span>
</td>
<td class="num">$ (90,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding used in computing basic net loss per share (in shares)</a></td>
<td class="nump">188,875<span></span>
</td>
<td class="nump">185,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</a></td>
<td class="nump">188,875<span></span>
</td>
<td class="nump">185,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 4,718<span></span>
</td>
<td class="nump">$ 5,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">16,861<span></span>
</td>
<td class="nump">17,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 1,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418184464704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (137,018)<span></span>
</td>
<td class="num">$ (90,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="num">(2,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="nump">139<span></span>
</td>
<td class="num">(284)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (135,792)<span></span>
</td>
<td class="num">$ (92,768)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418186213904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 679,508<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 3,516,641<span></span>
</td>
<td class="num">$ (4,157)<span></span>
</td>
<td class="num">$ (2,832,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(92,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(90,393)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 607,889<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,537,790<span></span>
</td>
<td class="num">(6,532)<span></span>
</td>
<td class="num">(2,923,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">188,560<span></span>
</td>
<td class="nump">188,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 366,638<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,574,719<span></span>
</td>
<td class="num">(6,907)<span></span>
</td>
<td class="num">(3,201,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (135,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="num">(137,018)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">189,235<span></span>
</td>
<td class="nump">189,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 240,865<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 3,584,738<span></span>
</td>
<td class="num">$ (5,681)<span></span>
</td>
<td class="num">$ (3,338,211)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418180153824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (137,018)<span></span>
</td>
<td class="num">$ (90,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="num">(16,861)<span></span>
</td>
<td class="num">(17,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">7,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">10,019<span></span>
</td>
<td class="nump">20,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,302<span></span>
</td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense</a></td>
<td class="num">(1,812)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Amortization of premiums (discounts), net and other non-cash transactions</a></td>
<td class="num">(3,129)<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,986<span></span>
</td>
<td class="num">(7,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,033)<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="num">(1,786)<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">5,591<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(8,920)<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">14,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(51,915)<span></span>
</td>
<td class="num">(88,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(107,012)<span></span>
</td>
<td class="num">(93,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">148,043<span></span>
</td>
<td class="nump">227,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(433)<span></span>
</td>
<td class="num">(4,203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">40,598<span></span>
</td>
<td class="nump">130,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash receipts from development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(11,272)<span></span>
</td>
<td class="nump">42,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">88,227<span></span>
</td>
<td class="nump">25,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 76,955<span></span>
</td>
<td class="nump">$ 67,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418267174816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in the field of immunotherapy.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of March&#160;31, 2023, we had approximately $456.8 million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Clinical Trial Programs and the Restructuring Plans</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced that our registrational trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma, renal cell carcinoma and locally advanced or metastatic urothelial cancer under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS) did not meet their primary endpoints. Based on these results, in April 2022, we announced our decisions to discontinue all development of bempegaldesleukin in combination with checkpoint inhibitors, including these trials, our registrational trial in adjuvant melanoma under our BMS Collaboration Agreement, and our Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 5 for additional information regarding our BMS Collaboration Agreement and Co-Development Agreement with SFJ Pharmaceuticals. Pursuant to the Strategic Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan), pursuant to which we we completed an approximately 70% reduction of our workforce during 2022 and sold our research facility in India in December 2022.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study) under our collaboration agreement with Eli Lilly and Company (Lilly). Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to plans approved by our Board of Directors (the Board) on March 29, 2023, we announced on April 17, 2023, a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we are reducing our San Francisco-based workforce by approximately 60%, which is expected to be substantially completed by June 2023.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to incur significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 6 for additional information on the effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2022 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 filed with the SEC on February 28, 2023. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the three months ended March&#160;31, 2023 and 2022, nor have recorded such an allowance as of March&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated,</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms, and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit&#8217;s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information regarding the impairment charges we recorded in connection with our goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), which totaled 22.8&#160;million and 22.3&#160;million for the three months ended March 31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418267265920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,955&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,227&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,165&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,894&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,522&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,048&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,359&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,726&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2022, our gross unrealized losses totaled $1.8&#160;million, and our gross unrealized gains were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418267265920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Condensed Consolidated Financial Statement Details</a></td>
<td class="text">Condensed Consolidated Financial Statement Details<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,235&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,202&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,137&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,889&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the decrease in the fair value of our single reporting unit during the three months ended March 31, 2023, we recorded a non-cash impairment charge of $3.5&#160;million for property, plant and equipment, which we report in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. See Note 6 for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the changes in our goodwill for the three months ended March 31, 2023 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"/><td style="width:84.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill &#8211; beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,501&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill &#8211; ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the decrease in the fair value of our single reporting unit during the three months ended March 31, 2023, we recorded a non-cash goodwill impairment charge of $76.5&#160;million, which we report as impairment of goodwill in our Condensed Consolidated Statement of Operations. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. See Note 6 for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability to collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract termination costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liabilities Related to the Sales of Future Royalties</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively. We account for these transactions as debt and recognize non-cash royalty revenue and non-cash interest expense to amortize the proceeds over the lives of the respective arrangements. We periodically update our prospective non-cash interest rate based on our estimates of future royalties. As of March 31, 2023, our imputed interest rates for the arrangements with RPI and HCR were 10% and 20%, respectively.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net &#8211; beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net &#8211; ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418271411056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2023, we and our directors were named in a putative class action complaint filed in the Court of Chancery of the State of Delaware. The plaintiff in this complaint alleges section 13 of our bylaws relating to stockholder action without meeting violates Delaware law and is therefore void. Upon service of this complaint, we will have twenty days to reply.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at either March&#160;31, 2023 or December&#160;31, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div>To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418267160192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): Rezpegaldesleukin (previously referred to as NKTR-358) </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and were eligible for up to $250.0&#160;million in additional development and regulatory milestones. The Lilly Agreement provided that, during Phase 1B and Phase 2 development, we would share development costs wherein 75% of the costs are borne by Lilly and 25% of the costs are borne by us. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). Although the Phase 2 Lupus Study did not meet its primary endpoint, patients who received the middle dose within the modified intent-to-treat population, defined as all patients who were randomized and received at least one dose of rezpegaldesleukin, demonstrated improvement in SLEDAI-2K score as compared to placebo. Nonetheless, Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2023, Nektar received from Lilly a notice of-at will termination of the Lilly Agreement. On April 27, 2023, we announced that we would regain full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 3, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and pre-commercial costs of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received additional non-refundable milestone payments of $50.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, in April 2022, we announced that BMS and we decided to discontinue all development of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. Pursuant to the BMS Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. Based on the cost sharing percentages described above, we recognized BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. As discussed in Note 6, beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring and costs of terminated program. The net reimbursement payable to BMS for the three months ended March 31, 2023 was not significant. For the three months ended March 31, 2022, we recorded $24.9&#160;million for the net reimbursement from BMS as a reduction of research and development expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SFJ Pharmaceuticals</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial). SFJ had primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we were the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin in up to three indications.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the SFJ Agreement as a derivative liability, which we remeasured to fair value at each reporting date. We recorded increases to the liability for non-cash research and development expense as SFJ conducted the SCCHN Clinical Trial and for cash receipts from SFJ to us to support our internal costs of conducting the trial. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to zero as of March 31, 2022, and we recognized a corresponding gain in change in fair value of development derivative liability. In April 2022, we announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in the derivative liability for the three months ended March 31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 3, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue, which totaled $16.9&#160;million and $17.6&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, represents revenue for granting licenses which we had satisfied in prior periods.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418267124128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill</a></td>
<td class="text">Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Costs of Terminated Program</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2022 and 2023 Restructuring Plans, we report the following costs in restructuring, impairment and  costs of terminated program:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, initiated in 2022;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Severance and related benefit costs pursuant to the 2022 and 2023 Restructuring Plans;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-cash impairment of right-of-use assets and property, plant and equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract termination and other costs associated with these plans.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior periods through March&#160;31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. Beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Restructuring Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all development of bempegaldesleukin and wind down the clinical trials studying bempegaldesleukin. In April 2022, we announced the 2022 Restructuring Plan pursuant to which we completed an approximately 70% reduction of our workforce during 2022. We also sold our research facility in India in December 2022 and decided to sublease certain of our leased premises in San Francisco, CA, including our office leased space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program pertaining to the 2022 Restructuring Plan includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, restructuring, impairment and other costs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin. Through March&#160;31, 2023, we have recognized $11.8&#160;million cumulatively for contract termination and other costs for the 2022 Restructuring Plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Restructuring Plan</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, pursuant to plans approved by our Board in March 2023, we announced the 2023 Restructuring Plan to further reduce our San Francisco-based workforce by approximately 60%, which is expected to be substantially completed by June 2023.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program pertaining to the 2023 Restructuring Plan includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Benefit Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under the 2022 and 2023 Restructuring Plans are entitled to receive severance payments and certain Company funded benefits. The restructuring charges are recorded at fair value. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2022 Restructuring Plan, we recognized severance and benefit expense in full for employees who had no requirements for future service when the 2022 Restructuring Plan was approved by the Board in April 2022. We recognized severance and benefit expense for employees who were required to render services to receive their severance and benefits ratably over the service period. This service period began on the communication date in April 2022 and was completed for all employees during 2022. We recognized $30.9&#160;million in total severance and benefit expense during 2022 and paid the remaining liability of $3.3&#160;million in January 2023.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2023 Restructuring Plan, we recognized a liability of $5.5&#160;million of severance and benefit expense as of March 31, 2023, reflecting severance and benefits which the employees had vested into and for which payment was probable and reasonably estimable as of March&#160;31, 2023. We expect to recognize an additional $1.9&#160;million for severance and benefit expense for the 2023 Restructuring Plan, primarily in the second quarter of 2023. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details regarding the severance and benefit expense for the three months ended March&#160;31, 2023 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three months ended March&#160;31, 2023, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Restructuring Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Restructuring Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets and Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. Accordingly, we assessed our long-lived assets, including our property, plant and equipment, right-of-use assets and goodwill, for impairment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our impairment analysis, we first assessed which long-lived assets have identifiable cash flows that are largely independent of the cash flows of other groups of assets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that the long-lived assets associated with our leased spaces that we had previously decided to sublease under our 2022 Restructuring Plan continue to have cash flows that are independent of our entity-wide group. We concluded that these assets, for which we had recognized impairment charges during 2022, were recoverable based on estimated sublease income and therefore did not record any impairment charges for these long-lived assets for the three months ended March&#160;31, 2023. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated our remaining long-lived assets for impairment and performed a recoverability test using the undiscounted cash flows approach. We concluded that our net assets were not recoverable within the remaining useful lives. Accordingly, we estimated the fair value of the asset or asset group based on discounted future cash flows of the asset or asset group using a discount rate commensurate with the related risk. For the operating lease asset related to our Mission Bay facility, we estimated the fair value based on market participant assumptions, including the length of time to enter into a sublease, sublease payments, tenant improvement allowances and broker commissions, which we evaluated using current real estate trends and market conditions. We discounted the sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 7.9%. As a result of this analysis, we recorded a non-cash impairment charge of $11.5&#160;million. We also recorded an additional non-cash impairment charge of $1.7&#160;million for certain laboratory equipment. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We report the aggregate non-cash impairment charge of $13.2&#160;million in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. The following table presents a reconciliation of the non-cash impairment charge we recorded for these long-lived assets for the three months ended March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired facilities before write-off</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired facilities &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,734)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment expense for facilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of right-of-use assets and property, plant and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After we recorded the non-cash impairment charges for our long-lived assets, we next assessed goodwill for impairment. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. Accordingly, in accordance with ASC 350-20 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC 820-10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we measured the fair value of our reporting unit utilizing both income and market approaches for our entity-wide asset impairment analysis. Based on this analysis, we wrote off all of our goodwill, resulting in a non-cash impairment charge of $76.5&#160;million during the three months ended March&#160;31, 2023, which we reported as impairment of goodwill in our Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418188000576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185113248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in the field of immunotherapy.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Results of Clinical Trial Programs and the Restructuring Plans</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Clinical Trial Programs and the Restructuring Plans</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced that our registrational trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma, renal cell carcinoma and locally advanced or metastatic urothelial cancer under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS) did not meet their primary endpoints. Based on these results, in April 2022, we announced our decisions to discontinue all development of bempegaldesleukin in combination with checkpoint inhibitors, including these trials, our registrational trial in adjuvant melanoma under our BMS Collaboration Agreement, and our Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 5 for additional information regarding our BMS Collaboration Agreement and Co-Development Agreement with SFJ Pharmaceuticals. Pursuant to the Strategic Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan), pursuant to which we we completed an approximately 70% reduction of our workforce during 2022 and sold our research facility in India in December 2022.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study) under our collaboration agreement with Eli Lilly and Company (Lilly). Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin.  </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to plans approved by our Board of Directors (the Board) on March 29, 2023, we announced on April 17, 2023, a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we are reducing our San Francisco-based workforce by approximately 60%, which is expected to be substantially completed by June 2023.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to incur significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 6 for additional information on the effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2022 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 filed with the SEC on February 28, 2023. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text">Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated,</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract termination costs when we cancel the contract in accordance with its terms, and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Impairment of Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit&#8217;s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information regarding the impairment charges we recorded in connection with our goodwill.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Asset Impairment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share  For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418187989632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,955&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,227&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,165&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,894&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,522&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,048&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,359&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,726&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418186264816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,235&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,202&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,137&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,889&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the changes in our goodwill for the three months ended March 31, 2023 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"/><td style="width:84.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill &#8211; beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,501&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill &#8211; ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Schedule of Liability Related to Sale of Potential Future Royalties</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net &#8211; beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net &#8211; ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability to collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract termination costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418188006064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in the derivative liability for the three months ended March 31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418188086608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring, Impairment and Other Costs of Terminated Program</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program pertaining to the 2022 Restructuring Plan includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment and other costs of terminated program pertaining to the 2023 Restructuring Plan includes the following (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets and property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract termination and other restructuring costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and costs of terminated program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details regarding the severance and benefit expense for the three months ended March&#160;31, 2023 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three months ended March&#160;31, 2023, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Restructuring Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Restructuring Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table presents a reconciliation of the non-cash impairment charge we recorded for these long-lived assets for the three months ended March&#160;31, 2023 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net book value of impaired facilities before write-off</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Fair value of impaired facilities &#8212; Level 3 of Fair Value Hierarchy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,734)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment expense for facilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of other property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total impairment of right-of-use assets and property, plant and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418188097200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418183959536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="nump">$ 456,827,000<span></span>
</td>
<td class="nump">$ 456,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504,977,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts receivable, credit loss expense (reversal)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember', window );">Stock Options, RSUs And PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418184676064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Estimated Fair Value at</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 76,955<span></span>
</td>
<td class="nump">$ 88,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">379,872<span></span>
</td>
<td class="nump">416,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 456,827<span></span>
</td>
<td class="nump">$ 504,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418180159728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 26,040<span></span>
</td>
<td class="nump">8,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">456,827<span></span>
</td>
<td class="nump">504,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">375,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">374,359<span></span>
</td>
<td class="nump">427,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">60,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">59,894<span></span>
</td>
<td class="nump">83,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">298,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">297,798<span></span>
</td>
<td class="nump">344,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Obligations of U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">21,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">$ 48,925<span></span>
</td>
<td class="nump">$ 47,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418186276880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418180115152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,234<span></span>
</td>
<td class="nump">$ 2,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">13,167<span></span>
</td>
<td class="nump">10,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,834<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 20,235<span></span>
</td>
<td class="nump">$ 19,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185190416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 136,926<span></span>
</td>
<td class="nump">$ 154,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(110,653)<span></span>
</td>
<td class="num">(124,731)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentNet', window );">Depreciable property, plant and equipment, net</a></td>
<td class="nump">26,273<span></span>
</td>
<td class="nump">29,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in process</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">27,084<span></span>
</td>
<td class="nump">32,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">69,137<span></span>
</td>
<td class="nump">74,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember', window );">Computer equipment and computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">24,894<span></span>
</td>
<td class="nump">26,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">25,339<span></span>
</td>
<td class="nump">25,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">13,566<span></span>
</td>
<td class="nump">24,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 3,990<span></span>
</td>
<td class="nump">$ 4,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185077216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 76,501<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability discount rate</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability discount rate</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418186063792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill &#8211; beginning balance</a></td>
<td class="nump">$ 76,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="num">(76,501)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill &#8211; ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 76,501<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418180035712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 14,888<span></span>
</td>
<td class="nump">$ 9,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">7,739<span></span>
</td>
<td class="nump">12,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityToCollaborationPartnersCurrent', window );">Liability to collaboration partners</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_AccruedContractTerminationCostsCurrent', window );">Accrued contract termination costs</a></td>
<td class="nump">3,461<span></span>
</td>
<td class="nump">3,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">7,827<span></span>
</td>
<td class="nump">7,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 37,410<span></span>
</td>
<td class="nump">$ 36,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedContractTerminationCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Contract Termination Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedContractTerminationCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityToCollaborationPartnersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability to Collaboration Partners, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityToCollaborationPartnersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418183959184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties, net &#8211; beginning balance</a></td>
<td class="nump">$ 155,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(16,861)<span></span>
</td>
<td class="num">$ (17,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">$ 7,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties, net &#8211; ending balance</a></td>
<td class="nump">145,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties, net &#8211; beginning balance</a></td>
<td class="nump">55,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(9,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties, net &#8211; ending balance</a></td>
<td class="nump">47,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties, net &#8211; beginning balance</a></td>
<td class="nump">100,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(7,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">5,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties, net &#8211; ending balance</a></td>
<td class="nump">$ 97,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities On Sale Of Future Royalties Amortized Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Potential Future Royalties Non Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418188050864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Liability for litigation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418180510960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Jul. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,594,000<span></span>
</td>
<td class="nump">24,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding (up to)</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount', window );">Success payments (up to)</a></td>
<td class="nump">$ 637,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Company | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,861,000<span></span>
</td>
<td class="nump">$ 17,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185084416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details) - Fair Value, Level 3 - Development Derivative Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at beginning of period</a></td>
<td class="nump">$ 27,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">4,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Cash receipts from SFJ</a></td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the fair value of development derivative liability</a></td>
<td class="num">(33,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185365200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember', window );">2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember', window );">2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember', window );">Measurement Input, Market Participant Subtenant Borrowing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_OperatingLeaseMeasurementInput', window );">Operating lease, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and costs of terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | 2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and costs of terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and costs of terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OperatingLeaseMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OperatingLeaseMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418184732288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Summary of Restructuring Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="nump">$ 13,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring, impairment and costs of terminated program</a></td>
<td class="nump">21,193<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember', window );">2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and benefit expense</a></td>
<td class="nump">5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of other property, plant and equipment</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring, impairment and costs of terminated program</a></td>
<td class="nump">18,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember', window );">2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination and other restructuring costs</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring, impairment and costs of terminated program</a></td>
<td class="nump">$ 2,476<span></span>
</td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126938061&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418186133232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Restructuring Reserve Rollforward (Details) - Employee Severance - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">$ 3,299<span></span>
</td>
<td class="nump">$ 3,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">$ 30,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(3,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">2022 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">$ 3,299<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense recognized during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418185254320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Sublease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ImpairmentLongLivedAssetHeldForUseOther', window );">Impairment of other property, plant and equipment</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">33,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_ImpairmentLongLivedAssetHeldForUseOther', window );">Impairment of other property, plant and equipment</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">5,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Operating Lease Right-of-Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expense for facilities</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of right-of-use assets and property, plant and equipment</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember', window );">Operating Lease Right-of-Use Assets | Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">28,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3 | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">22,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3 | Property, Plant and Equipment | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">3,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3 | Operating Lease Right-of-Use Assets | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure', window );">Property, plant and equipment and Operating lease right-of-use assets</a></td>
<td class="nump">$ 18,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentLongLivedAssetHeldForUseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment, Long-Lived Asset, Held-for-Use, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentLongLivedAssetHeldForUseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140418181096176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10,019<span></span>
</td>
<td class="nump">$ 20,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">4,146<span></span>
</td>
<td class="nump">12,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,061<span></span>
</td>
<td class="nump">$ 8,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>nktr-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20230331.xsd" xlink:type="simple"/>
    <context id="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i353f6dfdad124cf895b486b31ecc03e3_I20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="ibce58931b7d241b7a58b00661b49392d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedc5a121de294018bf52ef250166d0cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if7474e215440423fb6a4944a3ef1c112_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6bff78a906cc446f9c38659e714a0991_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i120490afb52049e28bacdb27bba440d2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia918b3420fe94c7497c1964c27923368_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c90841203bc402ebda13222c297e7b0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13b6287af2fb458e9dabde17f604aeb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3795d80c499a47ffb23780f216279dd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8558d20a9404b2b9666d7e7ac9e04e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea9c049960c045d389ad24714ff388b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if35b840456e243088bc83a33ff9929d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fb94b83c0574f40994d258fd6f726ac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i40a2bdc6f20b4830a5391065713122ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6bd69c0c70945bea566d50bd61df2c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf4df987b0bc42539160068723e3c35b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0dc70df4b4d8449992572edf6df98bb6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e2a84be71ba453bb40cfd7c3b534a9e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i04ab4c4b6c284ad3a661dc38dc01e5f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8361cd8a1de744a594fc0cdb561e6003_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia9c43dfae2834078a893893586390205_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95ac92307e2549dd9ec0c7643db84d0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89f442d205bc45afbe1def2527c44fee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c2adc2069cb43649c5971f223b18c65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b935c9a9f6e4254978f843e88b6b14e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5464511d66984607836e04c3376ea0a2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1f798d53e2a645d9a4273b63d8030705_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i37de0bff6b41411ba350a255586c2c82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i556866edd8b5476d870f3d0567b42572_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id08bf37b20de42a79a37455e0a5403db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e12e371ab794958bf783671a51d9a9b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9901f8efb7a84fd383997f807d327718_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id65e32b44a5744e18b29a445360764ac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7697166d42e141bd9a7bbec30e8e7d48_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ief4395c62e394de284ed9e69496b6151_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i69e3a6b241b64c388617839ca0e84f74_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic91f661d01a94c13b05ca1bffece360b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i169cb82e795a48b79820f86db1cd190a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icb5b1ea2c25240e78087bc3f10b8ba5f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5a68493d157c4d499d9c6cfe4dbcd7c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbf7c09b99a3408ab39bfdee5594026c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib2b17d6fbf5d49d1827a4d756e9436ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3e6b2bd66034d0595587cea80e41b9c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe8adc60ceae453793ca7d4b82bd2863_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73846d6859c748ad9e0bcaec151a95db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a9a2d6862b34886bc6eb8bd085e313d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibdbb7c8346d54dc6ab904f9d8a1cfa32_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib0cde2ed24ec4607bb959fcc112e1fa8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16c7d7f6cfef46afa7d17a7648fa22d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ddd871d7e454404902df8e801682458_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7135b84ff3e4425b84bf50f571ac57ce_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i032e78f5ed7c4d648dc75900dc5651df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a7ef44e372d4c86842156ea38bc9a05_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id6aa244acf4d42e5af8f92393337c196_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac97bb571c524e1ea1a69c1042cdf6ff_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i557700c0d761400a82e19e7b49256e39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27a52bcfffe64473afd94d1ad70a2304_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i825095a4840447b1884c349d7a55b45d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bed044d7775412580048660b77fa954_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66e54efca0a94e31868b7e6b05760280_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b13a843a33e4bc08464584072e4b021_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec325a50f7844edda0d300d4f35dafa2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4ac5fe1f84b4a0b91a45b1c7657c57d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i49f42788641442cdad7182512b26d5e2_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i7adb82d027d849da802db4b49a43ee2a_I20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-23</instant>
        </period>
    </context>
    <context id="i0868cb5a09c844a796ffe2c4ecb34a5b_D20170723-20170723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-23</startDate>
            <endDate>2017-07-23</endDate>
        </period>
    </context>
    <context id="i7959c4e63c52467ca26c517b3783d65d_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="iaf20dc9f8d6f48baa0bd1294dba2654b_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="icba9f64c9bff4236965a5e18df3794a6_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ib249192b630141c98908c973940137df_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i48302ef504774ac6a0914253d9ac0a95_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i15412e5663004a80831838e6da60e1fe_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ib2debb833d9b47b6a265922060678a06_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i17ff1e5d834349cfb697a5e4a5c4bbaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a9f83081651457596b4bbe97aaaa513_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i248ad8f8306145d79a154379e4c144c7_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ib5c61fe105dd4f8ca0cb30e7ae9ca967_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5256132357e4151bc701fffe762e23c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibe1d381685d046eb8df1f1376d3da9d4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87894f2d277d4d689189754384742bf3_D20220101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i54ea4f7910ee46acbba924e43878e0d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac1590dec7f141ddb038c9a92effcf1e_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i997d98245f4048f997e82ffee6686137_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if40ec0a96ce54f1bb18634012ce405b9_D20230401-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="if20c572ba8d44958a9a79ca58b613c8d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i526526b23308431d88efcd30d4d1d51d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if85a2540650e49ff827fe78c21240f01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62f8fac2f829451080ed7031388fb268_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6620bfd483ba4ec1bd4a2ee734818286_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia7cadf538c2947f1b43fbef0ac736b9f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyThreeRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibb06267cb11c41e98b47d0d573f0e09a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nktr:TwoThousandTwentyTwoRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifa6e43a4bdee434d8a2152922832b63a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id695df1ce72740ec955bff4bb989faa8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06ed89f1fe464363a9e387568ead9993_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3598e30999e54f9f9f575e5b881f2da3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib55817a7194945f1ae4c0a8163778b09_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i86a36c4159774aedad86844713f0d8bc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleasePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3677d6c99212474f8786bb289678a42c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc2ab344bd4f4b498f29e789a11c1690_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id62ae4528157426aba132831bb9e3a69_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nktr:SubleaseOperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1cda02f4555947ccabad36bcc6480d92_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34546a7702c6424eb4d1bd5155173002_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i793f4a945cbb4640999a6a1a0da30ac5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i17ebf75335184f2eb6750cf5620342bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f16114b074f437fbd1d96555474845a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iebffda948b374043aba705095a8d4ade_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM18yLTEtMS0xLTQ4NTk0_6443facf-8a92-43de-855f-267b559632c5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM180LTEtMS0xLTQ4NTk0_a362b336-1c21-41fe-b764-54e041f80d57">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM181LTEtMS0xLTQ4NTk0_0d304210-1136-4cb4-b080-97dcedb7efcd">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM184LTEtMS0xLTQ4NTk0_b290adaf-1b7e-4e08-8cda-fd74338fb5e4">0000906709</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80L2ZyYWc6NDY3MzljYWE5NGM3NDc2NTk4YWIzYWZiZThkNTgwNWYvdGFibGU6YmRhNWMzNDY5ZmFiNGVlMTkxYWFhNmJmNGRlN2E1YjMvdGFibGVyYW5nZTpiZGE1YzM0NjlmYWI0ZWUxOTFhYWE2YmY0ZGU3YTViM185LTEtMS0xLTQ4NTk0_dcaadd97-4d19-4c33-a6d0-bdf1099f14ee">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYx_faa48113-6248-4041-9d79-0f885705a6a1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZDQwMDRiOWI2OWFiNDQ1YTg3N2M5YmMzZGM3OWYwNjUvdGFibGVyYW5nZTpkNDAwNGI5YjY5YWI0NDVhODc3YzliYzNkYzc5ZjA2NV8wLTAtMS0xLTQ4NTk0_679ae417-d830-49ab-8226-de1e8567a2c6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yNjY_49aabee5-66e5-4155-877e-1fe6b2e42410">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6YjE5NDkzZWJlM2NiNGQ3ZjkxMjc5YTgwNWViODZmODMvdGFibGVyYW5nZTpiMTk0OTNlYmUzY2I0ZDdmOTEyNzlhODA1ZWI4NmY4M18wLTAtMS0xLTQ4NTk0_b14e6ea0-693e-4b65-8d82-0de10f3ce177">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYy_3d2c0cbd-b4ec-46c9-ba88-04d6b51be8da">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYz_78cdedbb-2f96-4ec6-ac95-79ee25c635da">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6MWQ5YTFkZjNkNjBjNGQ0MDgyZDU3YzFjMzdjNzVmZjgvdGFibGVyYW5nZToxZDlhMWRmM2Q2MGM0ZDQwODJkNTdjMWMzN2M3NWZmOF8wLTAtMS0xLTQ4NTk0_b7a480af-c869-4c7c-b402-ce7c27436968">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6MWQ5YTFkZjNkNjBjNGQ0MDgyZDU3YzFjMzdjNzVmZjgvdGFibGVyYW5nZToxZDlhMWRmM2Q2MGM0ZDQwODJkNTdjMWMzN2M3NWZmOF8wLTItMS0xLTQ4NTk0_583df4a4-56cc-4662-b2b3-92e5aac0d92f">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU2_4b9280ae-616d-4699-8e83-f363fe206b6a">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU3_08cc3e3e-9420-404e-89be-5ec913eb3c1e">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY2_078e4929-3fa3-4d25-80cc-fabf29483e36">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY3_d1cd52e3-3055-4486-b9e9-4de50b4e62f0">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY4_383645ce-bb33-46d7-af02-38d5e860fbb8">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU4_d994820d-d2ba-4559-81c8-e36c40dfb82f">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6NDQ3NDQ3OGVjZDhkNDY4ZDk1YTJhMmU2MDcwY2ZkOTgvdGFibGVyYW5nZTo0NDc0NDc4ZWNkOGQ0NjhkOTVhMmEyZTYwNzBjZmQ5OF8yLTAtMS0xLTQ4NTk0_569f133c-0e82-4885-8a23-761b382c6fb7">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6NDQ3NDQ3OGVjZDhkNDY4ZDk1YTJhMmU2MDcwY2ZkOTgvdGFibGVyYW5nZTo0NDc0NDc4ZWNkOGQ0NjhkOTVhMmEyZTYwNzBjZmQ5OF8yLTEtMS0xLTQ4NTk0_d9b9b58b-fbbf-4720-98f0-f241b7193e24">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6NDQ3NDQ3OGVjZDhkNDY4ZDk1YTJhMmU2MDcwY2ZkOTgvdGFibGVyYW5nZTo0NDc0NDc4ZWNkOGQ0NjhkOTVhMmEyZTYwNzBjZmQ5OF8yLTItMS0xLTQ4NTk0_f4b87212-bef9-4705-ae4e-1272c6bb9e4f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjU5_3fac94af-e9d4-4e1d-bf7a-ba0f49815e4f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjYw_c84ce3e2-4965-41dc-8cb3-098c8d8972ce">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZjkxNzYwMmJlMDIxNDY0Zjk5MTA5NzEwZmY1MGM4N2MvdGFibGVyYW5nZTpmOTE3NjAyYmUwMjE0NjRmOTkxMDk3MTBmZjUwYzg3Y18wLTAtMS0xLTQ4NTk0_16e39734-fbbe-455a-8ef8-f9c5a98b711a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZjkxNzYwMmJlMDIxNDY0Zjk5MTA5NzEwZmY1MGM4N2MvdGFibGVyYW5nZTpmOTE3NjAyYmUwMjE0NjRmOTkxMDk3MTBmZjUwYzg3Y18yLTYtMS0xLTQ4NTk0_0156c284-f66a-420e-86ff-539fb8c00e9c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGFibGU6ZjkxNzYwMmJlMDIxNDY0Zjk5MTA5NzEwZmY1MGM4N2MvdGFibGVyYW5nZTpmOTE3NjAyYmUwMjE0NjRmOTkxMDk3MTBmZjUwYzg3Y180LTItMS0xLTQ4NTk0_304635c0-e768-4a30-ae5d-05c8c01965ff">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjY1_0cc672d8-9208-407b-b86a-5f49bd16a067">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i353f6dfdad124cf895b486b31ecc03e3_I20230502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8xL2ZyYWc6MjhlYjI2YWZhNWVkNDlmMzgyZGJjNThmMGM2ODZiYjgvdGV4dHJlZ2lvbjoyOGViMjZhZmE1ZWQ0OWYzODJkYmM1OGYwYzY4NmJiOF8yMjQ4_a9846f54-0690-4024-af01-ba3c78cc378b"
      unitRef="shares">189235157</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMy0xLTEtMS00ODU5NA_8097fb0e-0d88-45da-ace7-db640ff789ea"
      unitRef="usd">76955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMy0zLTEtMS00ODU5NA_7cac3072-6ed6-42f0-b7d5-55dd08238721"
      unitRef="usd">88227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNC0xLTEtMS00ODU5NA_75f944e1-16cd-473c-8334-96dbb6333755"
      unitRef="usd">379872000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNC0zLTEtMS00ODU5NA_2485aa69-9504-4591-8536-b7ec707783c9"
      unitRef="usd">416750000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNS0xLTEtMS00ODU5NA_abbbf736-10da-46af-bc3f-a449454741a9"
      unitRef="usd">2995000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNS0zLTEtMS00ODU5NA_6817c814-e5e0-4f8e-9581-799e2e9ef577"
      unitRef="usd">5981000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNi0xLTEtMS00ODU5NA_43267d34-88dd-4e9e-a23c-0a5fe50c9cd4"
      unitRef="usd">20235000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNi0zLTEtMS00ODU5NA_1e5016d0-16e3-4997-ba48-fa1730c8baba"
      unitRef="usd">19202000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNy0xLTEtMS00ODU5NA_82845712-3f75-488a-afc7-4c709588809b"
      unitRef="usd">11009000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfNy0zLTEtMS00ODU5NA_060ff487-5ab0-42ad-a6cc-8d6aafb04cb2"
      unitRef="usd">15808000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfOC0xLTEtMS00ODU5NA_00c7fd6f-1cd0-4aeb-8ad9-f0dc96696f7a"
      unitRef="usd">491066000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfOC0zLTEtMS00ODU5NA_c2d1ed60-492a-4308-a0da-ccf5b3a88fe5"
      unitRef="usd">545968000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTAtMS0xLTEtNDg1OTQ_2a06a522-3637-4854-a016-ae9b3b1b85c4"
      unitRef="usd">27084000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTAtMy0xLTEtNDg1OTQ_1d2f6122-23e6-408f-9448-c682b33e6504"
      unitRef="usd">32451000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTEtMS0xLTEtNDg1OTQ_959050ef-5ac5-4705-982b-b16945198351"
      unitRef="usd">42187000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTEtMy0xLTEtNDg1OTQ_b3cdf7f1-becb-457a-8dd6-0b89f2a35817"
      unitRef="usd">53435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTItMS0xLTEtNDg1OTQ_0a4ac31b-580c-4dc5-8bcd-260d31d05609"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTItMy0xLTEtNDg1OTQ_76df6c39-b3b4-49e4-bb1b-104e56073169"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTMtMS0xLTEtNDg1OTQ_402479a1-0fcc-43b5-a894-ac0417058857"
      unitRef="usd">1406000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTMtMy0xLTEtNDg1OTQ_c8ed3fdc-82da-4373-a230-be7d145c284d"
      unitRef="usd">2245000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTQtMS0xLTEtNDg1OTQ_654e4f6c-29f4-493d-abc5-4e80f6e809ae"
      unitRef="usd">561743000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTQtMy0xLTEtNDg1OTQ_606845a9-56a9-4a3e-b1af-3b84bfb5aee9"
      unitRef="usd">710600000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTctMS0xLTEtNDg1OTQ_69846c38-bc66-4c7b-9ef1-cbdbd5fec0bb"
      unitRef="usd">3696000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMTctMy0xLTEtNDg1OTQ_38f1d761-46e3-4f6a-92e8-248c1c3e42e3"
      unitRef="usd">12980000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMS0xLTEtNTE2MTg_bc0418c2-723d-44ac-90f0-f5a4f43deb85"
      unitRef="usd">37410000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMy0xLTEtNTE2MjY_23308b4c-2878-4476-99d8-543de46bdb7c"
      unitRef="usd">36557000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMS0xLTEtNDg1OTQ_fab5b821-0c4a-480f-bca6-eee8b6dbf3a5"
      unitRef="usd">18773000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjEtMy0xLTEtNDg1OTQ_571f6765-4ee2-4650-8cc2-d7860fec59b8"
      unitRef="usd">18667000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjItMS0xLTEtNDg1OTQ_7717a767-962e-44fd-88e0-1dd3902e133c"
      unitRef="usd">59879000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjItMy0xLTEtNDg1OTQ_df3af52a-440e-4c78-ad48-43e2c6a3c902"
      unitRef="usd">68204000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjMtMS0xLTEtNDg1OTQ_a1e2b820-d02a-4b96-aede-214b155835eb"
      unitRef="usd">109389000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjMtMy0xLTEtNDg1OTQ_9c49092d-5919-42ea-9631-0d8afb687c23"
      unitRef="usd">112829000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjUtMS0xLTEtNDg1OTQ_958e7d4a-aba9-4b84-bc6e-2e3f392d9e33"
      unitRef="usd">145131000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjUtMy0xLTEtNDg1OTQ_ca6f3265-296c-4256-ad8c-5d7b9b0af574"
      unitRef="usd">155378000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjYtMS0xLTEtNDg1OTQ_01165e62-86a1-4d9a-8624-e279d8942d73"
      unitRef="usd">6479000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjYtMy0xLTEtNDg1OTQ_62ce66de-ae18-4c88-977f-a03f8162f41e"
      unitRef="usd">7551000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjctMS0xLTEtNDg1OTQ_53efd73e-94b0-4121-a7e2-7b802084e25a"
      unitRef="usd">320878000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjctMy0xLTEtNDg1OTQ_d8f4dffb-0a33-4db6-af05-e7fc66191e3e"
      unitRef="usd">343962000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjgtMS0xLTEtNDg1OTQ_9c6d0716-2ebe-4f22-b5fd-7c2dc7d39396"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMjgtMy0xLTEtNDg1OTQ_6cba65a5-4576-4eee-8c71-f1439d600279"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8yMQ_1dc055d8-9ee9-4953-9dd4-07195a410ef4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8yMQ_e5176c35-b896-4f60-8528-c7c56a322567"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8zNQ_093f385b-c24c-4d14-9220-6fadab580514"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV8zNQ_67a732d9-220c-461b-9ff2-8d1f30bcbd1e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_386c4dbf-c264-48f0-afde-580ca3af2705"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_83ec13c3-b59d-4434-b26b-7312c2993046"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_ba0f0766-ff56-4a15-aa0b-2167c1358b1a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpjZTY4Mzc3N2JmYmY0ZmNhODUxMjEzMzQyNTJlMmNmOV81Nw_c5b643a6-e5a8-40e4-9a02-253694717261"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockValue
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMS0xLTEtNDg1OTQ_53f22ef4-bd51-46d9-a906-5511e1ca4ed2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzAtMy0xLTEtNDg1OTQ_4fa17126-ec3e-4682-baac-176785f5225a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8xOA_3e9f0251-d396-449e-9e7e-eb96bef10b94"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8xOA_98dad5ea-ca02-491b-8b15-9554b4aa6d52"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8zMg_a4359de6-6910-4d2c-8dd9-6970321df1bf"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF8zMg_ab27a348-4654-4419-83b0-4e48f2a9352a"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF81NA_8ecd02c0-b2ec-4137-ac18-b9841b0cbb89"
      unitRef="shares">189235000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMC0xLTEtNDg1OTQvdGV4dHJlZ2lvbjpmZmQxMjlhM2E3OGU0NjgzYmUyYjJjZDZhOTA4ODRiZF82OA_411da63a-61db-4fea-9f72-4c6372e9023b"
      unitRef="shares">188560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMS0xLTEtNDg1OTQ_909fe6ff-5ab9-483a-8a4e-6a97e778700c"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzEtMy0xLTEtNDg1OTQ_bc833978-3e09-4bf6-aa79-b046218967d7"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzItMS0xLTEtNDg1OTQ_1b5fa1e9-24e1-4a44-8c2f-0add7849f927"
      unitRef="usd">3584738000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzItMy0xLTEtNDg1OTQ_567aeb90-d4d2-4b03-a40b-c37209b948ba"
      unitRef="usd">3574719000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzMtMS0xLTEtNDg1OTQ_193a4be4-57e0-4a01-87b5-a80c3627d250"
      unitRef="usd">-5681000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzMtMy0xLTEtNDg1OTQ_e815d0a5-8a5f-47d7-a16d-bba73b854854"
      unitRef="usd">-6907000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzQtMS0xLTEtNDg1OTQ_cfaa0442-4ff9-41f7-94fa-2e497befd353"
      unitRef="usd">-3338211000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzQtMy0xLTEtNDg1OTQ_475939d4-bcd5-4142-840a-2b6f506d49e2"
      unitRef="usd">-3201193000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzUtMS0xLTEtNDg1OTQ_fa1848df-be45-4c4d-b4e4-f6dd7e1064c0"
      unitRef="usd">240865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzUtMy0xLTEtNDg1OTQ_a426fe53-73be-4cf0-848d-c427b97792d8"
      unitRef="usd">366638000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzYtMS0xLTEtNDg1OTQ_9a501a48-cf05-40ef-b566-5c6746d8a090"
      unitRef="usd">561743000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yMi9mcmFnOmJkZjYwMTZmMjczODQ0MjZhOTI4NGUxM2JlYjM3M2IzL3RhYmxlOjI2NDEwZDE2ZjkwNjRmZTU4NmU2NWZhYzg1YTdjMTIzL3RhYmxlcmFuZ2U6MjY0MTBkMTZmOTA2NGZlNTg2ZTY1ZmFjODVhN2MxMjNfMzYtMy0xLTEtNDg1OTQ_8079c4f3-a6ae-403a-8e29-df5100aff397"
      unitRef="usd">710600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedc5a121de294018bf52ef250166d0cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMy0xLTEtMS00ODU5NA_a86aeead-5a92-4608-be29-5e8e292c1823"
      unitRef="usd">4718000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7474e215440423fb6a4944a3ef1c112_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMy0zLTEtMS00ODU5NA_c1e1f109-d7bc-433b-8c24-d29a219f20ea"
      unitRef="usd">5688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bff78a906cc446f9c38659e714a0991_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNC0xLTEtMS00ODU5NA_bc191708-1f63-4764-9944-97b3ab25d80f"
      unitRef="usd">16861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i120490afb52049e28bacdb27bba440d2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNC0zLTEtMS00ODU5NA_069ab7cb-a889-41e2-a7f0-f9fca6acb393"
      unitRef="usd">17561000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia918b3420fe94c7497c1964c27923368_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNS0xLTEtMS00ODU5NA_a3ac4c4d-6d29-425e-a9cb-0bae9d230228"
      unitRef="usd">15000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c90841203bc402ebda13222c297e7b0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNS0zLTEtMS00ODU5NA_0b767355-eae7-4adb-9ca4-c36b53c0e8ba"
      unitRef="usd">1573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNi0xLTEtMS00ODU5NA_82300825-4cf4-4050-b3d4-cb8331c972a2"
      unitRef="usd">21594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfNi0zLTEtMS00ODU5NA_f90a71f3-7ca9-4ebb-a9ff-ff127897f88c"
      unitRef="usd">24822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOC0xLTEtMS00ODU5NA_f72dec94-cd0d-4b79-bafa-72e7f815e6ed"
      unitRef="usd">7060000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOC0zLTEtMS00ODU5NA_4bd80475-f66e-434c-a476-7c0d0104de7f"
      unitRef="usd">5315000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOS0xLTEtMS00ODU5NA_ca6f9b5b-70b3-4668-b7a3-fe2adff1848b"
      unitRef="usd">30469000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfOS0zLTEtMS00ODU5NA_f71b5b86-034a-4e0b-8994-37f178546f82"
      unitRef="usd">107253000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTAtMS0xLTEtNDg1OTQ_f0b0ff55-1943-44bb-bc1b-930d577e2d29"
      unitRef="usd">21081000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTAtMy0xLTEtNDg1OTQ_fba673a5-c523-4546-946a-a5ff3208662f"
      unitRef="usd">27339000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTEtMS0xLTEtNDg1OTQ_58402f9a-2b65-4730-9b89-9e429c1b4a4e"
      unitRef="usd">21193000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTEtMy0xLTEtNDg1OTQ_43b153d3-ecd2-4cac-929f-ace7ab27f522"
      unitRef="usd">1475000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMS0xLTEtNTE4NDk_0d56b4ac-5925-4957-8bf1-1679539e2427"
      unitRef="usd">76501000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMy0xLTEtNTE2NDY_c3242916-9da4-4e86-ae7a-4a83a9f55ca8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CostsAndExpenses
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMS0xLTEtNDg1OTQ_e3e7b2e1-4d0a-4915-8fb5-088fbcc0ba9f"
      unitRef="usd">156304000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTItMy0xLTEtNDg1OTQ_7d960e7f-7a37-4940-ac59-1b44f3309872"
      unitRef="usd">141382000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTMtMS0xLTEtNDg1OTQ_6d660580-0cde-463a-885d-ea6a3495f387"
      unitRef="usd">-134710000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTMtMy0xLTEtNDg1OTQ_ec87e38a-2e18-4b92-b010-aa0182d1dd79"
      unitRef="usd">-116560000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTUtMS0xLTEtNDg1OTQ_f2280b34-7e1d-4942-aa19-5d3ad61b6f23"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTUtMy0xLTEtNDg1OTQ_70c86cef-7ab2-4c39-9292-bf7aa963966f"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTYtMS0xLTEtNDg1OTQ_639c4c69-997d-4acc-a658-1c8bc1917405"
      unitRef="usd">6405000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTYtMy0xLTEtNDg1OTQ_08e8b16e-2ca2-44c4-bcfc-576cfd7b0815"
      unitRef="usd">7529000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTctMS0xLTEtNDg1OTQ_4e9c7651-9744-40d3-b88d-a68635b94a7f"
      unitRef="usd">4034000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTctMy0xLTEtNDg1OTQ_d5fbafa6-f702-4642-8cbf-b21e8c811f39"
      unitRef="usd">395000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTgtMS0xLTEtNDg1OTQ_ebfd9989-b1d8-4f74-9c3b-8f37a4f85e41"
      unitRef="usd">-2371000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTgtMy0xLTEtNDg1OTQ_47d67fbe-d87d-468b-8ab6-630b133b2ee6"
      unitRef="usd">26293000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTktMS0xLTEtNDg1OTQ_656143af-ca5a-495f-b166-f8ee7378104c"
      unitRef="usd">-137081000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMTktMy0xLTEtNDg1OTQ_b9e5a499-acf5-4183-8d3e-49ee94d3f5af"
      unitRef="usd">-90267000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjAtMS0xLTEtNDg1OTQ_3fa77b11-f244-49c0-bf37-54c2b87622cf"
      unitRef="usd">-63000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjAtMy0xLTEtNDg1OTQ_09bc1ee6-00ae-4ac3-aa72-f9e906c22d7d"
      unitRef="usd">126000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjEtMS0xLTEtNDg1OTQ_09f11698-4b3e-4795-9ace-fcefca53cc7d"
      unitRef="usd">-137018000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjEtMy0xLTEtNDg1OTQ_a887334d-9769-4446-8630-7fe04743101e"
      unitRef="usd">-90393000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMS0xLTEtNDg1OTQ_7d0550ac-2e19-4f6b-a63c-9d29b1e0bcf2"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMS0xLTEtNDg1OTQ_d11ca5eb-7cef-4cd0-b36a-d1c8ce04c5be"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMy0xLTEtNDg1OTQ_4e0eb83d-ab4e-4d1c-8057-7b6777200ea1"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjMtMy0xLTEtNDg1OTQ_c899267d-3132-460b-9c59-bb76806ede79"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMS0xLTEtNDg1OTQ_2923bba2-d871-4778-9814-1e345f89f62e"
      unitRef="shares">188875000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMS0xLTEtNDg1OTQ_d5687a88-1037-4f10-b19f-6166cb6e3e85"
      unitRef="shares">188875000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMy0xLTEtNDg1OTQ_4828d82d-1c63-4b2f-b8b1-6c4b21f8ea60"
      unitRef="shares">185848000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yNS9mcmFnOjQ3MDIwYWM4OGI3OTQ5NDE5MjU1MTRmMzFhZDVjNzkzL3RhYmxlOmY1YjI3MTZjZGY2YzQ3ZTI4YmUwZjNlMTZkNzMzYWNmL3RhYmxlcmFuZ2U6ZjViMjcxNmNkZjZjNDdlMjhiZTBmM2UxNmQ3MzNhY2ZfMjQtMy0xLTEtNDg1OTQ_f6b1df19-4f52-4dcf-9d44-4028a25eddd8"
      unitRef="shares">185848000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfMi0xLTEtMS00ODU5NA_0420dd7d-2abd-4442-b772-054d3125c647"
      unitRef="usd">-137018000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfMi0zLTEtMS00ODU5NA_eabb4d63-bbfd-48dc-9d57-cce85e22d1cb"
      unitRef="usd">-90393000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNC0xLTEtMS00ODU5NA_a1ba5fe9-ee74-41a2-ab4b-421742040d71"
      unitRef="usd">1087000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNC0zLTEtMS00ODU5NA_06994001-2eab-4b4f-8f3f-deae8b6a5b9f"
      unitRef="usd">-2091000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNS0xLTEtMS00ODU5NA_e17f905b-b8cf-40c2-adfc-5625e27fa927"
      unitRef="usd">139000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNS0zLTEtMS00ODU5NA_a5bce057-a97e-4ad0-9560-6f18360b216b"
      unitRef="usd">-284000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNi0xLTEtMS00ODU5NA_4403548e-1154-40e5-bbb1-6ed325650d22"
      unitRef="usd">1226000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNi0zLTEtMS00ODU5NA_a4b6de49-c0f0-4939-86c2-abbece5c7981"
      unitRef="usd">-2375000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNy0xLTEtMS00ODU5NA_46af24b0-7501-4cde-b644-b5448f071c01"
      unitRef="usd">-135792000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8yOC9mcmFnOmExNTI2NDAxN2NkODQ3N2RhMzVmZWE3MjQ0ZDBiZjNmL3RhYmxlOjM1YzJmNWNmMWYxNjQ1ZjdhOGIxODA2NGM5YjAxYmMxL3RhYmxlcmFuZ2U6MzVjMmY1Y2YxZjE2NDVmN2E4YjE4MDY0YzliMDFiYzFfNy0zLTEtMS00ODU5NA_04f4e934-5d56-4be0-8e3a-b51fc9ae04bb"
      unitRef="usd">-92768000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i13b6287af2fb458e9dabde17f604aeb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS0xLTEtMS00ODU5NA_5383354a-de77-4452-a930-ce11e5a8c12a"
      unitRef="shares">185468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i13b6287af2fb458e9dabde17f604aeb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS0zLTEtMS00ODU5NA_7273d405-ec92-4f81-bd46-7a452026af0c"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3795d80c499a47ffb23780f216279dd5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS01LTEtMS00ODU5NA_c3b7a8dc-95e2-4fab-87f3-3d8c9f4487a3"
      unitRef="usd">3516641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8558d20a9404b2b9666d7e7ac9e04e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS03LTEtMS00ODU5NA_14edd90c-19a3-41df-aa7e-3881c4bb3f28"
      unitRef="usd">-4157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea9c049960c045d389ad24714ff388b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS05LTEtMS00ODU5NA_f464b062-18e7-4763-8dee-3ab89d2e419a"
      unitRef="usd">-2832995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if35b840456e243088bc83a33ff9929d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMS0xMS0xLTEtNDg1OTQ_12c6a719-bd2d-4868-959e-0864d9560b60"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0fb94b83c0574f40994d258fd6f726ac_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMi0xLTEtMS00ODU5NA_d2dc22b2-cb2a-4701-a2e0-9fe2cfa7c839"
      unitRef="shares">806000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i40a2bdc6f20b4830a5391065713122ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMi01LTEtMS00ODU5NA_cb3babe0-067e-41c5-ad53-a5e647ad2f12"
      unitRef="usd">188000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMi0xMS0xLTEtNDg1OTQ_c13d72e2-994c-44a9-afd5-3b2c1b68bcb1"
      unitRef="usd">188000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i40a2bdc6f20b4830a5391065713122ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMy01LTEtMS00ODU5NA_a0f4f0f6-7b2e-49ca-ab35-043a46156a4b"
      unitRef="usd">20961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfMy0xMS0xLTEtNDg1OTQ_a77b4872-6eac-4cae-b449-a671ed9c18b2"
      unitRef="usd">20961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id6bd69c0c70945bea566d50bd61df2c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNC03LTEtMS00ODU5NA_2c59e4c7-52bc-41b1-8e86-53d1f4581df1"
      unitRef="usd">-2375000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idf4df987b0bc42539160068723e3c35b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNC05LTEtMS00ODU5NA_12cb17ac-46c1-4f3f-8ba7-5bbffda62cef"
      unitRef="usd">-90393000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNC0xMS0xLTEtNDg1OTQ_837a78b7-823f-452b-a284-7b2f7af05f76"
      unitRef="usd">-92768000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0dc70df4b4d8449992572edf6df98bb6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS0xLTEtMS00ODU5NA_1261988a-512d-40bf-83a5-e21ae990f4e8"
      unitRef="shares">186274000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0dc70df4b4d8449992572edf6df98bb6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS0zLTEtMS00ODU5NA_3fd175cf-f14b-4a80-b22e-9c4e3c414441"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e2a84be71ba453bb40cfd7c3b534a9e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS01LTEtMS00ODU5NA_65305bfb-10d9-465e-93f9-38650233f440"
      unitRef="usd">3537790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04ab4c4b6c284ad3a661dc38dc01e5f9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS03LTEtMS00ODU5NA_28ce042c-e3fb-406d-9967-c1d65785bafa"
      unitRef="usd">-6532000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8361cd8a1de744a594fc0cdb561e6003_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS05LTEtMS00ODU5NA_a67d0ec0-9d11-4363-a8d9-47466271eda8"
      unitRef="usd">-2923388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9c43dfae2834078a893893586390205_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOmExMTgzYjdiNjJmNDRlMmE5MWQwNWViZDVjMmMwNzZiL3RhYmxlcmFuZ2U6YTExODNiN2I2MmY0NGUyYTkxZDA1ZWJkNWMyYzA3NmJfNS0xMS0xLTEtNDg1OTQ_3ecd4b8c-ba8c-41ab-bd50-1d90048f1a42"
      unitRef="usd">607889000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i95ac92307e2549dd9ec0c7643db84d0a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS0xLTEtMS00ODU5NA_9c436482-1b7e-4ce6-9161-c8505e332868"
      unitRef="shares">188560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i95ac92307e2549dd9ec0c7643db84d0a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS0zLTEtMS00ODU5NA_0cc8b874-0870-4db0-a6e8-4c26f4eb27bd"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89f442d205bc45afbe1def2527c44fee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS01LTEtMS00ODU5NA_09a0c13e-7993-41e9-b7c8-4d6704976a1a"
      unitRef="usd">3574719000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c2adc2069cb43649c5971f223b18c65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS03LTEtMS00ODU5NA_23004611-2724-4012-a25d-252efe76b1c3"
      unitRef="usd">-6907000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b935c9a9f6e4254978f843e88b6b14e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS05LTEtMS00ODU5NA_e41e06ec-11e2-4988-a4dd-707d2ff1a50e"
      unitRef="usd">-3201193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMS0xMS0xLTEtNDg1OTQ_9bcdc6b3-8af2-4860-8214-eccf68d30785"
      unitRef="usd">366638000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5464511d66984607836e04c3376ea0a2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMi0xLTEtMS00ODU5NA_14442ead-83f4-4ca5-a25a-43800bb21bcc"
      unitRef="shares">675000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1f798d53e2a645d9a4273b63d8030705_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMi01LTEtMS00ODU5NA_591743c0-4273-47fd-90f1-d0d6ad318a37"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMi0xMS0xLTEtNDg1OTQ_6479df77-619f-4904-b555-4cc2fe9c6138"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1f798d53e2a645d9a4273b63d8030705_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMy01LTEtMS00ODU5NA_26bc1e5f-ca94-4230-bee2-bc7830fa13b2"
      unitRef="usd">10019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfMy0xMS0xLTEtNDg1OTQ_262e9bc8-9b47-4c85-bdc4-e4d33f357101"
      unitRef="usd">10019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i37de0bff6b41411ba350a255586c2c82_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNC03LTEtMS00ODU5NA_ef87913d-60ac-4771-969b-c6a800240dea"
      unitRef="usd">1226000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i556866edd8b5476d870f3d0567b42572_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNC05LTEtMS00ODU5NA_e2be5130-cef1-4c4b-812d-0ff5f704915e"
      unitRef="usd">-137018000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNC0xMS0xLTEtNDg1OTQ_6a0a8f0a-63af-4045-b7f4-ebfb7103d9f6"
      unitRef="usd">-135792000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id08bf37b20de42a79a37455e0a5403db_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS0xLTEtMS00ODU5NA_744997cd-afa2-4ed0-bb44-874ff75463c7"
      unitRef="shares">189235000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id08bf37b20de42a79a37455e0a5403db_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS0zLTEtMS00ODU5NA_48231cc4-c72a-411d-aac0-502fd15df43d"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e12e371ab794958bf783671a51d9a9b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS01LTEtMS00ODU5NA_9061a569-0cfe-4ece-9253-fc41fc7f0854"
      unitRef="usd">3584738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9901f8efb7a84fd383997f807d327718_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS03LTEtMS00ODU5NA_f9e5d9df-1e73-4bbf-a8d0-a2a49a37ee95"
      unitRef="usd">-5681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id65e32b44a5744e18b29a445360764ac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS05LTEtMS00ODU5NA_1902a867-8c4e-419a-b1fe-f6f4b7fbc993"
      unitRef="usd">-3338211000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zMS9mcmFnOjdjYmJjNDc0ODc4YjQxNGE4NzA5Y2Y5Yzc5NWVjMTgwL3RhYmxlOjFkM2U5ZDA4MGU0MzQyMGE5MTdiNmEyMGI1NTgwMGI3L3RhYmxlcmFuZ2U6MWQzZTlkMDgwZTQzNDIwYTkxN2I2YTIwYjU1ODAwYjdfNS0xMS0xLTEtNDg1OTQ_64812398-416b-45aa-99a1-f304a97fe072"
      unitRef="usd">240865000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMy0xLTEtMS00ODU5NA_80669d1d-6cc0-4482-b060-51258d4db49c"
      unitRef="usd">-137018000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMy0zLTEtMS00ODU5NA_943d0a7c-71b2-4dd3-b79b-8da682b43134"
      unitRef="usd">-90393000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNS0xLTEtMS00ODU5NA_fb5a290f-b83f-4ae7-a847-c6aacf891469"
      unitRef="usd">16861000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNS0zLTEtMS00ODU5NA_a5a2d0c0-2ea3-4f7f-b43f-f0ee6233b614"
      unitRef="usd">17561000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNi0xLTEtMS00ODU5NA_6629ba6a-917b-44ee-80f8-3d8ff81ee7c4"
      unitRef="usd">6405000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNi0zLTEtMS00ODU5NA_f499d520-b359-4fdc-9c5d-1293d571516b"
      unitRef="usd">7529000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNy0xLTEtMS00ODU5NA_f301c851-40ec-45de-a102-86206114d6f1"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfNy0zLTEtMS00ODU5NA_2141c3de-580b-493e-9fc0-e15bcd1dbff2"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOC0xLTEtMS00ODU5NA_9e99db16-9958-4a59-82a9-75c4a357db2d"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOC0zLTEtMS00ODU5NA_59930016-3619-40e5-8404-381a5dc0644e"
      unitRef="usd">4951000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOS0xLTEtMS00ODU5NA_bfd40287-6e45-49de-a7a0-17259689f676"
      unitRef="usd">10019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfOS0zLTEtMS00ODU5NA_dde8efcc-feca-4fc2-b169-959f4cd65294"
      unitRef="usd">20961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTAtMS0xLTEtNDg1OTQ_4302b71e-4cbb-4241-8581-76913a924530"
      unitRef="usd">2302000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTAtMy0xLTEtNDg1OTQ_92cec53d-4f32-47b9-b824-8909ce967870"
      unitRef="usd">3730000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMS0xLTEtNTQ5MzI_b4e82d17-618f-4bd5-8d34-b4850939a4e5"
      unitRef="usd">-1812000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMy0xLTEtNTQ5MjI_642c8719-e5b7-46d1-a649-cb15f6a01f04"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMS0xLTEtNDg1OTQ_93deb2b5-4ba6-4804-bf7d-7557c71de635"
      unitRef="usd">13200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTEtMy0xLTEtNDg1OTQ_3805df17-7ec6-4a3e-8b12-23f5e11942d2"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMS0xLTEtNTI4MjI_ed771787-d9e7-4340-9a48-aa81e047da9a"
      unitRef="usd">76501000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMy0xLTEtNTI4MTQ_4655fa77-9b40-48dd-8b12-ded4f403624a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMS0xLTEtNDg1OTQ_2c26db4c-64da-4530-95f8-e97409805522"
      unitRef="usd">3129000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTItMy0xLTEtNDg1OTQ_304eb500-b8e7-43ff-b380-664c36aa3114"
      unitRef="usd">-1276000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTQtMS0xLTEtNDg1OTQ_da2346a2-5337-41c2-84b6-e571167c94bd"
      unitRef="usd">-2986000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTQtMy0xLTEtNDg1OTQ_75f55c9c-0c92-4f33-985a-98bc820ad245"
      unitRef="usd">7728000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTUtMS0xLTEtNDg1OTQ_505a178b-a7dd-44d5-807f-2e40c32dc70d"
      unitRef="usd">1033000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTUtMy0xLTEtNDg1OTQ_02c001be-e925-4696-84aa-f06c0405b0a2"
      unitRef="usd">-422000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTYtMS0xLTEtNDg1OTQ_c4eae026-c72b-4457-b72d-43146ca17418"
      unitRef="usd">1786000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTYtMy0xLTEtNDg1OTQ_997941eb-18d4-4c41-aa3e-f7d3706e37b6"
      unitRef="usd">-1787000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTctMS0xLTEtNDg1OTQ_d88a0b0e-b3f7-4c6a-a8f8-77569fff2f93"
      unitRef="usd">-5591000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTctMy0xLTEtNDg1OTQ_09b2313e-9a39-4e56-9b69-739a39b32122"
      unitRef="usd">-2864000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTgtMS0xLTEtNDg1OTQ_091e4a55-bf63-4902-9362-7886c76328e8"
      unitRef="usd">-8920000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMTgtMy0xLTEtNDg1OTQ_0838caa5-7acb-4b30-81e6-04b3524fec87"
      unitRef="usd">2998000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjAtMS0xLTEtNDg1OTQ_cd6684ab-3ee6-49b6-945e-fc7de1ca1bf1"
      unitRef="usd">1640000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjAtMy0xLTEtNDg1OTQ_46381562-4b8a-4504-80bb-210c5d9e5f27"
      unitRef="usd">14167000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjEtMS0xLTEtNDg1OTQ_3988cd3e-111b-46a6-a32d-efcf7f4b6f40"
      unitRef="usd">-51915000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjEtMy0xLTEtNDg1OTQ_cd3d659e-2720-48df-86b2-f910ed03482a"
      unitRef="usd">-88424000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjMtMS0xLTEtNDg1OTQ_d7852be5-5062-4943-8a1a-711eaa44ccaf"
      unitRef="usd">107012000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjMtMy0xLTEtNDg1OTQ_387df5f5-b977-4ce2-b8d0-18ae39ebb461"
      unitRef="usd">93493000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjQtMS0xLTEtNDg1OTQ_c486c6a1-3b61-41f9-a545-fc903dd72e42"
      unitRef="usd">148043000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjQtMy0xLTEtNDg1OTQ_472944b9-df65-45e6-a968-b98b92785e5d"
      unitRef="usd">227974000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjYtMS0xLTEtNDg1OTQ_4a5f0324-1243-4736-8e27-0a90699c1f2f"
      unitRef="usd">433000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjYtMy0xLTEtNDg1OTQ_68743085-35da-4463-8628-9da7cd099581"
      unitRef="usd">4203000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjctMS0xLTEtNDg1OTQ_f5f799a6-cc79-4b7b-be99-3d7d2cc1f015"
      unitRef="usd">40598000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjctMy0xLTEtNDg1OTQ_0e1c1a35-44da-4496-b6f9-3933653a88ce"
      unitRef="usd">130278000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjktMS0xLTEtNDg1OTQ_6f109dac-4a8e-4fb0-be7e-203ed668dc77"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMjktMy0xLTEtNDg1OTQ_2fda837e-9445-491b-96c9-9c1c5ff1e2c5"
      unitRef="usd">188000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzAtMS0xLTEtNDg1OTQ_2aedd267-bc23-493b-9c7c-3b0a187d1c1f"
      unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzAtMy0xLTEtNDg1OTQ_d427e19f-6825-42c2-a147-0085f10676d6"
      unitRef="usd">750000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzEtMS0xLTEtNDg1OTQ_e573d2df-4cca-4eb1-9065-c14b56cb7325"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzEtMy0xLTEtNDg1OTQ_20a57099-09de-4155-b09f-a30c756869d9"
      unitRef="usd">938000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzItMS0xLTEtNDg1OTQ_01ba43bb-1c05-45c5-85e1-dba1d621499d"
      unitRef="usd">45000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzItMy0xLTEtNDg1OTQ_a579a3ce-fc69-4974-a673-804cd30a9eb4"
      unitRef="usd">-17000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzMtMS0xLTEtNDg1OTQ_28a35e7e-3005-4f58-9a09-8852909348b8"
      unitRef="usd">-11272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzMtMy0xLTEtNDg1OTQ_cfd2cc7a-a34c-444e-918c-9836a876daa2"
      unitRef="usd">42775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzQtMS0xLTEtNDg1OTQ_e19e6465-f405-4c94-ba6c-3edad0923819"
      unitRef="usd">88227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if35b840456e243088bc83a33ff9929d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzQtMy0xLTEtNDg1OTQ_e5c3e9a6-1b19-45a9-8e72-eaff92877b4a"
      unitRef="usd">25218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzUtMS0xLTEtNDg1OTQ_3c23651f-e94a-42ad-a95d-bb46994587f2"
      unitRef="usd">76955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9c43dfae2834078a893893586390205_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV8zNC9mcmFnOjU3MmYyYzI0ZTgwYzQ1MDc4ODVjNDk1OGRmNmY0ZGMxL3RhYmxlOjQyNWJmMWE4NjdlZjRkMTdhOWI1MjJkMmM2NGEzNTBlL3RhYmxlcmFuZ2U6NDI1YmYxYTg2N2VmNGQxN2E5YjUyMmQyYzY0YTM1MGVfMzUtMy0xLTEtNDg1OTQ_32eb45b5-7bc3-4302-8210-ecc59eee122a"
      unitRef="usd">67993000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzA_122049d5-7081-4266-ac6a-f2be8a145960">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in the field of immunotherapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of March&#160;31, 2023, we had approximately $456.8 million in cash and investments in marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Results of Clinical Trial Programs and the Restructuring Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced that our registrational trials of bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma, renal cell carcinoma and locally advanced or metastatic urothelial cancer under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS) did not meet their primary endpoints. Based on these results, in April 2022, we announced our decisions to discontinue all development of bempegaldesleukin in combination with checkpoint inhibitors, including these trials, our registrational trial in adjuvant melanoma under our BMS Collaboration Agreement, and our Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 5 for additional information regarding our BMS Collaboration Agreement and Co-Development Agreement with SFJ Pharmaceuticals. Pursuant to the Strategic Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan), pursuant to which we we completed an approximately 70% reduction of our workforce during 2022 and sold our research facility in India in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study) under our collaboration agreement with Eli Lilly and Company (Lilly). Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to plans approved by our Board of Directors (the Board) on March 29, 2023, we announced on April 17, 2023, a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we are reducing our San Francisco-based workforce by approximately 60%, which is expected to be substantially completed by June 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have incurred and expect to incur significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 6 for additional information on the effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2022 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 filed with the SEC on February 28, 2023. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the three months ended March&#160;31, 2023 and 2022, nor have recorded such an allowance as of March&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract termination costs when we cancel the contract in accordance with its terms, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit&#x2019;s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for additional information regarding the impairment charges we recorded in connection with our goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), which totaled 22.8&#160;million and 22.3&#160;million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzI_17e3ee8c-81bd-488f-b500-c6afefbb4562">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We (individually or with a partner) are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in the field of immunotherapy.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTA1Nw_8a14b548-7cd9-419c-8452-356b687cf27e"
      unitRef="usd">456800000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Nzg_ea7fbd21-be4a-4a6e-b567-41a44c8298c8">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Results of Clinical Trial Programs and the Restructuring Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced that our registrational trials of bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma, renal cell carcinoma and locally advanced or metastatic urothelial cancer under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS) did not meet their primary endpoints. Based on these results, in April 2022, we announced our decisions to discontinue all development of bempegaldesleukin in combination with checkpoint inhibitors, including these trials, our registrational trial in adjuvant melanoma under our BMS Collaboration Agreement, and our Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 5 for additional information regarding our BMS Collaboration Agreement and Co-Development Agreement with SFJ Pharmaceuticals. Pursuant to the Strategic Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we also announced new strategic reorganization and cost restructuring plans (together, the 2022 Restructuring Plan), pursuant to which we we completed an approximately 70% reduction of our workforce during 2022 and sold our research facility in India in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study) under our collaboration agreement with Eli Lilly and Company (Lilly). Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to plans approved by our Board of Directors (the Board) on March 29, 2023, we announced on April 17, 2023, a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we are reducing our San Francisco-based workforce by approximately 60%, which is expected to be substantially completed by June 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have incurred and expect to incur significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 6 for additional information on the effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i7697166d42e141bd9a7bbec30e8e7d48_D20220401-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODc5NjA5MzA1MTg5MA_6df7beff-c24d-4ebb-8523-209d4e0cfd48"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="ief4395c62e394de284ed9e69496b6151_D20230301-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMzg0ODI5MDcyNTYzOA_e4874e19-d13f-4899-83aa-c08ae1eed4a5"
      unitRef="number">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Nzk_89d66852-e590-412e-b47c-5431fa36eb1e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2022 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 filed with the SEC on February 28, 2023. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Njk_56e2df1f-a481-4d23-92c0-f40747a8bce9">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzU_2b7cef1e-71ad-4a96-b790-74f5e9dbd5a6">Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. &lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODQwNw_e42d459a-597b-48a6-aa18-69cf332ae4de"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODQwNw_f6719913-a98c-47de-9791-9c6b306582d9"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1Nzc_f3e4e36e-63a7-438b-a0cd-fdfb8d32b71b">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract termination costs when we cancel the contract in accordance with its terms, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfNTQ5NzU1ODM4NjIx_37a7245a-ee8f-4f39-88de-69d01d198c9c">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit&#x2019;s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for additional information regarding the impairment charges we recorded in connection with our goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfMTI1NzM_f644b704-4fee-4bc5-b9eb-2a7fa1774a2b">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfNDM5ODA0NjUyNjU3MQ_53f1b5e7-a3cb-40e2-aee1-cb4b9ae41f07">Net Loss per Share  For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i69e3a6b241b64c388617839ca0e84f74_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfNDM5ODA0NjUyNjU3MA_4682982c-4493-49d5-a325-a86035c671bd"
      unitRef="shares">22800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic91f661d01a94c13b05ca1bffece360b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80MC9mcmFnOmMwODRhMGYwNDNhNTQ4ODI4OWEzMDgwZTcwNjJjZWIzL3RleHRyZWdpb246YzA4NGEwZjA0M2E1NDg4Mjg5YTMwODBlNzA2MmNlYjNfODc5NjA5MzAzNzY2MA_4e6b619c-d39f-4f87-a4eb-cdb27bdd397d"
      unitRef="shares">22300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfODE1_ac0bed6f-c6be-4f2d-b7b0-a35b6b986e96">Cash and Investments in Marketable Securities&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2022, our gross unrealized losses totaled $1.8&#160;million, and our gross unrealized gains were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfODE3_eca6adc1-a689-429d-8d57-1d3003b17da4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMi0xLTEtMS00ODU5NA_5217d5ff-903e-403e-a8c8-2d1a96b1a7df"
      unitRef="usd">76955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMi0zLTEtMS00ODU5NA_e22680a3-b577-475f-8283-ce28a4a21262"
      unitRef="usd">88227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMy0xLTEtMS00ODU5NA_23254b28-a850-4d85-b31e-0ff400061ba8"
      unitRef="usd">379872000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfMy0zLTEtMS00ODU5NA_4bebc599-e074-4e68-af35-5124c1e886f8"
      unitRef="usd">416750000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfNS0xLTEtMS00ODU5NA_5da5fd40-d878-435c-90b1-ab91c26487a5"
      unitRef="usd">456827000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjg3OTBhMmE5ZTY1NjQxZTU4ZGMxNmU2OTFlM2MzNWFmL3RhYmxlcmFuZ2U6ODc5MGEyYTllNjU2NDFlNThkYzE2ZTY5MWUzYzM1YWZfNS0zLTEtMS00ODU5NA_d047ab9a-2e3b-41ec-9508-55a79f4a6baa"
      unitRef="usd">504977000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfODE5_cb7f4bb2-2bd0-482c-93f6-f1d1b248d0ce">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi00LTEtMS00ODU5NA_d1d64dd9-c138-4f34-8d6b-cd48adfbeeee"
      unitRef="usd">60165000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi02LTEtMS00ODU5NA_f3982855-ed98-4731-adf8-82d0361e38f5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi04LTEtMS00ODU5NA_8199f73b-d6ef-4d18-9f64-d9fb4ecb3b14"
      unitRef="usd">271000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i169cb82e795a48b79820f86db1cd190a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi0xMC0xLTEtNDg1OTQ_d93bc911-1abc-4b06-b274-31085a390775"
      unitRef="usd">59894000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb5b1ea2c25240e78087bc3f10b8ba5f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMi0xMi0xLTEtNDg1OTQ_d0703ed1-6ad1-47ed-9134-02191fa22bb7"
      unitRef="usd">83522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy00LTEtMS00ODU5NA_43b20137-82fe-4e57-8dc1-215d9b0c4330"
      unitRef="usd">298216000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy02LTEtMS00ODU5NA_39c0ab79-03d7-46c7-96b3-9814eba3cc56"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy04LTEtMS00ODU5NA_3aaec605-9604-4881-88bc-00657e873c11"
      unitRef="usd">421000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic53e3e5c6f3c4b48b96216a450fc6d1b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy0xMC0xLTEtNDg1OTQ_3650f26e-fb98-4b41-a8f7-99b0740acf1e"
      unitRef="usd">297798000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a68493d157c4d499d9c6cfe4dbcd7c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfMy0xMi0xLTEtNDg1OTQ_13533ccf-e7aa-4e08-a880-db012e81681b"
      unitRef="usd">344204000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC00LTEtMS00ODU5NA_bcc200ef-faa6-4a36-8a23-f010662406b3"
      unitRef="usd">16667000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC02LTEtMS00ODU5NA_4bd1f22a-5eec-454e-881d-d3fef43b4dbf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC04LTEtMS00ODU5NA_c08f5016-ec3e-4a82-8c13-23cfaf7531ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbf7c09b99a3408ab39bfdee5594026c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC0xMC0xLTEtNDg1OTQ_fb3e72e8-c975-417a-9a71-12636cdfd2a3"
      unitRef="usd">16667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2b17d6fbf5d49d1827a4d756e9436ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNC0xMi0xLTEtNDg1OTQ_d66378a6-cdb0-4c97-a201-8ac68fbcc894"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS00LTEtMS00ODU5NA_df7cfcc2-79f3-487f-9bdb-56c2ed32579d"
      unitRef="usd">375048000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS02LTEtMS00ODU5NA_bc795709-c6ff-4dab-8219-5df60e846d67"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS04LTEtMS00ODU5NA_0e799508-ecbc-4c48-a137-206577a810f3"
      unitRef="usd">692000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3e6b2bd66034d0595587cea80e41b9c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS0xMC0xLTEtNDg1OTQ_78684afa-82f7-4421-b14f-671523165186"
      unitRef="usd">374359000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe8adc60ceae453793ca7d4b82bd2863_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNS0xMi0xLTEtNDg1OTQ_c1b5ea38-6b2d-416d-8ad7-09dcadeb07e5"
      unitRef="usd">427726000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i73846d6859c748ad9e0bcaec151a95db_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNi0xMC0xLTEtNDg1OTQ_31c10e1e-ff28-4b8e-9a87-4e16221b7203"
      unitRef="usd">48925000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3a9a2d6862b34886bc6eb8bd085e313d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNi0xMi0xLTEtNDg1OTQ_f67db87e-625b-4aee-83aa-30efb41d9273"
      unitRef="usd">47054000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibdbb7c8346d54dc6ab904f9d8a1cfa32_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNy0xMC0xLTEtNDg1OTQ_42678f49-6aa7-45ca-ab86-762f462f284c"
      unitRef="usd">7503000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib0cde2ed24ec4607bb959fcc112e1fa8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfNy0xMi0xLTEtNDg1OTQ_ca3e4bee-5fdc-4b36-85bb-72105d28a1b9"
      unitRef="usd">21399000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOC0xMC0xLTEtNDg1OTQ_2bcf394d-2db3-4316-800e-f67abfa813f7"
      unitRef="usd">26040000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOC0xMi0xLTEtNDg1OTQ_c9f83f5a-4d6d-4111-b5c7-c730ae3ebe72"
      unitRef="usd">8798000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOS0xMC0xLTEtNDg1OTQ_a54b152f-2518-44f9-8d64-d84c9622453c"
      unitRef="usd">456827000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RhYmxlOjIyZDZiNzdhNWUwMjQ5MDFhZDcyNTUzM2Q2YTEyZTEyL3RhYmxlcmFuZ2U6MjJkNmI3N2E1ZTAyNDkwMWFkNzI1NTMzZDZhMTJlMTJfOS0xMi0xLTEtNDg1OTQ_9be43e67-e208-4f99-9312-396e630d0468"
      unitRef="usd">504977000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80My9mcmFnOjQ3YTNmMmI2ZTRmZDRkMWM4ZThjZDIyZDNjOWE0NDU3L3RleHRyZWdpb246NDdhM2YyYjZlNGZkNGQxYzhlOGNkMjJkM2M5YTQ0NTdfNzYx_6742f9d9-25b9-4b0c-8f4d-d880612d9588"
      unitRef="usd">1800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODQ1_e53d4ee7-4c8b-4bfb-8a6b-33b2b3bfccb7">Condensed Consolidated Financial Statement Details&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the decrease in the fair value of our single reporting unit during the three months ended March 31, 2023, we recorded a non-cash impairment charge of $3.5&#160;million for property, plant and equipment, which we report in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. See Note 6 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the changes in our goodwill for the three months ended March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &#x2013; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the decrease in the fair value of our single reporting unit during the three months ended March 31, 2023, we recorded a non-cash goodwill impairment charge of $76.5&#160;million, which we report as impairment of goodwill in our Condensed Consolidated Statement of Operations. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. See Note 6 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability to collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities Related to the Sales of Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively. We account for these transactions as debt and recognize non-cash royalty revenue and non-cash interest expense to amortize the proceeds over the lives of the respective arrangements. We periodically update our prospective non-cash interest rate based on our estimates of future royalties. As of March 31, 2023, our imputed interest rates for the arrangements with RPI and HCR were 10% and 20%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net &#x2013; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODQz_4fffa539-0d27-4860-96a4-3c2eb0c19335">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMS0xLTEtMS00ODU5NA_9632621c-0591-400c-aebb-678e4da1c1cb"
      unitRef="usd">2234000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMS0zLTEtMS00ODU5NA_ca0e90bb-bbb5-4f96-8bfb-1b219773ddc7"
      unitRef="usd">2575000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMi0xLTEtMS00ODU5NA_27da6400-9ba9-4f30-a980-ee26c1851d5e"
      unitRef="usd">13167000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMi0zLTEtMS00ODU5NA_0c284ea0-d754-4087-bd0f-74bea2aaba30"
      unitRef="usd">10749000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMy0xLTEtMS00ODU5NA_b130e0b7-ba9f-4266-91fb-cac19b8fab8a"
      unitRef="usd">4834000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfMy0zLTEtMS00ODU5NA_a9178790-23af-4dbe-b513-7e4f0050c71d"
      unitRef="usd">5878000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfNC0xLTEtMS00ODU5NA_e6eeb25b-fe88-49a8-9ec5-f33234336482"
      unitRef="usd">20235000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOmEwM2YxNGIzOTg1ZjQ1YjNhNjI0NDEyZmUyOTRjZmRmL3RhYmxlcmFuZ2U6YTAzZjE0YjM5ODVmNDViM2E2MjQ0MTJmZTI5NGNmZGZfNC0zLTEtMS00ODU5NA_29bbe36e-b6b4-4bad-8d83-4b35bd6b3a45"
      unitRef="usd">19202000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODQ0_4e6a6fef-aa41-4f4f-ac27-5ad5b8de9125">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTYyOA_a74a4fc1-b54c-43f1-9170-5bba59d7517b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i16c7d7f6cfef46afa7d17a7648fa22d6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0xLTEtMS01MTIwNA_555b8657-f533-464a-bb2a-55a9c1849367"
      unitRef="usd">69137000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i0ddd871d7e454404902df8e801682458_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0zLTEtMS01MTI0Nw_5701ead3-dc04-4678-bec0-de909f2cf248"
      unitRef="usd">74889000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i7135b84ff3e4425b84bf50f571ac57ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0xLTEtMS01MDIzOA_5f4e2a39-aad3-4745-97ba-3134f8b570c7"
      unitRef="usd">24894000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i032e78f5ed7c4d648dc75900dc5651df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMS0zLTEtMS01MDIzOA_291ea3d2-a8b8-435c-a90c-7947ea486857"
      unitRef="usd">26205000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i6a7ef44e372d4c86842156ea38bc9a05_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMi0xLTEtMS01MTAxMw_27c297b2-c184-4b75-91e4-373702c0e377"
      unitRef="usd">25339000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="id6aa244acf4d42e5af8f92393337c196_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMy0zLTEtMS01MTI4MA_4c8b8a1c-10e8-43e3-b0c8-bec44911ed8b"
      unitRef="usd">25052000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="iac97bb571c524e1ea1a69c1042cdf6ff_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMy0xLTEtMS01MTAyMg_fc070b0c-5a1b-4fbc-82f4-06ec55b1e71b"
      unitRef="usd">13566000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i557700c0d761400a82e19e7b49256e39_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0zLTEtMS01MTI2Nw_0c1392a1-faf4-4704-a0c8-b7851345c339"
      unitRef="usd">24243000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i27a52bcfffe64473afd94d1ad70a2304_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0xLTEtMS01MTA1Ng_e4238f29-4ac0-40cf-b354-ae2c13742091"
      unitRef="usd">3990000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i825095a4840447b1884c349d7a55b45d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNS0zLTEtMS01MTI4OQ_ab1ef332-8fb3-4e40-83b3-51feb12d404a"
      unitRef="usd">4263000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNi0xLTEtMS01MTIyMQ_29a6faaa-a692-4a3d-8b13-ff0e000c113d"
      unitRef="usd">136926000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNi0zLTEtMS01MTMwNQ_b6d5ae4e-adaf-457e-b77d-3206ebd36fc6"
      unitRef="usd">154652000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNi0xLTEtMS01MTA4Mw_638bc908-f170-4c2a-8812-0093b9425a1c"
      unitRef="usd">110653000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNy0zLTEtMS01MTMxMw_4e33bb8f-9414-4b56-91cb-06100a740b55"
      unitRef="usd">124731000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfOC0xLTEtMS01MTIyOQ_a39a83cd-cc50-4b06-9dca-ef8df27f080c"
      unitRef="usd">26273000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfOC0zLTEtMS01MTMyMQ_13e5a2a3-264c-47a3-9862-ffd02c152e3e"
      unitRef="usd">29921000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <us-gaap:ConstructionInProgressGross
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMi0xLTEtMS01MDIzOA_feec51b0-d8b0-4d6e-9a58-e5e898784007"
      unitRef="usd">811000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfMi0zLTEtMS01MDIzOA_d218e596-d19e-4e32-9f56-38286ec3941b"
      unitRef="usd">2530000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0xLTEtMS01MDIzOA_effdb983-00e4-4229-8b1e-35132d1b8009"
      unitRef="usd">27084000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjYwZTY3MTY0YjdmYzRmMDg4OTJlYTBhODM2MWJjNjc3L3RhYmxlcmFuZ2U6NjBlNjcxNjRiN2ZjNGYwODg5MmVhMGE4MzYxYmM2NzdfNC0zLTEtMS01MDIzOA_927687f0-6551-45d5-a3df-03acc2f0f3a5"
      unitRef="usd">32451000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODc5NjA5MzAyNjcyNQ_ffdd8507-b3e9-49d6-bcee-feede323bd54"
      unitRef="usd">3500000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTYyOQ_a1888878-68d4-4351-9ad1-3ecb9e768f99">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the changes in our goodwill for the three months ended March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &#x2013; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjg1NGE4OTBjNzUzZTRkN2Q5ZWU5NDA3NDdiMzE2YTc1L3RhYmxlcmFuZ2U6ODU0YTg5MGM3NTNlNGQ3ZDllZTk0MDc0N2IzMTZhNzVfMS0yLTEtMS01MjczMg_92f3261f-1560-4995-9f40-5a0afbb1c48f"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjg1NGE4OTBjNzUzZTRkN2Q5ZWU5NDA3NDdiMzE2YTc1L3RhYmxlcmFuZ2U6ODU0YTg5MGM3NTNlNGQ3ZDllZTk0MDc0N2IzMTZhNzVfMi0yLTEtMS01MjczMg_a4d27058-1147-491d-a9b6-6ec2b75f866b"
      unitRef="usd">76501000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjg1NGE4OTBjNzUzZTRkN2Q5ZWU5NDA3NDdiMzE2YTc1L3RhYmxlcmFuZ2U6ODU0YTg5MGM3NTNlNGQ3ZDllZTk0MDc0N2IzMTZhNzVfMy0yLTEtMS01MjczMg_f69837d3-43eb-478c-a203-d21d79ef3992"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfMTA5OTUxMTYzMjE4Mg_b8c1863d-30b9-4205-8e90-ecc2044496fc"
      unitRef="usd">76500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTcxNQ_9b5804cf-bc08-44f7-bb0b-67a0e8bfef60">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability to collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0xLTEtMS01NDU1NQ_f3c70ed4-4fe5-49ad-8364-bcc112be9cba"
      unitRef="usd">14888000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0zLTEtMS01NDU1Nw_9118d5cc-d5aa-4fd3-931f-d42f71f31a27"
      unitRef="usd">9582000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0xLTEtMS01Mzg1NQ_7d85384e-c2c1-4404-9ccb-001c7d3efda5"
      unitRef="usd">7739000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMS0zLTEtMS01Mzg1NQ_a6290324-b82b-4320-8670-edfcc568f089"
      unitRef="usd">12262000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:LiabilityToCollaborationPartnersCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMy0xLTEtMS01NDU1OQ_231aefd4-3051-4607-9d00-5eb8115a49fd"
      unitRef="usd">3495000</nktr:LiabilityToCollaborationPartnersCurrent>
    <nktr:LiabilityToCollaborationPartnersCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfMy0zLTEtMS01NDU2MQ_a2c87c03-4188-41f1-a707-76cf49870aba"
      unitRef="usd">3808000</nktr:LiabilityToCollaborationPartnersCurrent>
    <nktr:AccruedContractTerminationCostsCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNC0xLTEtMS01Mzg1NQ_f527f909-9589-475f-977e-dabd5cb26dbd"
      unitRef="usd">3461000</nktr:AccruedContractTerminationCostsCurrent>
    <nktr:AccruedContractTerminationCostsCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNC0zLTEtMS01Mzg1NQ_43ec4c3c-5c6e-4551-9273-3f4cdf1a1d44"
      unitRef="usd">3902000</nktr:AccruedContractTerminationCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNS0xLTEtMS01Mzg1NQ_fb0c7504-ba98-462e-8a83-a037a0c0be06"
      unitRef="usd">7827000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNS0zLTEtMS01Mzg1NQ_f4bf8f72-e24c-4812-9e12-625087ef155b"
      unitRef="usd">7003000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNi0xLTEtMS01Mzg1NQ_4c538f63-8973-459b-a3d2-60b4186ecd10"
      unitRef="usd">37410000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjVhYmYzOWFhZWIyNjQyMGQ5MmE2MjgwOWEzMmQ5MTBkL3RhYmxlcmFuZ2U6NWFiZjM5YWFlYjI2NDIwZDkyYTYyODA5YTMyZDkxMGRfNi0zLTEtMS01Mzg1NQ_324557e9-f7e7-4e98-9ca3-05443b0e1c6a"
      unitRef="usd">36557000</us-gaap:AccruedLiabilitiesCurrent>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i66e54efca0a94e31868b7e6b05760280_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODc5NjA5MzAyNDk1Ng_fca04cb4-8d2e-4d41-92df-ca648dbcd003"
      unitRef="number">0.10</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i4b13a843a33e4bc08464584072e4b021_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfODc5NjA5MzAyNDk2NA_7c523e30-240f-40e0-b7ab-cebc899a586b"
      unitRef="number">0.20</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RleHRyZWdpb246Y2U2ZjZkNmVjMzYxNDU0MjkxMmY1ZjcyZTkyMzZiMTdfNDM5ODA0NjUxNTYzMg_c2507a5a-a355-4fe5-95f6-09c8afdc31fa">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net &#x2013; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="iec325a50f7844edda0d300d4f35dafa2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMi0xLTEtMS01MDI4NQ_67ea50cc-9ce4-483e-961a-5770e3ed04af"
      unitRef="usd">55167000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="id4ac5fe1f84b4a0b91a45b1c7657c57d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMi0zLTEtMS01MDI4NQ_64cc1739-a19e-4074-b652-ef6bfe63bf0d"
      unitRef="usd">100211000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMi01LTEtMS01MDI4NQ_479c5e52-e8ed-41c6-bfc8-97e70f271899"
      unitRef="usd">155378000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMy0xLTEtMS01MDI4NQ_30024f2a-1b70-4a82-9414-5366c360a128"
      unitRef="usd">9303000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMy0zLTEtMS01MDI4NQ_e1215c5c-0435-4037-b5a6-41e3e5f3e55d"
      unitRef="usd">7558000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfMy01LTEtMS01MDI4NQ_62eb37af-ce18-4367-829b-8fa958436cac"
      unitRef="usd">16861000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNC0xLTEtMS01MDI4NQ_9a521847-f677-41dd-8ad2-1186a872e7a5"
      unitRef="usd">1360000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNC0zLTEtMS01MDI4NQ_f0fa6db0-2cc5-4a05-bbaa-f4bf09cce5b0"
      unitRef="usd">5045000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNC01LTEtMS01MDI4NQ_5089519e-5b7d-487d-a847-cd082b8bdbd1"
      unitRef="usd">6405000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
      contextRef="i1392d90e68d1403eb5d86b75f73f66ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNi0xLTEtMS01MDI4NQ_981dfb6e-c9f0-44cd-b2bb-84378b2e2560"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
      contextRef="i7dbca468acf64efaa3f76aaf7c971a9b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNi0zLTEtMS01MDI4NQ_8aea7771-fe17-4293-9861-f5bda46b2abe"
      unitRef="usd">209000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNi01LTEtMS01MDI4NQ_1e7eeba2-5eb4-4253-b341-a0b7cbbde073"
      unitRef="usd">209000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i66e54efca0a94e31868b7e6b05760280_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNy0xLTEtMS01MDI4NQ_884db306-01fb-4335-a059-ce32703d8a5c"
      unitRef="usd">47224000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i4b13a843a33e4bc08464584072e4b021_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNy0zLTEtMS01MDI4NQ_ca48214d-357d-428e-837d-2886d5f391b5"
      unitRef="usd">97907000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV80Ni9mcmFnOmNlNmY2ZDZlYzM2MTQ1NDI5MTJmNWY3MmU5MjM2YjE3L3RhYmxlOjY0MmZhMzgyZDc5NTRhMTA5ZWNhZDJlMzE5M2EzYWU5L3RhYmxlcmFuZ2U6NjQyZmEzODJkNzk1NGExMDllY2FkMmUzMTkzYTNhZTlfNy01LTEtMS01MDI4NQ_66c081ef-f658-45fd-9a45-a62af642763b"
      unitRef="usd">145131000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81NS9mcmFnOjA5MTg1YmEyNTFhZTQ4Zjg4ZmZjNWM1ZDhlM2YyNGQzL3RleHRyZWdpb246MDkxODViYTI1MWFlNDhmODhmZmM1YzVkOGUzZjI0ZDNfNDU5MA_bbeae718-46c5-44e0-8fe5-881d4ce850bc">Commitments and Contingencies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 2, 2023, we and our directors were named in a putative class action complaint filed in the Court of Chancery of the State of Delaware. The plaintiff in this complaint alleges section 13 of our bylaws relating to stockholder action without meeting violates Delaware law and is therefore void. Upon service of this complaint, we will have twenty days to reply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at either March&#160;31, 2023 or December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationReserve
      contextRef="ibce58931b7d241b7a58b00661b49392d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81NS9mcmFnOjA5MTg1YmEyNTFhZTQ4Zjg4ZmZjNWM1ZDhlM2YyNGQzL3RleHRyZWdpb246MDkxODViYTI1MWFlNDhmODhmZmM1YzVkOGUzZjI0ZDNfOTg5NTYwNDY1NjYwMg_a2e7fa75-a5ef-402b-84db-cd08a66a217b"
      unitRef="usd">0</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81NS9mcmFnOjA5MTg1YmEyNTFhZTQ4Zjg4ZmZjNWM1ZDhlM2YyNGQzL3RleHRyZWdpb246MDkxODViYTI1MWFlNDhmODhmZmM1YzVkOGUzZjI0ZDNfOTg5NTYwNDY1NjYwMg_f8dec868-e1cf-44bc-8115-4950334fd978"
      unitRef="usd">0</us-gaap:LitigationReserve>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNDM5ODA0NjUxOTYxMQ_bf1935bc-b2bb-42a9-8b06-cece7b393633">License and Collaboration Agreements&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;): Rezpegaldesleukin (previously referred to as NKTR-358) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and were eligible for up to $250.0&#160;million in additional development and regulatory milestones. The Lilly Agreement provided that, during Phase 1B and Phase 2 development, we would share development costs wherein 75% of the costs are borne by Lilly and 25% of the costs are borne by us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2023, we announced the topline data from the Phase 2 study of rezpegaldesleukin in adult patients with systemic lupus erythematosus (SLE) (Phase 2 Lupus Study). Although the Phase 2 Lupus Study did not meet its primary endpoint, patients who received the middle dose within the modified intent-to-treat population, defined as all patients who were randomized and received at least one dose of rezpegaldesleukin, demonstrated improvement in SLEDAI-2K score as compared to placebo. Nonetheless, Lilly notified us that it does not intend to advance rezpegaldesleukin into Phase 3 development for SLE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2023, Nektar received from Lilly a notice of-at will termination of the Lilly Agreement. On April 27, 2023, we announced that we would regain full rights to rezpegaldesleukin from Lilly. Based on the positive results from a Phase 1b study in which rezpegaldesleukin reduced atopic dermatitis symptoms, we plan to initiate a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in 2023. We will also explore other auto-immune indications for the development of rezpegaldesleukin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 3, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and pre-commercial costs of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received additional non-refundable milestone payments of $50.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, in April 2022, we announced that BMS and we decided to discontinue all development of bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. Pursuant to the BMS Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. Based on the cost sharing percentages described above, we recognized BMS&#x2019; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#x2019; expenses as research and development expense. As discussed in Note 6, beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring and costs of terminated program. The net reimbursement payable to BMS for the three months ended March 31, 2023 was not significant. For the three months ended March 31, 2022, we recorded $24.9&#160;million for the net reimbursement from BMS as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SFJ Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) in metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial). SFJ had primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we were the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin in up to three indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the SFJ Agreement as a derivative liability, which we remeasured to fair value at each reporting date. We recorded increases to the liability for non-cash research and development expense as SFJ conducted the SCCHN Clinical Trial and for cash receipts from SFJ to us to support our internal costs of conducting the trial. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to zero as of March 31, 2022, and we recognized a corresponding gain in change in fair value of development derivative liability. In April 2022, we announced that SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the change in the derivative liability for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 3, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue, which totaled $16.9&#160;million and $17.6&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, represents revenue for granting licenses which we had satisfied in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i49f42788641442cdad7182512b26d5e2_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzY2NA_73096ac4-7438-4be9-afb8-a60f6b2fa946"
      unitRef="usd">150000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i7adb82d027d849da802db4b49a43ee2a_I20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzY5NQ_22a929f3-08ad-444a-9ba7-a455104ccb16"
      unitRef="usd">250000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i0868cb5a09c844a796ffe2c4ecb34a5b_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzcxNQ_4268448b-d00c-4ba2-8287-bcec79ca68e5"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i49f42788641442cdad7182512b26d5e2_D20170723-20170723"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfOTg5NTYwNDY4MzcyNA_183b7a22-9a35-4c33-b2bb-dd0b2a213249"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i7959c4e63c52467ca26c517b3783d65d_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTkyMw_430903be-3c7d-485d-853b-d82e96278f8d"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="iaf20dc9f8d6f48baa0bd1294dba2654b_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTk0Ng_5734b85b-31cc-45d4-807f-e699745e1905"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="icba9f64c9bff4236965a5e18df3794a6_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjA1MA_747d4210-03b1-4dae-84aa-3e8e39d01eb4"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="ib249192b630141c98908c973940137df_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjA3Nw_d0d79068-3ca9-4c5f-8eff-dbc96c3a6080"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i48302ef504774ac6a0914253d9ac0a95_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjIxOQ_92df7a1b-91ef-44ad-8e7e-b6de89132a1a"
      unitRef="usd">1000000000</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <us-gaap:SharesIssued
      contextRef="i15412e5663004a80831838e6da60e1fe_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjIzNg_1916b68b-03c4-401a-a2c3-184cee86fc54"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="ib2debb833d9b47b6a265922060678a06_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjM1MA_8d246f12-28af-4ca7-8ac1-bf11f3e695a2"
      unitRef="usd">850000000</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i17ff1e5d834349cfb697a5e4a5c4bbaf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMjQxMg_fff5db9d-320d-4436-bbc3-26af5dc31ef1"
      unitRef="usd">50000000</nktr:PotentialDevelopmentMilestones>
    <nktr:ReimbursementOfExpenses
      contextRef="i2a9f83081651457596b4bbe97aaaa513_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNDUwMg_e711e92f-3fba-4b0b-bffa-36cb695107a1"
      unitRef="usd">24900000</nktr:ReimbursementOfExpenses>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="i248ad8f8306145d79a154379e4c144c7_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTA5OTUxMTYyOTA5NDk_4c91193d-c3c7-4ec2-9e59-4f1d1da30a7a"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsAmount
      contextRef="i248ad8f8306145d79a154379e4c144c7_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTA5OTUxMTYyOTE0NjU_d2da0378-cb8d-4ef2-afae-3fa46b653216"
      unitRef="usd">637500000</nktr:CollaborativeArrangementSuccessBasedPaymentsAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ia9c43dfae2834078a893893586390205_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfMTA5OTUxMTYyOTYyOTE_60f300d4-5eb9-4cb5-8b8e-1cdf33a9793e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNDM5ODA0NjUzNjM1MQ_34f9f307-4deb-48b8-b160-fa3d9f7fdafb">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the change in the derivative liability for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib5c61fe105dd4f8ca0cb30e7ae9ca967_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfMi02LTEtMS01MDQ4NQ_230946b7-989c-40a1-bd64-6f1ac4ac41d6"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfMy02LTEtMS01MDQ4NQ_4327a393-4480-4eb9-8ac2-d400fbc9d7e4"
      unitRef="usd">4951000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfNC02LTEtMS01MDQ4NQ_e6a33ac9-dc55-49bf-abd1-138b7baaff0f"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ic20c05235e714c54b246c9c0a424d9a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfNS02LTEtMS01MDQ4NQ_bd27791c-e71b-40a5-91bc-8bb61690845d"
      unitRef="usd">-33427000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia5256132357e4151bc701fffe762e23c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RhYmxlOmVjNjhlNTQyY2YyMjQwZDRhY2M1ZDYyNDkwM2UxMzU4L3RhYmxlcmFuZ2U6ZWM2OGU1NDJjZjIyNDBkNGFjYzVkNjI0OTAzZTEzNThfNi02LTEtMS01MDQ4NQ_c4717aa5-5300-4eb1-9191-f7a6f58aab96"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bff78a906cc446f9c38659e714a0991_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfNzY3NQ_e85ad1a0-ed65-4492-8ef7-c7c66d1641cb"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i120490afb52049e28bacdb27bba440d2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfODc5NjA5MzA0NzM2OA_722f4ce6-2df6-4578-85d5-4d1cfcedafac"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ibe1d381685d046eb8df1f1376d3da9d4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV81OC9mcmFnOmM5ZTc5YWZlODhlYTRlODg5N2QyYjIxOTFkM2MwNTdlL3RleHRyZWdpb246YzllNzlhZmU4OGVhNGU4ODk3ZDJiMjE5MWQzYzA1N2VfODAxNg_174025e9-0be8-430c-b41d-f7518c34b188"
      unitRef="usd">40000000</nktr:PotentialDevelopmentMilestones>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfNjI2NQ_15e67658-0d2e-4b43-ab7c-f5fe3ce95779">Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring, Impairment and Costs of Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2022 and 2023 Restructuring Plans, we report the following costs in restructuring, impairment and  costs of terminated program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, initiated in 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Severance and related benefit costs pursuant to the 2022 and 2023 Restructuring Plans;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Non-cash impairment of right-of-use assets and property, plant and equipment; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Contract termination and other costs associated with these plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In prior periods through March&#160;31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. Beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Restructuring Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, because our registrational trials in bempegaldesleukin did not meet their primary endpoints, we decided to discontinue all development of bempegaldesleukin and wind down the clinical trials studying bempegaldesleukin. In April 2022, we announced the 2022 Restructuring Plan pursuant to which we completed an approximately 70% reduction of our workforce during 2022. We also sold our research facility in India in December 2022 and decided to sublease certain of our leased premises in San Francisco, CA, including our office leased space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program pertaining to the 2022 Restructuring Plan includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, restructuring, impairment and other costs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin. Through March&#160;31, 2023, we have recognized $11.8&#160;million cumulatively for contract termination and other costs for the 2022 Restructuring Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, pursuant to plans approved by our Board in March 2023, we announced the 2023 Restructuring Plan to further reduce our San Francisco-based workforce by approximately 60%, which is expected to be substantially completed by June 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program pertaining to the 2023 Restructuring Plan includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance and Benefit Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees affected by the reduction in force under the 2022 and 2023 Restructuring Plans are entitled to receive severance payments and certain Company funded benefits. The restructuring charges are recorded at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the 2022 Restructuring Plan, we recognized severance and benefit expense in full for employees who had no requirements for future service when the 2022 Restructuring Plan was approved by the Board in April 2022. We recognized severance and benefit expense for employees who were required to render services to receive their severance and benefits ratably over the service period. This service period began on the communication date in April 2022 and was completed for all employees during 2022. We recognized $30.9&#160;million in total severance and benefit expense during 2022 and paid the remaining liability of $3.3&#160;million in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the 2023 Restructuring Plan, we recognized a liability of $5.5&#160;million of severance and benefit expense as of March 31, 2023, reflecting severance and benefits which the employees had vested into and for which payment was probable and reasonably estimable as of March&#160;31, 2023. We expect to recognize an additional $1.9&#160;million for severance and benefit expense for the 2023 Restructuring Plan, primarily in the second quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides details regarding the severance and benefit expense for the three months ended March&#160;31, 2023 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three months ended March&#160;31, 2023, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023 Restructuring Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022 Restructuring Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. Accordingly, we assessed our long-lived assets, including our property, plant and equipment, right-of-use assets and goodwill, for impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our impairment analysis, we first assessed which long-lived assets have identifiable cash flows that are largely independent of the cash flows of other groups of assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded that the long-lived assets associated with our leased spaces that we had previously decided to sublease under our 2022 Restructuring Plan continue to have cash flows that are independent of our entity-wide group. We concluded that these assets, for which we had recognized impairment charges during 2022, were recoverable based on estimated sublease income and therefore did not record any impairment charges for these long-lived assets for the three months ended March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluated our remaining long-lived assets for impairment and performed a recoverability test using the undiscounted cash flows approach. We concluded that our net assets were not recoverable within the remaining useful lives. Accordingly, we estimated the fair value of the asset or asset group based on discounted future cash flows of the asset or asset group using a discount rate commensurate with the related risk. For the operating lease asset related to our Mission Bay facility, we estimated the fair value based on market participant assumptions, including the length of time to enter into a sublease, sublease payments, tenant improvement allowances and broker commissions, which we evaluated using current real estate trends and market conditions. We discounted the sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 7.9%. As a result of this analysis, we recorded a non-cash impairment charge of $11.5&#160;million. We also recorded an additional non-cash impairment charge of $1.7&#160;million for certain laboratory equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We report the aggregate non-cash impairment charge of $13.2&#160;million in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. The following table presents a reconciliation of the non-cash impairment charge we recorded for these long-lived assets for the three months ended March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of impaired facilities before write-off&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Fair value of impaired facilities &#x2014; Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment expense for facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of other property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After we recorded the non-cash impairment charges for our long-lived assets, we next assessed goodwill for impairment. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. Accordingly, in accordance with ASC 350-20 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and ASC 820-10 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we measured the fair value of our reporting unit utilizing both income and market approaches for our entity-wide asset impairment analysis. Based on this analysis, we wrote off all of our goodwill, resulting in a non-cash impairment charge of $76.5&#160;million during the three months ended March&#160;31, 2023, which we reported as impairment of goodwill in our Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i7697166d42e141bd9a7bbec30e8e7d48_D20220401-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA0MzM4Mw_6df7beff-c24d-4ebb-8523-209d4e0cfd48"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTM0NTg0ODg3MTMzOA_0f25516c-135f-4672-a25f-5d25ce42ad22">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program pertaining to the 2022 Restructuring Plan includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment and other costs of terminated program pertaining to the 2023 Restructuring Plan includes the following (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and benefit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract termination and other restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment and costs of terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides details regarding the severance and benefit expense for the three months ended March&#160;31, 2023 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three months ended March&#160;31, 2023, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023 Restructuring Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022 Restructuring Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table presents a reconciliation of the non-cash impairment charge we recorded for these long-lived assets for the three months ended March&#160;31, 2023 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net book value of impaired facilities before write-off&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Fair value of impaired facilities &#x2014; Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment expense for facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of other property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total impairment of right-of-use assets and property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:BusinessExitCosts1
      contextRef="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi0yLTEtMS01NDc2NQ_86530f71-6432-4374-90e5-4da6cc9baed5"
      unitRef="usd">1598000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi00LTEtMS01NDc2Nw_e8d129e3-4a16-4d37-a7e1-90f1718c0489"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:LossOnContractTermination
      contextRef="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi0yLTEtMS01NDU4MA_6393b1e4-d4eb-4d12-9ccf-a925aa51853e"
      unitRef="usd">878000</us-gaap:LossOnContractTermination>
    <us-gaap:LossOnContractTermination
      contextRef="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMi00LTEtMS01NDU4Mg_8cfad4cb-72c6-4c9e-910b-047bc2dd1d01"
      unitRef="usd">1475000</us-gaap:LossOnContractTermination>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="i7073174a61e4411996bc9b5a8cfbb0a6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMy0yLTEtMS01NDU4NA_6634853d-fb87-49fa-8f5a-c7e8a9280d02"
      unitRef="usd">2476000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="ib087ac812fc54a6aabbd60f0ded94e92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmE4ZDgzNzhjOTFhYzQ4ZDRiNWU0MTMwNmU0M2Q3ZjMxL3RhYmxlcmFuZ2U6YThkODM3OGM5MWFjNDhkNGI1ZTQxMzA2ZTQzZDdmMzFfMy00LTEtMS01NDU4Ng_e6681cf9-cacf-4928-87f9-1587c3308848"
      unitRef="usd">1475000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:LossOnContractTermination
      contextRef="i87894f2d277d4d689189754384742bf3_D20220101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA2MDMyNA_1d42a444-c1bd-44fd-b3aa-23200b19bb27"
      unitRef="usd">11800000</us-gaap:LossOnContractTermination>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="ief4395c62e394de284ed9e69496b6151_D20230301-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfMzg0ODI5MDczNDM2MQ_e4874e19-d13f-4899-83aa-c08ae1eed4a5"
      unitRef="number">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfMy0yLTEtMS00ODU5NA_1dc22245-85b5-4aad-a025-cbde3562d62b"
      unitRef="usd">5483000</us-gaap:SeveranceCosts1>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfNC0yLTEtMS00ODU5NA_bd26e490-fd27-41cb-bfc4-b06f28cc4f68"
      unitRef="usd">13200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LossOnContractTermination
      contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfNS0yLTEtMS00ODU5NA_b8fd9544-c14d-47be-9f81-2852b0f28d2f"
      unitRef="usd">34000</us-gaap:LossOnContractTermination>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="i91cc917126294398b7fa3f95a89652cb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjRhODEwNjNmNjRmODQ3YzBhN2QxZTgxNGU1YjIyNmM5L3RhYmxlcmFuZ2U6NGE4MTA2M2Y2NGY4NDdjMGE3ZDFlODE0ZTViMjI2YzlfNi0yLTEtMS00ODU5NA_3d4cc6ab-4c89-4f8b-a3f5-de0e3dd060f4"
      unitRef="usd">18717000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCharges
      contextRef="i54ea4f7910ee46acbba924e43878e0d8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA1MTE4NA_587adc7b-f199-4255-b544-fa4d2bcf5194"
      unitRef="usd">30900000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="iac1590dec7f141ddb038c9a92effcf1e_D20230101-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfNDM5ODA0NjU0MDgxMA_5972a09a-be3c-4b67-8a6a-98874ad5fdcb"
      unitRef="usd">3300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="i997d98245f4048f997e82ffee6686137_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzQ3NA_3ed23136-3b74-4bf3-ae2a-1752064c8348"
      unitRef="usd">5500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="if40ec0a96ce54f1bb18634012ce405b9_D20230401-20230630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfNDM5ODA0NjU0MDgyNA_cd2feb38-2f95-46f8-8234-bf627ff4cf2d"
      unitRef="usd">1900000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserve
      contextRef="if20c572ba8d44958a9a79ca58b613c8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMi0yLTEtMS01Mzg5Nw_481dbdeb-0742-425e-a264-8e92762f284e"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i526526b23308431d88efcd30d4d1d51d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMi00LTEtMS01Mzg5Nw_15a4441e-8b36-4ce6-b9e5-40796153d5ef"
      unitRef="usd">3299000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if85a2540650e49ff827fe78c21240f01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMi02LTEtMS01Mzg5Nw_5a4aad6c-3450-417b-b216-ff269043f12c"
      unitRef="usd">3299000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i62f8fac2f829451080ed7031388fb268_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMy0yLTEtMS01Mzg5Nw_17b1ff5f-9899-4248-88d8-c49d7b0966ee"
      unitRef="usd">5483000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6620bfd483ba4ec1bd4a2ee734818286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMy00LTEtMS01Mzg5Nw_90f6da24-0882-48ad-86f9-f61058a88517"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i997d98245f4048f997e82ffee6686137_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfMy02LTEtMS01Mzg5Nw_90124466-0f3a-48a9-8f79-8bf5cd0631e2"
      unitRef="usd">5483000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i62f8fac2f829451080ed7031388fb268_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNC0yLTEtMS01Mzg5Nw_bb74ec50-547f-45b2-a636-429ac54e5fb2"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6620bfd483ba4ec1bd4a2ee734818286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNC00LTEtMS01Mzg5Nw_a81c6d6f-4b10-46e4-9059-94ae0ece99ef"
      unitRef="usd">3299000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i997d98245f4048f997e82ffee6686137_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNC02LTEtMS01Mzg5Nw_4fbfc393-60db-4389-a568-097b14303d16"
      unitRef="usd">3299000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ia7cadf538c2947f1b43fbef0ac736b9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNS0yLTEtMS01Mzg5Nw_51b82e85-c0c8-4bb1-876b-12b4ffd8208c"
      unitRef="usd">5483000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ibb06267cb11c41e98b47d0d573f0e09a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNS00LTEtMS01Mzg5Nw_84db282b-4791-421b-9eef-a4c3f830e4a7"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ifa6e43a4bdee434d8a2152922832b63a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOmI2OWM5MTU4Yjg3NDQ2ZmU4YmZhOTUwNTcxYzc1MDUxL3RhYmxlcmFuZ2U6YjY5YzkxNThiODc0NDZmZThiZmE5NTA1NzFjNzUwNTFfNS02LTEtMS01Mzg5Nw_c5eb03b9-dddb-4bdf-9062-422846a06aaf"
      unitRef="usd">5483000</us-gaap:RestructuringReserve>
    <nktr:OperatingLeaseMeasurementInput
      contextRef="id695df1ce72740ec955bff4bb989faa8_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA0ODE3OA_8754093f-006f-4092-b89f-6a038b9a7f77"
      unitRef="number">0.079</nktr:OperatingLeaseMeasurementInput>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzUxMw_63179864-6c3b-4619-8d29-170ee7147440"
      unitRef="usd">11500000</us-gaap:OperatingLeaseImpairmentLoss>
    <nktr:ImpairmentLongLivedAssetHeldForUseOther
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzU0NQ_1fc27a6f-51b9-4e36-aa54-933acc8ae6ba"
      unitRef="usd">1700000</nktr:ImpairmentLongLivedAssetHeldForUseOther>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfOTg5NTYwNDY4NzU3OQ_9e2bdbe3-0e8a-4b6b-a408-f8bdba79d13a"
      unitRef="usd">13200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i06ed89f1fe464363a9e387568ead9993_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMi0xLTEtMS01MzkxMQ_5d4cb3f5-af0d-4597-8bb0-ce9c4a99c2c1"
      unitRef="usd">5114000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i3598e30999e54f9f9f575e5b881f2da3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMi0zLTEtMS01MzkxMQ_64f7e0a0-40ae-4a27-8105-96c2eda7da89"
      unitRef="usd">28434000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="ib55817a7194945f1ae4c0a8163778b09_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMi01LTEtMS01MzkxMQ_1f5083c7-6c18-4124-956f-031028989cf2"
      unitRef="usd">33548000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i86a36c4159774aedad86844713f0d8bc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMy0xLTEtMS01MzkxMQ_a23575ce-4308-42cf-8dea-978ce0c88ede"
      unitRef="usd">3314000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="i3677d6c99212474f8786bb289678a42c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMy0zLTEtMS01MzkxMQ_e2cc6eae-6182-4c1b-af65-37aaec3e53d7"
      unitRef="usd">18734000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure
      contextRef="icc2ab344bd4f4b498f29e789a11c1690_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfMy01LTEtMS01MzkxMQ_d3e56961-7382-455f-9060-ed8928c26ab6"
      unitRef="usd">22048000</nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNC0xLTEtMS01MzkxMw_1890228a-ccb2-4a81-a4c5-6e22e8ab94d2"
      unitRef="usd">1800000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="id62ae4528157426aba132831bb9e3a69_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNC0zLTEtMS01MzkxMQ_b72d4958-cab9-4bf7-803c-fdd4219380f8"
      unitRef="usd">9700000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNC01LTEtMS01MjA0Mg_31ae4e40-746b-4c37-a68a-953bff006692"
      unitRef="usd">11500000</us-gaap:OperatingLeaseImpairmentLoss>
    <nktr:ImpairmentLongLivedAssetHeldForUseOther
      contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNS0xLTEtMS01MzkxMQ_96444ec6-1919-49f1-929f-00c2f53ae573"
      unitRef="usd">1700000</nktr:ImpairmentLongLivedAssetHeldForUseOther>
    <nktr:ImpairmentLongLivedAssetHeldForUseOther
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNS01LTEtMS01MjA1Mg_9fd42b18-e05e-4fb9-b772-e7bb7fa7a7b8"
      unitRef="usd">1700000</nktr:ImpairmentLongLivedAssetHeldForUseOther>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i3bed044d7775412580048660b77fa954_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNi0xLTEtMS01MjI3OQ_ffdd8507-b3e9-49d6-bcee-feede323bd54"
      unitRef="usd">3500000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="id62ae4528157426aba132831bb9e3a69_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNi0zLTEtMS01MzkxMQ_7c815810-8630-4067-b1d8-8dae148749b8"
      unitRef="usd">9700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RhYmxlOjdmZjNjOGM0ZjljMTRiNTNhNDAzNjk5Y2JkYmVhNjgxL3RhYmxlcmFuZ2U6N2ZmM2M4YzRmOWMxNGI1M2E0MDM2OTljYmRiZWE2ODFfNi01LTEtMS01MjA2NA_ee2db79f-39c6-4534-a961-b9adec52b85a"
      unitRef="usd">13200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82MS9mcmFnOmViZjc3YTZlMTkxYTRjZTQ4MTNjMTJmMjYxODVjMmU1L3RleHRyZWdpb246ZWJmNzdhNmUxOTFhNGNlNDgxM2MxMmYyNjE4NWMyZTVfODc5NjA5MzA0ODkzOQ_6bbacb00-b763-4302-b537-69971992422d"
      unitRef="usd">76500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RleHRyZWdpb246YjI0NTY0MWM3NmI3NDhlZTgyMDUyOGVlMWQwZTU5OWZfNzEy_18bfd0ea-6422-48e0-bc1d-bcc3e3207cd2">Stock-Based Compensation&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RleHRyZWdpb246YjI0NTY0MWM3NmI3NDhlZTgyMDUyOGVlMWQwZTU5OWZfNzEz_98891d58-b6e8-4aa4-98a5-f70c19fc12ce">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1cda02f4555947ccabad36bcc6480d92_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMi0xLTEtMS00ODU5NA_b3e5afe3-e20c-4b0c-b422-2f4eb5a8f71c"
      unitRef="usd">812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34546a7702c6424eb4d1bd5155173002_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMi0zLTEtMS00ODU5NA_6585e262-41d3-4121-a91d-64270e5e6722"
      unitRef="usd">669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i793f4a945cbb4640999a6a1a0da30ac5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMy0xLTEtMS00ODU5NA_802529ca-0071-4d47-ab7f-0bc21c7cc04b"
      unitRef="usd">4146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17ebf75335184f2eb6750cf5620342bd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfMy0zLTEtMS00ODU5NA_12e2a9b9-dac4-413f-acfa-a2d737900628"
      unitRef="usd">12041000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f16114b074f437fbd1d96555474845a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNC0xLTEtMS00ODU5NA_fca70dc8-7e2c-44e0-bd8f-db4c004ef3c4"
      unitRef="usd">5061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebffda948b374043aba705095a8d4ade_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNC0zLTEtMS00ODU5NA_4c788b48-d8e6-4847-ae86-1ad1f1e8ea86"
      unitRef="usd">8251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNi0xLTEtMS00ODU5NA_3e23e881-4cd4-4803-9cef-e69ee02c6ba7"
      unitRef="usd">10019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifca0084f28fd4372b5b95e740a6ea560_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUzZmZjZmU0MWRmOTRjMTNiZmU1MTRjNWIyM2QxYjY1L3NlYzo1M2ZmY2ZlNDFkZjk0YzEzYmZlNTE0YzViMjNkMWI2NV82NC9mcmFnOmIyNDU2NDFjNzZiNzQ4ZWU4MjA1MjhlZTFkMGU1OTlmL3RhYmxlOmNhMGZjNzIyYzA3MzRmMTlhMjJjMmU0NTYzM2YwNmJhL3RhYmxlcmFuZ2U6Y2EwZmM3MjJjMDczNGYxOWEyMmMyZTQ1NjMzZjA2YmFfNi0zLTEtMS00ODU5NA_01d53df3-231d-422f-8d7a-3e399d213a7c"
      unitRef="usd">20961000</us-gaap:AllocatedShareBasedCompensationExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>%)<+AD-F<@-X/<YYVISD[^@/J,<_P]02P,$%     @ M8ZI5@78)DQ% P
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M>._B>)MM4\S)$MSP-2F F*!(!.MRASX2\(DRU2RC\U$#LDKBA+=!)B(6FH!
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M"?!!L>+'SULFY6@Q"4L#% 58"O$STRYR##&J.6/!PQ_L)9+*ZF=)W"2"ATR
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M>A0TPQ6]PE [ _J^4+2Y=A,7H'O7C?\&4$L#!!0    ( +6.J59"]DT*EP@
M .T6   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;,U8V7+;.!;]%91Z
M*;N*L;B(E)38KG*VCJO2W2X[TWF8F@>(A"1,DP0; *TX7S_G ESD->ET'N;!
M%@CB[N<NX/%.Z3_-5@C+/E5E;4XF6VN;Y].IR;>BXN9(-:+&F[72%;=XU)NI
M:;3@A2.JRFD<AMFTXK*>G!Z[O0M]>JQ:6\I:7&AFVJKB^N:E*-7N9!)-^HU+
MN=E:VIB>'C=\(ZZ$_5=SH?$T';@4LA*UD:IF6JQ/)F?1\Y<S.N\._"'%SNRM
M&5FR4NI/>C@O3B8A*21*D5OBP/%S+5Z)LB1&4..OCN=D$$F$^^N>^UMG.VQ9
M<2->J?*C+.SV9+*8L$*L>5O:2[5[)SI[4N*7J]*X_VSGSZ:0F+?&JJHCQG,E
M:__+/W5^V"-8A(\0Q!U![/3V@IR6K[GEI\=:[9BFT^!&"V>JHX9RLJ:@7%F-
MMQ)T]O25J@NX6!0,*Z-*67"+A[>RYG4N><FN+#80!<M>"\ME:8ZG%G*)>IIW
M,EYZ&?$C,A+VJZKMUK WD%7<II]"WT'IN%?Z9?PDPU^Y/F))%+ XC),G^"6#
M$Q+'+WF$WWE]#0.5OF&OI<E+95HMV+_/5L9JH.8_#UGL&<X>9DB9]-PT/!<G
M$Z2*$?I:3$Y__B'*PA=/J#L;U)T]Q?T[Q>Q)&0];\/<%L]&UXRH'L336,+5F
M=BO86I6H#;+>L -98T>UAM>%.7S.$.A\.T0:3'-1K83N=V)VR7?(!BLTI!OV
M(XN#.)FYWW2>LH\H",]D_:S1*A?&L"@)HFS.HC"8SY:DMD3B%&RC5&'8+%B
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M94U .K  WE<>?-+?L('Q?QL7_P!02P,$%     @ M8ZI5C?O-=X&#@  P2<
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M,-FJ@& "/#LOT%]8ZE016IC:IC+B43C3M5UCU/=#3C"%NN]M&M=J!6YC6]7
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MK?W,Q-;S(33N\#2^5D8L'JHW;D$C^8&:P2IQ:!#K_)(;C;48$G-SZ>A"BJ]
M>]I#@[SS;0^I)B@I(KR$RN:=X<ZD"4>$*IO'J"E:6+T8T%,A78X3W@VL"/3*
MRR=?8JFR/I;JZ+<MZ2H +6CI.0&DQ$1,XP2MS,-M+^4<=5ZK@G9G_/(8'1ME
MN;QAU3YMWT^[E->R5LOEY3:X"K)$4)F98NOQ\/SQGCA[\Z5R);^D-7%5Y7+^
M2 V6\;0 OT\=+!&_$(/VK;T7?P-02P,$%     @ M8ZI5CB(E&F^#   G2@
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M7\7G.[VP"TT_<:F_JPV>1/DA&>LQK6*^:)D5:3\4:-K/GM7_JV[9*M.($>3
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M)K\6.=T+11]LNSS\(&V="U9LBQ&;=@+;-\\F=9U0VKRU=YQ-S7&UC(MUX]N
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MV7+=!3QK_%.7^H^003G#"FKLQYCY=CSL$:R]DY/N?M5DT#*]$.QOQ)9[1Y9
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MLQX[0X?DL*0;;NYE]0U:/['ERR37]9=4;:SGD&RCC2Q:,"HHF&C^]*7=ASV
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M*]N='3V]G?I Q7.22WBI6T&:<SF!9T'L=BAW)XH7U2;?$U>*9]7AFM&8"1T
MOZ\X5V\G>M^PV2=>_ -02P,$%     @ M8ZI5D[&<@L, P  6@L  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&ULK99=;]HP%(;_RE%63:VTD0\*M!U$
M*G3=*JT3*NMV,>W")(98=>+,-M#^^QT[(26,LC+E!FS'Y_7[V"?.Z:^$?% )
MI1H>4YZI@9-HG5^XKHH2FA+5$CG-\,E,R)1H[,JYJW))26R#4NX&GM=U4\(R
M)^S;L;$,^V*A.<OH6():I"F13T/*Q6K@^,YZX([-$VT&W+"?DSF=4'V?CR7V
MW$HE9BG-%!,92#H;.)?^Q<CW3("=\9W1E=IH@T&9"O%@.C?QP/&,(\III(T$
MP;\E'5'.C1+Z^%V*.M6:)G"SO5:_MO (,R6*C@3_P6*=#)PS!V(Z(PNN[\3J
M,RV!.D8O$ES97UB5<ST'HH72(BV#T4'*LN*?/)8;L1$0!"\$!&5 \-J =AG0
MMJ"%,XMU130)^U*L0)K9J&8:=F]L--*PS!SC1$M\RC!.AR.1Q7@H- 9L*<%9
M3#1VKEE&LH@1#A.- WAN&JZH)HPK> ]?B93$;#\<EX,G< 0L@V^)6"B2Q:KO
M:C1GEG"CTLBP,!*\8*0-MR+3B8*/:"BNQ[L(59$%:[)AL%?PEL@6M/UW$'A!
M&^XG5W!\=++#U^CU,L%NF9J]=K7Q;:O;?D'WDQ#QBG$./[_@$[C!35:_=FU;
M(7.Z6\:\Y1<J)Q$=./@:*RJ7U G?OO&[WH==K V)U8A/*^+3?>KA39H3)FTJ
MB1G,2_Y=R(5.U^J8>V@9]KH=S^^[RTV6OV=YU8R:P4YEL+/78.#Y 8P7,DKP
M7@!,8Y@03N%R+JE] W99W:MXZ.DT)%:#[U;PW6;RL=LD<4-B->)>1=S;>]QW
MXHEPS:@"SLB4<::?(&8J$@O,4+S?Z"[Z0M(/-K.NM9V9>]?]3ZJSBNKL'TD<
M>(<F\5[%0X^T(;$:_'D%?]Y,$I\W2=R06(W8]YX_X%[S:5QJ;N5QL)7'^U<^
ME,S=J%)2*N>V>%-@C1:?]6JT*A O;5FT-3XTA:.M?IYEBJH3/]9SEN%.T!E*
M>JT>WJBR*.2*CA:YK86F0F-E99L)%K]4F@GX?":$7G?, E4Y'?X!4$L#!!0
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MX&2 V5=5,:HZ1A;N/I])@]7!-3.LWZ!L ,[/I33KCEV@^2.(_P)02P,$%
M  @ M8ZI5@WU6W@' P  DP@  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&ULK99=;]HP%(;_BI554R=MS1?Y: >16EBU2IM6E7:[F'9ADD.QZMB9;:#]
M]SM.THA"0%SL!NSDO&^><WP<9[B6ZDDO  QY+KG0(V=A3'7ANCI?0$GUF:Q
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MQZGAB+-8#PJ)@;Z2/*$Q5KIQ0QEF4XH3,%;ZAAXW!:Z)PC21X R,]62*LX0
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M[#)HA.I7_CC4X0@PN7X!$ ^ ^&\!R0 (E6-]9D'6DB//4Z,[8KRW8_.;4)N
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M&._@[K=:X\'P'3$.P/P/4$L#!!0    ( +6.J5;JF*'WW H   B+   9
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M[FD/+6JH%D$U"M485.-034 UB=+LPF^ST.!87F<90%-3J!9!-0K5&%3C4$U
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MEV7ERXUJ@L<L_U:?]N1_4$L#!!0    ( +6.J5:BT=*"%@,  )\'   9
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M0^P7>-]_D&E6KO[]E$J9;LNW&\Z67!0[J.]7:2I?/A0)#LOLS_\"4$L#!!0
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M&99,AD8F:N'6TN=2SHBVB(U"EZZN+L6"CL0J $<EP-%[IJQ1EU"[% LZ$JM
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MY1)P!$P9R.=S2L7S0$U0_6=A\C]02P,$%     @ M8ZI5NQ-&*,[!0  H",
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MC'Q,90/Q_880_G(A!R@/Y2S^ U!+ P04    " "UCJE6 Q<<QF8#  "_#@
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MX@CF #Q@2!S;]^#.^RA:O:>B]?\OA[\!4$L#!!0    ( +6.J5:7BKL<P
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MW[KI^''YV$0)YR/.%F[&=[]02P,$%     @ M8ZI5F/6BA2; 0  E!<  !,
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M2P$"% ,4    " "UCJE6&$O]C^\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "UCJE6F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( +6.J5:<N!1DUP4  -(>   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "UCJE6]\D>I4L&  #"&0
M&               @($;#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ M8ZI5LUF$V+T @  J@D  !@              ("!G!0  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +6.J5;8QT6"5P8
M *\<   8              " @<87  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "UCJE6!=@F3$4#  "8"0  &               @(%3
M'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ M8ZI5OX^
MNI&F!0  FB$  !@              ("!SB$  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( +6.J586=CW9&P<  - =   8
M  " @:HG  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "U
MCJE6GP0P_&$5  !"/   &               @('[+@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ M8ZI5LN*)<%#!   XPD  !@
M         ("!DD0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( +6.J59"]DT*EP@  .T6   9              " @0M)  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ M8ZI5LV*N8M0!P  YQ
M !D              ("!V5$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "UCJE6-^\UW@8.  #!)P  &0              @(%@60
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +6.J58XB)1I
MO@P  )TH   9              " @9UG  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ M8ZI5K*9/"2_ @  (08  !D
M ("!DG0  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "U
MCJE6CT'W.>44  !0/0  &0              @(&(=P  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +6.J58Z3G74_P,  ,P)   9
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M970R,"YX;6Q02P$"% ,4    " "UCJE6L.=,B0P$   \$P  &0
M    @($"H@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M +6.J5:_ \1;G0(  ,\&   9              " @46F  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ M8ZI5A?@!E2?!0  XB$  !D
M             ("!&:D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "UCJE6'+7&CBH"  !2!   &0              @('OK@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +6.J5;-FA& K (
M  <'   9              " @5"Q  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ M8ZI5D*G\:EC!   ,Q8  !D              ("!
M,[0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "UCJE6
M3L9R"PP#  !:"P  &0              @('-N   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( +6.J5:C:MGOQ0(  !T(   9
M      " @1"\  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ M8ZI5@WU6W@' P  DP@  !D              ("!#+\  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "UCJE69FT6 :H$  !H%P
M&0              @(%*P@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( +6.J58ZR23!'P(   P%   9              " @2O'  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ M8ZI5NJ8H??<
M"@  "(L  !D              ("!@<D  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "UCJE6HM'2@A8#  "?!P  &0
M@(&4U   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +6.
MJ5;"7#K.6P@  ')?   9              " @>'7  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ M8ZI5FM4"'YB!   VQ4  !D
M         ("!<^   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "UCJE6!$:E"$$$  !E&   &0              @($,Y0  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +6.J5;L31BC.P4  * C
M   9              " @83I  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ M8ZI5@,7',9F P  OPX  !D              ("!]NX
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "UCJE69&CH
MID4#  #,%   #0              @ &3\@  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( +6.J5:7BKL<P    !,"   +              "  0/V  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( +6.J580![QV40,  #$:   /
M  "  >SV  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "UCJE6M[W"2X$!
M   I%P  &@              @ %J^@  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "UCJE68]:*%)L!  "4%P  $P
M@ $C_   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +@ N 'D,  #O_0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>194</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Condensed Consolidated Financial Statement Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill</Role>
      <ShortName>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Condensed Consolidated Financial Statement Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables</Role>
      <ShortName>Condensed Consolidated Financial Statement Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables</Role>
      <ShortName>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails</Role>
      <ShortName>Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesDetail</Role>
      <ShortName>Commitments and Contingencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails</Role>
      <ShortName>License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails</Role>
      <ShortName>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Summary of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails</Role>
      <ShortName>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Summary of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Restructuring Reserve Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails</Role>
      <ShortName>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Restructuring Reserve Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Sublease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails</Role>
      <ShortName>Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Sublease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. nktr-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="nktr-20230331.htm">nktr-20230331.htm</File>
    <File>nktr-20230331.xsd</File>
    <File>nktr-20230331_cal.xml</File>
    <File>nktr-20230331_def.xml</File>
    <File>nktr-20230331_lab.xml</File>
    <File>nktr-20230331_pre.xml</File>
    <File>nktr2023-03x31xexx1011.htm</File>
    <File>nktr2023-03x31xexx311.htm</File>
    <File>nktr2023-03x31xexx312.htm</File>
    <File>nktr2023-03x31xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="351">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 351,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 117,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 337,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 31,
   "keyStandard": 163,
   "memberCustom": 25,
   "memberStandard": 24,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Condensed Consolidated Financial Statement Details",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails",
     "shortName": "Condensed Consolidated Financial Statement Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - License and Collaboration Agreements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill",
     "shortName": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Condensed Consolidated Financial Statement Details (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables",
     "shortName": "Condensed Consolidated Financial Statement Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - License and Collaboration Agreements (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables",
     "shortName": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails",
     "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
     "shortName": "Condensed Consolidated Financial Statement Details - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i66e54efca0a94e31868b7e6b05760280_I20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "nktr:RoyaltiesLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Goodwill (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails",
     "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails",
     "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
     "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i3f48ff8d3e3f4a3b93c848f7e9f009c4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Commitments and Contingencies (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
     "shortName": "Commitments and Contingencies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ibce58931b7d241b7a58b00661b49392d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ia9c43dfae2834078a893893586390205_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ia9c43dfae2834078a893893586390205_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ib5c61fe105dd4f8ca0cb30e7ae9ca967_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails",
     "shortName": "License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ib5c61fe105dd4f8ca0cb30e7ae9ca967_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Narrative (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
     "shortName": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "if40ec0a96ce54f1bb18634012ce405b9_D20230401-20230630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Summary of Restructuring Costs (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails",
     "shortName": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Summary of Restructuring Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i91cc917126294398b7fa3f95a89652cb_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "if85a2540650e49ff827fe78c21240f01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Restructuring Reserve Rollforward (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
     "shortName": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Restructuring Reserve Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "ifa6e43a4bdee434d8a2152922832b63a_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Sublease Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails",
     "shortName": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill - Sublease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:ImpairmentLongLivedAssetHeldForUseOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i1cda02f4555947ccabad36bcc6480d92_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i13b6287af2fb458e9dabde17f604aeb5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "i13b6287af2fb458e9dabde17f604aeb5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Cash and Investments in Marketable Securities",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20230331.htm",
      "contextRef": "icdefb24a2c2e4aefb243fe223e621645_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedContractTerminationCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Contract Termination Costs, Current",
        "label": "Accrued Contract Termination Costs, Current",
        "terseLabel": "Accrued contract termination costs"
       }
      }
     },
     "localname": "AccruedContractTerminationCostsCurrent",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building and Leasehold Improvements",
        "label": "Building and Leasehold Improvements [Member]",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, Amount",
        "label": "Collaborative Arrangement, Success-Based Payments, Amount",
        "terseLabel": "Success payments (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsAmount",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ComputerFurnitureAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture computer and other.",
        "label": "Computer Furniture And Other [Member]",
        "terseLabel": "Computer equipment and computer software"
       }
      }
     },
     "localname": "ComputerFurnitureAndOtherMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Gross.",
        "label": "Depreciable Property Plant And Equipment Gross",
        "terseLabel": "Depreciable property, plant and equipment at cost"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentGross",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Net.",
        "label": "Depreciable Property Plant And Equipment Net",
        "totalLabel": "Depreciable property, plant and equipment, net"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentNet",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly And Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentLongLivedAssetHeldForUseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment, Long-Lived Asset, Held-for-Use, Other",
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Other",
        "terseLabel": "Impairment of other property, plant and equipment"
       }
      }
     },
     "localname": "ImpairmentLongLivedAssetHeldForUseOther",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities On Sale Of Future Royalties Amortized Transaction Costs",
        "label": "Liabilities On Sale Of Future Royalties Amortized Transaction Costs",
        "terseLabel": "Amortization of transaction costs"
       }
      }
     },
     "localname": "LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "periodEndLabel": "Liabilities related to the sales of future royalties, net \u2013 ending balance",
        "periodStartLabel": "Liabilities related to the sales of future royalties, net \u2013 beginning balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityToCollaborationPartnersCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability to Collaboration Partners, Current",
        "label": "Liability to Collaboration Partners, Current",
        "terseLabel": "Liability to collaboration partners"
       }
      }
     },
     "localname": "LiabilityToCollaborationPartnersCurrent",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]",
        "terseLabel": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20230331",
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ManufacturingLaboratoryAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing laboratory and other equipment.",
        "label": "Manufacturing Laboratory And Other Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingLaboratoryAndOtherEquipmentMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Market Participant Subtenant Borrowing Rate",
        "label": "Measurement Input, Market Participant Subtenant Borrowing Rate [Member]",
        "terseLabel": "Measurement Input, Market Participant Subtenant Borrowing Rate"
       }
      }
     },
     "localname": "MeasurementInputMarketParticipantSubtenantBorrowingRateMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to the sales of future royalties",
        "negatedTerseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to the sales of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OperatingLeaseMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Measurement Input",
        "label": "Operating Lease, Measurement Input",
        "terseLabel": "Operating lease, measurement input"
       }
      }
     },
     "localname": "OperatingLeaseMeasurementInput",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other Partner"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones (up to)"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones (up to)"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure",
        "label": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure",
        "terseLabel": "Property, plant and equipment and Operating lease right-of-use assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Liability, Measurement Input",
        "label": "Royalties Liability, Measurement Input",
        "terseLabel": "Royalties liability discount rate"
       }
      }
     },
     "localname": "RoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Schedule of Liability Related to Sale of Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_StockOptionsRSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, RSUs And PSUs",
        "label": "Stock Options, RSUs And PSUs [Member]",
        "terseLabel": "Stock Options, RSUs And PSUs"
       }
      }
     },
     "localname": "StockOptionsRSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleaseOperatingLeaseRightOfUseAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Operating Lease Right of Use Assets",
        "label": "Sublease Operating Lease Right of Use Assets [Member]",
        "terseLabel": "Operating Lease Right-of-Use Assets"
       }
      }
     },
     "localname": "SubleaseOperatingLeaseRightOfUseAssetsMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SubleasePropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Property, Plant And Equipment",
        "label": "Sublease Property, Plant And Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "SubleasePropertyPlantAndEquipmentMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TwoThousandTwentyThreeRestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three Restructuring Plan",
        "label": "Two Thousand Twenty Three Restructuring Plan [Member]",
        "terseLabel": "2023 Restructuring Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeRestructuringPlanMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TwoThousandTwentyTwoRestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Restructuring Plan",
        "label": "Two Thousand Twenty Two Restructuring Plan [Member]",
        "terseLabel": "2022 Restructuring Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoRestructuringPlanMember",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20230331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r158",
      "r307",
      "r308",
      "r311",
      "r312",
      "r336",
      "r393",
      "r467",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r158",
      "r307",
      "r308",
      "r311",
      "r312",
      "r336",
      "r393",
      "r467",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r264",
      "r268",
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r280",
      "r367",
      "r383",
      "r394",
      "r395",
      "r415",
      "r420",
      "r426",
      "r472",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r201",
      "r370",
      "r416",
      "r425",
      "r464",
      "r465",
      "r473",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r201",
      "r370",
      "r416",
      "r425",
      "r464",
      "r465",
      "r473",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r273",
      "r280",
      "r284",
      "r285",
      "r286",
      "r343",
      "r367",
      "r383",
      "r394",
      "r395",
      "r415",
      "r420",
      "r426",
      "r461",
      "r472",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r273",
      "r280",
      "r284",
      "r285",
      "r286",
      "r343",
      "r367",
      "r383",
      "r394",
      "r395",
      "r415",
      "r420",
      "r426",
      "r461",
      "r472",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r264",
      "r268",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r281",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r172",
      "r281",
      "r433",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r172",
      "r281",
      "r433",
      "r434",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r123"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r127",
      "r378",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r89",
      "r335",
      "r384",
      "r385",
      "r436",
      "r437",
      "r438",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r442",
      "r443",
      "r444",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r82",
      "r83",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r109",
      "r126",
      "r154",
      "r192",
      "r195",
      "r199",
      "r210",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r307",
      "r311",
      "r324",
      "r424",
      "r468",
      "r469",
      "r479"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r119",
      "r131",
      "r154",
      "r210",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r307",
      "r311",
      "r324",
      "r424",
      "r468",
      "r469",
      "r479"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r207",
      "r218"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r54",
      "r206",
      "r218",
      "r372"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r53",
      "r218"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r390",
      "r391",
      "r424",
      "r435"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r122",
      "r396"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r100"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r104",
      "r113"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r249",
      "r250",
      "r392",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r442",
      "r443",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 189,235 shares and 188,560 shares outstanding at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r139",
      "r141",
      "r146",
      "r374",
      "r380"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r108",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r417",
      "r419",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r30",
      "r370"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Results of Clinical Trial Programs and the Restructuring Plans"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r40",
      "r87",
      "r296",
      "r300",
      "r301",
      "r441"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r40",
      "r61"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Development Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r132",
      "r133",
      "r323",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r283",
      "r288",
      "r289",
      "r290",
      "r294",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r173",
      "r175",
      "r177",
      "r178",
      "r179",
      "r181",
      "r315",
      "r316",
      "r375",
      "r381",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r175",
      "r177",
      "r178",
      "r179",
      "r181",
      "r315",
      "r316",
      "r375",
      "r381",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r117",
      "r142",
      "r143",
      "r144",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r183",
      "r211",
      "r270",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r314",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r265",
      "r323",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r317",
      "r318",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r91",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r265",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r318",
      "r340",
      "r341",
      "r342",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r91",
      "r97",
      "r265",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r265",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r265",
      "r274",
      "r279",
      "r318",
      "r340",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r265",
      "r274",
      "r279",
      "r318",
      "r341",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r265",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r318",
      "r342",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r93",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Change in the fair value of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Cash receipts from SFJ"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value at end of period",
        "periodStartLabel": "Fair value at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r265",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r340",
      "r341",
      "r342",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r266",
      "r269",
      "r313",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r411",
      "r446",
      "r447",
      "r448",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Estimated Fair Value at"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures and other"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r124",
      "r225",
      "r371",
      "r412",
      "r424",
      "r450",
      "r457"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill \u2013 ending balance",
        "periodStartLabel": "Goodwill \u2013 beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r237",
      "r238",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r40",
      "r226",
      "r231",
      "r237",
      "r412"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment of goodwill",
        "terseLabel": "Impairment of goodwill",
        "verboseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r40",
      "r60",
      "r65"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of other property, plant and equipment",
        "totalLabel": "Impairment of right-of-use assets and property, plant and equipment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Asset Impairment"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r101",
      "r105",
      "r115",
      "r192",
      "r194",
      "r198",
      "r200",
      "r376",
      "r410"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r155",
      "r170",
      "r171",
      "r191",
      "r295",
      "r299",
      "r302",
      "r382"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Condensed Consolidated Financial Statement Details"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r58",
      "r398"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r129",
      "r397",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r128",
      "r182",
      "r222",
      "r223",
      "r224",
      "r369",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r58",
      "r400"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r58",
      "r399"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, fair value disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r154",
      "r210",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r308",
      "r311",
      "r312",
      "r324",
      "r409",
      "r468",
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r103",
      "r111",
      "r424",
      "r440",
      "r449",
      "r477"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r120",
      "r154",
      "r210",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r308",
      "r311",
      "r312",
      "r324",
      "r424",
      "r468",
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Change in fair value of development derivative liability",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r17",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Liability for litigation"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Contract termination and other restructuring costs"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r41",
      "r106",
      "r114",
      "r118",
      "r137",
      "r140",
      "r144",
      "r154",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r176",
      "r192",
      "r194",
      "r198",
      "r200",
      "r210",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r316",
      "r324",
      "r410",
      "r468"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r192",
      "r194",
      "r198",
      "r200",
      "r410"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment expense for facilities"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r44",
      "r50",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r130",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r76",
      "r138",
      "r141",
      "r145",
      "r326",
      "r331",
      "r332",
      "r373",
      "r379",
      "r436",
      "r437"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Amortization of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r241",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments during the period",
        "terseLabel": "Payments during the period"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r34",
      "r52",
      "r149"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2023 or December 31, 2022, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r151",
      "r404"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Cash receipts from development derivative liability"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r36",
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r52",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r118",
      "r137",
      "r140",
      "r152",
      "r154",
      "r162",
      "r170",
      "r171",
      "r192",
      "r194",
      "r198",
      "r200",
      "r210",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r306",
      "r309",
      "r310",
      "r316",
      "r324",
      "r376",
      "r410",
      "r422",
      "r423",
      "r438",
      "r468"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r64",
      "r112",
      "r377",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r148",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Accounts receivable, credit loss expense (reversal)"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r84",
      "r116",
      "r487"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Workforce termination, percentage"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r40",
      "r244",
      "r246",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, impairment, and costs of terminated program",
        "verboseLabel": "Expense recognized during the period"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "terseLabel": "Restructuring, impairment and costs of terminated program",
        "totalLabel": "Restructuring, impairment and costs of terminated program"
       }
      }
     },
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r241",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r77",
      "r110",
      "r387",
      "r389",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r117",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r211",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r314",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r189",
      "r190",
      "r193",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r271",
      "r272",
      "r370"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, excluding assessed tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r412",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSubleaseInformationDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r67",
      "r68",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Restructuring, Impairment and Other Costs of Terminated Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance and benefit expense"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillSummaryofRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r76",
      "r117",
      "r142",
      "r143",
      "r144",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r183",
      "r211",
      "r270",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r314",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r183",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r77",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r51",
      "r424",
      "r440",
      "r449",
      "r477"
     ],
     "calculation": {
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r266",
      "r269",
      "r313",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r446",
      "r447",
      "r448",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
      "http://www.nektar.com/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillNarrativeDetails",
      "http://www.nektar.com/role/RestructuringImpairmentandCostsofTerminatedProgramandImpairmentofGoodwillRestructuringReserveRollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r407",
      "r417",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r184",
      "r185",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r174",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r173",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding used in computing basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nektar.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938061&loc=d3e54681-109401",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r428": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r429": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r431": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r432": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0000906709-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-23-000008-xbrl.zip
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M[Z']PC44OA>%\0T*(T<1*#Z48@QD9M:PU"")4I4YZYW)?+!N:?4#?D3Z;O1
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M'6'PM^;2@.<HL&&**N)&,SH?#'AU1B=YZB=G=%C)\]4I&_G7+S_NK/_P;-+
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M3ACRF40R,Y8&C(PTFH?Y7Q-KN.7Q5N@LIYYZ,'@#M<P NJA8U4HSCH(5#B]
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MM-J*P=[_^0<6Z!7%RTF<^#OE^LE9]+NR6[%H43;V1V-_S-#O*:%_>0Q\W6V
M!-WI+[(%LG>TP=OK7[[N?_JKTR+MO/WV X7WG;6.+ =+Y!3:R>&9[M9ZZ[H%
MDK? DMC:A?YV/W[=(YMH?]W!V#;.VU\[8(FL 7AM E#ML1:^Q0(QF'GA-4J%
MHCYE1@!J.4E2!"8("M1ZG&4C"X0]:PMD=WNMO;-9V1FU";+3V"#7;)#!A2".
MC9!0%MU:F7W[[V10W.>V^N_YT7_WFY[71;>;]^.Z4?(F!_T'TF%\^7*6MME&
MM3@4WU:_;"&1[T%AH?//U!&+K'&I8=ZFL29\:K2,1P4Y83@V7CJ]M(I2 HI+
M_.J1H6_)$GT,62+T7L.>N<QL^X-J?;8WB$=R_'IR\_5S)F$BG3$I"4JD(#LB
MU5;Q-%/>$VX%Y5%NVAO_WEW;COIM>^W]QL?=S=<[<R1#]T3FWS;.M!U4/!"7
M/<L+VB>ZG_2/O8W9 2[)>TD^Z"?VL'*Q?__%H&%AG#:6K>",3]UK(RM,3=\7
MA,XBRF;L"]9<^!@V]'?E;=;.8(W>,1VG/!ZE0519.=4A2^7Y:_!EK_B%, 0;
M<V$&_K@L3F(["QJ4JOW#UJ</X ?&=[2_M(_^/ +_$+76X9GUCW3OZYNCUE=W
MU/[Z-_3^X)I_6)SMKW<.XWB@[P3:1C':'35$>]<=M3ZUOK9)B[8_@6_YYC;_
M,--,(AU2*X5*F<TLV%N(I-9GEF0LGN8NEU;7?4>?ZM(_P$&\DB712,+W)&%7
MGVV.\MOJE+0%=@0>F\4WK[(XE]0%IEG*A8V.A""I(8:FBGBNM8V;/L+2JF(I
MQ90IAK[)Y-,&\UIY/KJA43'Q;Q7")N#]%_&TE^1H6.9]E]LJ E"$/TSY8C6?
M1.3JUO) ]_*OU???GUC^GW3R-K=WDE$QG+*:JJORFK2+E=\7/S8T<Z!;<Z[T
M_?[HGW?0 ;R0(/<0K^TC^<R,(J"'?2JP< !22J722YH&*N*<(F$$>&V,\Z0U
MBD7]J<^3/XMAQY_HTB4[Q7!PN'@>W&.QUVOXN%7N%J>+:20^B+GH9R2MI9[Z
M5#&"8H:53Z4R/N7>*DR]H1;[I=4=(/^;6-(K[]OB.BLMSS[<.2)5I92VRO=@
MUH/R>:96_X-B/.0SRJ1GBJB4!DU3Y@A/)0+C)F@3B&(2B"V65E^#@,/D]7)]
M$Q@>B9CO"Z!69S\_KAVX7XU2]+/#UG'B:4H1YREC4J1&>?"TG.?(,)C2@*+Q
MB;F<(_2^7Z#JMQ&18^SMN 1AS8]U)_%GW@[C]ACX&8PAW[\[X/;KV3Q1#ZV5
M7O^:XL ^4TEADJQ/C:$ 7,)EJ0Z(I%0Z[J5 P1@)9@[FUX4AG2%1XJZOSOO#
MHO>KKK9]9)^= K5!D$L=,3H%.Q/L3VQEZF/=*^2"D=%)AEM23M$-%WG^H>IR
M7>A__B$)SE[UDX'O^.-(]:17D7TY 0CK#*,+FFB0T20FT/S^-&%T)5=('0O_
MT2@Z42M2W2\P_2/-8F@6B9F$T7]L!]?5X(&:M^#!/>.'.Z CR^J,X]&JE2^]
M2XZ'97\8EZ\&10)W5&$$3'XSOT<-&S,TUNS@Y8^$HT9\&C-Q7L*D)/VBD[MJ
M ]NKT:6H>Z]=6:R9W,T']:9'K^UA8F.=FWM$I7Z%B2EU!67]\ZXI.K_U[Q.L
M^_ZTE/4;GN>4M4<+R14K^3-[J'L'\$,O.3W,X9=+2?T)&1RA_^TS-V,^?(QU
MDD=/'QU!Z#DFIL* A;3:ZJ61]OH'&O\/5MO1_OHA/+/']M>_X+W=OPY;W8^D
MM6Y/H1]?MG9O+(V@]KJ-_V?[G]I?MMY^0.VC0[CO;WANXWQ_=^^T_?5/&/,'
M'BV]&ZM_7*B *;4I\F#9,2EY*C6A:2:PH9)8$4Q6)\"!$.P,"OME.?GO:H$?
M)\>Z3$YBB;&?6!1L9&(V,C'"_)T*\AN!N(= ;%P5"*>,,ER:%!S1D+*,H%3)
M@-) &#895M03!GKBW[O;C\_ULU:]SU(BQEIB8Z3-ZZS ZR'EJ.L7.)K\V$)S
M;8$],",S@DEJ?% @-(BGVC.?8I*!"HG5,UD H5G;65_[D+SM%$9WP+WI@(.3
MU&=3?'_%_<YETXJK\UY<>GW)6;7"7#\;5V2_'96X^=0C\GT5E=CLN;A:[!-S
MGMA#;[\D79@/L#9]M1X?/;Z)G,;?\.]U OVA[B<A[X##J#L=N"-NFHE^Y'^&
M>?0BP7DT?G0#-#QR).M',8UK^/7VAI%/.>&*CH4D^IGQ<MS>D+CJ2)CJUN/2
M6U\Y%9@DU;[ ?O(;M ?BE/2'8"'W#V.Y]W*\?6!PJ ?71W&JKW8U]K-^>#20
MWY<3W7/);V1BM 8D$VXR1Y%GX*'J?G@R=F746-Q)U*]Z4O54]P>)0HG3Y_V5
M*YL/9KWP\7I8EM"5>BM3U,4#/1CV%Q)6'A12Y)]IT%8Q'5*O'$N9QRXU(=.I
MT2@P)3&O8&'/]^^,)MY3)C_!-$>N[-\S1'B[,)[]X%NGB@23+-HNDHO]6,\)
MOZ(@@PQW\\$ 1+_"_[+H10.D<Y[$TZ3.D\UHEVA;K1ZMZX&N-]Q<0[;+-B;C
M9=M#N),A'G%KVQ\,.W46SDZZF_P6YS5[12A9&=TP.,RK?/#CF \^:X2K^WN!
M6;[_^^,BTL2DQCD= =0OATA[IY^M9-:#"9\R)>(6;F=3:0U-D9)6.JG 7/$-
M(OTZB 0@H)..+L'BT=8"(I4ZPDH4TC):(;?^F@!?I+=>Z'<!RN MY5CW@S!W
M81+.EZ/1!<V!D1)7@@Z2@[(X'1R.+Z^ #>:KOH&XY[UJ!V:UJ!Z7J@@,\XX>
M5I?QJ_%MW[WA[OZ-;XR&U^CF._HZOC/OU8B+B4G)V)2<M!]7GFCA3*U(+GYJ
MX0RO (9.?_L)64%B!KM:?K[9;UTC*R++IM_9GY_:;W>64SJ#_4*4WV^A<[I%
M'AYIY>/1(S"7>YG+UX!-!T5Y?DL IKJI0BT[NFFA8S&QMD/[Z]YIJ_M7I[6^
M>=9>WT/P&V_MKO'VUXU3Z 6&YUB;W*CW$&L[T/;1VOE>]^-IZV@#M8_BV+Z<
MM=:_T-;NGS#BCV#:'-"]V^H]8.&IRBB+ 4P?\SAT*GV0:5"6:R5-AK%>6GUW
MNT9YLNT]TY"'Z=8]N:C)M4 S,%5$6+MDCMH('''( LW'##B"O;IMZ7?<EWM4
M%?[N[(BGN/49:;+V;=9YP[8+-0-398B=VNNI0>S"]:F_CIR:A9J<A:GO51M^
MU?3_.>S#F_O]YUC:ZY%,O?-WNWM733V$N;!$@JDGA$X903Z5(H244Q6,M AY
M9>]7VJM18W.'6ANWAU\:I)H=4HVG_&TUXZ_K"6\0ZZ<1"]U(%*"("<HM2GTF
M9,HT1:GVW*6(6\ KK 0/81K%"'^ ]1_AUI]*8'CTP'GX1H Z[HRX-:Z>A]L6
M^:JE/3"]>T6U,C?LU\%M&&A=U/B6.H-%6;VK$P^-3TYS>#6\-NG!V(H8KS[)
M^Y4IWXN[4P%3P,"/=6&J].:![CE=NGX2MX3F[JXT>OJ;_OW6./75HH13AK;[
MKK4\U\65_J'O=,9LE/P&S%$M<=29*=]>0+BZ2KH'PY@G&LW!DMR33L?L_8;(
M.<]2"3]H$1M_1M:*C#B9*H+B<2F928T$!X 'IHS#0B.1??],@3F%F-W#\6Z\
M" G%<%#!>X7SA[KT_3%0E#>W\WTG2WVYRLL8L>V;*A\"[A[V\IIIZ^:7KC(R
MY30(%YQVF# ;I.*&26$H]M8BZNGH5'F.R!+@FLW!U>W_<VFS_>:6M+"J=U7G
M=JI7;5V.[2I[P_!35U3GP<4&P;8 "QS:0K\<LW]@G[623 3.4B14K%Q!6-PO
MC%.CJ<UB58M,FJ55+-4RH7P9\VS,\&,*K]Z&DD;;+V#A#'LN'3%VJ/Z\>BPV
M3XJGU".]I*7/:S5"ZB,*5N[$A<ES&X^+VFI[6?I.=0#FC9,<+Y?YJQ5[=/F(
M-OVB,QS<?.3N?-WK)Q;>[P3*;&G\S&%Y:98?^-247G\![AGX\J7NG.KS_M*+
MNXZI9&0EX\U)E7-_4N535(>XM7+NG)=9VFRO;_SOPA6$%2"$TZ_<*K,5*>^W
MY?S'TD9 14TS;63Z\;MZ@\\$>XZ>KS<=J6\9?;/"%#1'^/;MOMP?WS!=6MT9
M=D%6SJMDY+S_Y39\FWY8]G;@J;:-/55:T6WTF^$;;] /+,$?)1V[@U:W+Y)@
M]I!5DBD'&7^J.L:]D.('%-F4Q/.V'?I/!14_V)<?X#>QM/I^;7LWV7R9O-EL
MK[5?;ZZ]2\"!W-INK>U6)QE_BQ=G ""-!I@&61687 /?3?#*+('_N_K\U614
M)WT2!?\<'9A(7G!<8%;CJ@1\JG9=5]E&;RZ6**HREO6FQ"I$15XE'WMZZ'*X
M[65C#BR&.0"$%@^#X">PXANIGXG4$W*GU/^I.R#U/MDY]'Y"WJNS0)/Q,:#5
MYIIU;WT5W1[]2AHD6 @DB,1OD*!!@IH9^)U(,*'UP?7?.O;U:RX+$PS@+7Z\
ML[A.A[@%)AID6!QD &;(&F1HD*%B!GE/9(B)#:4_A/MBJ8-W1;]!B.>+$, 4
MLD&(!B$B,U!\3X2H4D4.BPZ\HC_*<4DV_C/,!^<-4CQ7I(C,H1JD:)"B8@9V
M7UM"]P^3-YWBM+$AGB\R #-@U$!# PT5-V1QG_, ^C0HDA]8B6B$?3&$'<B+
M<;/TNXA+OQD:+?V29NEWCL@[M=Q5(&]+]_1!!:@7>P_6\[X=UL=R1L-JK:<[
MY_V\LLXN<3@"=;WK+=ZS[?O#SO4P<0/0"P'0D0ON-)U_'8"N<.[ZWH$&XQ8=
MXR1?6OT0]\_F@VJ71P57\$-G_#VB7:?H#^-^K#53#,=EW*M4UP;"%@+"(I')
M V--SP#"%M+&E'*$O:RQ,>>(O%/#WWH1<5 "!2OL?5\6UKL(MPVX+@:XRN^#
MZ[5]!*K91C /J?N+N8U X?$V@LV7R5;<F=CL(5AT):]8LX?@&2OY2-YW_D!W
M:NU>G3G2J/?%4.^1=K2)SR\FK&9C6%V[@JM/P??)8\AZPS53XIH8W$K>:#LH
MR@:H%P2HLP:H%U7DH*%F)?49&\ 5?3_VZD)N/AZ5MZ,[=8&W49KKQ,&D,0KV
ML5]5#!J9RPT$+P8$5V1FS4+#@F(PG5CE;3!X7N@[/0P&^J[[H*M,E(_'L7RF
M[^5%.8&]#<XN",[2!F<7%V=%LZ+[K'$6Z-N"9\#&#1Y,VXD,F@9?%P1?18.O
MBXNOXX)<O,'7.:+O]/ 5Z+M5'4*QV:MKJ4-3#;(N"+*J!ED7%EDQ&2&K:)!U
MCN@[-62-]-TX.\Q-WFP?7!1 C33C/[19^.:YBHU<SKE<\J75':" 'C1.Y ))
M)E"-?W/CV+W."9R0H]L.3KEY?,OX/).9G.#R$\F]LZ)1==@%F<8Q,A@MC1]Z
MR#DRS2$R\W6(S.@ $U!;WS[O8DH,>OMI+&^*\E27+GU7%%_BT6:3!1KND..K
M_;ZB5"E>X4]X7EO>3^I#U9.\9SM#Y^OZMR2^M1YF9S3,_L4PJQOPJ^J@S[Q7
M5:SI>MV+-\7*5_61G:,#JK*U\9EO$_D :W80?\6*TN5$]Q/=K8K<+%>) E>?
MQQNW/#]YSN2H(3;9T$JRUNE,=#@I1B=<5C,\67P'QC\HRJ@NDZ"A,5WZ^X\_
MENLY'I8 L>.3[6 V/PQU"=C2.4^VZWDM>@EP3#?!*/VP/)KEV%X\4?.X+([J
MX58-=.M]F)&"RXG799S2_G(\0-7WXA%XP $>^MOSR;$^K[H"%XMSW8FSLIST
MZPR,<C3<R_-6<^AX?[EZX]7AQWD][@ #53-?F*HS)W[4F?$^^6J@81A-E:2X
MK(GZV\58EA,S'%3GQ7;R;JR0G@R*91B<M\!RU>0Z&$*G.(ZM+2<7OP[BF9;U
MN^%MPT@!(''OX/<;?:T47M5N4@PGAV:O[,H?=?*T*"N267V<#^"F7LPX^5Z;
M\3S"@3_(+5PHR@/@YZ_ZHF%;] ?P.]PS'/6QGK=;&CT IJFN%Q'58A]'O1IU
M.I*^ QS2JS3XS19@1-97I(_L$9G+):X<QM' 4&-UF!&UAA=$@8[YJCY4_'UB
MJK_;QZK8%) ,/HYK3\%]D6G+6'<JLL%U8L&5_M!T\[I< MP K0UA(HOR/-''
M\1#?..*\4[/NG6\>]1RT2*_HUB>0UG2LW@!,5L4!82:^TWOH',QQ?' YN0@=
M+M>]M-;W^_5!E/%\XDY'FY'. CDO(X",9,@6W:XO(S]=T#S*P67R$@S+ >%'
M$M:),]R/1^#>;/@89J_GR_XD.XZ%-0+0 #C]/+[0)V[HZ_.5DTJ#QN'T_;6>
MW3GV^.9;)1=:',V)3ZICF>,YR_"F:W3\EC1<<&Z\"7R)_#A>J2:UZ!T4\?4=
M>,/!I7C<1!;=[P^[QS5!:P/A? QZ(]P!:OFJL95D$V YSHC5_2@0=R-OE('$
M -6CZLQ#7A]$'%L;UNEE(%? S: ]#\XC QQ&I3#"<^,[.1!N>8S>HY^!'-=_
M.LT[G>N_^;-CF.'^]9]K ;OVX^6DW;@$"))W;[MP,>?CWV&R1Y?&)%R>N!2'
MW/,']8;^B/8^LOD8^:L#F\O*OIJ8D*@5!X?%\. P.?7):#IJGJS/]XXC'&$[
MV'&C4\!'"OY;-('^Z3P>"AW[D?<J)0I6=K_HQ2XLUX2XTCST]"HGW-5V%):(
M*96D1,+WP.P$O3*HV0ZP&#BZ'-5BL<6P _B7AP!S$&<Y<CHHXE 677@1(.E8
MX4)?8Q<BC]YGB"O)UB78WJ5[RLN*,)=*LK)*3N,AVM$ZZ9U_XR7+U;P!ML8.
MUF(<YQ-0O(Q'D%7O&$;5$">[5OC?4<#52;LQ[3W4:>])WU>Z?' 8A_P^XOSF
M<A+#O[6QA=?&+#>9+#_F.F"8XK2&M6)\6GBD<3P3O&_+W,!; 1;]:>QU/:??
M,X=J.^T;Y*_GM7[+Z>'YQ1Q'MAC1>62VNHLWCLS9.)E=[7R<^!&?1=V9C&0E
MM@Q2X(IJUO+H@538-SRN[OHVJ8"9K3\>Q*9+_Y]A7M8XU-'5>?>@!3N M%'Z
M1KHQ<L)*M%KC0_7\Q/Z,#BNNA?8T[_MQ:Q5I[V5.QF9&-!L=MGT=6-K^"VCT
M&Q!W P>'EY 4YV;T*ZB9\:\ "5%)%4G=8K(+G=;'?@A8%WDW60<%<AIG'23T
M>*0.*XM^>33DRCHX+J-F@O'!+ *O]W.7ZQ*8^>XC;.?"Y]LM@96B>;Z(/IX?
MD\R4M;*^-&CB.=>30'(+CHP>GLE.*[XB^7U"#C<#7W&:4[J";SG$U( 548=&
M -8R]NHISVI>GM".8Y%VA1U6UGD4EL$%8XW [B*??N(*X-4M0C?66Q][^455
M6?#*/J[LK/Q>.RVUKK@P"H:]025JR>[5;G3ZQ;B;_5K,/>B9RI2\UCV8A9/<
M^N2B6Q/V1B\:RY4UH4?X%L4=NC#6\WD9\?NX-E23XC2:R=\]N9K],G%/>G?<
MLPEA/LL0IOB6FKAK9>">\6^Z-)<JZG;M>O.XW?FP!6X7U.3:GT^^0KSHIN07
M<8E0=,!<KH-0P\AC<7SNLLYD#)Q,F.;+5TW[VKN9<*$K7)WPVFH7J^-/P-<<
M![#,L ]][5?X7D<2_(7E'Y^/:A[F,G?#RBLJRK$"T0<',; 0S;+3B-QY[\O(
MEX*^1[\:&K_F:L$K[_"S:C_/UV;&1'AU_.1%Z.H;WA;,*-@@?A01&8\A5#T^
MB1'0&%_IQR@1&"F#VO@>A8V3B8CQE3#Q1&@YN3,J'4,1XQ? Y-RF=/N'HYD!
MG!C&48/F!"O6EQ?NUJ1#5#M-QL=@!TS5ESH&,AI&I7T!A?+($2O)7C$<MU[A
M$<Q(]$DBY7/XKU_99:#7^GGEV!<QP.IR6P7K1@&1<U#FG=K?'LW:2E56&MP*
MN-XY7T[.+U\2FYOH?![]PWI^:E];5WJ]XX$05QDWON,RNED/&?IPE8,O8EW1
MRA_HZEZ8K1PLA=CE*_S:@MD!'[^L^*]VGBL/LNZ!'^07=0R!#KF+DQX)&R?3
M]T[RLNC%J5RI!'S,+<!+)9"^]OU!_"MK)OX;F_GV?%9QQ5$_Z]'6S#+!BW$B
M)H:P?&M4H"AO#PK<R]>YH1S$DP%>A<G74:9VL"-;UV)PG>>!?*-"#1>&[X3?
M>GJ8 X_6K#/RX,%7[!8QLAE-RO[+[\W1R-*C,()KLW8EAX5>G\<4RR?3<Y4K
M+1[)(;FM"U?G!K.H\[]EF-64W[ZZ4+(]N=JP/K':L!%B<*G_=,-;6OTNV]S*
M)!EY$B:Y7=K^YQ\J0^0)O=8;3,(JZ+E<RXN+49.K3"#:.NGXWL'@\/QJF#(:
M1=4BS"C<%O5!1-VH74:@>^![-=Y/K%V-UVX 66XL?85J46.\7A/C_J\:FL^*
MYJ>U%7D(]U40?^RKN8KJKUHKO%QB*_W7XU@/"]1 QP_!SDE^ W5ZDA?#?N>\
M#BJ4-82 X=;^]^YV2KFLPQ35-\+YA6EXH6+B0DSDE3XXYWD YHLV3'*HRRIJ
M'Q*?5^&'F^\&'KEH=13BO5@(BUUP)]6!OW#G!5?W!T,'=DO#3#-CIL@QQ7 0
MUS[[M5TV:=WEW>ZP5^E^?7Q^VVJEJV/X8(E&4_'\QEHW,&$/>E^W$"W0VH4Y
MU-%TO'!3:L_*00O]2R.OYN83W1GZ\7+Q<7Y<!1$;?I@9/TQ(]24G "TBPE<D
M*#KGW2JZV#L:1O<4K'[?!8\2B#_P]G"TS'L,QDE<^;]T+4?![?J'Z_JCY@IP
MQ6J_]J*A:D&MNOGB<>C']:>+&$WT]=(Z:+E+_FWX9&9\ GHDKD94$93*>8M!
MVKP;E_-TC2-5&L8U(+^^FJKAUSH*<!+[!K?6^1H7Q9EKC[5FC]IMB_KA C?J
M4,)%T#WZ>YVZ"W7ZTL@GK=8;*[?H&%Y0.?CQ'N.KE ]]HO-.M'RJ1;:&969N
MJXZ2EL)EPD'DE=LQ 0P-!Y[.N:]7N#4HA#+W]?+%:!%Z)6G<TGEU2^\ZJ>?U
M* EPNUY;OY*HV[BHSTKL1^Y*'J.6D<Y5M+6R"B>3.X_+O(@AW^^G=R:_U7&J
M.I@?O=QXYN;=F:+5,]]H[_?(JZ&PPRJ >-&/>/F+/[\[C=/7@94?=Y#JH.4H
M3Q!F9MB[]*P;BV66?%BY'1.A[W'VV#@EN9Q H[%S$UDW,EFU,#01+:E=F-K5
M!@;J#P.0NK(MQJW!KUWOZ["Z'995UM@%DT3R-\2>&;'UI/0E?2"!O? B1YG[
MD:R@O,!-<!,&Z]6$Y(/27R;]5L([0K-A;QPJ SR!CWG_<&1RYE7*QAT)R(?Y
M<;_:H9'H >!5G70Q$3B+B:%7,G\F1S$)/A>;#L89*G> 5,2\M _84^4C7ET=
MN749I,XEO&7=I#;'(IO[LLY&:[AWAE!5K]A&!IN,D0%C#,LK"-8#@.D4_?XX
M>G.-DF.TTO:P6J*N4O#[XRAP )PR>2<6!AU[4!4@-A;U_%K4KZ\ R_L1L#2V
M\W,%@KM"_76X/.J(FY'VR1#Z9*RVRAD9"7Q<6J\W]$33'"S9ZRIF8K?-]RS:
MC4Z>O,OC@G/EV]4YSTG0>:=.2O$=T'/E:%\-F%CV2^=\E*Q^L4VIVO->[9>K
MJKG%AGPTJ;0]KZ(URZ <^[7ST._K\_&(JK6&<3QH(M6QYZ-E%J-3,6PP[%]!
MTMMVP#7!GUES<M1%I8])3G$K5TQA!6>MSGO.3V(DN5?TTHL+>0^H/1B.,JTJ
MXE7)T7663MSG5)1I_S@>SQ[7L&Y$&N-VB-'FN# 9@+Z^8V_,J=$/&&U;NNT5
M%]9\S)$OP. [&&G9RIH;I=!6Z2R'M_/7-[I1;9R(0:XJ:0B$)R^OBVIA*IU]
MV[:^*TNO0*;+4/V--WU?KS=:?/9:?&=X?#R"RM;D!MOYU.&_7,HW:U*^YZ O
MCYWRW6CT']7H=3!DI&NB:17C&1,E ZK]UJ6OW<]1L&3B:K7><[F<._)I;;V8
M-Q%-^T]]:O9E]FI4PA.[^?Y3':)=[73N.5W&D@+?3P*]<VOHY:I3;=TV5N&L
MK<+C86D/==_7F\U'">!5O8-HZU^L](81H]R>/U"%/F+,KW?0\1?AOKA<.-XR
MUQMV#7@*T'X_JM_<EQ/Y*S$\EU^84G5V=0RJ5+S1\Y>9QA?/7DG%KVPW:&[\
MR#C 6"\ZC 2CDX_,N7LG&C<VV.QLL$W0$YVXF7Y8GQ99;8E;!B?V2@6%[4MS
M^W5= *0)M#Q;(!I[3>-:(>/0Z3=<K[&G=2,A*>Z2B/L:P,PWNI_WJS(=,3+1
M:5;X9IB3I <7]2FJ @+]_M!?KNW4E\>V0ZWN[Z#@<C)NJ[(YJK6^JC4WF2WM
M8UULZ^MZ&I' KC8O8G&G27RYV'(+[_6]BU#]X# O7:U[1D$ <U%LP(UW8TPF
M9X_SE$:!M&I19NSX5_F\X^H>]3I28[O,E-MN;&):'B\.YKV3HG-2;R[O5.<1
M'U^>1WRQ+'-S+6>B?D]<MZMO'=L-%P9P;7F,LF5C'"$$?VWSU@\:O?>U2)Z(
M 39[%Y(U#K!I4YSXM,HF*>(N_FK/TE7#/R[O3F8:3EB $W):;W8"EZ3>KSA^
M&#I?;X$ N?I&T.R7BXWPJ90!%4T9T&<84'E\'KW=2GZ_MKV;;+Y,WFRVU]JO
M-]?>)9OM-UO;K;7=S:WV3V_=5]_9NA\5Y/>4:/SEB29EHI[42OWOS;]CAF8T
M3URU.[GH5*:0FTCAW+E2;!.35Q][50*W=[=X)O>;5T+N,Z_SPEKMC7_OKFTG
MN__:V%Y[O_%Q=_/USIVZ85[Z_'JKO;[1WME83^#3SM:[S?6U7?CRY]H[D(Z-
M9.=?&QN[\S^*WS9C?DHQA#9BA&]4Z@MLYWJ#T._S/X +6;GH:U65_-(H* &I
MTRIM[+CO7XX_O')Y_[BCSU_FO:K1ZJ%75[-P;BFW5 V[OGRI)%=0K2A')Q6,
MWCRZO%)=&I>XOW(M0RL4R3LOHQ5\Y[5O-8O)BJ3BIYK]]C6.9]39^S5[S^-U
M4#PH8**]'SM5H&;F.\\5F"J+R^]Q>,56K2H!D>+EF(]]63?I^Z-[;A.Q[JVO
M7(W17) K<_$=[C#:?CDH"[#;TE%W+7B.8#).]X2))\7"M9V=&SKG&\2_<TI&
MF!G-!!0CP$EEM"1Q *]^@+F^.^4/:>.'^_C#_!&J/P_ACZ?Q)5^/4N(UN-N#
MZZ5%?FBJK\W 3Y%KUFT\H=A?\4H(JTXM>:+XP6L]RI.W\4,,=8+Y=O.0AFLJ
M]EZ3@Y(?G:)'GH!*-_SW=;WX0T.<'%J5+SE78_LC/XN'][RI]C44O638RP?;
M,>8P[+NE<5W=ZH?<6,^EHMADCC#X6W-I$!("&Z:H(N[S9K0A$*5XJ:K%U=6=
M_C^74I"76!LUMI@>:'W\,O+36L_%?S8NF6EM\%J792QM_G=T#I9&->CAO6>#
ME[UA-W5%%22)S8($PO3Y2A8KE]71O\_->G'RCFR?[-'6T!UMG.R_54=;1Q^_
M[G?WC_:['U'KTW9W:W?[J+7;SN$[;L'G]J?-\Q;Y<+9WM(??T79G[VN!6V2_
MNT?V.^WU-U_VC[Z@O:\;7_>Z\'UW S[_G;>.VE]:GS9)^V]YWLI5UW;?]+:Z
M?\&]>Z>MW?UNZ\A^W5K_@%I'^X=;NYNL_?;C68O\U=D[:M$6V?SZCFX?[G7/
M.EM'T,;ZQNG^^@:!]YRVC[:[^[L?6;O[D;0_[1_N?3W >[L.^GOY#+QKN$\^
MBM;1'FKM_ODEOF]K=XVTW\;^'9#]W3V\WWUSM+7^]V&;M,Z@KZ%UCL[>[6X,
M6CL(;:U_Y.VUSQ*I+!CD4^2D3!EW.M769ZDS@J$0,JF\7EK-Q++B_(\75SED
MM8X[/$0D0-Z3'Q2-:5H"#4 ]4X"B@<D0I*,>/FEJ%+42?LF\"@@IRRJ (I@T
M #5O /7U&D!E5EN*,I(*[T3*2$ I:!V><NX<DH3*C."E52F7"<GF"*">P V8
M0WMQY[ H!VE<S9ZHSGF'L7@Q2^3'9NE67%YH\)J6=;4V3CAX4Y0[@$&795G7
MO1E<?AMY<@V,30O&VJ]OV%D9#XHQCU,LK$M91FTJ*66I$LX802G-.%]:I9E:
M!D![*([=CB4S-;3NZW__\L(]+<ND$>ZG$^[K-@IADFLM5*HX8N!$*9Q*3@48
M*MYF*,LDM6IIE6&QG,4SJ.=&N)N@5A7.MM4I'O&4#NO!Q >9>H"%<E_/<:%!
M;&H6RFCJMR]FONT'#6)-&[%V;I@CVA@3,H HC)Q.F= A-9:&5#.F&&<9PQH0
MBRPK]0RC/HT<3]T8:>3X<>3XNN4A),ZLQ"SUW*.4!>G!!I$XS93RQ"L?>)8M
MK?)E)?$<R?&4@B/5NPFO;(=Y#<J.,J!/0!"*\GPYUONY,[7BE_>-IF567,PW
MH% #/U.#G_R&&<$H$9FC+)72N90!X*2:4)LBS8/GR"KK&)@1:)G0!]L135!C
M?@5W6G9$([@S$MSK=@,&Z<3"H10+3U.F5)8:S20P$LXHLM)HHY=6L5H&NLV1
MX#8!BRB86_7YH%?RKYJ(Q>.8%M7<KU53WO@WT\:I6])3B&0\PR2E(>,IDU*G
M.M@L939#X.A(B90!G,++H&;FR,%I A5S:F TXCM3\;UN9B"! E N2[DV*&5$
MNU0+:U/IA-;!(&8- ?'ERQ+).1+?>4G>P'B%/.$9]T6L@CXU,V,T1_=)J'^>
M&#:U19,&OF8!7ULWDS80LEEP(J38@JO$M#>IU$ZE 3FKA% B9. E,07FAQ!3
M<I/N*Q\+%/OX=45^:NLKC<C/2.2O6RR6..R= &E71*>,(IGJN$1J;>"&:BF#
MYTNKG/%E)1YLLCR2R'_'G!GO4(:!^&^CQ&/=^01AGJ<QL2XKU\7S9.J3].*N
MJJKB]-7%HB:N,U.C:DR)]Y$.:SVW,:9"$XF>9G[_[EH$V\K.:J\?X*W=#Y^)
M1D)S0E(J:)8RR1D@+A:I]LI0@XWD-JXA9<M(LCGR$9L0SYS:2HTD/YHDGU^5
M9.Q($!@DF5 O4H9D2!5C,K5"$D/A-XY DBE99OP99J/,O[6Q55<,[!TD'1\K
M-E=SDQ8AC460IQ7?>=X@-;5EI#$IWD5*;,?.;(6/?5\Y>@U*30^E-F[8&XHK
MQ)$/*=>6IRQ#/%6 3ZG!0@$P*4DY7EIE9!G+!V\H;')6YE>4I[:DU(CRHXGR
M-8/#4.M"%G!JO#4IXYE.I7,B14:J0#3E$L?L5[K,YBK][)<);[PM"A?/GFN"
M&(]C58SG^RKJA/S,N_2K+XL&<'X(<#9OV Y(,VV!3BF7R*;,@0$AC74I$<A1
M[! 72-7':^!8\7QN7)PF6#&GQL/M$MO8"0\4VVMV0B9<$):JU%##4J8\2XT!
M*<:(>1#9C(+I7Q4YXNA7#DP\A<S5N:S7@@^-KS+[[-5VT;/->O*TL:=UPV1@
MB+!,:9RB8,%DH(:G6BJ6:HL8SA"7DH./@I<9FE8&21-MF$,)GD$":R/!,Y+@
M:]:#E=[1X&PJ2=PK3S,:-[FAU/C,8<8MD<S%O?*$-4&&)TM3_=;RQ31J/#_C
M"I#W'OZS >/I9N(VZ#L]]/UPPWX2G'D&WEM*5(B^&W6I-G'AQDL4!/REM%]:
MY0(O9XQ.R7F;EQS<!U:O;7#M%\.UZ:8;-[@V55R[9E4*)"3C6J5<P%] +9\:
MK$-*C60F&*Z]CS$IC)8%>G#-N$?"M2?<-S4O9Z.\VUS[<_/=YN[FQDZRUEY/
M=G:W7O_[7UOOUC>V=ZIU@>Q5LO'AX^;NWL,/S)@@)P6*N6(8#Z1Z^/$I]W7J
M9]#%7\9K&9^>,G$\[$..4)GBB3<S:V->=E7.2;7)8WU^=ZG)!P?+%MA\NVV(
MS\9$FW;ES/<U%S5;PZ9NLMF;KJB23%@J4V.%B"4H3*I\P*DUSC@>O$7&+*W2
M9:&>82B_0:1GBDC3K@':(-(,$>F:$TEEP"X3.&55&:\@=*J(EREATF)+/2.>
M+JUBLJSD M4=7[@-J4V'YV7+[R*4A$4C-Z <>I?XL^-X9OO/Y;[\$JEV4[28
MXXR_NW2X&Q4U;15U-+'=9G>#M'8//IN8YR(M23-"7<J8MJE" :6!:Q88==[(
MZN";98:G%>:<HR6:1HQG8&8V8OP(8GP^(<9'>Y\)I4@:9E,B,PEBG(E4*2=3
M'D68"?" ,PMB+)8Y;X[AF[>8X_6-OQ-!Y^6+ F_'11F)U>P ?HH=P&,X.V_
M;)8VR<AM#MIP(PE.D64Z91+%TV^T2+WWT@AG M5@DV"YG&4/3BF9OTA>(\NS
MW0+<R/*C&"8C6>89#B(3,2',DY0)CE)IP=UPF10H>,N5D94L"S%/V_GGI9+]
M/)68G3!+'KYC^-<M.CDM"Z5QL6:)9#<W%V<9SG0FLE0)XL'%"BZ5TJ,4.T<5
M(AY3"BX6CR<$3ZO6_8(DNC9R_YC63"/W,Y;[:Q:, W<C\%AMEB$?TPIDJAV3
M*:.>6*&I!>%?6A5RF:!I%4!\AHF@<QA9Z?A^OPFOS%5XI=DS.0M,N[GK66-/
MC"0H=2@"FU&QGJOS*<',8,XEY3Z>VX/4,I4/-F::$,O\RO.,0RR-/,](GJ_9
M*$ IA0!^4ZZP2AGQ&KP4BE/DI Y&R,R2F&B$R;(D\R3/CQUF>0H;9,)>3TK?
MT0/ODD&1# Y]T@>F[R=%2,)P,"Q]4A;GNE,;)S][$/$OL5C]4"ND]V507OA1
MY]LU47:+'2#'5GA?# "O<MUY4Q%E>TP3P+*1O]7V@ZVPV>\/=<_ZUT6_V8LW
M373[>$M)6.DSQW2J3=R+9R2+*=Y@K8#2BN16GD9T8WP9TWDJ$-4DJ<R9M=+(
M_7S+_?7*+EH$2@1/B1(6K!H.7HJ3-N4N,\H@'7C&XO&$?)EFO_+YA$]7&*Y3
M] [2@2^[MRX.-=[6+.O$3=B5C9LU"T#:NUE?%F/!O2"I%!JGS"D-GPA+/<F4
MDXH1EX$A(I;9PU> FJ#)_(KQ5(O%-6(\>S&^7MN#6"^$\ZGV6*;,2IFJ+ NI
M1C1(+$A@V"^M9LO\X>?@+'"L9)Y34II4E+FR1R8PK$&NZ2'7S2WNG/H -H9/
M%8L'MF."4YUYDF9&(H(D\X3K>(076I93\XB:))1G)/$S2$)I)'ZJ$G\]^T0&
MYD(P*=*4@LMA1*H#XJG/@@6@5MA3L%4HH\M*D 61^%\F_>1UT>WF@WBX9;\Z
M.SB*(@S ]^SW#9<?J]YU)YW&,'E[+;:*6"/46OW#E"]6']ZK*=<EF]'(9F,D
MG?7SE[V\ STIA_XZ9DYPPUK/O9[DA08<[P&.!S<7AJQP*,,B)=[XE 5"4L.#
M2S-+G,T<!?J(R('74/$7JV4W(_.@X?79\OKUH(4U6G#-XSEZ(NZF\:FT&4X#
M9E0Y@1#)U"V\OC,H[)?#H@-PVA\7N(Q'V _.FWJ&O\+>XO>E#[XL?;3Z@!.6
MD__^%AR\]^7.H2[]5+R&S?:;FX=_CWI3L>5[76Z5.X.X"/NW[@S]Y=M'3@-J
ML.+[6/%U;=!Z?04K3MS;OYG[UU^=?=(Y,4?'1_ <:WVUM$W^ZNYU]]!^MWVX
MM0[]/MKXVOKZX;R]^U>GU6UWM^*8XT'A%G'N9*J\5RE3G*;*.9:"JE5<,XQ\
M8-]6*W?PT<_%FQH^6E ^\AQGPE*>&JE$+'^&4LF)3&UFN="4$"ZRI56T @AX
M,]!^XX?D6)?)2:3OJ^1.WNM'NO<?![XJ'NNO#0>'10F([)I R)SRXM?VA\](
MT4 E-ZDE+!X-BEFJ"$&I"-IIPR7B^%N8=BM?S0C.&KY:(+X2F<XH<2H%9@*^
M MJG*@222H<#1<8:%]<2,5I&MQP3<!/C:CY+] 7QYPKKMH:#_D#WHFW[W3.,
M&YW[Z/R(VZ>?J126.1, YP1+@?(HU<'YZD1D374@&>(_BG,/YJDJ[_(6AEKW
M?7"AHMW6L--\LI.DWF)J:6JXBN4!*4L-$2;-*":6*$41$W.E-AN(FGN>,AH%
ME F1AL#!+="8IUHCDQ(L,F VX :L'YVG&HA:5':RW A&8WDPKF7*D ?+7B.2
M$DZ%8AG.B,!+J[WB^];7_>TS=\$525$FQ27F)'J0M'1I#Q.*EY/(<_&&=6]]
MU_AR_"-93J"58P^-GOC.>;/I_''2E*Z*=Q4J^JY0-V[5/87Z1J92(,0',!<<
MC_7OP4/2"HF4<XP]MIIY1Y96JQ4)\FJ.LBR;9.DYS3AJA'>&PGMMK9$%C3-,
M0*5:ZD%X)4F-UC;%F<@D#YQ4:8;S)[SSDB+]M$M^<>V]Z,W%>E_=E6:19GK"
MNO$]\[F[W_T ]W8.6V2#;KW]B-I'!S#FC^=[1W\=[:_'<:RQK?7M?/^-/-M:
M^TPC40GH:$?C(@U3/E4^\ZDW2A@?,#+JB1?[&B::>R92TFG'O4YM]+R8PB8%
M+YZGBG-FF-;"<;)0*WT3/-<LQRP((WYM'7S6C'+EO$B%PBAECMA4.O ]A,H0
M)=@%;,*3Q2L;IEI0IC(DTS26?!2<@8K$*I4T[K_Q@"U$*\I)W'6#'FV1;UH!
MD1L,>6?TO.'(N>%(W%[[++UUB%B4&N)MRC#-4FVQ3(V2P _(&B-5K*JNE@GE
M=S-@SSV*?FT8[UDP'@%#CV'LM* Z%=B9E(58:"YD8/)903/B%<!.+!PIY3(7
M-Z%PS'C?#IA'MIQ=Q/R7*)0T P4QBK@UXO=CXG=]QPI2P8L04JZ-2ID$29*:
M^51HE?DLDQE"%N1G6@7D%W1_[O,6SADHT48X?THXKX6]C964JDRFU*-89S"(
M5.M,I08Q0<"8$IG+YDPXFTTN5<1;'^>Q+$C>2_R9C67=BW 91&J6UQ_I!%^8
MI/@NW7FO<[?9&U%E J8:TWYZ\'7S@!IL>-#8JY0PCU.F&4NE)2%%P+V99"HH
M O!%E[EDRQE]<'F09M%]?D5Z:J?Y-B+]N")]_?0\D6EO%$H=<^!D&T13S9!)
M+3C;2!G%I-&52&<@T@\W3.9O*;YZ-^&5<3'7]5#7K!UVAW5U]Z*JC6J+[G'I
M#WVOGY_XI%/T?ZXPZN*Z1+\]B@T2$S'ATRWGD(_I4959?#U)C<T>$,>_ Y)4
M)9UW]5D#8].#L9O'S6!%-3.>I3SS""P3A%.9&9YJB2P5!&C.T=(J7Q;RYNKP
M[TW,XSD(^,];)(V SZ& 7[-3O,3<(<U3J7E(6>:R5&/A4F-T1HWD#/Z+A9$5
MNGG([Y,(>!,WN6ZT.!]RFP]^R6#)DUHJVWZ@H4=N0Y<]F+?^!%'6:YHTV#4]
M[/IPPSBQ06O$&+A7(:B4X9"EB@6=$L]49GQPE-/H8U$JEPE^B('21$SF6*ZG
M;J T<OW(<GU]$T/& 9!=/"O*<9!KD'#)$,BU$8$CX9CR),HU07@9')3YD.MY
MV<$P#T7>^W>6KFMJOC_]:L]D8<&-BBH-G$T/SFX>@A<T!GWD0FH\ SBS#+PK
MYED:A'.9QT@PBY96"4/+4MQ,^9O/0M!-Z?<%7!-J!'_&@G_-CM&,B. Y33,:
MBQS;@-((!*EE)#,JRP"S)=@Q0BR+AR_J-A7@9WQ<397=^J.6S3W+I=?#?4F!
M**X8FHZO"?8@R)N[A;;__E&S?$J3\VSTP P._5GKN48KS%(KW#R*4&F._G_V
M_K6IC6-K'X>_BLKW[WDJJ5([?3XD=[F*&)S-W@$<@W?*>>/J(\@6$O=(LHT_
M_7]US^B !+8Q H29J@2##C,]W;VN=:UC$\LU\ODT$(XC$$,A)1)>*BZ#MMCD
MD)HD7<57;=OORPM8CR3=L\NKQ=(62S>.4[=8>J=8NL2P-5:P5HDA*RTP;)R+
M,B(U*"0!.\*FQ(QZ\DP1W)67U'<^1"PM_/N7L84;3KGF@B?PU%;'O4&Y>Q&9
MA6O["+N_NB^WX$GL6)_SJNS@/->.#8;CS*@K>'G0Z<'(CBM@VV>V&N<$\/%)
M'$607CL)O1SA!,D-<3"J?RL36@*?J3>P ]\K#D=XH9Q9\O0B#U^8FV9 /.>C
MG0U')3ORURJ?)-_[$'_[V OCDRF,+'RK668\_XIU,(+)^.JO;,JDRR639.%G
M'FT!',%2\BER$I+AGC ']BKA7CC* G%2O*6YYVS]I9-J[G ^CLA5T;Y'-L$#
M_FK['^WYZ,DO%S<C[,3II-,Z#W!YRJZ<F)1N;6)JH0 $'E:V+"B(>*SRIV!,
M=F/&TCFILJ+ZGZ\O$2#<4<:#+#GYO)XL!O_[BUT^$&Q9'NY^FZI+M^G^SG^.
MMEYUCOZU\VKKY<[KH]WGAU?*\*:,^?D!:+S]PYWM#OQV>/#G[O;6$?QQ> 3_
M[.WL'QUV#EYT#E["$QWMP@<V_GE^VAT Z XG<(TPZI92'-!/9[&JZWX!H6L6
M UOTY\U_F-=3Q3$;:]&7<T@O*AJ&T[=GH_CK])??0F]TUK?GO_8&Y:+E2[\U
M*K71 QG$EO1S>>SZ[0;?C'D*E"-#7.,H:V[<H-_3\M82W:C?4_0I$>+*M_%3
M<N5[7[HL(4\UD]]UV2^_)^CW7?4K@S6:?=-EO^*,_&K4P:Q\]!+;K][+=V/G
MZ*]M<%RSJ2K&SAY\[F34V0&-$>:%^!?8[$WG9\%8_W9:N]ESESUD5V;S7^]Y
M']FTT>MLK1_G#,97\4,<3.(:SMQ;UYZZS?/XKCW&34G'O=^TEY?5,$P\S);M
M7W4\\(V3]!Z^#_+']"3&X(4EE(1(#<=$NR1H3%1@(F7 /KS=+E$9@@GZMO!,
M@S@OJN%I-N?R$/[NC4^>3T8P'[':^>3[DSR/6Z-1A/_"@ZF1V#]LO(SO_F)[
MV[L?W_R]QP_^V&4'1W\)L*?$WKMRG].]SR]._MG^[[O]S^_G7L;3-^3-NUVV
M=P3C^^,-??/Y+_;/T2Y_<_KZXS_O]OOP^OO]SWN?W_R]?[KL9?SG71Z'_[1_
MN@]CA$]OA_[>NY/>/T>_G^[1U_ ZC.?S_@D\1YIZ&/<.,3[8?BWVM]Y:+6V,
M-B!A#45<8HU<=C**F'V-U!--V9-GN8SS!ZS,;F'K!X6MI+CBD1+!.>:4)2<M
M-YQ;%A/QA- "6W0*6[2%K4V'K<]+L.5))(E@@X)R'G'&7&XJP5&@QE)B$L71
MUJ6;FP1;ZZP^)[1PPDU%H]K[.1P@;T<GG6IX;OOC\TY5BU&G1"; LA\/<SBD
M9I;9PYLFXTD5FX_WXF,K3;\&PDF7DM+Y[!+O.9?)>*:E,%$1;K$QI"5F#PGA
M]I^O$#/GB2$*Z!A)DB&N)$<&5!@RRC'KJ @:IR?/B.QJN5K\U;;E^V$$'9"4
M&VR3$_F72#7,0W!4.6>!W(26RCPT05^F,E@:ZY1WR&J="STC158EC)))WDKK
M'3-@@1'5%1LEZ*UO+ ORGSV?<S>ZG1)G<TVDNV13U^UV&L;S*.O7KX%RUA#M
M&*<X1<.]XD:!^I/<4V4H8U+?#9UI@>S;@>QPU97$K"\%8!*L,,2IB,@:P#7L
M;#0!%HU2#4!VXRJPS?,CM7(\E6/A#=8<L)$YSS&-+EC"*,V',JNH'&[9R@,3
M\A6VXI143 @4;52(V^"0\98CSZ03S.-86O^1KE#K2N_?(,?+Y@=TZ\*NFY..
M1U^6ZD-,CG(+R!6Y+;^S%"EE45(BN6C]*P\*R'HK;$7#HF%-<\UZXHAC@9%C
M 8#,:5A+;Q2U],DS"DAF^ ,I7VWKUN\RQ.0M[!^>J$Z!,T6=<$9$Q;&5T0K9
M,IV'!A#+3"<9;!5)#"EOP9R)SH$YDQ)*B5"EC4I:^]S9HJMS]MB# (A'4]]^
M<!:S)V9P#(\Y&M?5[?'367;5C&Z2[':Q2FK]R6[?:F?>QAC;'D_U*=6C4J5U
M/!R&49ZST![J=<=,.2_!0?HC+T"N.HW5AYZ/HT-8BE;?K4O?':P&').B,),&
M&'#  7&73QBRR2)%(^@Z(J*,X<DSU<67G*#7QAM_&'%>.Z]MQ?E.Q'F9OG(7
M-.9*H"1E1)QQCRQ7$M@L#K!Z/(!4YPPI=G.'?!M57'M9QBB6FJ?,6P/8A?WA
M62X ;Z.(=^ZTJQ<"@&M[O@P[M271PM?:X&LUF.BM3 9T#U+8,<2EU,@IRQ L
MIPU@@FNN73[<O,OE)ITOU 84-YV.M")]5R*]XE!3!%9/2X09MXA'[) V8&\P
ME8C2@LNDZ9-G!*LN%8\\>+B!G.2/.(BYC4VF)#:<]@:]T;@J[65:!\D=LY)F
M*0#!MBXL1 MBZRX\.=I:;7B-'4Y)"$0,!V+"G4/.$X<,PT$H%6F@IL0-\26G
MAK5^DA]&JM=.3%JIODNI7NJUEYR5BEF!O* @U4!&D.'2(BM28A1K*6D"J59=
MQG[ <]8?0D$9;APCXVKBQY,*1M_M]$[/;*_*_+U;>$D=[,L]]F(%(E1*S,ZJ
MX7%E3[^KDNQ16%BWX329+U+V_F:_;\Y:&._.UNOYB:V.XZ@%M?6!VLX*51&:
M8YI,.5M((*X81L9I@TSDU !GX9;'0E4N.V>H]:'\,!)^&SZ45L+O1<*7#Q-C
MC@@6&(H^'\3NK4>&FH2LC\HZJI*@V:72Y6J3JBX>41E\$=6Y4$PS2S[V^OVV
MMOWN'";-E,\7(I_!W$+3^J!I=TX^CG;X_O;[MS@("0S#(V%RDK41"FF7"")2
M&<%,I)SF[N6R*W#K)_F!A7G]?I)O$.;4^Q0#^ARK82O'UY7C\YD<T_WM-V\]
M TDU1"(3+$<\:HDLD O$K6;6)"&\U4^>E>.BZ&\;),B/)M>Y+OD:?B'C^>9I
M(X^WS.-6LENSN=2X=5L6<CLLI#&0(HO*T4@0#Q@PRQ"!='("80W_>(\=0%BN
M29==AF]<YG5-87E _I''*_^WD@[;RO^MLY=&_E4P$D>5D+),@?QSC*P7!A''
M>6(,&ZVR@X23+M,WKN*Z(_E_1.Z3NL<.T/M.JH:G4Y(S'-RH,> /!F8_W2V;
M&<$#PV_+L#:KN-L=^.%I;/TKZT6VO15F(X.46&B,,"PJXC*?#J=%0-%*R[@1
MB6D%R,9RZ^;5@IV?-ZTTM:U=OTL<6 .K:7'@GG!@B>%$KU5DVB*P<C3BSE#D
M8.&0M9AH&D@(R@ .$-D5EQ3N;1P./!JW3>Z-/'?:](JT='YJ7#8_MT7JMUJD
M_A"X;P'UYR=V<)R/J.LDVZLZ'VQ_4HY"7"@*@]^KWH>2*MCI-P?VGK?!Q3MS
MZ"T<DOP"UNB_>8FVPKO):)Q7IXU+K$7OO5[-PZ948\<X4I&$;-E34'G$(!&8
M#9(XF?+!)9L7EV@#C)ONH;N.0+=L]H92O>ROPUY+'[._SN6$)F9R0A-0VJ2L
M-9(9*=.39XQU.54;)-2/* _[XL$>^73S*H[&TUAC!V2U/Y>?VSWHX^$F;]ZQ
MSZ[&M\'[<?4KK-QS6+C=9MV:*,2K>IF.AH>P0 ?IU7196K!;']B]677A,>.Y
MEP!Q1@&%L=XC*X5&Q.OZ] ^.Q9-GL@O_W,!P;S.S-UBXUT9>6N&^;^%>8C)8
M1^V(C(AZ"TR&>XZ<3QX))7T*RF%-1&ZG)>AJ0=F]"'=;YEYRM:>$IO'(S4_R
M6';1=3N#>)../(_".%N[M^4@KP7@W/!BG*$MDET[I/D5OL*C\4H*@HSBN65V
M8,AI'8"T:,E <7&;6XKQ+F;KZIC=.EPV4*;7[G#YFDRW8GL]L5UB(D&DW,A3
MHJ1P/N*94Z2]2\A1$K77A"1FGCQCYI'W ;S/[.W!%X.!-V4:/V82YV;D/;54
MY XP[7@UK]NE8(PVR)&@$4^*(^/S(=")*<N3%I&3)\]HEZG5XK)K6U>;DOO4
M)G1O(GMI$>!N$&"Y]%T%J9*+*.CL/)4:A-\ZB23#CC#F:(P2$$!VZ=J:6VQ<
M[M,-/3#WELSM(DA&S*UY/O1&65[ASRGK&=M/-SOW_0>#MLV@.?-LSNGY1+W!
M!&;R8):1_WM9T_IS1WD-=SZ-*PMKT1O8ZGQW'$]'@)1YN-6PWR]867O:6IA<
M'TR^7XTQ"4DXLPEY*W(!G "[CTBP!76,BBE-,/<Y35Q=VJ]PX])#VS3Q!Q:=
M:O'D@>/)$NUR)@K+C4'6)X$XT0SIP"(@2XR&!Y:$34^>&=RE<C5!9^/@Y*[=
M3/?!N%[.6-9/+@YBZHU_7@_?>AP1^MOF5(!MC;WX>[TZ+41=!Z+>K79H9LDJ
MY0A!B>8PE?$8N<04$MQ3IY6DU -$R56KL,VIV5B)O4\'3RNG:Y+3Y0P9XSR)
M42*,;<SI;PQ9JRA*)AHL/:5!!3!-J/SQ6A=N-&'8C^-.'YCY;9&U2R%GDV:A
M(,[_N[7'WVRDW0QN!'NP+2"^#1A>[1*-32)$FEP[G.TX900RUD>4? 15*ICW
M!8:SAXCHS3?IUN0A:L&N!;N[<H:U8'=[8+?$.:W6BC$>D%'2(,ZY1%HRC%2*
MF"O.8/5B<5^Q2Z*&&X=U#1N=CF/&X@J2W6\Y/X-'"L.)Z\>-[3CP34-\#(3_
M=SOJ^?JLV5Y_DLOU!HT)T#F+L+M.;!5OD@3X@^K 'T7/O8S585[B]9)[>J6Z
MV['5 .9M-+WO=KWI9KH-M[KM&W3;:D<P%; 0V/K<"0AT6Y(.6<D\,H$:1R)V
M/M$O>]+N>R<4(&KWP0WW02 $[+;HD,J%]-P'C!R3%@7BM0>:XX4#CH.?JE6&
M<W/*\X!,N%9%;=*S?8^*NJ%)U@+3+0/3<LIFQ-%I%I!U/"(.>(0T%@HI)Y52
M%.-HR7<IJ#O;!RU56<].\-H8*E5 C+!<DH0=,KDMLW-*:BQCB+EI(7[*5VNC
M-T-%/8;$D;_+'V -6AB5/8ZU(3CJ#"?CT1BLQ5RJ-!G!^[T!S,'IV:04+[GO
M,":_HW*AGID5&_X;S/L?(>I=K\1MUUI/-\!6O?[[DU,7JX/4@& !Q-'!?#.T
MGLOU0>9?*ZR>&LJ<LS37.Q#$E=+(:,(1B8R+I$V2-&[JCEG9*@V?:O?+[>V7
M(*165FM$<#[Y(!&P HE)2!(IO9.112V>/"-:=_4EAT.NMV+F9F#]@#*K6N5T
M%=2L/2NK54[W"3;+EIVF.F@:$/&2(>YH0DX[@J2'WTG2T4J\J3NF54YWOU^2
M="2DXJ468/\%GY )I:<,U9:*&$+063F)KN:K.2<_@G(J!N0O8PL7O1_KKG.Q
MH<1"-ZZ%!_$Q%]4T"N;9_[KJEV?7_MJ==]0XB1WKLT%J!^?9(AT,QW!U$'*P
M2DO#TN/*]CMGMBK',8]/XB@"%-E)Z&5K%3 HY"S?\EN)UY<&IJDWL /?@R\"
M3(QC[@0\>GKE7#0#XO2IRJU<SX:C7MZHOY9VJ+T/\;>/O3 ^F2K2A2\VFQ'/
MOV(=# )4VI5?V91Y5TL=2A9^YM$6G!0L)9\B!^$WW!/F4A0D!R0H"\1)\9;J
M)],OG<SR&LX K9&KHGV/;(('_-7V/]KST9-?+LS#:6^ EN9]><JNG)B4;FUB
M:EP Q3&L"]M^!2"*5?X4C,ENS%@Z)U76NO_S]252(&(9MK+PY,*]+ G_^XM]
M=MGRWQZJ;!P8J<MSJ7?^<[3UJG/TKYU76R]W7A_M/C_<^#$_/P#JL'^XL]V!
MWPX/_MS=WCJ"/PZ/X)^]G?VCP\[!"WAK[^6KG7_!YW;_N]/Y\^!P\Y_KI]T!
MH/UP M<(HY\W?[BOISII-M9"%^:JHA 4&$[?GHWBK]-??@N]T5G?GO_:&Y2+
MEB_]=FJK8P#(1K]D<%RB)^6QZ[<;W#3D*5,F0V?CZ&YNW*#JTX*J2V2K?D_A
MIX3**]^&=Z]\[TN7)?2I-NR[+OOE]X2^I<&*;[KL5X()7W5,F)6/7N) J/?R
MW7@0]-<V.*Z)6A5C9P\^=S+J[( F"IT]6_F3#B/="US^IO.SX/SY]H3,S9Z[
M[(Z],HIRO>=]9--&K[.U'GIZ)V[KN=H2A[:>Z[M\:P?/&]_:Z<ZG_2-X;7OK
MTS[=?W^P_1?;IZ].]C[_]_2?OW?8WKN_\#_;O_?^>3?WDQV\VR-O/O_[=/_O
M_=.]O]]\VG_W%_GG73@Y^&/WT\'V%MW_8T^\>;?UZ<WIWJ=EWQI<]]U>]LW1
M-Y_^>;<#]_WOZ3[=X6_>[?"][3<PSGYO;_M%[\WG%VFO5_O5]@XQ/MA^+?:W
MWF).<0@J(&I=R!4.%#FE*,*"!T:H\)*KMIRKQ;K'CG5M.=?#P[K/2U@7K7,\
M2(:<2X!U.N1D=Z$0[&HM0&\%XMV#J^;Z47/*BH265N\E6ZR*)W$PRH>63MM=
M9XZZ</#M/16(W=HUUGITK=GP=<XVQV1011C*9[#KCVUOT"QP/B'.?K"]?G9+
M(0!'E ^%@TWP(=8'+-ZH^>>/E$=Q5Z>I/%^4QKGFVIHNTHMAE4^..HQ^4I53
M_>:'8<(R'Z0C^ZG5<NO2<OO/5QB])<Z*% V*0$\0)Y;F!'J'."4*R#['01%@
M]%VL-^E(S/;8E8?#6%L8V$ 86":[6!H#FP@6%V@OXHZG?-I!@NFU43MI83>D
M?.0!-FOHX[M!?/;A$)[<L!8&T@$!J>+ GW?&%5RQ7T+MBQ3HD77;W%2"\Z)>
MKN?-:AWEQ:J'N#4(1_.ENPSG6BC[=B@[7&$TD:ADL'#(:9\0QQX83<AG8TH*
M9KM*UM#BHURM_KJ_SG]MG\X?@\^T4G]74K],8("A^)CK?:U1N=]GP,C ,B.9
MB&82.T!X!P1&KQX>^2C.P]U(=UQ[$,O&TYC6^%H[=JU&53G'3' =$2$BERE$
M@9S+!2XQ,"JDP('2[(.A-^]6_+ "JX\8$#:?Z[30< O0L$)KN),A<H,\3AAQ
MPPS2,ELTSD4?A5=&-T=1KI;9MC'(>RA4N2 LU\N,NV[EV*/*)5GOY/PXV'][
M6767P'X+^6N'_/-5-BAMHMQAI 0L&H<%1DYRCIS@7">LB,<Y(L=$5QFZMO.'
M;RA1]^SX:C&UQ=2'P*=;3+T;3%T);_+$HV$<B2 DXBYBI".S@*DD>6,CYB[G
M\M&NDC=)6]X(2+U0_+]2@-B4ZN6[%\G9E +OMK#^?N9=KZ.PGI&VL/YQ%=:W
MI>YK*G4_/#IX_I]_'?RYO?/J\/__/YH2]5MGYZ_7NT=O-O[YOK'D_6)QN+P7
MG;.A1?" <4]QC7/7K8*GYBGC5[_]O87EYJDAYA:*X+G6[5C;L3[VL=*U]&RX
MD_*2!U%R#_;TZ7!0NO74G?8VI<#G0<S>2UN5J?NO[4^N;IO=SMPE^\Z>]<9@
M5?;JO;?SR<?1"*AU^0NFM=-.Z76G=,O[R>FDG\WV,HLE]%Q^NQA2^_.2D%H[
ML=>8V.V8>KXW;N?P.MV$AB#MM9H9#_W[DV$?#(-18Z_5$/!_D][X_-&U?_G=
M]NW QXX==[:CC[GI;>ZPU*&8DC:][SO;61/F)-7*)IH<%SJ:8%W(:>T2<QN=
M>+N;IY?0KR7VU>RH[-B'V;+Z\]ZL!7%X]^;TW^_VMST^V/;\S;N_/NW_L</W
M/V^)-_2->//9B_V__POW/OXX;T&\\PG^_OSF7>CMO_OWZ?[VJ_[>Z8[8^_NO
MC_#97FY9O'>Z]W'_\S^]Y7##FZ.=3P?;^[U]NDOW3M_@_3]>G[\Y>O_IG^TM
M\L_?_WZ___?>^9O/6VS_]-]I;[4$03#-F. 6YE,IQ+F@R!J&D8^$1&&U)]36
M'8CY)?&&'SJE[U8%?^/@\;'V2KE&L'5=8+>HF&MEW*+8]5!L.6BJJ&*!8X&B
M-Q3QI ER@4ND+  :IM(F[ '%;EQ'U0)8"V /&,"8,B)H[+DQEJN4'&5*XT2)
MI,J$<", :SG:VM"-+*&;9T[9TM1)Q(QNUB&M$D,L:&\2YZ"2V)-GK"N([$J^
M6O7>@EP+<@\<Y*Z3$Q>T$#I0; W'W%%GI)1!166]B9A'=C7*79$*U\+=K<(=
M6X([PF,(!GM$C&4HYXD@:U5$3&OBN7,LY=,Q>)>(U3X_&U=(TJ)<BW*W@G+1
M&H^!R$D,_XC M+&!<D5X2B HCK8HMUDH)Y90+G')'984$1T5XDHRI$,$E+-.
MFT C!_3+Y7*:T:XQ#Z!DKD6Z%NENPVA-3#@-3$[(2#G#@&U>,\M82L90$TAK
MM&X$OGU:/GB74"^M(@:Y0'-38JG!?C4182UYR U/7#X+4RK3%?BA1!9^\++@
M(IIU_*W3&XTF,71* G<G%GDI#5+B8%0W<COKPTW:%FY?"([BY QWFGDL%$\<
M&\,#%3H%F125UE_[Y-8"8;ME8;8G%<S=2WB,87/(;_GYNQW%\'QAF5H8NPZ,
MK38\ >SRE#J*O*,6:!JLE:41(Y,B]<DJT$7FR3.-;]SNI&W1=L>R7%)BZ&_M
M,FWV,EV#*7)LJ0M>)HH=UPQ;P0S!4BC""*71K@MO2\9D"[?K@-N54(=CSN::
M5RQS;SSB!;)!,&1%E%S90!/)_:7TC0EC*\<MW+;+U"[3 UVFNVT1T6K%.S9"
MEGTIGK"@:*0(3$B/.+<&V10$8HYZXJ1VWI%-4XN/(:>\B )RMN[F,-_PC^SH
MGN]3&NTA*^TRM<NT61;OO-O[Z&BX!5.71V#[+VTO[ Z:4L*BX]VRCG^5?<2C
MWC@>QNI#S\>:%+R*?G@\*%<I_* -N:R-)IRO&,\6)YYPDD@Y"L:S\199QP3"
MG%DNB9"6Y\;RN&ODNI($6U1HP;M=IG:9'MHRW:?]W.K8!Z1C5TQQJQ10+441
MK#Z8XMY&Y#@'>UPJ$H/Q1#NZ@4KV,60N/%_S^2T/USW8>G';96J7J5VF1[5,
MUZH1DBY(X[%7V'#A,I&306!XD81$O7Z\?;,?!#';?[Y2-42],)%[A01UP,N(
M(TA'+9%@@20N-*SK&HZ?:85ZDX4Z\9",5@X[SVEVA4J,)7!U%IEGPK5"O>E"
MO5PD0ZAW1&4[2WJ">#[F6SL+,NY<2L%*ZF-Z\LS@+C.LE>H?4ZK;(RX>NE2O
M^% T4U9IIY"F(-$<-#:R5/,<MTC*)BR2DNL[XZ)-9KAV@[P]6_F3:7<\NH;N
M>%\_8(0\LLYY.(#M 8S%\: Y-\90H6@,268*XYPL96W?X$UN.^?="8JM=LXC
M5!*CM46"Y/HV[(";,"M0I,1&8W#B4>><+-FE:O4H[QO5M]U(FAY&?>_Z 6/C
M\/9[:W]O-C4/%$-7>>&Z +3MQG=39%SNQL=2($KXA!+A#G&K,7*41F0\!T.<
M$\XY67\WOA846U!\]* H(K6:NZB(LUPPYSCV*2C/G&#<FG@34&RYY-H0<SES
M3PJ&A4L.$1P,XE( 6+)D$--28,I8XAR7#G],=97!+7"VP-D"YWK=C)A;QSUW
MTE/-;6!62A(\T\%C$D4R5R-GVT_K/B!T)?ZG?<2<>A09X"C',B!CI$*>!"F4
M%LXF^^29! B]R4GD+7*VR-DBYT7DU$P2'[0E(2K.K3 \>>R#$Y)$B3%KD7.S
MD',YR&JE"CAZC$P@!'$F&;(ZTU#%I:0YJ]7JG#EA*.NR2TI,6_1LT;-%S^\T
MV*WQG(5D(]6,8Z6M-@S^$UHR@RD6K<&^$9BY$L)FT0?NM$?.ZIQN9AUR06!$
M@L&8ZT0LIT WL>IJ_2,X.DL _)=R?/2S[STXNSVQ^D&= -R.M1WK0QIK>V)U
M>V+UYLQ>>V)U>V+UQDQI>V+U'4UL>V)U>V+U79Q8O8Z<W,=Y8K41UAO*L(I4
M<!."B;D*4'(6G.8!V]KATIY8_177R[L7[_?H:_'/]A;?^P/&]_FO\[T_=L3>
M4>CMG^[ [[MD'SX/_[)EU\O>WW]]_N>H_WYO^_CC/T=_?=[?WOV872_9%?/F
M"'Y_]YH<;&_!O^&R$ZNSPTQR31%QN46PCQ(9(@GR6F 1&:-:EKQ;W15RS9D2
M[=DYFR3W[=DY7_4NKPOL?M0<V;M#L>4<6>R]=EIQA+7"B >'D951 YY1F7AT
M5+G0GEC= M@C!S"=SS>F@6+A/!<VN4A"3%10Y3E/,=X$P%J.MC9T6\YGQ<9B
M3UA$RIA\A&LTR"D/Z!:DPMPH:8DM^:R*=U4+<BW(_7@@=ZW<4T]M\!1+XUTV
M;HP71I%$*7-$>RFN1KDV@^H^X&XE]Y1AS"4AB"K*$<>$(DM%0*"G8HI*.N)9
MSCTUN#VQND6Y1XMRSC#AC35)1I[M4:63YBQJ[4!"^!>X7(MR]X%RRWFB$7@<
MEM$C0B)%W&B-+ \!*:P"38E8@6,F=123+KE1/YX6Z5JDVS2DNP;0L<1U2CJP
M"+]9!K#G-;RBHDD8&\];HW4C\&TEI],X'[QT#&F;:#ZQ&B--"4?1^R1A.;'2
M @!.RJYD[8G5FR.:[8G5ZPJ."BZY("1(:327L-^9C)A[QI2,%EM:>JVQ::\U
MUIY8?>\PMGIB=6ZO0:,-2(/VR0WJ139&+>),8^P<)<Y[,$8O:8/:-CC>;%EN
M^U _B&6Z!E,D21D=!(O4 O &8SE5S$D6- :V@<6Z\/:+9W,N4LK4^Q0#^ARK
M80O#UX/AY1"(,$1QYC'*2XJX2@$9G @*.$@;&-&6J9E(MU#\P&2\A>)VF=IE
MN@>-Z4-,CG)+/8W<EM]9BI2R*"D!'=IJS >C,5?\+Y(K$Y)22!*3$#>8(R>$
M !O&TQ2-EX3I3529CR$7O3WINCW>L5VF=IE^&$NY/87SP5"%U9.NJ70^=^5#
MWAH.%C;#R,5(D?-*,YPL8?D03H*[>&W)A2TJM.#=+E.[3 ]MF>[3MFYU[ /2
ML2OF.)4T&N<U,HXK,,*U0"YXCB(/C"4F%&R$#52RCR'CH3WINO7PMLO4+E.[
M3(]RF:Z3BZI"Q"XEZ3CAA#C+!+94"*&EIUY?/Z/K<1^:>4=T[)+SK6/2RA 6
MD,3Y/%RE"#+2..2EU1A3CD.TP,:ZE,H-"HVT\KSN*AHAI)8RAJ"=X$H&K7!B
M 0NI',\GH'V#0+?'X=ZK9*_4U5 7!6$8^9@(RF>0()V/E,0IB93+I8F((-E,
M@:&U(<?AMF*];K%>@^^E%>M[%>O5= :+K4[8(LEL0AQS@9Q*'$67G"*8!9-D
MEFO15>8F9]*TF0QK.>::M<=<WT)%2<#:):8<!7[*J57&,L6%B-@*#B+@2BW<
MMYD=;;N]VX>QU79[*I^MJWQ -EF*> P8.<<YTHJGI 27S*O<;L]T*;MQ2<D&
M''1PMT7![0$Q[0$Q7R:&ZP+0MH7?39%QN84?UY01[SGRBEK$"0&,M!XC@6D*
M1(3$V2VT\&M!L07%1P^*/!(:F2+6*<.- (3,I<KPMR#!6',C4&RYY-H0<SEM
MSV )2R0-PCY%X)(^(D,%0\ESDKQ*6 M>V@)JWE7K;K'0 F<+G#\F<%['SV@,
M)DG'Y)35/ 6F&5AW26,5&%6*Z*N1LVW"=1\0NAP&3":*8$)").:R8N=2/JP5
M(TLMSZ9!C$8\>2:Z4I/VH-86.5OD7!MR!BDBHRZ?<*TX$%#MJ+&<"R:QDMSZ
M%CDW"SF7PZS$8&JU5$A[#N23&(L< 1J:9.).)>>-89E\,J:[E+3HV:)GBYYK
M,]B=CT(;1IP*E,-/"S8[QE(2QPTS-+0&^T9@YB4E^9I09C3@I72("VN1,9:@
MQ#"W8#A$K.B39Y3CKI8_0O3GFXZY+O?&5QQR?<>"2,L)>B>Q8WTNR[>#<YB"
MSF XAJO;"EX>='HPLN/*]CMGMAIWAJDS/HFC"-)J)Z$W+O7\@Q '=67_H$QH
M/L^PDWH#._ ]^.)H#"^4,IZGL\6<SDW]Q,_*.7TK;TXGHADMIT]5/KO[;#@J
M13R_5K%OQ[T/<7YD=X:5A2\VFP#/OV(=C' ROOHKF[(HYN)L+/[,HRUP)%A*
M/D5.0C+<$^92%(1[X2@+Q$GQEO$GTR^=5-,G.+/'$;DJVO?()GC 7VW_HST?
M/?GEXF:%G3J=]SSIR_-UY:RD=&NS4DL,@/.P*F5>OY9FG?E3,":[,6/IG%19
M:_W/U]='@?"54^U!K)YGA0<R\K^_V&>7K?V][M&5HS?+'MW?^<_1UJO.T;]V
M7FV]W'E]M/O\\$H9WI0Q/S_8W][9/]S9[L!OAP=_[FYO'<$?AT?PS][._M%A
MY^!%Y_G6X;\Z+_X\^'OSG^>GW0$@\G "UP@+Y5L;.]S74[TQ&^M]H&MG>O.B
MJ^?JHI #&$3?GHWBK]-??@N]T5G?GO_:&Y1+E2_]UJCS1L=DC%SB!F7.Z[?G
M\/D4UQ#:I,DU=_[Z"?6*/96W</ ](4^)8-]UV2^_)S"_G<&*;[KL5U(1OYI2
M;'ZT4Y)!)\7.'GSN9-39 555'S@]2V&\SNG(USEB^MO[DV_V_'TQP_-ZS_O(
MIHU>9VL]L!3ARQ_ZN1V==%)_^''42=7PM#,\BYDC@F&5#=L/8(C$T:_?=<;[
M-;K^?]?Y[]_:Z^(VQO@8"N_WX[B3R^QODIS_HSD\+WO$S79<;D9ASLMJF'KC
M/V$W/0P?YO[SJ0_S-=L[?7/^YO,N_N?H^..;SW^1O6W/#[;_^VY_^STY^./5
MZ?[I&_S/'WN?YC[,O\[W__[WZ=[?.WS_7>C_\^[5^[VC<'+P]R[9>_?O]WNG
M>W3_CYW/^T>_]Y=]F/O;N^3-Z9M/;XZ.Z3[][^G^'W]]VJ<[XLV[U^=[IW_!
M.-[@-T=[9.^/_Y8^)DMQ'XVE-($$)'WNQIU/CG=88B0(%3KPX+CQ/V9Y70M*
M/RHH)6\QUCQ1G0)GBCKAC(B*8RNC%1(74*)34*(M*-TW*"WGCAO. K;*(T4<
M13P$AIPR#NE@I::.,Y(]OP9WV8T.TFM+ Z\E@@O]RCKC8:>*('2^UX^=04/[
M\JOY=Y\-A$F.F/0&Z[<.-L4"N$V67ZL;^I2*#=\3^\,!*LM=#<]M?WP.N^)#
M'$QBI\2N8 ? EAB?Q,X(X'"4PP!I,IY4L?DX;(5'UI#KCKEUK;T&[\?5K[!2
MV7!_5:_3JWJ97M6K=#0\A/4Y2"_*XKR:KDVKX]:EXRZI'$U.6&IP0DZSA&!]
M%;*:J]RQQOJD#>'2 /&672UODFVU>;R[E?!U$M56PC=&PI=9K 4!#QBL:AHM
M0SPID'5 <)1P! 1GS$D"+):HKM@4"5\3BWUX["4G 55Q-.[$3[G);NR W/9[
MUO7ZA:_>+IMINR=_+YG9;99MIUZU):QK46[]*+=ZH*J4U#@K+3)$.<1YC$CC
MI!$+^91O$J/R@'*RR_&Z,B W* .\E>];I3*M?-^]?"^SF,2-"8)BY)@PP&*"
M1\:+@ @U+ A%!)'NR3,@,?0';'/^8)C,\Q,[.,Z]SCO)]JK.A]S_/Q.4 %9
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MXY-1Z0.\6-H%\_^A2,=-O#=N6(58H?'P[%?\%)A89S3L]T(G/]E#1+/-\.S
MJCV'17M9#3_T0@R_G[\>Y2ZC<T?T;.E:8%L?L*WVXV-&:Q]81(00, BEE<@R
M&E!,/JG$G4P</WDF2-<0<7,?S[>*T@/R_SQB=+B],%6+#O>$#N?+5@T+4IB(
MJ**EXTY"6CJ*DB$X!LRXIO;),ZV[G*[&JC8.'7ZL$G=U>8E[9D*I/_PXZJ1J
M> I\Z$,<+9&A&]6V?\LBW7?=^[7'^-B"FR\GE3_)F>.Y/5.]17+WLK;ATATZ
M[E[:\S+G1\,M_W^37A6W/MA>/X= 7@RK0U!;A]%/JB*PV]&U1V>L4='MK29>
M*2VHBP()G(U\PQG2EEBD"(G6<NZ]3?D(4=7%-SH\HXUU;K"(K]UYUXKX?8KX
M2HMJ%9)( CFC<FYEI,CI@!'1-C(3G>.2/'EF6)>;F]2DMAG@WRVK>W;<2,,Z
M:,FCB#>LGY540]C 8?0"C(?Y>KRLXEF#95N#\-SV^Z.#=#68M4"V/B!;[>/C
MN99>6H*8DP1QD@RR@@N4O,$L! 4[@>98A.YBOHID;;#QAQ'^]?.55O@W3OB7
M Y&*&LZ=02%)@;B($EDC-9 :[0P%*R:*W,2+JJY1#RA]_ =(X?J17$+M@66;
MZB1ZV:S,R[PN ,<[TU5ID?5:R+K:*H!;D3"C'!%8-,05DTA'JA"V!DMC/$DT
M/7G&;]2PJ'7_;+#PWK[[YPO"VW*F-4KV$F>26G&&M4!,Y![[7#*D)=7(!*M\
MP,8(34"RN["DFR';/U:@\BMI6V=-D+_CSB^-5M[$^?.#)6?<)Q.Y(B5C=[IB
M;4K&;8#9:HN ))(RQDKDO3*(.^60B\8@%E2@'E@*)@+ #'?%S4MXKBE%#\@Q
M]'B!8>TLIP6&>P*&Y=*^2#RQ3.1NJYGE&(F<3  ,AC$IF-7:QWRR,NY2]5"0
MX<?*7_^VC*W4&]B!7T?&UC72ZKXKV^I;3<O;&.-CBXU.7?/U'AF=V"J?8S,:
MY:I+>,I8%?_<^!PFXS378-:'[V7O71L]O9_HZ2XL#@AR/$B'9;5>YU7:A1<&
M(-41K/_R\N\6M.7SA37+OH'V"-'U*,GW*^Q9)H+![/>(6QT13PX#>U81EI?%
M7,$9O%*;>(1H&SO==!J\/M%O1?QZ(K[$@VD*5C.0:<,YD&%#'#+2&V0\\2(E
M$JD' YGH=7'@#>*Y#X;-%,Y;SF,[&S>4)L0/L3\LWG#XO>I]L%E69D?R?=_!
M*0\W<+$I+&9[MA2[@]&XFN3U>3&U4*XR[5O"\GUH]GFUKP2U,00J%7*>YA9<
M#-#,*X^8PY9H%<#F3VLC+&UX<G.E_%8)RS=+>2O-UY/F)6X2.%61F(2DSH>K
M &(C2[A"L+("+!.I9)!/GBEQXQXQ;3#RYL'(RQQQ;3!R(QC*%3&'EIC<%I2M
M-HZ(0K% 0T*Y-@[QZ @R6 KD"7=">J<8%>OVI+2!R!\(%.XJ$-GRF#4(_[*/
M!5NAL#$(FQ 1)[E%, 9:8QGV2D@M33"YEJZ-,VZ.:.ZD%/TX9W>#1H0W!IWX
MR9_8P7'L5':<\[X'-0?*R=[EEQQ1^@!R<L/& (\7XM;.>^HU/$@[S<J]@H4[
M&&34R__OS-?K500SKN?',>0WM@;AX@L+GVRQ\%I8N+O:))TXRYESB'B<*W*\
M0%I$@H*S), Z<V/"DV=\M7O6]YETF\*!VA9:&Y)S?D4+K18J-@ JEF@3D"9C
MF<]=@:5!W"B.K%0,:<Q]8-B:Z/B39V2U@VC;2NN>G$*]IOUNYZ?0-.#].;<8
M72]/^C%-P<WH,WHCP'L)3SX,JRV8?7^25V,16FNX;3-<UP>?JTV:J+9,Y&P=
MAC/32D(C8[%!6@MJL&%<NWR8+^E2=9,>3:VSZ8$@S'TZFUI<><"XLMSE-.7*
M&6619=PCSGE$AFB/C&;2:B6#M10L.-I5ZL967.O06F\2T64DK&/''1>/>X-!
M#M[E=@9%WEH?UO<@)TM<IZ0#B_";9<XPK^$5%4W"V'C^=C<#)J&W"I@M_JT/
M_U8;2D5BHN12H,0SK_*&(V>E1RP&&["A3!-3NCQ3NJX#TC>%7+5>K'60*R:<
MYI@+&6DNM-?.:V892\D8:@(I$$%:B'A($'&^'.WW+.:J8^*(05Q8L+JBHBA:
M6&2JE7+</GE&19>2=1T<N'$4::-=6%^H+;R*(D5X_4IR](T$MGZZ7QFL01A.
M7#_6ZW,C+-PXHOG_[FER?A@%X7P4VC#B5* <?EJA'<92$L<-,S04!?$-X<]6
M06R(@GB]>HZ0ITP*DE TW").;4#6B(!R6V5CN- J@0VM9->(-=O0-Y2R>W;?
MM3C;XNS:<-:"/<Y"LI%JQK'2%D 7_A-:,H,I%K6MWN+L0\+9Y2[V-#HNG$#*
M>8; VJ)(4X)1]%Z8&".A^40FJ;KFDB[V#Q%G?[3&L>V US/@7\:Y^S3\&WH?
MGOTO_)A^X]16Q[U!V9 %81>V6R[ CM7=XSC-.'YT$CO6Y_8<=G">'=.#8<ZZ
MM!6\/.CT8&3'E>UWSFQ5DC3')W$4 >SM)/0 9#/0AWRV>OFMR)C-+S=%*O#%
MT1A>*/TFG\XD?'ENF@'Q7!]\-ASU,BK\6L5^*?WZ[6,OC$^F6F?A6XWDX_E7
MK(,13,97?V53)IW@BW.Q^#,/M^@@P5+R*7(2DN&>,)>B(-P+1UD@3HJW3#V9
M?NFDFC["F3V.R%71OD<VP1/^:OL?[?GHR2\7=R-LQ<597YZP*Z<EI5N;EEHD
M0",/J])WX-?20"9_"L9D-V8LG9,JLYK_^?KZP/(<933(<O,\$Z*2B6.?7;;V
M][I)5[PT99/N[_SG:.M5Y^A?.Z^V7NZ\/MI]?GBE!&_,F ^.=@X[1P>=YP?[
MVSO[ASO;^;?#@S]WM[>.X(\7N_M;^\]WM_[L'![!"WL[^T>;_U![MO(G-4EB
MI-O)3HF-'_-/KZ<JXN?5L7X;O.43?K^H1TTQ6>]EFX&.[)!.4T;6:6RA_<DI
M7,ZO(8?LHMUS4!W;0>]S :+G,RT+?X"]\[("?3P8ES\/THNIVCV<:=WMWLCW
MAZ-)51J\P+[H)2"U@_$6Z/S)('="? G7\[TX.H(Q_]X?^O?W:P/AO:D-=+KW
M\6#[U<G>'V\^[F_OG^P?_07VSRX_^'OG\][V\<=_COS'_7?_?O?/W[N?P9[I
MQW^].O_G[W &,RS??-[B8.M\_.?=%MZC.P3L%+[W[EB #0/7_+V__WF+[IW"
MV-[MI[VC70)_OP4;!7,3P(;!FB!.I4362XL2=5%;PH61N+9L>X-)#%O9E 3=
M88@7!+8%YSA:"_O%";!WA236*?6D$\&R/,N"64U CRTN9?& 'TY.84>?9Q6Q
ML#B=^>ITILLS-9N:7;:D1>"]9F3UM<L*?GUT%Y^&&A*PD((YPKDDSC@6DZ1.
M:"?A;SRS^M>]TP?OQ]6%;5X>^OQQ[\C=MT1%%J/V2!,7$-<Z(2<P1K K$\PO
M6-R2KJRA%LK9I+07@7NL'4U2:B45B0H,\;B\(^\#6\L5?^V-04_Y;T#;Q8UQ
MI>*[./::O_6R;3+^E9'L ;@GJO]WK&VI3@;JK,B1RPVV.JXW/#NQU:GU<5+<
M#)W&!NN<1!O^;P+V5JS@<[U!YQ!&_:+*P#[RPV[G.4Q;&E:#GBT(TAL 23W+
M/+7^]#;831_AED\[<.N?8 IZ'WIA8OM] )FJ\[$W/H'!9'-N$*N?R]B:'D>E
MI4#GK'<6\U-D1 K5Y+@#>!2*53<"X\^..S#:/CQ_9SBI.C9\R W%0N=LV#\'
M2,A[\=WD&#[<&4=_,H Y/C[/[1['V?DVZG8^GO3\27/3G!H-7QT/.W%0:#+8
MEA?Z+<$(!K (I\-^]).^K3JY45DYAZ\,9 PK'L>=]X/AQT'G-.;DQ-[HM!P4
M4SN6GG8.8(S3>2^3M7CYQ2?-]VFZO!^7?0;KD9]^E*>W/PFYJ^72VV.PL>IS
M /.LY[&G7NR7V&7O]'0"9O1)K.S9^9+9NXSBEV]AN4E;^'+E\E6@>?;%V9\W
MK^B<V \1/EC.H@@E8WZJ!H>#XV'>EO-#%_-VR9NQ7"_OH_CI+&9W;WYCBH3Y
M]^9Z%RXWO\S3SM:HELE)?PS;<GJ=Y:O ZL-#C"9N-(8+9'\&<*E\&E&^_2 >
MU]W _%*OW'R<1IFI^=:8C">-2):GK?TC,.HL10L?/ZMZL M@">%;U7!R?%)?
M^S@.8BW@Y?H FW$P@HGI9M]4W[K&2BVC@N6>))C=254$^KB*-1$L;\Z;AXP!
M4$:UG&3/S-(2/\OS SOY$M.CS-:)A=D_.ZN&GV"\XPCC_7^W'W@5%^A"]N]?
M]/8O>?R![RX?![<[/[SSV^(!\M$QCRVR__%MIKM.<(V4#P9Q8H""<$$1$]*!
MC/M$5<S%H_+I:EI-!Q"H7U!BH2!IX=34_#KL\?>Q>$H[H]D)?4]7&.TMVE3/
MAR/8(:/1$*PEV#Y_@UK<^=0;'U1@+YT-1[8_;\MP4)5M-FE$:E1STT>W,3(E
M/7X;K4HN4()<S %U*R-04JE@C^3CR#4UVNL'2#%?%450(.\YO%OXV%&5\?YE
M-3RN[&D-GQG*+VR&SLL+K:P?"BG='=3(7AYJ"Y1./T,[+=!N!P,P/;-N*BQK
M6)3X<0\>>LY\8&+*7+EX>@9*L _\J!\G[WNUT ]/':B9H@0*W3PX@RD93B=I
MK<\KGW+U+>[<U:A"7A/$GG)]MAKI X)>NYU!\RG^6^=6AOZ-2Y71$J RAU$
M!D]A^ .X:!?6)"^%CWWX 4O9RZ^6Y01[N9#]&3<'UK]PA4F5B6D_;VV?WZ^:
M/NUYG0_S&L-:^\[S"[1B:THBZO7\O8+=,.RCO?-8C3J'H'&=ZSQOK)>??M\[
M_+D#%D,.),&-@:'#_7I50VW.<W[?&9"Z\>AII[0:S@T^ZJA2S<; 2H!GOG)3
MYG%F+3TJ?"FSP6P5-8P-'GS9@OBV+>I/HG]?A@5OG_1<;SRLRD":VJ=FA/7.
M[UXI%/G:-KR;?,AL<[I6"Q,,<W/5U';+XN4/O<SG77;H+PRVVB2<?_M#_">>
M S(%>TN2)FXD:.+K<G:?8I8G= 16]^EP,II*59&..N99C/*&]/OW"ROZ?(BV
M%S;<DJ0<OOAW7LX%*Q]V_6&,G>) %IF"=G(R0K.'>H.:D^85A>UEJ[+UOK)Q
MRJB^8Q@O)U5N!UY,GOR$7Q7^1A!#&<Q,Y/+H8H)QCXLT?NQE.R];Y/F:J_OV
MK%:G3SL/46<N@U)_-%Q INQ#&,TFL8K#95^O!\Z906Z!/I23,#H_C8?',;L+
MNF76\@TNH1D_=SMG"VM6NU)@&/!?=AWU8[8/85XNVF57FF5@\KA8+5EF2AI%
MI R<1@*663!6.1<]PU%'%;AN"E+YM""5,[QHHM%EFGWA*4IZ5C_3[<R^]\O]
M#]++!C%&._W>:<:S&.I"5/CI%T^01?21<>Z#;2_VWVV)O<];,/YCL;?U5H:D
M'(@;\I2'W-[0(2TH@\4P@4?L$ZS1DV=JM5'K_P\V7IC46P @+4OMQV'U'N36
MQTZH-UG9=WFCCH;]T.BXQGN3K"_MSC-,[@Y"S]:>1A_S&I8O7IW=L:D"?3#H
MO(BNFF12DMT:,^?&(@/.7J"SXB4,=FQK]TM^M5'2<Q5=Q<^K*MH&(#2=,X"
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M="0NIVUHXYT,1GJA$E<L:A9DXC$QD1BUB3] GSJ0LE[Q$B_FJ!6!>0DRXGL
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M;/"RNSY/J>%IW="A8?*YX,X-A^]KY?1;F?0F%-D4G,+E^[GSV32JTIU%)7/
M]+3D:"^<RY"K%.M,JX+&3?KV]"N_Y<]>B-_-LW:+8=QHV%D-RC0O.Z?0Y#%/
M3W>8=ZY;/%"BB2/.NXW-ACIT[S*Z?\AQOMTFI=Q65:E&FNOEE5LN+L1QLVUS
M@8^/,8PN^?R\2G:F\ M7*=M]3ECL[&*+^RG'BVH3;/J-CQ5LH[I%[.P+)98T
M<VU\RT/D*M><89!9QN*X+MJIM:50,Z 24I_=L8Z8Y3RA[VM<N>D48MX^N,0V
MYPLR=:U_7,B5N8(J3"?K7OM+S;7#/*!WD/X<#H[_S#6--4]HXWC[G_?>)LFY
M4Y@#-8@1<><%<B8Z1*U*EB@%Z["2F/T ^$%>:U06NU-6NS/?$@],=/^>58TL
M"25 7#\_9;\\95-!M,P+<K;<7+/,%=87J,(%-%VH'2IJJ;Y+)@MUU7ZQ,,\+
M*F2[HR3P-7TX<CI5_EY.X (#+:=?]&W#([)->#9C%<6WC(:I6.S-+:8JK!]G
M65DAUI9*L5N+_WM<2M1G>18768F;9CA- >UR%5'N-V4!N7>A[YW9II52[HN9
M$\!#H0<+"M;.,@?F)<#E0D6IUFT0%CZ=<^GK%;2#2X92:\:YBKLPK&5E-<\)
MR2Y'F)U):4@XNC#V;QUNM[/PC#GKO[35F.E!4'@Y.;[D9Q42E1/ARTUR1+?D
M;TU/=ENH5RJ*MS=Z?_E]Y\-J^D78T6*&^7<V>7\,JK6(0IBVU9XF54V='U,Q
MNRA?;677EYG"CJT&):DG5H>P$O%QDX+][3UQL+V%]]^]/H?_V=Y?;P5+Q(FH
MD&7>(8XC139&@KSCSMC(2<(K1\(*Q[55SL>@(\=<.N-3XB08:91((2WSB7U
MEC]+LQ/ ]+(,/VB!UU<GYEDGMYXHC:B:ME;3/E+S,JPK.AP<7NBG<C#+@>W.
MS-N2-SA++:U/+3P]S5EY"PV!2E??;"9-5>*LC'AZB9*A#V:Z+Y'?XI/P"_UJ
M8 E'>0GGH>-\E7JR8D VTP2PINN>T749=#V(_*7222;3D@*5"X7)*[/QM$S4
ME_+^.Y>D_->#K4NQ<SI.N&S@^?\ZM_*T+@=KLD6G'XV+-=:S',ER)NFGNEO3
MS'^2Z[/RC;)]OI!-VAS#L9  /2CJ>_;9>?;SZO@N.WCQ[SB]=YA.9)U+<CZ=
MP.D"=*8+L#C1M<MD>-9LF&IV0F+S3C:>1YV?7AV^'OU<9YLO>#8N?.1E_LB4
MI(R'@/)PD2O+@.JA+E4"21.9E2X?\BBY9UI+HC0SWN*H>5+\*P5>\Q,?IQB_
MM3"S\V:;.\U\O:B&ISEP,)F>A[ZL$K8*!6Z/?OPFA;'UELM\H!_UB'/#4#D;
MW3(*/[3$3'BI2$XIHO224R#K.IKI49!YGUUOYWA#DI0D8&+K7"DLO"4NRU)D
M$KNOU)"U.^=^SJGYO/_Y#<T[)^:3 8Q'@9D<JM#_'WOOVM16SJR!_A47>^]3
M,U46KZY+TLP^5#$AR9O98S-)R.3 %TI7,/&%UY<0^/6GI>4[]V"("6MJDAAL
MKZ4E=3_J;G4_#48'#Q8Y;ZFT'GXK2\EAMTC.;15A5^T,($VG96"T?57WY6L3
M1._FE&S]K^W_ZWHKYN5EF;+KLTS3<$MKZ;;41\XVJM34GR0U]0=XHC?ZG=FE
MI[5\CD%_KSUV.<J5G:@;TX['L\UG;5S3\_%^<?*>[>\U.XW..WJP]Z%SL/,!
M/M/@!WO')P<[[\X/=IHGL'?@YLXGMKQ?-'?\<8/NG^^?P#W>'GQIOH7Q7!RW
M=]_"?4[^_-*@#=@[WN/FGH?]XC4Y- [;X(N(7&$#[!#4(RLM!@-#6'"F5!'T
M)=:1H"4W',S'$$!4<;!@%6BL*'8T:A\O-1Y^-6D__6ZQ_?1L,>88VV_V4Z_T
M 6\=S[W]V\<5S8_N./A1.^S&JX7TXS&XAWNAWYF;KZSU+UA2V6$JY3;>$60*
MI1&GVB/EA43$,XR9)=*;R^TY?L1._.H^W=;G3X%S'#?,1*&>_68SZ7@ OF".
M5_1&,#H_^'5:A#.^YL2$Z<.V@C)IR>D@_#9Y\;MO#4[;YORW5C</.7_I][$R
MC.V>*YK#9O4HWY[MZ)NXW-6'??CC)W<>O[V9W_K7T%]^K]";G(MKW\:;Y-KW
M;KHL89NTD-]UV9O?$T0]RF#E]6_/7_9?>7[+.89E3(O]_VZPC9E9EG- ?\,U
MDD%K<KWI1_6EC]+3;^G#OU\R6B_U!,XKOFH%4K?9"5FL)OR+OO8F'=+\DX^6
MS.R0<153,_OH6%_2=H 3^M=R_*^6GO+W9S5MBW[8PFQ]_Y._I F<]E&=T([<
M1^*L<5^.^CVPZ=%XN"Y&'-U-4Y"2MY]F F[?N?#"SK6\$RU+TVT/?5>9P+7G
M,"W__6B//__8^<A^K9[['EQ3U@6A-"-6^A1EED8HBW%1$,LUT]0?OKLRL,RN
M\MK  EZVB8>OQJ?[>3.X6_B//4\C^7B_\ZV]>W+$=O?^.&YT7HN#O7W2/'G_
M[6#O$S]XV_C6['RBNWMOVF @7S0_O^E,O@/W&AW03T4* S;>OC[?WVNWFR>?
M*(P5QG?\!<8*]]\7C<^?+O8O&F3_\T%LM/"WO_9>#QL?,=[=^22:VX>"@B4M
M8D0:,W (TU]&.86H)T87EAB9#M5D4=="7!,T?"QU 9RHW5-M;MJW;D/LY;VO
M KT*]!9 CT6N8E2>!7AEF-7,*?B-##IBK!W/H$<)K4!OW4#O8@GT J6%PH8A
M*Z1$7(J(%%4,N4"5X0;6L* ;6TK5*97/!/3NZ"$]!RC*\3"4BQ7G0BK7>CCT
MRH>\$G6?-?RLRN;:GN2OO.GU/YKYR/A.L,/93Z_*:I,*B%8&1.>7K"_*J."6
M*K"Y!$;<*X$L(P'A&$%>,*RM41M;3.JZDO1^2/1XEM2MP8*7HI&K,@@JC?QQ
M&KEL&G ;K!-:HX E1SP4H)N1"20(Y8X$I8ITP,1)49<"/[U&WC\LY4*(\4H3
M@[ U-P3V4O9;&9RZZ_G*W<VR<E[&9MGX0 0FI.9[HW3);)C-&6WD!3EX*YR:
MGP;K'VI]=;\,^]GS^S!-#;WZ-'AY,Y@[%*Z ?U7 W_QX.1#FC8B>8^255(@S
MX9#&EB!C-7&TX J6'(!?%'6U J=P=2KVZ%&RQ0WD[E&R"F K@'U"8[H"V#4#
MV&7+VF,N 4P-HH%9Q$D @!58(2&,U+#DA35F8TM@7M?R9P#8;*K_*QNH5U#F
M?D\9UN.FJ:7LBQQZ+HO[&^/"V-WNAV1=ISJB/Q)YR@M.2A.'SLK(K:6(6H\1
M3T4:FL4"1>()7%!Y[,):)*6E+F&IZBR"3/=RC=A]O*@)%<WS3T%CQ285Q2/D
MBC')5YXK5FPJ3)_)6/4F8,DSR<%[K+$^IWE]3F-]+!FX&PZL+M?P.S[Z+#+G
MYO(T_]T*_92(>%[[*[52ND,:XNVG!^1YSLJ]$S)_5O%X4&+EXZK7:C_ZTZ3"
M;H_):1,APF!8Y1+?>P+?]A/!P*=N/R1^1)C'MZD%;S61#Y_(OS)=1#63#]BD
M5[L5_>P3]"(2_WO]TU[F*>OVAF,R%ML##_\N>G;?/-H53>)3"M =IY$^QG15
M:<=5VO%":)<4VEE%@]3"<&6E5A1'57A+G"<:F^_-^UO,+9J:@,D"S('>EW 8
MDGY_T&I>^./FYT]GC9/WHK'SYOA@QYTW]SY=P+CH_M[K\P/XLWP8DL+#S<X[
MUJ2OR<'>]GESY\M9X_.;+\V+=Z2YU[B ZQXW]OYLPY^4@8R7#T.(+[CW&CG"
M5"*5YTCY(C&U<&5\M '^V]@J<)T45=E%A7\5_CTZ_LTZL64?9.:")%?NC]R\
M>,]\6P3%V/H6/$ITYA4>W@\/Z1(>1@;+JH1 P6O 0\D( AA42%&/64$"4U&4
MC9@(_;T"Q H0?S9 _.49(6**R<PA8H5\]T$^OH1\BF@=);/(%R$B[HE".A8<
M>1TM#\XR2SBXFI)<0KU?*\"K ._9 MX:X-UU=3:5Y[M"O/O6>%7F6C=WCLCN
MWOM#KYEUFA!$C'6(6UP@2R5'C& E#--82C#UA*XKS2M+KP*^%PQ\S@I+0DKJ
M%)3C(!56TCH6";;*&A%776!8 =]*@:^U!'Q88A8\086!O[@,'FG".,*4:!(-
MI=;*C2W%ZH+>L]9W75D'+H\KYO^>Z6%9ZK,0^BYU=3PUIZ'_7<<_2S/P7:=E
MM\_B3W-:=M?IHO>;KI^O&-T)%E@0KHC,<0MFLDZ9_X8+P('"$UL=$ZW]GG%^
MZ9B(,TLQ81(I&@/B0<"KQ(E+B?#:8L<9PZ!96M5AK1^Z9UR-*H]J$%?:O5[:
M?==#D$JK[Z/5RX<=3#MLK-0(,R\1+YQ$NK ,:45XL(8Y)XJ-K>MZ=%3ZO*[Z
M?)\8_H]6Z"J&_P"%7H[A,V."*[  -4Y]@)4B2"GK$,:%D$%)Y@C9V.+T(3'\
M2IM?WNY<Q6F>0)DO!:A9 >M&BX"B3;D(EA-D5(0]&BQNR;%QD81D=,NZU->U
M8*O4^B=0:V$*Q37S1$C'/=?::U>D?DW>.B\=J<*O:ZW62^%7P@0#TSJB((T!
M7QHGUD6%D;>8T*!(H8@%JYOS.L4//GA:H5JOB/)MK6.LNQ;&4';;360%GS8_
M;M:.>C#";MGB_BATW17L;JL@,%K1E/XT =>[3M=-N\,5T_7S[0[11NFPMEH;
MQK$REFD;?0A":(YIX:J Z[KO$LU7EP*NUCF*<8@@7:9 W+ "*4,9BIC@HJ <
M%Y9M;)&B7A2KXBA:(S*W2KF?6+FKI/.G5/;E."RWGD1*#1(A.,0%#T@IXI%G
M,43.+-CY<75)YY6V5]I^MV!LI>VKT/;E(*W#*@I,"A1<ZG1D%$7*$88H<]%$
M*1@QH=+V2MN_6]NKL,X3:/6E:&VT+$@:%'):"L2)-$@;21"A!2N<CYZ:RF)_
M 5IM:>H)78!R"\^U)XI*P[T41="<%2$\;K"VVJ:_7Z&7TV2+@DD%WK?S%B,.
M:HT,Q03\<%>H" ZZTGP=]^D5Y<*6BDDWJ5CSF.U441 H AJ S-^I7=<3Y\8^
MQC5N^]Y+K=.X[^/_-'M/8*& _0>0"S/NL=!"*.F"43AP8G45"E[_C>CC98H6
M\!*B<Q1)'1GB2D:DK;=(%(X&SZB0VJ?>;**.^:K2 -:E4*T"P H UQ  J_3D
MQP"^Y;"X=5(+B35R14R,!,8BL+4U$CX6."A>^$*N+CVY@KP*\M;FN>^3P?VC
M,:_*X'X YBT?#N @=>Y&%%PB)7!<(9/JKFC*X)9&$1S9QE:A+Q?FWCN#NP*\
M"O#6YKG7 .^J8Y,GP+M+QR92%8J;:%)EJ42<4X(LX1$5D@C*2"&(2C5HDM>9
MT)6I5R'?"T8^&Y3QKL  =H$+)C5S1GIN%: A506KZ@#6&OF6SI<<L2(8IA#L
M9AYQ4G@$RRL1UMX9'RR6(37ZI;(NZ:IJZM>.A^49U@@T>MUP/NY76(NC[^Y6
M\%++ <BZ3%=UC2>\QHO/"Y$L1RR5T$XF;GT=L'4F."*(T<+?N39WKDWTM%/N
M3FO@VKW4)K?:LE>V95]!&<F((SB0@&*DJ2)7!:2- K<ED (,+RLI9K!EJ[JF
M#^^64.5XK:TN,Z,-!5TNJ&5<J<*Z(EAE/58B,,+\70WQ2I>?4)>7S.]82&^5
M#*B@PB)N0D"*&8,8#M%RXC6529=E'8N'T[^N77;76EO8K])8(HPF]03K15"A
MT]Z@=:=^D!7-X=/0'%;76,]KO'BN#.NME4XQL+4%]ZXP5F,>M5>&N&@8K<SL
M-=N:KR"^X;20*G*-"F/ N!;.(&-5@61!(X<_5'&WL27K E?<=#^S*F/G PV>
M\N!X@:6U6NCH'"$TD&A4966OH2HO![D-"]R";2VB3TT6$H^!L!9)2K#P%%#9
M:K!52)WI59WN57'L.UK99G"\+J'8YV%2-_^UO2X35EVCBET_X4[L@E":$2MA
M,X:_C5 6XZ(@EFNFJ;^K49T@I]IO5[7?[EY1A4RMBTQSCZBW#'%&8+_%.*!8
M2&/!9B(L2MAOBSKF>(VB6I7&KCI"';F*47D6X)5A5C.GX#<RZ(BQ=ORNMG.E
ML2O7V&4+64?%HC"(^R*E@1""K' 2.<FP"2S8(.G&EEH%Q^MCAZ&I_'FKC/=Z
M0].N.5"'FNGZ^0IC>#W.!DDI5;7!-'WJ,0*P=TSP*:?J-P83['NC-*R<XC.7
M_D->:K[@PZ;FI]D@'FK2=;\,^WEW^ !ZT&^Y8?#II_3G]7]&K:^P)X!N;'?]
M<K+A7#2FVEA6MK%<D5EM!+=$T(BH( IQ'C52/C7T5=SI@E(NF-O8XJ*H*_I@
M1IH5ZMCSR+JN$+9"V,<UP2N$73N$73+=M0V<A4*B0#$@;-0:P8Y*$=-%*!CV
MF!=J8TM@7M?R9T#8;/3_*YNY6Y/':8XZH$D.?O:MKUO_"W]-'@%LXJ-6-X]%
M3Y"NU?4@EK\QDI+/GUZ%:5)AT)+:\#C GWX(M0Y\_GA0"S P7VN8OCLNUX61
M>BU90-G:3XI:3U_JA]I9^JO;JPW[,(88^H.:#<.S$+JUO\+7T*Z1_(WR-4W9
M*^E>T;3ZM:_IX*EVW K]=)OSS=KVL+837.C8T%^X*=RK-^K7CE*=+2#,I-"V
MUH:?81Z&R16!'__[\<%(/ &SZ'6H5#Q/5&J'?W\X/_CL3RWE17/''S?H_OG^
M"=SC[<&7YEL8S\5Q>_<MW ?0IT$;8G_O/6[N^=B\V/]V6$A.H_8:C#:K4U-R
MAU3D'HPVA0M"O18*((5L7A<+ 'UIPT_U+(17"M&1:74'I13#"U#RG&G5'6Y.
MD2@K<KI\DJ!6=Y3[(92JG1=$L!A3]Q'BH^:.,!N#(-P)2YDGMA"'O-BX&0^(
M>@+MEU=J?[,W##56&].VU?YW <66NBGY$&$14]OKP$U^S6*@%""?DH*+PYWL
M(A%,T,Q7NGSTW!WV^N>S\^8]N/X?[9[[\H/%N]D:BW>GV6ZF;^T<P#5 (/?>
MD^;..P&;7J?Y&4;4^20:)R#$)Z\OB?<^_41AA+")_G/2 /$%%<"-DR_?&IU]
M<G#B8-/]<@[;:*L!XKV[\YX<!L$\#T$B[I0%\8X6*5-8Q)BE%@3).2M+Y *Y
M"WX[0434!AP4X8LB,DZ<4$'! E!0"Y! 1O!&+0!BG,*L#_NCD/HDITUF *(.
MK_(.F/"H]J;5-=W<,_GC$'Z1^WGLA"' V>#R7C:O"4N*4*[:[8-:? A!)7:I
MN:)7@6M9&,F9,M83ZKRE@F_\&%7)5_RM!?M)R]U!>:;BO#A#]]ST'U?E/KKC
MX$?ML!NGHWTUZO?AU5[:MUZP^ET<<K @C6 :84]!!U6!D2X,1PRF&[8:HAD3
MR^KT0VRTZ=(E\1BT!L/!U)+JM=N],[!D:[^TNO";W@CNXP>__C81R7$4=FQ&
ME_8P#+MM3@?AM\F+WWUK<-HVY[^UNOGF^4N_CX5W;%NGB/22.9S%N7S[][.6
M'QXGKW 3EY[A.!H^OO/X[<W\UI)Q7[Y7Z$W.Q;5OXTUR[7LW79:P35K([[KL
MS>\)HAYEL/+ZM^<O>TM*SCT2 =8DZ43=9J^4U:;)5ZA-O)$['"G\K!,Q\90F
M<[&8WW[_A*T8<73/*F'K@SFK@=<$7S;M2X=+MSWH2R6+N._C_S3AQU7E[$RW
M8A"_QD3ZFF&X&S\$>(JOSX4FXCL-KC+(V'E]!K_YUGS[[F)W[PB,J_=D_Z1Y
MW#QY!V[_ZW,8XWD:[T'G0V<YR+B_MWUQ< +C.6F(W9U_.LT=&!=]31LG[W&Z
MY\'>.]%\V^P<O#V(C8]E@'&.$$P7C(+MZQ 6FB"0"H=,L!85$AP);X@CSFYL
MT3IE#Z]2NY^J/'JNSR)"W_F<I@*\EPEXJTIYJ@#O20'O8KD]DL%!8T X:ZU(
MARH%4BE.1"PE6DKFO4L9C'4A'UYB_S2 =T?/Y3G T.=>_PL"%_FTWW-A<'V&
M$[WRZ7Z^-,N5&UEI@M]U_RZGMP*=QP&=UB4KBTIO"I &I*W1 #H,(Z,51B'0
MPA$EB!=A8XNP.KEO\Z;'LYCND03]<ROARC?^2@F?1 F7=W[LJ.+!8.2EX.#J
M*(FLQQ%);H.AQEC#,"@AKDM^SUK!'U,2^/PB3&]:W=;@.!T2]WHWT-K=6%UQ
M^:E_/L19^;8_F?BW:=XKQ'D<Q#F_M.U;PG# %G#&Z(@X+0JD"?@:SCBBK8K&
M*K.QQ>MJ9<&5-0J@5.K\: 9$I<Y/HL[+!H311"JI,:+,I(8Q-B K"$,R<%A(
M@9TD?F-+U)5\>"G5ZM3Y?N&!4OG8FAL29;54ZU*ZR-*T5JGT5<;\8YI5 +T5
MX*X*<)NO+ME/H0C!)OK$&)1"7!N%=' "1<8HXXP57-&-+8KKE-TW6+MVA42W
MG4-56%9AV6/:E!66K1;+EHU'JJT-K "3L; <<6L\4EZQQ%DEK"\L,UQL;!%=
MAW5[/ECV<Y3L? XUN,8HPFR/^J$6%\)4,S.S-CH%I>P'%UHP7;T('^QW:J>C
MOCLV@U#+$STH2R/.TA7/%Z[J8!Y-JPN7&X9^)_B6&8;:V>*!URS_*E]E>NG^
M?&I6S9J4?0Y#F;Z?"E^<26FLL=_KY,*,G(H*BU\FE9^:_K +H]NL?4YU&:X]
M\J'F6_"MX>S"]<EO\A?+!YD]0<J)[8$P' >3^ GFIB5]SH?T5#"S<./!, W.
MI.D9I 6NCU_U1L,T]M8@C7?IF7(]2?K2X!3P)K8<@ Q<OJ3I34\P^^+RG*6O
M+B[9YI/57?P-ZN3.7W#2-S[DH3!%#!$9PPGBD<,K1R42Q@NK?-"$7DKZ!B$L
MJ]7FA&B8\Z_;O;/03[I5BE&_U@W#6EE<E!.O\]>F.G;6;X$2^=Y9%P0P@NBV
MOB8]K(5O63)F5Q_VKKS03)6.6P/X8,(Y^/(I"$WHNGPID+*3D(IC:Z.!.0I9
M@=(GNH/YT?=#KDI+]TG*UP^#D!-K2]7X&MJ]TUP1DO#\:ZYEJYG!/#SXF@5\
M&:0[GAV'F6K[S9NK1ZZNHQKCYQCD>$HUSQ37\('?\E!AGF89YO^S6!TRWDCP
M["O&PK8Q&E[_E4N9O3\(R E?FIVYOX_[,U/["+9AD(4OR$08[&^F?6;.!QO_
M6MRL &+F)W#YV:]]PA@?[0G++1,LLC&N_S:"W;.?/@5C,FLSEMIQ/R'M?]U>
MRB<WMG+93-+X5PFDN\/!__[++ OY]852MQ8^+15*.14+P61TTEF.!39::LN-
M4911S+F^ME!*KU&=U-_]'D#4\+Q>^[MM$JH RJ2:_8PQWU4[53Q!Y=1DU'G,
MVUT_'?%+W3Z;.\F3V,;-DT_?FGO[Y[O;AR"^AD>7.+JX0S#%!&DB,1+6&J&]
M%$3:M:B@FHG@Z50$PV1!JZJJJJJJJJJJJJI67U7U_&BP_QBUVFFP&2'; 4SZ
MXUX;'.@..!9?<YGX/6JMRL=_L:4']WS\GR;82PHGO8P%F-*1%R8:Z8DTLN J
M&DI]<2<RO9UPVH?WTIYYK266655>0!CX9/_L8 _>V]O'^R>^LW_QH=/8.>*[
M>W^V]_?^.-[=@>M\_O.D>>+8<ABX>?)'&W[_K7GRH=4$4Z_Y=O]L=^=(-#K_
M'#?>ON;)Z-OO-&CSPL_76\$SOSMK;A\*(:PJA$11,(9XP0VREAHDA-&.**Y9
M 3Y1H>N$/9C2Z9[ZLK8%5Q7JO4C4P]Y[)8F7@0O.,=>8^JB"PJ10E(M;^[-4
MJ/?#4.]B#O5P\^Q02$R"\0QYASF@GE3(!H=A>C76D;I(N=K8DKRNU(/;M#P1
MZKV(1HF]SND(/(HYSSY9L6[RZT$O#L],/WQ7)O>+Z#$E"8/]GL?( N<TO;11
MX"@D,4Y(%RK+;6TQ;&:Y[;R[V 7++?) #=/()"#CD@NDI36($<:CL@!QN7 4
M,$P_.)N[:ANWOBJ-&0U211&\=-R##^:=%!IC[T0AB(^56;*V*GVQI-)4@U7"
M/$5&684X$PX9C1V2FLM@N"J4*+O94/S@8O"J>]R]%+*QD'<2+AUN51UYEF"I
M,#)$S@.3U','HLLI$06(M[).&RPJ2V--8:DU'R/:_M8X.Z3243 M*$H!(<2M
M!$N#!(Z89!)3AV&-$RR).F.K\I:J)EMKJ-*^,(9R;ESDGM,@3%114Z898](1
M7526QIJJ]/E" (0WM@\3'W%J$8X(#LG2" Q9['(4A'--2/#*9I7&XK[9OT_>
MANLG"W+\56;)IBR^AYD9+\+[,0YV)G!VB1.4!S"?B2FT(YA3YV,18V5FK"TF
MS9L9YXVCP^BPQ*D#@##$(AZM0XI&CG 1G!"6!$EL)J411;%&WD\5T%BQ2@LA
M)<8.>UD0N)A1-! =I.6:@@/!=&5FK*=*SQ49)3.#-L\.L2-,4T- ID"1N<0<
MF6QF2"4(X\*!QY!CE)2S-5+IEQ#0>#/J@PJ.^B%5PWQ++\9%+ZGM3Q76N Z<
MJ#0B-9V.,12<2V:BU]P3XR4V8&?PRMY86W":MS=(\^@P<,I4I!J!1XL1QRXB
MRP0@5*  6Y)3K,G&%JMK7;4._XDU6E&!M3!<<0P*;8E2W#&N/2BZL%SXRMQ8
M4XU>3.O@N^\/#3@)B8L!J6@9XH%CI!B\$B0&2ZB'%<[\5K1XL+6Q?D&-Y\&4
M,Z<HJ93QAIH-,\PUEP\)?3R AN)90]I*FEU7D/;TD+9P]@+/^_Z0:E-$8PPR
MA:9@J3"/E"4,Q8@#R)LCA/D4%"GJFJXJ*O(L^E97./!$+9DK'/@1.#!GVC3.
MFN\/;>&%"3P@XQ/7GY !62D]8A07P7I61%< #@A>+QY^8O,D./ 2@BQ_A<'@
MMYJ9M0D&-2NU*2W+"XNR_/(#J/'F.C3OS,T\O&Z']"*UD^_T8(XN\N^O!;@*
MVQ['QMGFC;/#(N<$885B*BWGCAJD%*$(]BC8LS@5ACC -H(!VRX[;K]649B?
M0>-712!7:?S::?Q"^DDC993QP)BU*B+-2<HH$XF(W%F$"Q <(SFV(I'/45Z7
MC*R'QE=1FJNB-/5$8U6%:-8X1/,R>#2?",IV7RT&:%+,F6FCF .Y=@*,%XL!
MRKPS*,!>%JF,6&%7YNS+51UQ5_&9GP0$GBP^4X' :D%@WIY)45K"@C#4,$2+
M1),EX956!44Q>DP=$32P ""@ZYI>-F?6$01>0G#F5:\[&/9'I9:VNK6[-WG\
MF7RT'Q"4F9_XW'?NJ _S/HXA5T#T?:4Z905A#,$)8C'RL#2(^R(@#<N$@@A*
M*ZE !N3&EB(/1J$JEK*^>KJJ4,J->EI9$RM3XN4R8$^)"D(7R!,=$ ^,(AU%
M@9BBJ@B.:9X2X6E=L'5*3'M1 9(;Z4:O#(K<T9Y[R0U5'G5J?AIT7Y455CF+
M3YYW7,([ *ZW6C&$<>"(4ZI32D] 3!!&/;$*-FF =UG':E7$+>O77NK>\:0*
M/RO\7"OKN,+/)R\J*_%34UDH&3$JA""("R^083XBS(QS-.+(C-C88K3.Q8J#
M;<^\I57QPQI:;0]J)C6A&;6'$PI^4(9^8I^N90+^4(NFU1\WP8%/I*8U Y@Y
MF.)^.$W']=VCK-0U7S+PI*\,C_LAU#IP]^-!+<!#^MHBT7D]]>3IIXX@Z3U3
M@YE#S@R.$]LUW*YL#7 ,,Y;O^=_W 1$;/.;<2RD%)U3 GLU546 K931:\"O;
M3]S8]VXZHMWX5Z][]%?K:_#;@T$8#OX=VOY-K_]I$.X&*\7SA)4'='URHGFR
M+1H7V^< *^?-]X=@87DEL$26!8VX]@4"LSF@&(('=YI9+SA Q.9U+%J@ NTD
M ;%LN'23JW=VW *).YO(:1)G$/0<-LF26I\7MI*M<M*((C<HRUF!IRFV8CKI
MRTGR7_62QJ9.4"D$D^ D?^KC$/[)UX%O[\*@<@;+8+/V$=2@V1N&6I%'G$ G
MO9-;$I<2 S]MWK$1R]ITE4G=Q,]@(1;'_;@]83ZZX^!'[; ;)W>OFL&,F\&\
M/S1$P7]2H4)YGNCI"-+&$\2"LSK IARUOM0,YAFT6]Q;Z C3*O<JD"S7:I?)
M8Y,]"_:*[E$83-3T:"PB6>GNM"%=UV[F=I5\VH8T6FY*3+ZG'XWBFXQ_;W.8
MF]Y35*^^<0S=Y.Q'-8[YV5JK[-TF_"^NU<ID"ZG]/_^E*"&_UVP 1>PFD+$&
M; EW/5'U \[!JKX%JWG\*N"Q9!M-Q/DE!#>.2//M:[Z[]\=)\P+&N??A2Y.^
M%P>?/XGFSC9K[OA6X^(UW=]S9#FXL0LVU?[>D6B\;;#F'MS[[7MVL--N@VV%
M&SL.-^F[B\;>P7'SXI]$ 7P^#6Z<N(O&T:&FD=&"1$1$@<%ST0+IR#$2!IMH
M+7&P<AM;LJ@+O*HS_&?2F>!Y' S._/AD-!XMNS 58=ACU(Y\E^-W%ZB;K>9?
M+R3IX8F KW4)^ SW5&*A$"%< O 1CXRV!2J"HU:*J(K"7@M\=Z\(J5C"'F;"
M@F&_'O9K==#W2%.SWMO"#TB4N-KNC:UOP:.+T.]5R'\?Y#^_A/RQT(K)U,.&
M!8NX5 X9BAGRE'BI0V1:TXVM#$#T]]7:O&MPH%<VE%\ZUJL.].YYH#<-Q3[X
M9.^AMJ18I2WYTH[R&GO;8G?OT[?&'MSEY#4'=+#*$54PCQBV&G&*!5)!8Q2<
MHYASKHOHDEUXVUG>Y9,Z,YB7ECEO[7N/X3Z'VK%)AWGA:ZLW&K3/LZ@>=4&O
M_.SBIWU8XCZH9"WV>YU\(^/^,VH-\IE=/AG\>!Q,_\RDEG:O>OW3S7QNN U;
MS5& YWC7=9MIB!1CDM^!%Z*>M/$TP(-_#>WS[SL2?*JCM6WG^J/@_VH9VVK#
ML,)@+X%A==*63MK<M^;[0VV%PCP1DCJL$.=1(FNQ184T."@;0RSPW4_:UN9$
M=[SPM=??3I->#>YX_+4VF]YX^&$\_*0B@]9@N@/.SA"?R3$?F-2;N#2K[WO.
M5^A-SL7J3^38)BWD(QP?"J(>9;#R1QT?/HLSP1L. %_61.P$%SH6]O/Q7- 7
M=Q@Z <_4K!?0\TH"M'N<5+S8X$X5OKEG^.9UY[3=.P_A0\BD4'-6YZM1O_]"
MF)[^@7_W+W8_OSD^@'$T3]Z?-]Z^%XW.:]HX.3K;_?SZHM&!G_?^^'(I6?OS
MF];!24/L?W[3WC^!L>R\.SO8^7*^GW+"=K;%_E[C''[^UGC[8:%+,5B\)&5B
M,B=Q2.EB,0C$M?%(L8*#8>L(H39H9\W&%DF=UM7JSS-_8#G+ZK(T*JC[V:%N
M51D:%=0])=1=+$#=V:$F1'GA'/+"&, [SQ!L7Q%Y3J,DD1%#Y<:6K@NUJI:*
M:\8!\PR;+4ZM4G@KC:DV[+?@[[ <H'@9.1=/S5\WGOU7X\G?2W,_B0U5B/6(
MQEGCXB@99](KP10/R%%'$.>8(^T2#2<F3L)N%'VJI)-U^?"^SE7#Q?75Y970
MT%6Z_(.LC[$NFX)JS"AX5HI:Q!G%2!42H^"C<Z)0$2N=*'7KM%A5?X JB>J.
M70#&=OAY;=BKY2!^[O"<M/+4](?=T*](YQ[7T)BNP%[OU?S\_SV>_@J@5@U0
MYXN1H-WWA[!]&+ H.&(XE>T76"+M,48B6$6(,%Q'G]HM<GW=27Y%3O<3Z/-*
MC(U*GY]>G^?#';0!!@=U2CK,$"=*P5^1("-!J67A(M=*8I,BNZRN\*H"NU50
MX[Y';=UAFO$ITT!2S4P_4,4UGB2N,9[_O=GTOTJS7Z'3BM%I@62M=(>BH#)J
MK)&&Y41<BHBTE %Y8[UPEA;>EM9&L2J.H"JTL8;JO-+01J7.3Z;.R]$-SH+C
MCCDD7!$03\1?FDJ&8%6=C\00SWGNU8ZKX,;3*N/N\#BD#.;%U,@JGO'8:2UY
MWB]G4E=@M&HPNGQL$BUV4F".K-'@^10T(&440P8S:;##-N B'9LH*M?(\ZDB
M&6MF6U2:_.2:O&Q61&XCK!A%@::^/:GIJ [P5T$%5C)$(D0J.J]C_.#>7>L7
MPW@>A!I[O:%IWVI?5.S0%3OT6IEG%9X_/IZW+EEFW FF8L&0TN <<J%MHH8&
M/,>6D]0[Q1,,;J*L<_+@UBEK0 U=4>M7X+E.X+G"'MX5>#XZ>"X;PXQR(6"M
M$"R81#R ;ZN=80@+SIG%@;@B'>@5=?C43P">=Z#A2#\G 6]U1SG<NU"[.U82
MGBIM3WME]?YO_91YW_H:9@6V_[-8F3U^5#S[BK'P8*/A]5^Y5-CX@\J?B5BL
M8Y[_^[@_*\L\"LCV@_F"3(3!_F;:9^9\L/&OQ<+G5A?-3^#RLU_[A#$^VA.6
M\N,3NTA>[=] 7D,_?0K&9-9F++7C?@+;_VH)%J.+@1,?-7>$V1@$ 0O(4N:)
M+<2A!.\IUY/W8F*P&(+P@.-DMJY:QB5)+P'4@2TEF(Q..LNQP$9+;;DQBK+$
MO:&?!>G W"Y2&Q?&I#R\5+#_$;:+3+CQ9C0<]0/<_]RTTP>_BYC@1U*8OTMT
M((2.Z4 HSD0Y@"OY43_\_:[VIM5-A&VUO?YH,*S] K_ZM>QD &N>IP:& )KK
M:_:\]N\ LW#LS'1&SFN-_&[9\>"OOU[5?DEIC!.VD7KMWZ\^_+K(0%+/Q"89
MA@=I#/W@ KQ1ZT^FN)8E.G\*UC$Y]7D\,(Q1-./>"35SU _YKH/:66MX7',
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M1!5&21ID:D- ZN!ZK!$+1\6GLV+]?A2?H]+OI]?O97<CXF@*;S&BSH&[8;!
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M^R7_:O(L3SW2J]'OU]]J'\+%:3JC]V'0#J,OL*J_G*;T <"<=HI9Q- ?1U3
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MKHG_?_:^O+EM(]OWJZ!\,^_9582"E023^U(E+\EHQI83VYE4\D^J 31$V"#
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M<6BY030&ZI)H4]ARU9FSKZ*L7Y6P!_G6(;*>NC8.]'KYQG_[\M@Z_0C[P<\
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M;Q3WI6S9<Y'1HMY/<.#+4Z+0M8KXJ[NG#J9F?N@<.4/G4&KF#PZS_J 6NW<
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M[428<=L5WF! H$!DWG([O(@<#00$=HCV?YS18)/?@TBL%-4-\?EGP.!D02^
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M*F)?3P*EE1]15P?5!^%':PP58= LM*D4"#Z ^#\D09M4XLHNB>BH&:9)/G3
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M"MH=U)/,5C$A=&=M@]]0J?93Y:]1?'R+\WUD'%=JQ\Q%*''5.%JX4.T\@ F
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M_]_>NW>W;659XE^%J[I_O>P92-'#STI/K:783LI52>RVG:Y9\T\OB(0DQ"3
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MH*+C!;4(6WM*HL[AZ8G^U,BOXR,%0T>2$:)\A.(YRK[QC2C;V6]R#I9A+B2
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M$G]93E XMM-64#1E>A1TC-L:P% Y8M/#+QQA!:&[]+"19LM?5[-3NUM=G=:
M2^M=[UK]Y2@9$-<;KGN-]3TXR>@,\<9\?$QW<<Z]3W.]MGS@#;@*4OI$&_BH
M2-2%,Z3KTK9I.0@%UT2O9QGFV4\_0ZR2MDJ-L4<J*SV*EIBO1L1$#DV-*O+
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M$CF_EYP"R4^-+XRS$IR^\S2LZGT,,KBP<A%!HP#XNW8>OO()?L39Q:GMY59
M*\*'D!0#> . ^5Z-9909\<Y#7+N&G8.MM<[BT6/O%:R'/ [2'QSK2T :'TJ
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MM^FK]T:M:D4?(?51($5C&!L8W(^H1-T>6]6?3*W87C&;GS23ZZ?Q'I]K1I-
M3#8-]^N"^Z!%,==W -[7$M;'3__NY+LQVCV"DB!7=UH3^JD.7@TM K F(U!?
MA?%67(AT/02GHA.B'F),HT*H4*\!9Q#<&?4C*$N=!]OI6-/4F3L'P(Q^$>8F
M'?+8#<D^!Q+U"9EQI!=*6N$$*T#I%4LX"-)$R &YH !'B:^MC\0>]B^[;W=Y
M"VQ\+([8?)]?<&:#URQ>!I<7EF?"_I6 CPD*816*,;T QI.-450E0$^+"7AF
MLMA!2PXX6FTISC1*;JY?#CI*^<\5"-D4\1S;1]O4'P4JU"$V-@T.4-<V*/ )
MB&G[7P4C0%>MG-:E1*C@WA:,7L3Z,9$M.V,<):GO'QLEHT"?=Q/1ZLS0E;2Y
M-F\:,$QUCB678F_2J*>U$YL"@"+AQ4Q%9%W+H(096H*>JTE[JBT9UD<(%0M/
M8_BR[FSP0>E*R'_7M0H;J8E; "$L&_:]>)<[<OVCRJJV@P 4^;& &92ZD#$9
M5<F]Q&.&\?AR[>:]8VQJ+TA>NAP][:->T'  L" 2DGK[B-8P3+$VM*#_9$:K
MN'4$T$8=)C&]:@MQRD ),R**FTE=HC21,0^-RGB/4RX8N9M"RB/I$.&,4KZ)
M6',5@P]'6?D@QMDHG%E=MSZ>!P-1@W8I,C.Z&\3K<MNYL7.NJO<568WPO&%_
M+5K!!4?^<W\85E&JR4-_!_W[OFM>^]V9DVMZYG@0V!3I'*6M]R?&M+8^D]:L
MVW9\'CG:"G%&Q+=8L_)ZR0K+D,&21X.?^ --7*_^K2\V5)C^N+TMBK40884P
M+]4JQ(3D)JT5-X\KW_MH'B<@)Y6CMBD^>'X-=AB%AC>UVN%47:XPU?,8?''F
MN5A4D5'6T;3%RWR>QJ4_'M1@?PLUN 7/\O5"#:Y,OC'"%' R\F_YU.<:,^,;
M&P$A(WE:$\J]P !P(C6A$23K,#>V&:43Q,FWUN0A[9^J*L-'6(.SQV$'D/J:
MZUUE&]W)_6FJW(\/^NJ)7W &;YEZXN$!JR>.AIYKNF8]\10XVJFC,Q>F)*-U
MB[,8)4=8<8;U58!^BR3SD6,3:/_C(HWDBPJ]<.2SZZD8[DM-(CG'>FA6FQI^
M3CQH(?M*;OII4JO;173U(DH::OQ"\E/._4+EXICT<3C#X1:4\7NE'-,26V@;
M#)77IH8:W=#RFCZ%=*QN%\"-6Y'4<O2YM<SV9T:[S&XR61)TM3!['!$CH H!
M%7BD7+% +$0SIE9.$PD-GH7R B)>,'^<]-SJXI%F*:*.9;\W24QMU\A-K9'2
MEY>64EZBS&"8L;-RZ:=']0A6;3\SPNL@1*U$?1LC,:H7$AZB8F,BFY_2*,IW
M@MQ[$U'PB5>RG?0;.QF\XC;K$T*:T]R&W+%,JR-H"HL^=U,5*NL9[,PT*CV>
M%F3<EV>D-C,-<XX\4MXQHTQ>DC\;XN$0EF7Z9P+B9\Q> WP0P_S!3G0< @TT
M4&I1QLX@LF+A*Y\NY;U=+=<Q$<AOD%GHN0;CQJ.L3FA[%UQWT7Q7S(K@-%*B
M $PCEL2=TP#9D*#RV:?K)*N8 R2L>\A5<5>F_^J]8O=T-XMD!D*#UK8%55.
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M6&M+S2/1G(SA!I-LH$2\0_HGH:0=2K$.A1E'GAP;8-5V]4(IU(H/2^9H0KZ
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MP8NOYL$.K\@WH8'=)?L"#)((9<QZSO,$D%\^7'0Y*AU"K)@D2G[)ZZ\%P(S
M7#:A8IS28))E8[W)= MZ4@DA6](U&3P2R*ZU A=RBXYAG,?E;&8* NR$@6'8
MB C0+;NFE0Z<3]A>0M/8Q/TO3I$:@+(9<5Y&2T9Z#E.D5K:31%J.-I9B&\:V
M+J,O5YWM4,T3X':VXKU)&!>=^QWF[>Z7[I\[44?QR"OR7D)PLJJPWJ7@,!2)
M<+8Z)\6UTJ10"/#.CFJ9@&O%B^-D=MXTA%3O'%Z4:JE"4<9RAT(U&$4WUN:R
MR:LJ^T?!9FF$Z\L7WY*#F[(:+KR+H:@/HJ0\K[YUT@_KI4=S],D4?"GA0_3G
MA)O=X]7LM-!R,[?OLU)WYB?WK&PT88.3X7UQV>/_97"-Q!"7RMP4XI.&W&DY
M!PPHX.6*I!U(,@X<Z,!H2CS2A2\(X$:&HL/ BXN1LR @MQS-J8R6=ZKL#42/
M%*HY<D^\F9YI=J.B0T$+$?O!-H&MV%X5DJ,A=/;TZ4_HU<SP3F&41&NL-2A<
M^&%X>"$9</*A\V+#2KXE2W?=(+9GJVY67U0,+3&AX.QFO/^#ZW4$?LET[QBK
MC-BN+MW^8^975)Y+5++#+^]IF.NM]]L7S^XK@2 Z)Z) D%!4L(J Q60Q+].S
MKQ]'=P?Y(#ML9&NF1XJ]"&V5EL1W.Y63JR $2W5R<@:<=?.N/%?W^8TXFJ9>
M.$4LD=F+EQD9OY3,;Z/TBK 216GKD44]J:=3,*^4"@&]SKPZL_[Y9\A8("0)
M,;95%8 13]2A$C!L&NNR>@UA =W$21#%8'3((M/*Z/A@,^?V(77@</E;#'1J
M5C]:SO5S;VGN)_P)E/H'>P=[&0M$:]T!P4\(%]NNI\R%MK]Y\$1H#2SGN?"I
M0RI0%+V[<4EC74)$-7%,U-N48T82JH9;NP#_U8[)^O)ISN )4_"*+E@B*A@\
M-HH9@N-]7H0P@!F90NAIJ@&B(*P@ ;I1U$&-K[<[>7N&=:0/&^,13DM4_F&H
M*S$Q (D@8OI=UT@)7J,N90Z7W00Z.!W'?G0;XM0P(E&)#<]7%TS<$1^4Y*E)
M\YM3XQ+A%Z"DPI.P.5)0<#HOR"3,^%U+J6,(RTM75#-.:C,S%O=_P-=@UX0Y
M6*3E+N-6.+PHO4@X @C/4A#S*XL!DB*C0%7D KY3,X2_Y7PXA,GX!=,=!W!D
MP?5YO\$_-8ERSNC$77:16G;XJ*U?TV&0#-$28K-H7MROA:/.[Q@AF2N;M-?5
MYQ=]'!V6,I0>+0N%Y#_EM"9:,^C+M H%$#NBE@]C"3M^FW6[TC+53@.>B6AB
M].PEXVSW;1$O$?'R8(MXN07/LD6\]*C<$_;M2/8F[!]6HAII%#*<(C<NT5<'
MW4/,"K%9!_!FB*1OB0-U3=KSP<!;+WH47TX)(YI"JJ(X6QOTK*]MWG=]G^#Z
MRSOY%6H;CM-0._"-=C"?!V,TNV17C(11+ACRPGB#+&U[9:Y>2=?V6R\5"5\[
MOO6(L. 1H++[3/@1_=ORHP@3L"N<)GSL_'EFO;-]65W5:+!T[[ M5D-.3P.9
M-,AFK'E,X I[:^/^AV_OI<EPG"YV)T=IKRO+B^4@".Y:'35QWW)A'!'G*CX+
MDTLF[?QPK3ND)=<)QL=68I8L*%MXG^'-X<*5K'X76YSK=&"23NNW"JAP#WR2
M2%_$?B:359')28@G,7=@B.ES.O1@+TH@LD8B '#=(VXP?!?[)MK)RVJZ2Z$*
M(7%<]"*</>)S4J'(\,]'5#GZ?\&1G>99V/OO.P&./,_+$)&6.V_SZGV=X<*,
MD+;N@9]>_??1S^]>_OT__FW_\8-O;3C:A'7IYSJ\VJ/L\?YA]N#)D^Q)]OC!
MD^Q!^+])^)<GA]F3_<>XW=-L[]%^MG?P0$-A_[;D>0=_<\X#RZ^U_QB(H,/,
M^!.)4CV_%*H(,(:;0[]NJ#Q]]D A09@^4_%S-F&RV+GPI1(:#'5!I$=EF;F&
M_..T-5P9^WU%5=(TP@A4O=]VD9Q=E])."R0;3?6,4U,H.YT43-033K-S1]MC
M;Z/+"?SNK/ R4<T4JJZRE]P@5(I+.E*;IH<OYU=>K&A PM$E:TDXN[B2MF5&
M^TAFM+$1OI(?C4_C] 0&20S6E!RIA1VHC'+S+%)Z<HZ1:=EIFIIZVL'WAC"]
M^VOE(G)F'>/S(&4;1KXO.8.0S*(S\5>4RLZ=HT'1*;<1HRYUXGM$>F=JYKM8
MK><%-!6@* =IP. W?=;RNNDW<3)=&,G(,IX@BL)FMN-U"-IU9Y\"'130FZ-)
MD/!C;3>D,DY[S!WA*CJ;S++TA8)B1W1DZ@(>]@2+070 I)\E;2"[/:(KM]I7
M1F*#D2E7^,RZ37*E=G)HM2LYK4";(!B%F#/!&A2P5S^38D[$"%CWI_#0!W8R
M%W90,!B7X!GP:ZH\4MFM.KY/6%&M/H-S5-AUD37]3-F]GYU1'JVQY#O@//0O
MS\.K7^2-L.?Q-<J3$[Y V7H/"/U>9,_XEON'5I^^!#"2LS*<@6V[>OJ>SO:8
MEE._8U$P=H9;Q<(%]1$(7LFG5<ML5N#@(TT'I?93*DC T@4AR7:!3US.QR9:
M1R.4UK$EC#JN[&REYDZ21,HFOME>]W<F9W^/3^*:C6J[DU^4E%Y49F@;TN-:
M!YN^CVQ4*01$%FBCW]OP9FHMD'.3^LD:G5N%%7/?I8#)HM4H%^[@*4K<Q_>N
M:11I:E2^#1; *ZM]2\MG8OJ4UWZ4B(^>>X3 A RE7JLW?L,YQ\$*'YAQ=G%&
M1:!%";=3-)TWZ*YMD[HN->>)S._E1Q=D[@9L\@?APR*+(QR/CNR'&<K%EGD^
M1R.FNYQ0B0>HIMP%[8KVK;DI/I]@L6!9CWVGT!Y3,U<C>0]K6W:V?G?R5U7C
MR:M$X@P[?>4:4SWG_.]PN&;K3U<)E1E-I2"/>/.X^"0:Z_=*[RJ1+#$O-(1$
MJVH7A.A(C2KBX<&?A8>HV?.<3;[+4<Z:O#TK4+#L.#[D;K##?3Z*O@+,5U^+
ML=\-OZ3S>LJQ81B9W'.$<9]T7&%>*XC NJ[-/;;-B^30M*':X265X:W2@25P
MZON*:/;Y N23%MQ S:H(5[6UCR+].8[ETL[OF$.]:^"Q5TDW2P) 0I?>:/\&
MUR)E=H6T#J7]_@I!#DL1J:V?)*131YB98N!?!+-97S( +(9J@S06!1C<3B&9
MDH^ZF_;VC[XF+R$^&/.3@LY<Z]F05\TP%J<-DU>Q^!2,3*9>[V5$.+LNIOB<
ME*_@1J;2T5RDV4$'DP(9J:#BU\S-$(,>LZ_TT5]?OCXZ2GNQO!^:O-WO]A(9
M+R=NMO3]E?P2%(2XX?8+R1XAW'%L<-[%">3T+W$J$G:0S *EC\7G*]-^S0MH
M?71G*W'8X;JEE 7B\+$K?3JOCQ&S]@V?-*;0YFGR94E4.870_68I@)]M4VS1
MZ[5?A<N2WS^5$L2\?%\P"4*8)8K*HTB3JJ:= %[!;7>"2[QC/,H*UNPMUV?A
MR HO5Y7YL!<*+F7\_!G3TS63U[)FJ"?MWK-GKX^,2+^KZ_?.,_E;'H*$X"SP
MR;W'TTL_ +=IF]Z<.T%;;E";)43*KKTA1 ]%9]4/H%L!:W'+G^ #%,L1UD&F
M<>R+D_8LCRJ82E4^(^PL!ZGQF_DQ7>^,T7!K[DNK<M46,_>2PFK%#B,3TMCI
MW.-!R<AD7(!-J65NJW/:OLRD3GU^*B#3\+Z0<HV4(LI6&HHT32"-N^ZKS@5S
M3T@X&/WVS(2'9%/&K+(43_FBJ<Z@^7J]JX9W7Z U*=$>0XLYG1@*(1P2BZE!
M<LTY3#5)!9N9GB+Q2DI&M/GILO0;HV^Y&6ZX!8$8".3A%@1R"Y[E<X) ;M$Y
M]LX7DUQKZ\'>_J-O'CU^FH'ZN5(7[ >&]4V>DRE\';T)]\M[/SQ__>9^Q!HF
M;8"^1S ,WXM?)C\5,&=Z@/+!1Z)IB\(Q9FGZ]"$=??M/,A$8,6$SI'$UP!%0
ML30SV.E"YMMG=]DGV]&$<'+H'3O=R<F<Q.]BHO7%+PCE2B<OG.(71W^LX#S)
M<H0W[SWJZ"G8BT,&3\+'!(TXG5IANQ<[E&^1N"'J$5-/$N5:&/V7(!(40NG:
MF@24_4DC5U82OU!-DY&$<RLV\WD?IRNC,SX;[:H,GK"ZR,I5 *9A($+&(X ,
MYZ!%6/?*^U&,$@_64A=K.!]6ZB7PXJE:25]R;C8.=WCBBS/)V2:#(56$EFX2
M[L*_B[,FGHIQ0OAK?HSSPYLHW"+<HXCTA$4:W7BLAL/<)P_LUDEXN+/RN.QX
M0^M8#W8*HU.U+;6_>M5BO%!=Y*-P-$WNO7A!SJN/V7K^,6]OBA+ [QKERX49
MU2[\K%YHP,8KDOF(JTA)#) W)YV3R&9W\MH<EN#$K8([3!AK<CO83ZHK]5<Z
MMT\E_[-:ZJ2=AC?J>&#^X]^>'#YZ\.W!WB18X+FDG1_\?\RT6%'U2((LJ4K>
MM6#F72U<%J@[*#@H)M3F'!QK]%96#B^4[.:VJRE_CVWM] PDNRQSU(L&>B;.
M6GPLC:)M+Y8!D4[OUEV0&@#!#LS>KOKU::*/.<['Z)6;@DMMW*6<-PM'8\DK
MQW4>02!FP>1.LFRQL6@O2OC&T0E2Z=D@5/$LFF'6')MS8M@(6Z)R$'0/#CSB
MN>HK/%J<&ZEXV^NB4 3Y<=^[QG3"1O&3#DLE: E-"XQF3P>)'"[3^';,A"G+
MWH!K0KF47+0:Q)PDK3\=9>.BZ!;;,/@A]*%D^Z:DJ+%3P8-_-/<__YTSJ'<_
MD?YJV-^IM+1G^;_R9D8R=#I\$N4U/9[R\[*I)?6M5*S2")N?%-UX7G87I3;/
MM[DAN8E"-=%L\F6O5"T@U1&623*U-->-'16NT*??PE"-O.Q=PTT<86=)17B'
MD9?!//18$?CX$\IBGV1<6TOF_(4J8\#%=JR]<FKX!4%G2HL^HD]:&BE/6,I5
M=<6,@5O\(UYDL"J4_ TL&\#\\<VF9]0 @R1\D\_*.H^LOF1^Q,()2<38@QG"
M0?N'W,J_>IC\9KAGHQ/"CN!7DE<%N!F<3W9PS\)OYVHW2?",,CW@0ZL%Q!D?
MDKX2'*2=^)>+/-CC^U)AT<W%Z#'(2S#A7+*-VL(9"2803MX*Y]H9-0**%&#-
MG:7I\0P5>N=YT#J-6  CER;B];"@^[U&@\Y1IZ$2Q3WJ,?3!=;?ZC>_L<2/]
MAHY+AV)Z"7YH6]-O#;-T]\^C=UQ1F4;AS1 5H!)13]]37C3"_KT38Y0(:7_R
M.EHE?VA<\1^'6&!:[KI1ZB9#BB58+7P6EGHA^"B''?,9Y#MVN)!AY3G@V0G&
MX1RI=Z)N<)V5W5E3%.1)=V?!GT<58@2!D,7& /)VC=3)4A,_'[U]?O1?DQ\X
MQGI;4+A!%X)F DRT_]GH6@$(12KN_[ZW^^@!K9-_/]S=?TA1+T\1/&/?]RCO
MQ+HZ6MY;<X/2<W<8M*X5>)A?'PZ\<5(2Q(IY65E8RP=&>-B5A3]N&;7<C])H
MTJ+4Y:@7AM*LDK:[>SNF>!!-:=F#HN@5OI&@BZ=ULZ1,*7I$5'4$E^6+W*>:
M-J&89<+[S]%^TE!P,50P<DR@F\]E0_5I0T_*N:3YDFVG.*8LV7#VQW@\TVCC
M]9L"-)Q Y@N;7-U;Y;&@J8M='5!O?(R*+H'Y$;;*O0;XN3YN:$YLH+$0Y)G4
MU+$7?33"@>,)J;V'%\N*G<GHK%_?_7%GYL<9R+&.-2%91L!H5Z(E1<@=<61]
MS\\C5(06QMI[_?FZ29/DO#KLIU%V;O8$VV@7\6Z/;IK+<E-](SW+'^P^I+'0
MOG6?*@B&]V#R)E'A>#W/JV^O=11M9^$WSD)K>4ON7T!V0Q")+DBA0"1+T3]M
MMYHI9Q['0[9;QUJI_+Z5Q+42N!:$CC6L"D*+S'7PVQW=\V2)EVW,RKY5(UC9
M\))G1HV:E ,R(:S@[ G.M\&+45Q2+)9D+(-YF1>K]^$25 (_RV<]$Y;2ZCM3
M?2WIH>TB_H1%W#%]D8GV0$'<Z]#W,''B<8]JQH+NRZV..0-<!RLB-AZC?VAG
MU@"Y7 !<2_#DV*)+(,D"58,=$KX&JTNIK"H([^9S^^-VE7P>4X=RZ&B?9][&
MHF#PAA@_S0Z4>*DNSEW7WA;9L*SYRXOEJ>OC@KQ"BU8J?;!="9]G)3CV<# .
M1= \I:56-*-,"3\\T&+O\7:R;FJR?#"AL./14L?Z*?CCH;<>;=%;M^!9/C=Z
M:VM;/M*V]*(:[7'TC8T#YI48NHQS0:1M@+ "\N4UO;VQA3$R66@>8CK: <XA
MEN]XW!X_GRU CGP%4^"CJOH\>@R$3>B<+JYQ0SNE7M+'*2)7B7F*XH""2%_E
MI)OXS^R#N!6[G?//-N>J^I,TP@%990#3J)86R2=4"ZENMAOTQB;+V=OCANL5
M*0U(RF:AZ$D-POHT&0Z$NIVSFYHS(2T.$>^4>M0LXE8P >4A26>""B%.H 6F
MC_%MJTAOL9VG&YLG4%(PW"P8MJHH9GWA")1,MN-_0^,O?,66&P*KSZKMFDN!
M&* ^9C# @7XAYZ*YE,AHL[(Z\6)(JK+96.)*,,.G11W5$@"6NG8[]BV"$!]U
M+%&1#<JF1MIM55.F9-&V@Q;4P<0SXE+[P;L3KIT8-C!NREVZ%5%'QWWHR9J3
MRK>RMD=>:IQ)># '5YLU.57?I_+L[04(*-#%0&F&R661-WUYHUR@=I38EF(,
M!#W]HQHTCO@<B&"?F#&H07&'VVM:L&I0(958OQJ%JD1"2:'PIUHI\]:-RW6>
MH"J]ZFJ\!=XS-M&T9\7\!&I,1&RH/;U=(:-[%-^#-<^(6F*Q[,9I\)7I7@=6
M-93 X<DR[RJ'Y\<7]:7=F]G]'RF'<7=Q4<H28JU5120]I!SW3I>_+T -&C7)
ME#;B?4'T[)BEI!Z33X$]!SM;P<PPH&;EV@I]R*DYZY1@%4_4_ C I[M>$"IW
M#2_[FCI,VE+X2Q%2$)\IG-6">Q04#:,FG:FPDE;C97(53W:5&?A\= ( <$S8
M^&Y@2J2=*ETA[I&ESVH+Q+@I)R.<_WDPGNV9(C%RABV%94:^=DU<(.20&R$<
M9AH)#0+V4O%R@7;)5ANQ^#<R_0#&48]X!T)E.H^W#ON-!<,DEEN+9@[O("Y?
MKSB..B<Z.R5P07>5MJCZ&4X5>AQK-@[Z.9^Y!+0.<_QKK6PB?E<#<P9$I%[4
M%4BWTW^30 @G<H2^H5JX?$23XU_</T >72XNKN#ACN=Y]9[:"*;O%0ZW;$C6
MA%*2[#5ZW@EPM!GK [5B$A.+00$UAWU!@-!PB*AE%_=MNP9N++<BG;0E"]&,
M\& >7TXNPJ8E/*NT&6?<^0;*,#K=T9=!H)3!CU7]B^:S(IN>&YUFSP1L9_CS
M'=BS<^SE<!R7TR)MV.3FX@AK0#.Z&GW)NHV<\77#BO"@8 $IH%#ZX=Q7I4L<
M[. </[Y,[7_XDE\\LD:VZ:(;3H4O2L4H0:*PYI(3;>5\0OR/Y(2OV:]WK3W<
M1/36AS<)$9O1\DWKQ;%M!Y3A- VFYYPN8AH\5N?F_G%AM6V,-#P-CKC%>*H&
M=&6QC7M"XXC^].OF+%<W(3W?,FKTNK02&H&,G#B?@%Z0CND3%BL+S_.!FY,*
M:@Q1,N)^:#99@)E*6;/(IRP6Y6KA%,#DJ->T68S^@&N4=INBV@F/1N*J":)?
M! =H, 0.QV4V[C]D 78FUR#;QE%D!T2>^J<I]Y;2GN3M6?Q=)IX+K0G6QIT7
M+EKF/)5<V]Z#)R%A342:3/%A89W<(YIF)>^8DD(*M*R)@H\>!GL-\1,ST[;W
M7:L$6A1MI$2=.[XIO:'2*-LBN7*IW>[V0&7H\3T77T7&*]4:A1PL.IUBPY3+
M PN+0"9RBF$:\W*^:HK,6 &4 K,1!=?,"!;J)O*KS/-E*ZPGI L1;T#63"!R
MN$HEW=0KH@RQNV/W.I!^A.6'=3]#_/?LS2OZ[Y]>)2SR84_FYAZ0Z[B:$WJU
MS41T67L7'9/QS,1H]6Z^W5GY8XVE].Y* AS%WK>4KN'"R$B8B<2Q"9$ !]OR
M?$&D-JV8OBARE) 8>322DA^-X8G 1)'R[#POVF79%2GUE36!V<**B=F-2VC8
MYS&RA'2YQ&;WNCG-J_)?VB1.:^R^^UZO@;_WY; 4[SN3[1>CT WI:H2I/E_-
MR>(0I*ZKT2&;27<V';=5&-N=^H3F^AQUD%5EX?%,R@K<_^)5J&"LWU+R:WI)
MZ2X=-6M8E(Q7;">!\GIZ:11.P<[<.U^$<K]1D7B7P 6?BP<QD&=';?]XCN"8
M4]8'9J#\YRJACU@0I),,S%GXBK&4A//FC$DQ$R;@(RD>48$FLX8ZK$FZSP[?
M")M_"[4UJ.WC+=3V%CS+9U;+_$*+35&I*9^4&:*RF@J_KE@B_G%!)=Q>/1A*
MQ)+)$Z\W)O.B52)# ZU>D+R*#K/J7#OZ#"_]/*)<'-GACPO.'^.9^2A$T:E=
MM=,B^ EBL,U<L<EAUI3K>%6_KV,3Y=#2\P3:%.S=$!$)Y*6"SQ:,?+L(;RN*
M?!WE6>K%8E4IN RT571>-\!5B/M'II?(O'&RA*,V^/:E,969(UC5DH/!((=;
MG995)O']"@6TQ'/4,?!D^M\SLTC'@1%D+2"(021H16RM!-5\$SM!12/.]]"Y
M(V8SQ5=T"F,39]\+=.0Z-:C-YM()"GT8U.H3+[O'\MMV?>R#OADY%W$\FO0H
M3EG@H%:9ZF>FQ(.CF' XY14=6><IUZ((^L7)9#"W]:.>ESY-[W1&=>7VA!6X
M$E.!XN!\'7OQY"BL5*6/;)FL3=4$E?] MEPI_Y(Z,M%^1#JZ./+7)P2YO1';
MLPCD[?(/R!'QJV[D7&.&_2'MVEV+43:H4U1$^EZO6G7ZV0_,E+L[8TR.)ZE(
M@-",.6A6\Z+-_'[FBH%BWT<'60P4U//0U>5 ;!G-4C2=-&6B"B^(;'P!Z+7X
M%V#P>7+9B2>%1:)RT1G'*P:+UQE!&/98HK\@5+HQ5>@L+1QWPR_9 [CBV*X1
M\>^^W157FL8FF+T<Q@UIQ[&Q)2[=.6 =B\*]?,.,L!T;0&X%$.%(XNR I3*"
M,&/B-5[C\\+H<QDC@H]?:GSW1F0+WW(X9-TG$"1\UR HO PQ))VG-.&[$]U'
M5$"0H9[<D[9J^<@8/L) -\I&YN0D[Z_;>0SMU1SD".V'4.)$Z)N0N^J=(X9N
MD<_X;?2C5 G",Z2 ZTL'3M0?)M^S)-1T8#4^5141R<F3>7TQ3N-8KVEM_ I8
M'-]%VMV_AR><U0L3J:/-,&OR"_*(5(SNQ2^>(D8//C>N@E.UKFD/@E5<8*VD
MK(H'S/J^ADKB]6BX-AFJ.YB;>F'&2L4ZA.5J+Y-]_O?=,!3@N^+R;BZ0'C9-
MD1X\8V0)AM<HV+]KB@]EQV-['&:*$H#(;XE0<'CH>J8#7'Q80LDJ?/ \;&'<
M1)_FKI6@7KIWZ(VFFE!B5*>VOADKIK.+R;D>6T^Q\2\3TRY"*Y&1W:X+0&L8
M^ EKYU[4P0$-9AEL6 HFQL$L-, 7J#0%*X=$7*1)J68F9']*0\(PYBL>C\D(
M&7"KT/0:+D2I&M,GP6LM*$#4-:-$Z^U9N0RKH[LHBFILF#QTG01+.F4SQQE#
MSY7QHJ*R%WYW3L$7Z5K.M-)TU>#BEI+S"T<&G47T.A']K$4FCGH4L.SL":I#
MX=!H,#-4&)_KP,OE3^MZMO:2.%N8?>[<B(_X%PG]</SYZ"^61;V<%YM&DS*^
M2]$C52K]>/3JW)B8YK5&[Z+(-LFCFV>H9R,(,,D9\_;6A%C"F3J?%W2L?@6'
MVP^]PX@E%K5](AY-.-.&4=PJ*O L\E,HTVLUDRG-X$%_E&#-[3R(>E3.4JA
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M .;+CK-ERM"KS0N.*B%J.XXG&9./Q;LQ\L/KG.JA6 <6)1M_?O<_4$L#!!0
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M7WI]O'R\^S5]"O./^#ZL<+<43*L)<E396P&B1 4*:S,UPQ,P<FUBL,I'U[S
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MY!&E8)-S2EMC_%J*[ $WOV?RYNEKJZ$%U)1&Z^[U\<Y*-!K!^ J0EWINH2S
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M ?Q/INY3\WT<T-YQ$N5NO8M)!*Y\U(("LZ7-C*,<C$L1%).!>):Y8?>%OC\
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M0AQ^3?'%=)IFTW^F4<3MZO=I&@0CJ3?1 CHM"D1@ @RG&4'FD*(N7*[-D4[
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M<&T75#(061!\.Y@")GG41'&18^W4CP,0Y):3Y,/P8QO1]\"+LD0>Y6,W2JM
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M1$",.N3USC(U?E)R@EK0.DZO%=7"B3F+IH%?YP(CSS1S$IXAQ?;.XF3A];G
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M"6NEP$:KP:W<KUQ3,U-JO)7RS4DU]*^ZT.\EB_GH$^\&/%>E_ZX39MP:@4Z
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M$LQ"&!&>,4(2@9A11YIK!9D:31^FS'6RX)1QM+3*(KYF?8QL^E%0]V[E[QK
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MSJ7,N8F_<':&J?D*&]G [UHZP]V:\_CULXP35#R3B2D@QD1Q4>D^/E W=[A
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MGYSK96JR]ZE]MBI[[TWVF;T?Q#V9MUTA]#<XBW)!8H(@3I(,H@PS2)@DD*-
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MI5EHEG-=DRE!,$UT]RU!M!T9QE &8< 3*2BV(^^>N:;&QXVH8*EEO0'+6EI
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MNLW&.NT7;3:_S3Z-X76Y6);S@FO_IHZ_+$13H2Y%*:5)S"!!80@1P8IV,Y%
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ME86)0\)@&$=Q*M(L0VEF90Q9"C U&VDK8?V$6=I&MN ;FDP>(?7,90>% &[
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M ?OJ@8U^KJOY>5T$I]4 _4CZ M4$O4)^NAJAWRFO:%I]NN@&P92&<8X@94$
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MRW $HH&3ET\ZY2\;=CJ]6SXU)%7IX[\_F W'DQG<E^W"'%"*V@,6*ZZ0R#B
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M7>1E.\$<*B_;3=B Z)>C3E:-+?27%R%4491;['J'751YHH\LCO,<*P5$0C1
M@D# S:_,?B#&)!:80NQ4^7N@_-F=)"M-[?53Y53[Z>4YVJX=H^N'#H)#@,VX
MT([,TZUMV<SAK]+_^/A7[-*8QX7=(V)G7/@GBN4)/PQ^$3_#0>R,!1KPVNFB
MA(;;?!0_=,5K!JPCO[PLEK;?UZW99EO'BVV%???TO%G_J%RP=> ,Y$(FJ4H
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MRJO':R\2@YJ\MK]ULBZOO88UV[SV?_C*9)>JG]8A"B;5A&<(IR"79F.!>)H
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MTP12P'ANO=]) @BUA4<,6RF69!+%<%!VS@5A<R.H=^N5M&PD(YM]O5XN9!6
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M2B_$PI.)6M!T(YWK,1J97W8*1OOV->'YI!N$8%WR+@J9N"]>EZ'GG? Z/SW
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MQJ3"^K%T:57]\867 W#XV#GX4"<9D9'IR]@062.BVHJH-B.J[8B^KB-KB77
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M<5>M=21JM:/M06_SR\*5N7Q@[V:LD< <_Q:FQ'&G<=10N8H]Z[]S&0RH1\&
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MA<22,R92 BA4ADYPA@R=B!2P+.&9-(22Y9E7A95.<7-CE"JQB]6G%+\6)XX
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M,Z<MGI&4'Y<E<V>YW<#0\%WEX<(;7.^;A.'7XT5PD_^=W/PU?@<C:9$H48I
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MCY5!'VGO:!88JD1&4,!:._ <HUW%*/JP(GG'564P]LA.(\6X=4*$5M3>S Y
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M7%*R]HO"4_3TX"KC?GE,U#?;A"AF5(X47* 21+06O H&_ZJ,M:5ML*J=<GD
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M+%H3O!2FMJV\2\&P!9;#8^L(?32 )I19Z22Q>J9X/U[\\0)I&"_+5R.'].;
M/!#D (0J.;W( 6X,*FP(AK ^C-@V<H8M3QP>9[4TU03HCO05;HRWB%(H(B40
MSDI[<A[ 2D5+%XG$@O ^Y=HWYO6H'[8<L05(#X*#!G; YB'NK"3 +]WTT]A/
MUJ-'-C]:>\4YI"PQB$;OA%$0.0HP*5/@-HEL Z7!U,X,VIFX8<L2A\=O/UIL
M )ZW9LE>[\4'4V7O;T&OK _:6_"B#,4A(8'S#B7)H]8FD!BJF^)#Z!QV;/#P
MH.U=MPW@]Y6;3[M3(LV[)X<'IX7)%&5E@);18Z+THG2JS*<-C#'M9?:^>FN;
MITD:=I#P\*BLJ;$& 'B="7^?#Q>85@+Y"(DH$*[T07>:0M TD,"E#[+^!,S'
M:1EX?/#PF*NBI#:?(G<MKOQ8_MIKJ>AZA1,6C#[&TRG*1JD2-F6-GEVT&03%
M^-MD1 V+@4K%//>JMJ?>9]GHA_ YQ<M)6C7]>%B/^.'S;+XL"8>W%-*)_M;-
M:K+$<1$A^B1!<&MP'W$#B>B8<PQ,R-I%'L=3W7!1Z3X(NV_L3JS.!L[@:U&N
M7-I?DRO2C.?3]\54E%N$7]QB?"L#Q4OKM>024E2A##^.X)G%<$U')S%,DU[5
M3C;:E\9A7QE[ V>OJFKTA-ZK-/B(<_J0=4Y>^MSCF?U4L:NW-%JN%+J+Y=:0
M<096&0TNE1G50C!2/=^ZQP+H&Q-_O<@+W#WXU3U#'C@UGGH/*3/T;Q/!K2IE
M FJE),IP$WSM-O"[TM9N8?0^6-E^^%;43 -'[-89-#<<94]DLBP!9VBNA6.Z
M=&Z68!D&[<XX$D7M@/=YJH8]1OM"665M-("OFWVSN4^_U?&$F>QM5N"M<^B-
MHB-J$LT@?7919B5RJGV']P0YPV;8]&^WCI/_@%#JLBMO^-B,%;Y:IZ5_G)59
M;N?YW0R=C25Z)J\OERB]][,K-[F^3+A]#\Z]$#*"C![M,Z?H[GJ",L 8B/H<
M@@[L.8^L*D7#9M_4QMUPRFK*V#T<@7V/,ZT96G+GP6<=D;.$D3CE!)1P3BO-
MI-2U(]7=J1LV4:=_4UA5.VT&I\^V5C@\'MWUHT_1(**'J'/?+@!>,"9R!,,Y
MFJCH)'B7!#!-?,B*$TUV.T].UB;B9A_<3/:YM17.EM=W.?=O#QG5:',C9*'0
M7R#2@O.1(+^4.2N2UJEV5\5#:?T^&DCL 9WMQJQ');9IVJKU4#C<!-8FH:7.
M$CU>Y.U>[Y_0U0L8G@")5I=TV !61]]533&7J!.*5C8U)^LO<;-UMRS9*>QV
M"P+#<G%!LDZ^.,$9Q: I_D%I3I)GRFI/)MV3Q.^EB\0^J-IN<.MKK4T[^WA3
MAL.-YI.?UUL3B1[-V9&E^L[S,O".@9"ER9W.%KPLN&3"4T&=(Z[V'?ZPK21N
MMM KQ,OL*J4/:?X5W:7'YY^>3;J/[!*(WJ<P^S0=_Q.)ZL9YW-ML60ITGPP'
MDT,J+4\M&!T->.T")RHKFON+IBLS\UVWG]@'T]LM[)#P:-,6']2FX2S&<?</
M)F^F>3:_Z/[UZKGV$/M=G8:AVE?L+)>F.EHPB9"5/D",M@Q+$AFL04SC%SZ9
M%'Q.M6OYVNIH<7:MW_.G]=L=^2/IO-*XN8&JB-&U$@0LT1*("@9_0H6_G[JV
M0\.+_6CX$?IA[ .[K?TP>E1= ]?^=P*"<O2LAI[AX97.OHT7(Z>"YR8(L(P+
M$ $9P\.( <G<>^F9LK;79HD/21KP>NQ4L'BJ">"1.FH <A_Q]^Y%HB]G%VX\
M15_'J! Q[M1)%T:D 5O:)0KODG52)1%JWQ9L)::A>X%C53[K0_X- .G&U?Z:
MYG@(I%_3A4_S$;>6$BT21$YQKP7M<:\Q DDA,RDD@S^K75_U."G#@JB2HN_7
M2E60>@/@.4,C'<>3R_+X<%.]\>I;F:V<XFL49@G8+C=NQOT*L5^N'O^ ;G<J
M'YS/N;R&*(.19-#@&),83AI/ F&:Y]KN;H_L#).N-N2!VPHVFMTFO[F+M#8E
M*1KG.3% ;6F<Z30!7\;V&*.RC53K5/V&_SF:AK6ZS8!G)U ?J,G!4^K*??GY
MER+"Q?L/OY<2HG?XG_51Y#-7U@D/AE,.PI:G"U_$% W)D4;A^+W$^FUY<D\M
MTR+,#E7GK!?9-F"_[G@_)36YVT<Y$)($XY!L+DQDI-\["T$8QF)TG&C79U2[
M(628O-UF8MF#]-$BJ-9;+A@K+*423.*AO-%2L,EJX)Q[24QP6=>NP=U"2D/1
MZV%*?@XV!TA\Z#/KXY^SCY]GEV4>WL<_48I7'Q$#Z0%G:SM+G->*APR!\C(U
M@C$PJ'Q07"6'I"5ZOTG(EC-LKV4;P\TA6IZ=1.1#@^D@\_UV/$UOENEB,;(1
MCVKK&-B<!#H'*8/5.D"P3J44LC7WNP74?&"XIF.8^H$ASK]3*VUH?)82_VZ?
MC4-Y>G^TZ/_LJQM/BD1?S^:EM.)6[?^(&H81C: 0LV8@/%5@=-*0E?4N!V6S
M?O;1MP8AW]MKPX%HF0VDNM:<N;LI<;]=EG.A5/PLND?WQ:O)>).'VN5JX)^E
M*^K(*8U"C0RDP<A(D(2NC<ZEZL<9XAQG#Q+I^TKYW(?L[^UB[SAL#Z7O!B#^
M;C[[.EX@0[A;7\XN_3)?3M;B15ER:GCB'%SF&K=K*$-D8P1TR5-TGGIM:Z<K
M/T7/]Q82UP%E-0TU@+8C+T#/+@K7Z(P;@>>% R=,!)$Y T<4_M5&)IS&(" V
M]H:R(OQ[<VGKX/?T.F\SUW'7+G&[_MZ;:9%@R0&XZX(=G@EY8@I/V'FO#YF>
MHG.?R^@MEUI=&JPO/:0(.*TI<$V2\&C?N:CM//;9N>\Z(>_-M#A:G2*NO[?J
ML/6+FY3$@0^?4UK^;3Z[_%)LP4W6GC4IVA @\3(SNM1)NY ":"&9%BP1R:IW
M,CR2YH:[]NV#K@>-T4ZIR@8\EV(02NWKO7!W^<+-YU?(6"?DD9:4.:$%4.X2
M"$,H6&X$!&]B8E(29FH[S#L1-C (3XJ5^Z,<JBNN 33>OV.Y.<%>)K^\=>ZM
M>GF-<FESR(0$$;PKJ5P8)D3J@0JCE;#.DU2[)FM/$@?N'SDD0OM4YO=^UXO'
MDV$NX1&E=#FB @?/E0$N ['.)$/<;FTH3G'7VUL7K4'@>7+]'8[5V=)-A@[;
MWLWFRXR!\VR6=_TG_4=JAQ-UPN"LDN1.$8]Y$H*7G@"-AH(@E(!/SD-R2@F5
ME$_5LW=[C<?N=C?&O7RKU\HCO8[Q%WZ;3>=W6Q]W[YZ,D>B%L)"8QC,)=SV8
M+!U8B]O?B*A$]1XZU8AO.$+;!V_/M*X^D7(;<(ZO&?_EZOK+OX_3'(GZ?/4V
M?4V3+N>(VYA#S 8RBZ;X4JE4 %*0G/ND-'4BU&ZQO!MEC>#QM+#9!MYZ.FP)
MF6LYKARY!_QM4INHBL83CUN>1O2=F%LEUA)CDK5.2U&],GHO AO!:46$; -A
M=76UA,4WTR^7RT4G,;;.=@LN$MRT 4B4"<,%Y\ C5H"25"92ZRAL[<*-)\AI
M!&?U0; -;D=JI%%PT34KF03BJ14@I%,@A(]@G(Y I/(YAJAD]4SH)\AI9&[)
M(. Z1",M@.OA;4AGZGVVF<J4(9<!D )#0?"29>#:>$ZC*_-,^W\<&JXLLC$/
MKH*6&@#;Q[F;+G#E;A)5U[<)172KM<BM&[E24[UX_$?K#:P<;JZ@&.3H/?)>
M6GY3QH K0H14,6I9&Z$UZ6_N%6E_0-WO=S"4=AM ]HO9_$MIXIONOC*LSP1=
MED1W&80M)?LLX5EC69E=;O$G6F?-966H/DG0P.T2!L/)@\'TM936! (O+M*\
M".F=^Y+FFU(;SXU0FN$I0[OGK00.=S*@8$*047I;W4@^2LBPAWA#B#M620T@
M[?</?YM]3?-I=VA\2M/PX'%US1>S05'/"1 A<G&Q/;AH#5#FO>4J&$%JF[U=
M:1OV";(9//:BR@8@^NMLFJY6;UVO+Z=QPT5@5'L:T;O!(*^,[!!@M7"0K/$Q
M,T]I]<R-QRD9=IY/,_"KH*8&P/8BS9==VO>RB.IE^E*J6C9='!(UF24+,C T
M[4QK<"(*X")RH9W+B=;..7V"G&%G]C0#NUH*:P![-:XGWEY7)L20;,Q>0_!)
M@Q!)@1&"@'8Q.B=]J-]MO"H# R<6M7%5-!@B&M@.][.G[OHR9Q<SW/C_7-4@
M=HR.')-:"1) )HI'C9<*7 H)2$I!$>EDJCY#9%\:&WFQ.3V<GLGLK*K;:NER
MO6$WA,N+RZZ"]F_SV6+Q.\K830K#?\/C\)>49_/TT7T;V>1<(!9])R<#,FTI
M&!E*SP2?B4)Q&%H[X*]"^/=_RW\2E/> @O;-]E:FW^+?;I@.7/FH!05FB0'A
M* =3LF45DX%XEKEAK4#_#N'?O]<R+/0/1\'^T+<KZ$_3IVY2[<EK4$::!NE8
MUF"S+8<:2^ B#: 2#SHR3@7S Q6?#'NIT2Z.J^CR8"O]-<W]K!)*;Z62/Y)I
M.S+!<YFEA6 IQN1&1S!*<Q!:J,!9MD'5[O;X-$7#WG>T@\B*>FO 6RAU#2.O
M/#=2>&".,A!$"7#>X=YQA,:83-2J]C2OLNY.B%(_/J+VUL'W7CNGJ;"9*@/.
M*HINA7*KXH$@DN&6LBRB;J9V3O^X #RY,K_O0KK*X]UJ+'O"8KA3#W%[LOPH
MDV2(L0&TE@2]/9[!B200\HHF/(")J)]1V6.Y6YUH+27CB50!N$^FC#?7X T*
M12L>#>6$:EX[?_ET,?LP96[[X*R?$'P?I3;:7FJ&UF#:#1/=S,1+\>$$O)4I
M66R&DLYRL4A3W#=7ZY\<9&-KK5W#T/8BATK6]F:1ZUUPO0E,8BZ4[%7-C477
ME"#^\1O -</_#1816OO=_0ER:L3=W4>_=W_^BC*?H_ 7OZ5E-W2JS"I;C'R(
MDDH707$I,89SJ623&?1K2$ _*EN?:QO2YZD:UDK6PL=CT71%;30045]S](_9
M_(\WTW?S64B+>RP%G32EA$*TRJ//; EX;3@$$Y@6)1^V>C>F'<@:]MFH=X15
MTD=+$,/38[S <^)OLUF\OVNB]U$Z#F7 $F LIL&FJ('JDO=E?>E9V1?$MI,U
M[/-,[Q"KI(^6((9<C() _'NG0$>&LBEM<EQR%'C4$>46*(N]F2M<?]BWD-Y!
MLZ^$&[U$.="[17O\)<V75V6DR=)-8[EX^G+K-T_I]3]+RX!1P'YR.D%4@ )7
MB5(\)#6)("PG8#GUH)(+7EK!E*G]>-IC5+ 1]/E=09_=$O0JG3#G))DW"J(C
MZ"IDBSN59@\\IT0<$3K&VK/%=Z6MW0AA'ZS<MY.]:*:!$W8K-[]<E8SMKH(T
MD<QYN5%G-I74H^C!A)2!9<\CM9+4?P3>@:QA<=8/'AZ.-JBJG);Q5AA:%P*X
M3!5G,:.@V'I"NRUA$35$A6"S#JYV>Y4=R!H6;]6AL"O4#M3+T(_#OURB.%?/
ME6^36Z3/LTE\<_%E/ONZ:B*RJ4N2/H<R"Y@*27%WF@Q&E[1\(IVB+#$B=AOF
MMMMZC6+H4!W/^A7XT!A:S=U(\]>7\^EX63R):3Q??KXN\N6$R$C0H >>_&J8
MG3/6 Y%!R6 ]M62W.9//+#3LC5BOJ*DIXJ'A\JN;7F:WGHZ%'U?Z$* CNN'H
M6FX;UIB)498FPTJ@S'+I*D2$!QMLP(^1U!.Q$WKV6W?8NZ]>P=2C H;&U@TW
M][F0.A.KC0";/')AO0:OO01O&$.;JJFR<B<8;5UBV(NO7A%31ZP-N-6W[>?K
M\;?RU4WIM? B8.RA.$6O,' !WB<"+*A C<^>^=HW)-NI&39]MR\L5=9" WC:
M*JFWUZE^NJ2X&QLAB%*01#'0\)$F#&RETHR[)*FNC*OGJ1K651KV4N PU0Q]
MLKU,N&P8%[%LY:Q+31I9Z[(-D@$-9<0=9Q9<"1VXD\DZI9*]W^ICRTFW\Y*-
MAFL'*GK6N]0;,%RW$MHV/*XR1+],TGJXX[JNN/O^5N9'Q'&3G%7 C%2X18,#
MCU(%RWWBK!0<Y]H=^VO1WFB\>!QL!U7P\%6%.^_:\HX;*2'!& :>:X/R+:Q1
M@D&TU=)K8540JIJEW/5I_/0QY8GLY+X2;Z Q07GU[29YHXJZ9*1/J+/%RN ;
MESEZN1$<IQ9$Q(C8:^X )2>B40CMZJ\]3Y#3:/!9QY;54D,#Y^[3NP/_1[BD
M@&M.D .,J9PR 6@RN90CIE ]!#W:7)T^"*V#J6J*^!$2?'YS\[DK@[5/EL;S
M8,63)^L\S?,)4G(08TQPBB&"$J44+UKP"H-;1V+R3%/AJO>K.4E*3DFG_',\
MF:Q">#S1N4I:@&>XGX16'@R+ ;A /LO5CJ2U;=H64MI-N-D'"=L3;@Z7>P/G
MXJTQ/%V![8N)6RRZU_J(L8=4D@(QJKMAYF!-J>SB-(MD.6&TMI^UE9A6<FF.
M4/7V 5E'R+TE *WJLQ^IR.Y*L'^?SGS)\2Z"ZT:8X(]G>#Y,5N'Q;2FL+[JI
M%DFC&PE94=R<7$OPZ!M Y)0$;0E-MC?\5>:ED=+-XZ#V=-/'8?0^].7PATMD
MRRVVQ]Z;UQ6?C0Z:@M2J-/9'Y[:T% 8;G' !R9([/H+NN& C@!L4&K.>]=2
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M,NZD=.C+>*"5["1-:0RZ]ISHP^MO3E T.PPZ=BK=V4=5#>!MWV1O'YP2PGC
MF,^!<,F H92"<M*&&*F)U-;V:+__TIV]0'%DZ<X^&AKZ,F>'*A+GG* F!Y!&
MXW$22G! &0'M;5:)JA "><Y+_2%+=_;2\YZE._L(O5T,75>1""L#->5ZW%&/
M5AZ#0D^T+3TZ6.)&.F%VZUK_HY7N]("A@X3>P$%8P:5X>]/-BED5LDD@<R=7
M$<$)J8!;4L;3R:1U[>?CFO2W4F;=A)LW&#"&-JSW+SP^=A<>YULO/% 8F[LW
MFI3*+G'@1"@07K#203= #)000Y#+^^.,GGN[VYN&80_SX4#SZ/M?OQH</#>X
M8[80[Q:?5\P@QU_3]#+=8_P>OR-FB,]29# QE#,*Q6L9L9"B$%81SY4W.^'T
M@,6'-;)M +1OG372Q'C-YILI6N:T6*ZS-^[Q><-A#&7\M<'32G,!@F<+-G@,
M'C/!?9@Q7K2[=2O8;]UA$R": F0?FFKE.$>ZSZ>/;JUU$W%D]$:HW5O_*!(6
MLD:'"?GE()2/I=92 -<N4<*=PK_L=9X?0,2P*19MP/-4.FP%JP<X+B;[Y!4&
MF])RB[(U ;Q0 3U_(KR43.30A.O96\Y&6TCM68-5"THJ/]Y?7(R7G>#=M,NB
M&J.DI^'Z9?BPY_;G/K3* _E>E%=ZTKZUZMG]51\^,B9GC&1*@I"\S-14'ASB
M%+PS7C'&K BU'\3V(O#8VZBW:.,_=9I[GTI#PS0BB?ED%8>DI2D!F<* +#G0
M)4LF2,]MKMV"[P$10\?4?2'D_I7/<=)OLTCI[3@45[;;T;=2@:]O;A=G,8[+
M=]SDS33/YA?K&3,'IP8=MV %.U:1XR-MW/I$[,@YVT[.!KK"Z&@=,^!XP2\+
M$:Q. 8AP-G%O1(Z[Q7\[+]E@E@ZW3D>F<,-R@5Y <AZLSQ1B8"'P%%)DM<O]
M?Y0LG1[A=H*$G7T4/V"<LI@OR^"1>!F6Y_,/>$B@O+NW_F""\)YJB$SGXC(K
M=%_+</IH'),T4Q)WRK_#!6Z!%O]V ]AM:_]PZ3E[86%643%M *O(:\W!IE]U
M\B(R@R)@W7P)2=&MH1$%%#P/)/'@Q$XS.'9#UT,"AH%8'9T^!,B1 A[ZFN2W
MSN-A5&RZ96:6(N<&>-<ML[/I(6/PKJ)BRJ&K*L).CL.]#QY<Z<?J:59):(,K
M?/_WD@V73N7$>(#,72K;@Y:1# HD)=J2E G-NTV2/9B$8=Z[^@+121310%I,
M"8"1@,\HNY?(Y636S3:X=6A?UP?.WJ5YB:)>S^9=>=?BEZN2#-F9:9*1-4H\
M)!=,F;(@P+ <(2JG==!*1"XJ._-5"/_A$F$.<:B&@\+WC?_"\MK.<,NB$HR!
ML@G/&*,L&!YQYU/IC.?4L^I=H*L0/FQ ,0#@ZD'^0.T/[6&<?XGCK[/U6:4E
MB=:AH3"*1'2-B 1C&+I&W(?H(L]$[)8><_M3OUM,':K160WQ-F *'R]M".@C
M)^$9^LMXK AI AC!D*<0?'!6".5J-UX\O#3I!$WNFSBJCU=5 WC;-YE=6B((
M50DR!FT@/-'@$VZGA,21'(/BJO80UA^@-&DO4!Q9FK2/AH8^"%?7!%R:->TD
M*T9*ATMN=6FQA&2;X"@DJHQU*2;\8H^[E>L/_KZ*CO;2X,-;E\/$.304?IF/
M%\O9Y-<K_+@/_W4Y]O[Q)Y4-:]XFRVD"/+XE'NL*912RQ0V&G*F@C=_QJF6_
M=;^ORJ.#@=2C,@;$64SCT=OTR4U>39?CY55GF945S# M0=N2P6"L LN8!AUI
M]ES:$-A3TVH7*?SUT^SKS_C1JZ,,O[@YP1Y9<-@$RT8\J&,5,3"&5E2OHQ2A
MDU#<1.#>:! V<W#:1M"XYZPFI'3=/0I MU<;YAP[6EVS"K(;^GQZ-1F_'4\F
M5]U;_\47-[W:E/$:R20C'@BCHF12&C#>&F"!!V:H,0\ZG6PYB;:M,)S2#U?6
MK+;D6E'_M6=%J=!&@'.E13</"DP4%!BEVMFL*+O?X?X9I0_I7M17]0%2&EK!
MC[D\M\$JN664I% ,GBLCIA-8FPIV$:76"ZWXX0[GOKN]^A5+/0C4E./0F.BN
M)-=]7#<%]UGZ8(0"E;JT5VK!"B? 9*Z$BL[*N!L,'G[V,*YA/<T?*:V!LX%N
M-ZKKY%'J?#I/)Y:.F#F#$.7Y.JD +B<.F4=)&'%2W"\4/"@9:-OZP]:Y-!(P
M5%-0@R!;;SO&M4A$!N!1H#-$<>^YTN -;27W*GN,UFODG&VG8+C\HSJ:?08J
M!XAYZ/S$3G!W3T]M'$M1,R!(+0C/8FG::\"5J9R9B^S)3JV3G\M,?+AT6_ X
M1)NS>J)MX.'FPZ5?C./8S:]6B5 ?EK/P1[=KO.-624M!&H>[AB%+'CD!3KW5
M6JOD=SNP]DGJWT;,L/V0&SF]ZJJL!>S=D/^;N\ O;\GI.NE/&9H=\B'+LWNR
M#"P1!G24E%A'2-9/78L=!,)GJ1HX=;^.^N^#JJXNA@ZY/GQ&65XW/KOWSA"=
M,<HP"EQ$= I()&!CU)",+[&CLCS>\Y&V!%]/K3(P2"JK<]:';(<&R:_C25HL
M9]-5[AGU07NA3;F 1GEX#%V=BP&RB\IHD46*NR50W?G8G6"@?_"3ZTAI-X.3
MC;L8G'0IT$([NHOE*=2QB,)@F6FGB:-AMZOZ>Q\\8 7B$<IY5,<'2*H9+9]/
MT]J8(8T&K5=)^.<HAUQ&YZ)E!,<C\\%Y(L5N>20//[L%71^BI$>U?9C$&O!
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M\9U!+O<H%(]N(*2,V4,>P"8ENN!$,TI3WJWN\KGS:K/@;L:$_/_ )SI,!RT
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M9@VN9.6R@! 3 \63@N#HU-9.EV!T"-9,^E332S&K+B*S2C= 66=B4:(-B,Q
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M(=0 %)YY^& /2,I=_Z;[W@.8?-?LGF'(  (1P/DY/ U#- N<@W>O6Y=W]!#
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MIWZY;M\S>;H@HDE/_7)]<W_M&28'"-KK""92'>6;<Z(:?22\>(6&2 %)A3\
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M%-LLZ1E"RJMG!"GK,HB_/?2 M+ GPL/5C#J?K5LKM4H,T.DT'(.<PM;94C'
MZ[.FC1$C,02#D+#O#&?W1@M3G\-V=C8Y1L5T IE4)5!+V@<%8$A&")N\8)AQ
M..5T7EZ]5TA!7J7C8I'H*[G.S*(SD[/- 7]<+8&;H012F*N<6&)&D27";I?1
MYE-:_^^Q"'R&:>'KV4561[MUVU?-SO59NZMNSE7_HM-3M\UW;779/N^KMY?-
MZU_^TVV71^MMER\'2;" _XSS2?3S_P=02P,$%     @ M8ZI5B?T4-L."
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M3- 4%'D#5[ 9J2G4!!O/5]WP1A#8^_L@D%@L<\38P64EICR'-%KU2K/,P2_
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M%X['KPG'O?XZCC>FK34X;TYX&Z,:*V$JA0,K-RKGCMFY =!=;>D0C-WE DW
MM^1CF4H[=UG^L6'=VO+ \Y@*R^*>Z$H=XQ/(;36AHM0%,&U\51)%2@MO@*]2
M)Y2CV$@!;;10X=:,$T$%'N"+M24+S^%O \#1:P)P(.+S*4]+SU8NNA3'*!3E
M%'$QCQ1\RZ)B _8-MX_7@!ZO4 1SFE!ICE5IG[9@D_S E]+DRNCX^7T/&R_J
M<[\$*7@"]GBXA;H!H[P!W(G7A+N*.$-(UZ'AMN!5#>=;'L7?"^C2)7451:5V
M %C)H(_TFBEC\=P=4Z(O$Z&CW\+1#]M^0B4&DD%D#Z0KP[%W(G]ZX X6\G)I
MUTZP*N%F66XX"O3()^%S@_='Q=MSELH;2JNCA ?R]3_LHN;??S,V>#N;,7_\
M*!:+HW['48XR5P%Z1U<.8B^H/-9JV*5U''6L5=HLD[U_@"ZS3%I+])6$,%;N
ML!KM0L(^W\DV8 S^-8[?\==5TXNU1[^5$N;[=5;FD3]MV/G_;NM/2_(G*>HS
MU(L28',;7+=ACB0!&E6B7NYZ9L1O7.8-]9K/O;[2]">>BY.A%P&NVJ"$0X9'
M&(T+*!I:$MJ3X*SJ4Z@ 82@CZR']&^1^4V; ![SD)U,EDD?/T'QJ9V\CJ[_"
M[= )DG>L01MUA)T\V0$X_H"Z0E@]Y#Z93U4Z)9< <SZISMEUQ8^4%:F:$UIG
MB0J,R._A%WC[GU0'R[1A_?:H\N 8X"+=@"-37A@:+BX.0<M%RN=#F7MW>*7#
M"B]C9:W*ABXK3AV]HQRHWGIZO(3FZA7P_J!YL-MW;X&MQG^Q&+AZ0=ST+XA;
M5JRW]?>;O?V#)YO;S<XWMNT.GA[T:YK/&#O8W<R@EG=$< ;<;0J>OZ_U:@N%
M"FS#;G'+EDLP>-?A[Z''@[-77[+_A8O#O]X_ ]I]/F.?^#SL) ["6\ ';_HK
MQWQESFWF*7P3T9>ZYWMXYMU6'TO4_[*/E]<G5V?^%??EAXO/2]>\ !$O\,X&
MHM7*]R__"[C&G>2QA4]>IY?7/G;P7G[P\8#[Q.0TD12S\UN*2K>]9I>A\JRS
M+]@^2Y?-?/(\J^JW]6"T/-^M9,PGOU]9R:8//H$I5/@&:!A.5*>T]E',72@\
MG[;O5/@8\2CMNLHSW]%4O^&K'O]]T?%_ 5!+ P04    " "UCJE6]?Y80@X(
M  "S)   &0   &YK='(R,#(S+3 S>#,Q>&5X>#,Q,BYH=&WM6FUO&S<2_GZ_
M@I5QJ0WH;?5BR[)CP+6=5D#CI(Z*X#X=J.6LEC!WN26YDM5??\/A2I8M)9%S
MS<4UKD =[7*&',X\?&;(Y>D/E^\NQO]Z?\52ERGV_O>??AU=L%JCU?K8O6BU
M+L>7[)?QVU]9K]F.V-CPW$HG=<Y5JW5U76.UU+EBV&K-Y_/FO-O49MH:W[1\
M5[V6TMI"4SA1.SOU;_ O<''VC],?&@UVJ>,R@]RQV !W(%AI93YE'P786]9H
M5%(7NE@8.4T=Z[0[7?91FULYXZ'=2:?@;-G/:2L\G[9HD-.)%HNS4R%G3(K7
M-7ET"'&GQ]N3P7&GUX\'O-T^'G0'_?X1GQQ&<?3O"(ULH7C0L6ZAX'4MDWDC
M!3_^L-=I'O4+=S*7PJ7#J-W^9XU$STX3G3L<SZ!^^!FZV>C,P9UK<"6G^9"F
M5 NJR^98*VV&>VWZ[\2W-!*>2;48_CB6&5AV#7-VHS.>_UBW&(:&!2.3(&CE
MGX VH7GT. \F'V$_2N:PG$+4\49?W:5R(AWK1LW.0XO7)\[-%.?N=(%:V.V:
M[3$Z&\QW,O[BZF8\>C.Z.!^/WEU_V##_6QO5VVK4J,X^\%P8SG[F1F"SJ;,8
MC)/)@KF4NU=[_<')+JX^Q.$*+K"+:4-!@N/UE[Z7N4"_#QO^S3?W_?9I1LWE
M'/[WHS]T2_>H26X8L93/@!F829@CA;A46O9;R0T"5"W8#13:.*9S]D:;C$7M
MQF\LT0;%@!5HA18,T*V"O>4F3E_M18?MDVY4#U2C$[3\UG'#QBD87D#I9&PQ
ME,<O()2=9Q?*G[C%0&"HL@6[S?5<@9A"/434A#@*C2;D&C,&CL!ESGB^8&7N
M3 DX \PAE$XP;IQE^&0D5RSA,;XR3&?(>$X'N0V!'&*PEIN%%\GX+1!$5GU:
M?"?0&!Q242[",;Q + WF'A3+41TM$6#8/)5QRFSI_]SKS\% U8F?0":MPB3E
M\]U<NA0G: N(R< U;,9ZAFJ"31;K;G@A".S^?1 (+)$YQMC#92VFR/A,8ZM9
M:Y8Y\@MB"PLD_!VKTK,+PF8M?G6$G/3L5&#4/6 ]D)6Z1V0%!OMH9 2]H,JK
M[B5*A0((0XU8H>&"/3&W*4N4GMLE1@U,I758MCG&_<LZR:&5]36HV:4Q&]:^
M$+3UGAW:Q@]B\VIOT(F.3FP%J*IX\/R@DT3BX[X]H,"-&#= $,&0RXD"2FB
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MMDRH4/#>+>>ZBYGYO[PF(1-L97.U3_+ Q6CV3*]IS87QZ?]02P$"% ,4
M" "UCJE6Q[Z7<MW3 0"D"!  $0              @ $     ;FMT<BTR,#(S
M,#,S,2YH=&U02P$"% ,4    " "UCJE6/CNC,1<.  "7D@  $0
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M,3$N:'1M4$L! A0#%     @ M8ZI5B?T4-L."   NB0  !D
M ( ! FP# &YK='(R,#(S+3 S>#,Q>&5X>#,Q,2YH=&U02P$"% ,4    " "U
MCJE6]?Y80@X(  "S)   &0              @ %'= , ;FMT<C(P,C,M,#-X
M,S%X97AX,S$R+FAT;5!+ 0(4 Q0    ( +6.J5;D/%E1^ 4  (L6   9
M          "  8Q\ P!N:W1R,C R,RTP,W@S,7AE>'@S,C$N:'1M4$L%!@
0   *  H IP(  +N" P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
